Clinical pharmacokinetics of nicotine, caffeine and quinine: a systems dynamics approach by Teeuwen, H.W.A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113472
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.

Cover drawing 
The original drawing was made by Leonardo da Vinci (1452 - 1519) as an 
illustration of a paragraph in the well-known book of the Roman architect 
Vitruvius, dealing with the proportions of the human body (sketchbook US B, 
fol 39, recto. Library "Institut de France", Paris). 
The square was transformed into a block diagram representing the total body 
transport function Ψ(ί). 
Thus a connection was established between the universal artist and 
scientist da Vinci and the integral science of systems dynamics, which m this 
dissertation was applied to pharmacokinetics. 
CLINICAL PHARMACOKINETICS OF NICOTINE, CAFFEINE, AND QUININE 
A Systems Dynamics Approach 
CIP-DATA KONINKLIJKE BIBLIOTHEEK, DEN HAAG 
Teeuwen, Henncus Wilhelmus Anna 
Clinical pharmacokinetics of nicotine, caffeine, and 
quinine a systems dynamics approach / Henncus 
Wilhelmus Anna Teeuwen - [ S I s η ] - 111 
Thesis Nijmegen - With ref - With summary in Dutch 
ISBN 90-9001927-8 
SISO 612 8 UDC 615 017 547 94(043 3) 
Subject headings nicotine , clinical pharmacokinetics / 
caffeine , clinical pharmacokinetics / quinine , clinical 
pharmacokinptics 
The text of this document was formatted by University of Waterloo Script 
The original typescript was printed by an IBKl-6670 laserwriter, using the 
fonts 'Prestige Elite', 'Prestige Elite Italic', and 'Essay Standard' 
CLINICAL PHARMACOKINETICS OF NICOTINE, CAFFEINE, AND QUININE 
A Systems Dynamics Approach 
EEN WETENSCHAPPELIJKE PROEVE 
OP HET GEBIED VAN DE 
WISKUNDE EN NATUURWETENSCHAPPEN 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR 
AAN DE KATHOLIEKE UNIVERSITEIT TE NIJMEGEN, 
VOLGENS BESLUIT VAN HET COLLEGE VAN DECANEN 
IN HET OPENBAAR TE VERDEDIGEN 
OP VRIJDAG 12 FEBRUARI 1988 
DES NAMIDDAGS TE 1.30 UUR PRECIES 
DOOR 
HENRICUS WILHELMUS ANNA TEEUWEN 
GEBOREN 19-7-1960 TE HAELEN 
Nijmegen, 1988 
Promotores Prof Dr J M van Rossum 
Prof Dr Ρ J de Schepper (К U Leuven) 
The research described m this thesis was carried out at the Department of 
Pharmacology {Prof Dr J H van Rossum), University of Nijmegen, Nijmegen, 
The Netherlands, m cooperation with the Department of Clinical Pharmacology 
(Prof Dr Ρ J de Schepper), Catholic University of Leuven (KUL), Leuven, 
Belgium, and the Department of Analytical Chemistry (Ing H Hissink), 
Division of Technology for Society, Netherlands Organization for Applied 
Scientific Research (TNO), Delft, The Netherlands 
Investigation of nicotine and carbon monoxide intake by smokers of 
conventional and ventilated filter cigarettes was subsidized by the Scientific 
Advisory Council for Smoking and Health (W A R G ) Investigation of caffeine 
and paraxanthmc pharmacokinetics was supported in part by a research grant 
from Douwe Egberts Royal Coffee, Tea, S Tobacco Factories 
IV 
"Learning hatb gained oost 
by those books 
by which the printers 
have lost". 
T. Fuller, 1642. 
To чу parents 
To ay beloved vife 
Together sbare tre 
troubled and Joyful tloes 
CONTENTS 
Preface xi¡ 
General Account xii 
Man's Predicament; a Philosophy xiii 
Nicotine: Natural Occurrence, Abundance, and its History as a Drug 
of Indulgence xvii 
A Note on Experiment-Induced Artifacts in Smoking Behaviour . . . xxiii 
Caffeine: Natural Occurrence, Abundance, and its History as a Drug 
of Indulgence xxv 
Quinine: Natural Sources, Abundance, and the History of its 
Applications xxix 
Brief Scope of the Present Dissertation xxxiii 
Glossary of Professional Terms, Abbrevations and Symbols xxxiv 
SECTION I 
Chapter 1: Pharmacokinetics, a Systems Dynamics Approach 1 
Introduction 1 
Dynamical Systems Theory of Body Functioning 1 
The Behavior of Physiological Systems is Dominated by Attractors . . . . 2 
Dynamical Systems Theory in Pharmacokinetics 3 
Systems Dynamics of Subsystems 4 
A. Drug Transport in Tissues and Organs 4 
B. The Density Function of Transit Times 4 
C. Flo« Vessel Analog of a Tissue 7 
Control Systems Dynamics of a Subsystem 7 
A. Analysis of Input-Output Relations 9 
B. Special Input Functions to a Subsystem 12 
С The Output in the Steady State 13 
The Arrangement of Subsystems 13 
A. Subsystems in Series 14 
B. Subsystems in Parallel 16 
C. Subsystems in Feedback Arrangement 17 
vi 
Systems Dynamics of the Total Body IS 
A. Anatomical Organization of the Subsystems 18 
B. The Feedback Control System 22 
C. The Total Body Transport Function ψ(Ι) 23 
D. Dependence of the Body Transport Function on Forward and 
Feedback Transfer Functions 26 
E. Dependence of the Body Transport Function on the Extraction 
Ratio 26 
F. Analysis of the Body Transport Function 27 
Pharmacokinetic Systems Parameters 28 
Calculation of the Body Transport Function 30 
Input Functions and Application Transport Functions 33 
A. Input Functions at the Application Site 33 
B. The Intravenous Input Function 34 
C. The Transport Function of the Respiratory Tract 36 
Analysis of Input Functions and Application Transport Functions . . . . 38 
A. Analysis of the Application Function H (t) 39 
B. Analysis of the Input Function by Eliminating the Transport 
Function 39 
The Metabolic Input Function Ul 
Conclusions 43 
References 46 
SECTION И 
Chapter 2: Simultaneous Estimation of Nicotine and Cotinine Levels in 
Biological Fluids using High-Resolution Capillary-Column Gas 
Chromatography combined with Solid Phase Extraction Work-up . 51 
Summary 51 
Introduction 52 
Materials and Methods 57 
Results and Discussion 61 
Conclusions 67 
References 68 
vii 
Chapter 3: Estimation of the Nicotine Content of Cigarette Filters and 
Glass Fibre ('Cambridge') Filters 71 
Introduction 71 
Materials and Methods 72 
Result.s and Discussion 74 
Note on the Analysis of (Hass Fibre Fi l ters 78 
Conclusions 79 
References 79 
Chapter 4: Capillary Gaschromatographic - Mass Spectrometric - Selective 
Ion Monitoring Method for Measuring Relative Levels of Cotmine 
and Orally Administered Cotinine-D2 in Smokers' Blood Plasmas . 81 
Introduction 81 
Materials and Methods 82 
Results and Discubbion 84 
Conclusions 87 
Reference 88 
Chapter 5: Rapid and Sensitive Gas Chromatographic Determination of 
Caffeine in Beverages and Biological Fluids 89 
Summary 89 
Introduction 90 
Materials and Methods 91 
Results and Discussion 93 
Conclusions 97 
References 99 
vili 
Chapter 6. Simultaneous Analysis of Caffeine and the Three 
Dimethylxanthmes in Body Fluids and Xanthine Beverages . . 101 
Introduction 101 
Materials and Methods 103 
Results 105 
Discussion and Conclusions 109 
References I l l 
Chapter 7: Selective High-Performance Liquid Chromatographic Method for 
Estimating Quinine Levels in Biological Fluids 113 
Summary 113 
Introduction 114 
Materials and Methods 116 
Results 118 
Discussion and Conclusions 123 
References 125 
SECTION III 
Chapter 8: Nicotine Intake by Smokers of Filter Cigarettes. 
Part I: Conventional Filter Cigarettes 127 
Summary 127 
Materials and Methods 129 
Results 135 
Discussion 141 
References 147 
ix 
Chapter 9: Nicotine Intake by Smokers of Filter Cigarettes. 
Part II: Vent i lated Filter C i g a r e t t e s 151 
Summary 151 
Materials and Methods 152 
Results 155 
D i s c u s s i o n 160 
References 166 
Chapter 10: Carbon Monoxide Intake by Smokers of Conventional and 
Ventilated Filter Cigarettes 171 
I n t r o d u c t i o n 172 
M a t e r i a l s and Methods 173 
R e s u l t s 177 
D i s c u s s i o n 181 
Conc lus ions 188 
References 188 
C h a p t e r 1 1 : I n t r a v e n o u s Single Dose Pharmacokinetics of Caffeine. 
A Systems Dynamics Approach 193 
Summary 193 
Materials and Methods 194 
Results 198 
D i s c u s s i o n 201 
References 203 
C h a p t e r 12: B ioavai lab i l i ty of Caffeine in Coffee and Tea, and Dependence 
of Caffeine Total Clearance on Dose and Ur ine Flow 207 
Summary 207 
Materials and Methods 209 
Results 215 
Discussion 217 
References 226 
χ 
Chapter 13: Clinical Pharmacokinetics of Paraxanthine, the Main Caffeine 
Metabolite in Man 229 
Summary 229 
Materials and Methods 233 
Results 240 
Discussion 247 
References 250 
Chapter 14: Oral and Intravenous Single Dose Kinetics of Quinine in 
Healthy Man 255 
Summary 255 
Materials and Methods 257 
Results 261 
Discussion 268 
References 274 
Postface xxxix 
Appendix I. Synthesis of 4',4'-Dideutero Cotinine xxxix 
Appendix II. The Laplace Transform xlii 
Definition of the Laplace Transform and its Inverse xlii 
Some properties of the Laplace Transform and its Inverse . . . . xliii 
Some Laplace Transform Fairs useful for Dynamical Systems 
Analysis in Pharmacokinetics xlv 
Summary and Conclusions xlvii 
Samenvatting en Conclusies Ivii 
Dankwoord Ixvii 
Curriculum Vitae Ixxi 
Publications, Originated from the Investigations Ixxiii 
xi 
PREFACE 
GENERAL A C C O U N T 
The work described in this thesis derives its relevance from the massive 
human consumption of the three alkaloids studied Indeed, nicotine, caffeine 
and quinine are self-administered extensively by people spread all over this 
planet, belonging to many cultures and religions, either sex and all social 
classes From infancy on, children become habituated to the sight and the 
smell of adults who smoke and drink coffee, tea or quinine-flavored soft 
drinks Sooner or later they will let themselves be enticed into the first 
trying-out of these tempting habits In many instances they will indulge in 
the pharmacological actions for the rest of their lives and so continue the 
habit 
Western society is infested with oil kinds of expressions and manifestations 
of nicotine, caffemp, and (be it to a less extent") quinine иъе It is sug­
gested that nowadays man does not only seek relief in tobacco and coffee from 
the stresses and distresses of life, but that, as an element of modern soci­
ety, he or she adopts the habit with the codes and prevailing fashions of that 
society Smoking and coffee drinking are now more than a personal Indulgence 
in a psychological and pharmacological gratification; they have acquired the 
status of a ceremonial gesture with a significance of its own in the compli­
cated social rites 
In this preface we will devote a few words to the side of human nature that 
leads man to rake drugs that affect his mood and behaviour, or merely the 
taste of the nourishments and beverages that he takes Although caffeine and 
nicotine exert pharmacological actions throughout the body, their appreciated 
stimulant actions mainly involve the central nervous system, these two com­
pounds belong to the former category Quinine, which is esteemed as a bitter 
principal in soft drinks, belongs to the latter category The rate of quinine 
self-administration by devotees of these drinks typically is small to such an 
extent that the (untoward) central effects of quinine in general are not felt. 
Subsequently, separate sections will be dedicated to each of the studied 
alkaloids, we will mention their natural sources, tell the history of their 
past and present useÇs), and we will try to extrapolate these data in order to 
predict the nature and extent of their future uses 
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MAN'S PREDICAMENT; A PHILOSOPHY 
Opinions tend to be sharply divided as to the purpose of life, or, as some 
like to word it: man's destiny. Profound metaphysical questions of this kind 
are entirely outside the scope of this thesis, but, whatever the personal 
leanings may be, it must surely be conceded that human behaviour is partly 
governed by the desire to avoid or abolish pain, fear, restlessness and other 
disagreeable sensations. One of the most influential great philosophers of our 
century, who has dealt with this theme exhaustively, is Sigmund Freud. It is 
the central point of a doctrine propounded by him, in which he asserts that 
man is assailed on all sides by influences that disturb his peace of mind in 
some degree. 
Freud dealt with the question as to what man demands of life by formulating 
the pleasure-pain principle, pointing out that human nature is bent primarily 
on seeking pleasure and avoiding suffering and dissatisfaction. Apart from its 
formulation, this was no new psycho-analytical discovery. The early philoso-
phers had already quested for solutions to those difficulties of life which 
may conveniently be condensed into the words: man's predicament. Such solu-
tions ranged from the unrestricted gratification of all desires to the avoid-
ance of any dissatisfaction. 
In 'Das Unbehagen in der Kultur', Freud, referring to the causes of man's 
predicament, states that we are inadequately equipped to meet the challenge of 
life, which brings us grief and disappointment and all too often imposes 
impossible tasks. We cannot face life without palliatives, whether these be 
distraction and relaxation or luxuries and intoxicants. Man strives for happi-
ness; he wants to attain and retain it, but it will rarely endure for long. 
Change sometimes brings a real sense of joy, but usually it is transitory. 
Freud detects three sources of dissatisfaction: our own bodies, the outside 
world, and our fellow-men. Our bodies warn us of danger by sending us signals 
of pain and fear; they have only limited powers of endurance with which to 
meet a host of onslaughts, direct or potential, upon life and limb. We have 
learned to control the danger immanent in natural forces to a considerable 
extent but, paradoxically, that danger has increased in proportion to our 
growing control of them. The third, and to many the most important, source of 
unhappiness is the unsatisfactory realisation of human relationships in the 
family and in society. 
Man's attempts to rid himself of his sense of frustration can be divided 
into two groups. He may either eradicate the cause or, if this is impossible 
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or too difficult, resort to various mitigating expedients Whatever one thinks 
of the cause, life ob\ lously imposes such a heavy burden upon man that he 
finds it necessary to seek a moans of lightening this burden and of turning 
his environment into an artificial paradise, of transforming 'being1 into 
'wpll-being' 
The technique, in the broadest sense of the word, consists in attacking the 
the causes of dissatisfactio , As far as our own bodies are concerned, it 
amounts to hygiene and medical therapy To protect ourselves from the forces 
of nature we have developed a technique in the narrower sense, namely houses 
to shield us from the elements, roads to facilitate travel and vehicles to 
minimize physical exertion It is in removing the difficulties besetting human 
contacts that we have been slow to progress The tensions between small and 
large groups of people, neighbours, colleagues, competitors, social classes, 
and nations, set up a mental stress which we are still powerless to combat 
Freud believed that, here again, we are up against a bit of indomitable 
nature, namely our psychical make-up As far back as 1930 he pointed out that 
the then prrvailing spirit of unrest, unhappiness and fear were largely due to 
the realisation that man now controlled the forces of nature to the extent of 
easily being able to use them for the extermination of the human race He then 
could not have foreseen how amazingly our efficiency in that respect would 
have increased within a few decades 
Much has been written about the makeshifts resorted to in order to reach a 
compromise with the sources of disruption referred to Freud calls the taking 
of drugs the least refined, but the most effectual method, for, in addition to 
creating pleasurable sensations, it assures detachment the subject knows 
that, whenever required, the drug will afford escape from the pressure of 
reality Freud considers many psychic symptoms of great diversity to be a more 
subtle means of escape than the taking of drugs, mentioning neurosis, relig­
ion, phantasy, day-dreaming, humour, and a large number of artistic and cul­
tural activities 
The fact that the means of escape adopted are so numerous and so various may 
be accounted for by the general human urge to replace the existing world by 
another In a literal sense, the quest for another world finds expression in 
the desire to travel and make voyages of discovery (During one of these, 
Columbus discovered the 'New World' , as well as a new world of drug indul­
gence tobacco) In this context, scientific research and discoveries are to 
be classed as originating from the same urge, and sports falls into the same 
category Temporary release from the drudgery or troubles of life can be 
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obtained by active and passive participation in sports The (ab)use of doping 
agents may give an extra dimension to the feeling of escape during active 
sporting, and the commitment of mass vandalism may do this job for the 'pas-
sive sporter' (1) Cinema and the mass media may legitimately be said to serve 
the same purpose 
This is not a complete list of disguised attempts to put something else in 
the place of an unsatisfactory reality, to resolve man's predicament We do 
not want to complete it either Our main concern in view of the subject of 
this thesis is with drugs taken for the purpose of rubbing of the rough edges 
of reality It Is evident from many sources of inquiry that mankind had 
recourse to these from time immemorial, and probably they will accompany man 
until eternity 
The most innocent form of pharmacological indulgence is the flavouring of 
foods and beverages with aromatic 'drugs' to improve their taste Man probably 
leamt to sweeten his food with honey before he mastered articulate speech 
Today the the quest for synthetic low-caloric sweetening agents without perti-
nent side- and aftertastes is an important research topic in flavouring indus-
try Modern man wishes to enjoy sweetness as eagerly as his Palaeolithic 
ancestors stealing honeycombs from wild bees Like the latter tried to prevent 
being stung, the former tries to elude obesity and caries Spices and salt 
have been man's table companions as long as honey and sugar The history of 
bitter agents like quinine is less well-documented and illustre, presumably 
because a bitter taste is experienced as unsavoury by a major part of the pop-
ulation, especially by children Caffeine also has a pronounced bitter taste, 
which contributes to the bitterness of coffee and tea and which is masked in 
cola-flavoured soft-drinks by the addition of large amounts of sweeteners 
Drugs taken for their influence on the central nervous system are less inno-
cent and must be under suspicion, even if their effects are mild at the 
amounts in which they are usually taken After all use of such drugs may be 
dangerous for the user and/or people in his proximity if the drug induces a 
state of hallucination in which physical perils ( e g , in traffic) are no 
longer properly recognized (alcohol, opiates), or if the drug may effect/ 
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catalyse a state of rage and agressiveness (alcohol. Rohypnol ), or if the 
drug merely intoxicates if taken m large amounts (caffeine, nicotine, alco-
hol) We will try to formulate some of the 'merits' that qualify a given sub-
stance as a desirable tranquilliser or exhilarant 
Primarily, of course, it must produce the required effect It must liberate 
the excessively inhibited, remove the anxieties from the worrier, and cheer up 
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the sad At the same time, however, it must be no too injurious, at any rate 
in moderate doses Man wants to compromise between the euphoria of intoxica­
tion and the desire to preserve his health, a compromise which determines his 
choice from the many drugs and the routes of their administration which nature 
and human ingenuity have placed at his disposal Experience has shown that the 
true exhilarants often weigh the scale in favour of intoxication Pure pick-
me-ups seldom do any physical harm but, their efficacy as a means of escape 
being commensurately small, they are felt to be inadequate in acute condi­
tions 
Often it is not the sopofonc effect of drugs of indulgence that counts in 
the first place Drugs Ііке caffeine and nicotine may intensify perception, 
facilitate flow of thought and increase one's ability to concentrate on diffi­
cult tasks, and thus enhance man's ability to cope with reality, be it for a 
limited time and maybe at the cost of some dullness after that time Also, 
these two and other drugs (e g , alcohol) may promote sociability rather than 
a desire to flee from society This stimulation of performance and the desire 
for human contact may be valuable in theirselves, though the resulting conduct 
(in case of alcohol), the adverse health effecLs and the involuntary co-
smoklng of fellow-men in our close proximity (in case of smoking) may tip the 
balance of appreciation in a contrary direction 
The universal popularity of any one particular drug depends on its accessi­
bility Formerly, when one had no option but to take what nature afforded 
locally, the geographical factor was very important At one time the Eskimos 
took no kind of a drug or an intoxicant at all, for the simple reason that 
there were none to be had, whereas the Equitonal aboriginals had quite an 
assortment to choose from Later, when international trading grew and facili­
tated travel brought the peoples of the world and the continents ever closer, 
geographical remoteness counted less as a limiting factor The changed atti­
tude of 'civilised' man towards intoxication and its social side-effects, such 
as body neglect, a repulsive appearance, economic dislocation and agressive-
ness, is significant To the primitives, intoxication was of supernatural ori­
gin, the strange, to them inexplicable, behaviour which it evoked put the seal 
of sanctity on it The intoxicated received prophetic visions, spirits took 
possession of his body and spoke through his mouth (oracle) Thus intoxication 
offered the supreme means of entering into the presence of those higher powers 
which, in their view, held the destiny of mankind in their hands 
Cost is another factor comparable with geographical accessability In many 
cases it is fixed mainly by the authorities, who impose excise duty on some 
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articles (tobacco, coffee, tea, and alcohol), or even ban them (marihuana, 
opiates). In the latter case there has always been a black market offering the 
forbidden drugs at exorbitant prices, burdening society with addicts operating 
in the criminal circuit to raise the necessary finances. 
By weighing the advantages against the disadvantages of certain substances, 
it might be possible to draw up a set of norms which should, as far as possi-
ble, fit within the framework of hygiene. A wise selection and use of the 
drugs depend fundamentally upon precise knowledge of their effects at various 
concentrations in blood plasma and other body fluids. Knowledge of the sig-
nificance of the different ways in which one particular drug is taken is like-
wise indispensable. For example, it undoubtedly makes all the difference in 
several respects whether tobacco is chewed, sniffed, or smoked, and, in the 
latter case, whether it is smoked as cigars or as cigarettes. 
The problem approached in this way is a fascinating puzzle. However, it can-
not be wholely dealt with within the framework of the present dissertation. 
From now on we will (have to) put our minds mainly to the one piece of the 
puzzle we chose to study: the characteristics of the time course of three 
selected drugs in human body fluids, and the way of their disposal. While con-
centrating on pharmacokinetics, we deliberately have to leave all other 
aspects including the social, psychological, philosophical, and preventive-
medicinal aspects, of the use of these three and other drugs to our colleagues 
in these respective fields. 
This dissertation contributes to the knowledge of the pharmacokinetics of 
three of the most frequently enjoyed drugs of our era, and of the main metabo-
lite of two of them. The scope of the present piece of research has been list-
ed briefly in this preface. The natural sources and the utilitive histories of 
nicotine, caffeine, and quinine now will pass under seperate review. 
NICOTINE: N A T U R A L O C C U R R E N C E , A B U N D A N C E , A N D ITS HISTORY AS A 
DRUG OF INDULGENCE 
'Fumer, c'est mourir un peu'. 
Adriaan Morriën. 
Nicotine is considered to be the principal alkaloid in commercial tobaccos 
which are derived from the dried leaves of the Nicotiana species tabacum and 
rustica, where it occurs to the extent of 2-8% combined with citric and malic 
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acids The nicotine molecule contains a single chiral carbon center, of the 
two optical isomers, only (-)-S-nicotine occurs in N laotiana species The lat-
ter enantiomer is more potent than the (+)-R-enantiomer in stimulating nico-
tinic receptors 
The botanical genus Nicociana, established by Linnaeus in 1753, belongs to 
the Solanacpae family, also known as the potato or nightshade family, and con-
tains at least 60 species Morphologically and cytogenetically there is direct 
relationship between South American and Australian-South Pacific species, 
whereas North American species, although related to the former, are only indi-
rectly related to the latter This combined evidence points to South America 
as the center of current distribution of the genus Nicotinana (36 endemic 
species), and, together with other pertinent data, argues for the origin of 
the genus in that continent with subsequent dispersal to North America (15 
endemic species, 6 of which occur in South America as well) and to Australia 
and the South Pacific (15 endemic species) 
The only species which has never been found growing wild is Nicociana 
Cabacum, which is the species the most widely grown for commercial use It is 
an amphidiploid having arisen from hybridization of two South American 
species N sylvestris and N tomentosiiormis The earlier mentioned 
species, N rusCica, is grown only in limited areas of China, India and the 
USSR and plays a minor ever decreasing commercial role 
The many alkaloidal and related materials found in plants of the genus Nico-
ciana comprise nicotine, nornicotme, anabasme, myosmine, anatabine, nico-
tinic acid, nicotinamide, nicotynne, 2,3' -dipyndyl and many others In most 
Nicociana species, nornicotme is more abundant than nicotine 
Tobacco holds an unparalleled position among crop plants, while in overall 
situation the status achieved by the tabacum species is quite remarkable Some 
of the more noteworthy points are listed below 
• it is one of the very few crops entering the world trade entirely on leaf 
basis, 
• it is the most widely grown commercial non-food plant in the world, 
• in many countries it is an instrument of high importance in financial and 
economic policy, 
• consumption is rather diverse, by way of smoking, inhalation of dust 
(snuff), and chewing, 
• as a habit-forming narcotic, tobacco with fair regularity has been the 
subject of attacks aiming at curtailing or abandoning its use However, 
consumption has marched steadily forward, 
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• tobacco use originally having religious significance, subsequent claims of 
medicinal benefit have alternated with accusations of a causal role in the 
etiology of many diseases 
In order to understand how the present mondial status of tobacco use came 
into existence, we now will devote a few words to its history 
Before the coming of the white man, the two species of current economic impor-
tance, N tobacco and N rustica, were under cultivation in parts of both 
Americas and of the West Indies We will never know how the Indians came to 
use tobacco Maybe they burned the spontaneously dned-up old lower leaves of 
the tobacco plants, the so-called sand-leaves, for cooking purposes or to 
chase away the mosquitos, and inevitably inhaled bits of the evolving smoke 
Anyway they proceeded to cultivate it in the neighbourhood of their settle-
ments Apparently N rustica was the tobacco of the tribes east of the Mis-
sisippi, of a number of those somewhat westward and of the Indians of northern 
Mexico Andean Indians did not seem to cultivate it N tabacua is commonly 
referred to as widespread in aboriginal cultivation in eastern South America 
from Brazil northward, and m Colombia, Central America, most of Mexico and 
the West Indies In North America a number of indigenous species of Nicotiana 
have been used by Indian tribes Of such species perhaps the best known is N 
bigelovn 
Tobacco was called 'tobaco' in Mexico, 'petum' in certain regions of 
Brazil, 'uppowoc' in Virginia and 'ziq' by the Mayas The native Indian popu-
lation of both Americas used tobacco as a stimulant It was considered a 
divine gift, an important part of their religious life was hung on it, and 
many medicinal qualities were attributed to it The latter idea was taken over 
by the Europeans later 
Tobacco was completely absent in the rest of the world No written tradi-
tion, be it in Sanskrit, in Hebrew, or in Egyptian hierglyphics, mentions it, 
and even Marco Polo who described every event and detail happening during his 
journey to and in China, kept silent about anything that could pass for tobac-
co 
The non-availability of tobacco did not prevent the rest of the world from 
smoking Other herbs were burned in order to inhale the smoke According to 
Herodotus the Scythians possessed a plant, the leaves of which were thrown 
into the flames The old Egyptians smoked majoren, Plinius prescribed the 
smoke of coltsfoot as a remedy for coughing, and thyme, mint or cannabis were 
to be smoked as afrodisiacs 
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Two crewmen who accompanied Columbus to the New World were the first Euro-
peans to observe the smoking of tobacco, the 28 of octobre 1492, on the 
eastern shore of Juana (Cuba) 'The two messengers who had been put ashore to 
scout the land told that on their way they had met many aboriginals carrying 
burning torches and also held special herbs in their hands to incense them-
selves as is the custom imong them' (log-book, the 6 of November 1492) 
Columbus was handed a gift, composed of dried leaves that were considered very 
valuable by the aboriginals The leaves and the burning torches (cigars) were 
called 'tobago' Bishop Bartholome de las Casas, who accompanied Columbus on 
his first journey to the New World, wrote about the Indians of Hispaniola 
(Jamaica) that '„hey always had a flame at hand, and certain herbs to smoke 
These were dried and wrapped m a dry leaf' 
In 1496 friar Ramon Pane, Columbus' domestic anthropologist, first 
described the ritual of Tahitian Indians sniffing up tobacco which had been 
grinded to powder, and in 1499 Amerigo Vespucci observed Indians on Margarita, 
an island near the Venezuelan coast, to chew tobacco In 1518 Juan de Gryalva 
during an expedition in Mexico encountered a precursor of the modern 
cigarette a small hollow reed-stalk filled with tobacco In Florida before 
the very eyes of Ponce de Leon (in 1513) and those of Verraz¿ano (in 1524) the 
Indians also gave evidence of mastering pipe smoking 
Columbus' crew returned to Spain with a large stock of Havanas-avant-la-
lettre Because of its supposed curative effects, tobacco was popularized 
rapidly in Spain The Portugese soon obtained the herb from their colony 
Brazil, the Dutch laid hand on it by plundering Spanish and Portugese ships 
Around 1550, a lot of smoking was to be observed in Spain, Portugal and Hol-
land Before the end of the 16 century, seamen of the three maritime nations 
had spread the fame of tobacco and the techniques of consuming it to seaports 
all around the known part of the world 
Well-known is the story of Jean Nicot de Villemain (1530-1600), French 
diplomat in Portugal His queen, Catharina de Medici, suffered from unbearable 
attacks of migraine, until Jean Nicot sent her a sample of sniffing tobacco 
(1560) It did the trick Catharina was given considerable relief, and in this 
way tobacco started its career in France 
In Italy, cardinal Prospero di Santa-Croce introduced tabacco one year 
later, and John Hawkins in 1565 did the job for England Germany became 
acquainted with tobacco as 'Cathanna's herb' in 1570, when the Huguenots took 
it with them while fleeing from France A Spanish diplomat introduced it at 
the Court of Vienna in about that same year 
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However, tobacco had powerful enemies in those early days for all kinds of 
reasons The Christian Church associated inhalation of tobacco and other herbs 
with heathen worship and strongly rejected the use of this 'Satan's herb' The 
Spanish Inquisition accused Columbus' crewman Rodrigo de Jerez of being pos-
sessed by demons Pope Urbanus VII threatened to excommunicate every smoker, 
but Ins successor already had to tolerate priests smoking during the Service' 
King Henry VIII held out the prcspect of whiplashes to smokers Elizabeth I 
tried to confiscate pipes and tobacco boxes Her successor, James Stuart I, 
forbade the smoking habit altogether and issued a 6 shilling penalty In 1618 
he accused Sir Walter Raleigh of high treason and let him be executed Raleigh 
ascended the scaffold smoking pipe Many English pipe manufacturers fled to 
Gouda in Holland when subsequently they were forbidden to provide their pipes 
with a baked-up sculpture of Raleighs' face 
In the Middle East smokers were hanged with their pipes put cross-wise in 
their mouth or in their nose The Persian sjah Abbas ordered smokers' lips to 
be cut-off, when even this horrible sanction was not able to ban the smoking 
habit. Abbas' successor went as far as spearing smokers The Russian tsar 
Michael ordered smokers' noses to be cut off, inveterate smokers were sent to 
Syberia, and whoever even there got hold of tobacco was decapitated When in 
Japan the god-emperor (mikado) altogether interdicted the use of tobacco, his 
citizens for the first time in many centuries were provoked to exhibit civil 
disobedience 
Despite all this profane and ecclesiastical opposition the number of 
tobacco users kept growing steadily ever since Columbus first set foot on 
American soil Governments' resistance against smoking rapidly disappeared 
after the authorities discovered the possibility of lining the Treasury with 
duties excised on tobacco The Republic of Venice was the first to do so at 
the turn of the 15 century 
Cultivation methods for tobacco plants and leaf curing techniques had been 
improved markedly at the dawning of the industrial era, which brought along 
machinal cigarette manufacture (1884) The resulting large scaling-up of 
cigarette production, accompanied by a resulting decrease of the cigarette 
prices paved the way for the huge mass-consumption of tobacco in the shape of 
predominantly cigarettes as we know it today Other factors spreading the use 
of tobacco and stimulating its consumption rate are 
• large-scale wars, like the Krim War and the two World Wars, caused great 
population turbulences and migrations and hence an intensive exchange of 
certain habits, 
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• the financial scope of the citizens of many western countries in this cen­
tury substantially increased and enabled them to spend more monoy on luxu­
ry goods like tobacco, 
• a chango of the cigarette smoke flavour from sharp and irritating to mild 
and aromatic, promoting inhalation of the smoke and hence an effective 
self-administration of tobacco's main pharmacological agent nicotine, 
• agressive ^nd intensive advertisement campaigns, in which smoking is asso­
ciated with all kinds of desirable situations and characteristics, 
• the introduction of cigarette brands relatively poor in nicotine, necessi­
tating the nicotine-dependent smoker to smoke more cigarettes to recieve 
the amount of nicotine that he/she had got used to while smoking the older 
higher-delivery brands 
The total world production figure of raw tobacco amounted to almost 6 mil­
lions of tons in 19Θ3 
The growing consciousness that inhalation of tobacco smoke is a prominent 
hazard to health is causing a shift in smokers' consumption patterns towards 
cigarettes low in tar and nicotine It also tends to stabilize and even dimin­
ish tobacco sales figures in Western society 
Tobacco's 'active principle' was first isolated from leaves of Nicotisna 
tabacum by Posselt and Reiman in 1628 They isolated a volatile substance, 
pungent to taste and smell, which possessed the 'narcotic' properties of 
tobacco and was so toxic that 'a fourth drop was enough to kill a rabbit' The 
substance was called nicotine in Jean Nicot's honour 
Nicotine has been used as an agricultural insecticide ('Black leaf 40') in 
the United States In recent years, it has acquired its one and only therapeu­
tic application as the main ingredient of a chewing gum that can be pre­
scribed by physicians as a help in smoking cessation The gum is most effec­
tive when used as part of a comprehensive program such as in smoking cessation 
clinics Typical results from trials of this kind are 30-40 % one-year absti­
nence compared to 15-20 % for placebo-treated patients 
The use of nicotine gum in general medical practice is less encouraging 
In one of two large studies having been reported, one-year abstinence was 9% 
for nicotine gum versus 4% for physician advice or no intervention In the 
other, both approaches scored 10% one-year abstinence Succesful use of nico­
tine gum clearly depends on selection of highly motivated patients and on the 
motivation, experience, and time spent by physicians or other health care 
providers 
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In pharmacokinetical terms, the failure of nicotine chewing gum to effec-
tuate high cessation rates may very well be traced back to its failure to 
produce transient high plasma concentration peaks, as the gum releases nico-
tine only very gradually If tobacco addiction indeed is a 'dependence on high 
nicotine boli', a nicotine inhaler would have been a more adequate choice of 
formulation than a chewing gum 
A Note on Experiment-Induced Artifacts in Smoking Behaviour 
One might think that, if by way of experiment, a volunteer were asked to 
smoke 'as he (or she) is accustomed to do', this would yield reliable data 
Yet the very circumstances of the experiment often tend to modify the tech-
nique, in that the human guinea-pig is inclined to smoke more or less inten-
sively than he usually does, with the result that the intake measurements will 
show an intake of toxic components, such as nicotine and carbon monoxide, that 
is not representative for the intake in everyday life of the experimental sub-
ject Actually, this is comprehensible, for, if the persons undergoing the 
test were doing nothing else besides smoking, they would have kept their mind 
to it much more than in normal circumstances, this, together with their desire 
to co-operate and to meet the expectations of the experimentalist (if known to 
them), may easily have led to a more or less intense smoking technique 
In fact, there is no way to be absolutely sure that smoking pattern or 
intake of certain smoke constituents observed in the laboratory is representa-
tive for the everyday life smoking behaviour of the subjects Nervousness In 
anticipation of the next venipuncture, boredom, the consciousness of being 
observed by the experimentalists, the supply of free cigarettes during the 
course of the experiment and many other factors which are very diverse in 
their nature induce changes in the smoking technique and pattern of experimen-
tal subjects Even if the subject is allowed to smoke in his or her own envi-
ronment and is merely requested to save the butts, one cannot be certain that 
even this noncomittal type of experiment will not affect smoking behaviour 
The nasty smell that evolves from the container when adding a butt to the ones 
already saved, and the thought of their unsuspected high multiplicity might 
work out as a negative feedback mechanism that restrains the subject from 
lighting additional cigarettes too frequently and, when lighting one, makes 
one 'dawdle over' it 
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However, if a subject's smoking behaviour is affected by so many circumstan-
ces in the laboratory, it is not unlikely to presume that many factors outside 
the laboratory affect it as well Indeed, when collecting cigarette butts from 
filter cigarettes smoked by fully ambulant subjects over a 16 days period, 
large differences were found in the intra-individual daily average of the fil-
ter butt nicotine content Obviously, there is no such quality as THE smoking 
behaviour of a cigarette smoker Whether in experimental conditions or in 
everyday life, each cigarette is smoked individually, and the smoking parame-
ters employed are a random indication 
Realizing this, there is no sense in eliminating every potential factor that 
could exert influence on a subject's smoking behaviour from the experiment 
Factors existing in the 'outside world' should be maintained and imitated in 
the laboratory, and only clear-cut artificializing laboratory circumstances 
should be abandoned 
The gist of it is, as natural smoking is mostly done simultaneously with 
some other activity, in the laboratory the attention of the subjects should 
not constantly be focussed on the act of smoking, but rather be diverted from 
it by accompanying activities like reading, writing, drinking coffee or tea, 
playing cards, knitting, watching television or whatever While doing so, they 
should not be observed, or at least not be aware of being observed, by the 
experimentalist(s) If available, a separate room is an ideal subject 'home' 
and an elegant solution for those scientists who wish to keep their laboratory 
free of nicotine contamination regarding possible future analyses of the 
volatile alkaloid The volunteers should not be aware of the experimentalist's 
expectations or beliefs regarding the outcome of the experiments They should 
not switch from one brand to another on experimentalist's request, and not be 
supplied any free cigarettes in the course of the experiment 
No matter its importance, in pharmacokinetical publications the psycho-
socio-economic design of smoking experiments is rarely discussed In many 
instances these aspects of experimental design probably receive the attention 
they require, authors considering them too trivial or too detailed to mention 
in the methodology (which actually is the reason we discuss this matter in the 
preface of this thesis) In other instances authors do not seem to properly 
recognize possible artificializing conditions incorporated in their study 
design, nevertheless they often claim general applicability of their results 
and conclusions We feel that the frequent omission of these details from pub-
lications has contributed to the diversity of the conclusions arrived at in 
studies with a seemingly similar design 
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CAFFEINE: N A T U R A L OCCURRENCE, A B U N D A N C E , A N D ITS HISTORY AS A 
DRUG OF INDULGENCE 
" 't Swarte watervogt, dat alle kracht bezit, 
Om 't sieckelijcke lijf gezondheid weer te geven. 
Dat elcke kwael verdrijft, het koude bloed verhit, 
En 't dichterlijk brein vervult met jeugdig leven." 
('Tot lof van de koffij', Anonymus, 1792). 
Caffeine, theobromine and theophylline are drugs which are similar in chemi-
cal constitution and pharmacological action. They are found in a large number 
of plants of several families and genera distributed widely throughout the 
world It is of interest to note that wherever those plants are indigenous, 
natives use their aqueous extracts as beverages The consumption of some of 
these beverages such as coffee, tea, and cocoa is practiced all over the 
civilised world 
Coffee is obtained from the kernel of the dried ripe seed of Coffea arabica, 
С 1 iberica, С canephora (robusta coffee), and other species of Coffea 
(ИиЬіасгае) The kernel is roasted until it acquires a deep brown colour and a 
characteristic aroma It contains about 1-2 % of caffeine and small amounts of 
theobromine 
Tea, the prepared young leaves and leaf-butts of Camellia sinensis (= С 
thca) (Theaceae), contains 1-4 % of caffeine, some theobromine and traces of 
theophylline 
Cocoa is produced from the fermented and dry seeds of Theobroma cacao 
(Stercullaceae) which contains in the kernel li-3 X of theobromine and a small 
amount of caffeine The shell contains about ^-2 X of theobromine Heated and 
deprived of husk and membrane, the seeds yield cocoa nibs The nibs with most 
of the solid fat (Theobroma oil) pressed out produce, when reduced to powder, 
cocoa for use as a beverage The powder is often flavourpd with vanillin or 
cinnamuiL 
In addition, a number of caffeine beverages, less universi in appeal, are 
consumed in widely scattered areas 
Mate is prepared from the dried leaves of Ilex paraguanensis (Aquifoli-
aceae) which contain 0 2-2 % of caffeine Mate is extensively used as a bever­
age in South America 
In the vast territory of the Sudan, natives chew the kola nut and swallow 
the extractives The dried cotyledons of the nuts, from Cola nitida and С 
acuminata (Sterculiaccac) contain \\ - 2\ X of caffeine and traces of theo­
bromine The kola nut is a valuable possession and is used as a basis for com­
mercial exchange 
Many species of the Paullima plant genus (fam Sapmdaceae) grow in the 
Amazon basin, but only two of these are used by the natives Paullima sor­
bii is as a beverage, and Paullima cupana to prepare guaranà, a dried paste 
prepared from the roasted seeds The two species are unique in their genus in 
that they contain a large amount (more than 4% of the dry weight) of caffeine 
The earliest use of the xanthine beverages is lost in the obscurity of the 
past However, legends telling of their discovery reveal the reason for their 
favor For example, legend credits the discovery of coffee to a prior of an 
Arabian convent Shepherds reported to the prior that goats which had eaten 
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the berries of the coffee plant did not rest but gamboled and frisked about 
all through the night The prior, mindful of the long nights of prayer which 
he had to endure, instructed the shepherds to pick the berries so that he 
might make a beverage from them The success of his experiment Is obvious from 
the popularity of coffee today, a billion pounds being consumed yearly in the 
United States alone 
Another story tells of the discovery of tea by Bodhidharma, who lived in the 
6 century A D Bodhidharma, the son of a king of India and an apostle of 
Buddhism, traveled to China to spread his beliefs There he lived under the 
open sky, mortified his flesh, tamed his passions, and subsisted on leaves. He 
sought sanctity by attempting to stay awake for 9 years while contemplating 
the virtues of Buddha After three years of practice, he fell asleep Upon 
awakening, overcome with chagrin, he cut off his eyelids so that his sin might 
not be repeated A plant sprang up where his eyelids had fallen He ate its 
leaves and found that he could return to his worship with renewed vigor This 
plant was the tea plant 
From these old tales it can be inferred that caffeine is a stimulant. The 
name coffee is derived from the Arabic word 'gahwa' (pronounced as 'kahwah'), 
which was degenerated to kahweh by the Turks This word means 'that which 
excites' or 'that which strives upward' and summarizes the pharmacodynamics of 
caffeine to a good extent 
It is beyond the scope of this thesis to unravel the history of all the 
above-mentioned xanthine-beverages Therefore we will focus our attention on 
coffee, the most popular xanthine beverage in the western world and the most 
important source of caffeine in western diet 
It is highly probable that the province Kaffa in Abyssinia is the cradle of 
the coffee plant cultivation During their military campaigns in the 13 and 
14 century the Ethiopians brought it to Yemen, where it flourished well on 
the fertile terraces Subsequently coffee travelled northward along the shores 
of the Red Sea to Mecca and Medina, from where the innumerable pilgrims spread 
its fame and its use to all directions The boom of the Islam which was going 
on then and the strong expansion of the coffee-ninded Turkish empire certainly 
stimulated the spreading of the coffee-drinking habit In the 16 century 
coffee was a commonly used beverage in the whole Middle East Women acquired 
the habit to an ever increasing extent Turkish law even acknowledged the 
refusal of a husband to let his wife enjoy coffee as a solid reason to 
divorce 
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In 1554 the first coffee-house on European soil was opened in Con-
stantinopel, a century after its conquest by the Turks Samples of coffee 
beans were subsequently introduced to Western Europe by enterprising mer-
chants 
In 1645 the first Italian coffee-house was opened in Venice, in which city 
soon a comprehensive coffee culture arose The introduction of the coffee 
into France passed off rather quietly By 1676 Pans accomodated several 
coffee-houses, which were called 'cafes' after the name of the brew 
The coffee took Britain, presently the classic tea-country, by storm The 
writer John Evelyn (1620-1706) mentioned a coffee-house in Oxford as early as 
163 About 1643 coffee had arrived at the status of being the favourite drink 
of the upper class and some thirty years later England counted more than 300 
coffee-houses One of them was Lloyds's Coffee-House, opened m 1688 by Edward 
Lloyds near the London sea-port, where over a cup of coffee many loading 
receipts and ship's insurances were discussed 
In the Low Countries, the interest for the coffee habit spread in the period 
from 1640 to 1670 Amsterdam soon became an important coffee trade center In 
1699 the at that time very young East-Indian Company established the first 
coffee estates in Java, where thp Dutch cultivated tobacco and, later, Cin-
chona trees as well These estates all were very succesful, even today all 
around the world the name of Java is readily associated with high quality cof-
fee and cigars Coffee trade significantly contributed to prosperity in The 
Netherlands at that time, and coffee consumption became part of the luxurous 
life-style of the Golden Age Probably the Dutch took the coffee to America 
while founding New Amsterdam (New York) 
Today the annual world production rate of coffee beans is estimated to be 6 
million tons As coffee consumption enjoys unflagging popularity, rarely turns 
out to be addictive and is seldomly associated with adverse health effects by 
medical science, a further increase of mondial coffee consumption rate is 
anticipated 
The first publication reporting the isolation of caffeine from beans of Cof-
fea Arabica by F Runge dates fron 1B20, and as early as 1B75 L Medicus 
reported the clarification of caffeine's chemical structure Classic pharmaco-
logical studies of (mainly) caffeine and related xanthines during the first 
half of this century have elucidated the stimulating and antisopoforic actions 
of this group of compounds, thereby confirming the ancient beliefs inferred by 
legend Moreover, these studies have revealed that methylxanthines possess 
other important pharmacological properties as well These properties were 
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exploited for a number of years in a variety of therapeutic applications, many 
of them have now been replaced by more effective agents. However, m recent 
years there has been an resurge of interest in the therapeutic use of the nat­
ural methylxanthines and synthetical derivatives thereof, principally as a 
result of increased knowledge of their cellular basis of action and their 
pharmacokinetic properties. 
Literature uted 
• Extra Pharmacopoeia Martmdale (R G Todd, ed ), The Pharmaceutical Press, 
London (1967) 25 t h edition 
• The Merck Index (M Windholz, ed.), Merck & Co , Inc., Rahway (1983) 10 t h 
edition 
• L S . Goodman and A. Gilman, 'The Xanthines', m . The Pharmacological basis 
of Therapeutics (L S Goodman and A Gilman, eds.), Macmillan Co. Ltd , 
New York (1956) 2 n d edition, pp 339-353 
• Norman Kolpas, 'Het goede leven koffie', Het Spectrum, Utrecht/Antwerpen 
(1977) 
• F Runge, 'Phytochemische Entdeckungen', Berlin (1820) ρ 204 
• L Medicus, 'Zur Konstitution der Harnsauregruppe', Liebigs Annale der 
Chemie 175 (1875) pp. 230-251 
• Kurt Benesch, 'Süss wie die Liebe, oder Kaffee Gestern und Heute', Paul 
Neff Verlag, Wien (1974) 
QUININE· NATURAL SOURCES, ABUNDANCE, AND THE HISTORY OF ITS 
APPLICATIONS 
Quinine is the most abundant alkaloid occurring in cinchona bark, the bark 
of the roots, trunk, and branches of several species of the Cinchona genus of 
trees (Familia Rubiaceae) Best known are the species С officinalis, C. 
succirubra, С calisaya, and С. ledgeriana The alkaloid content of the dried 
bark of these species amounts 6-14 %, of which one third to one half is qui­
nine Except quinine, more than 20 related alkaloids are found in cinchona 
barks, the most important of these being qumidine, cinchonme, and cinchoni-
dine. 
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Cinchona trees grow wild on the eastern slopes of the Andes The trees have 
special growth requirements, and their cultivation in other parts of the world 
has met with many difficulties The early Jesuits ordered a new tree to be 
planted for each one stripped of its bark Later, however, the indiscriminate 
exploitation caused the Cinchona trees to die, and the resulting high price of 
quinine during the middle of the nineteenth century was an impetus for plant­
ing the trees in other parts of the world Both the British and Dutch govern­
ments spent considerable time and money studying the chemical and botanical 
aspects of the problem The Dutch were more fortunate, and as a result the 
chief source (more than 90°,,) of quinine today is from the trees cultivated in 
the former Dutch colony Java The species С ledgeriana is g.own there which 
yields the highest percentage of total alkaloids (10 - 14°„) and of quinine (5 
- 8%) Hybrid species, usually of С ledgeriana and С succirubra, bring forth 
a large proportion of the bark of commerce and yield a high percentage of qui­
nine Cinchona alkaloids presently are still obtained from these natural 
sources, since the laboratory synthesis of their complex chemical structure 
(including 4 chiral carbon centers) has appeared to be too elaborate and 
expensive a proces to provide a practical sourer of those drugs 
It is not кпоьп whether the indigenous South-American population was 
acquainted with the farmaoological properties of cinchona bark The first 
written record of the use of the bark occurs in a religious book written in 
1633 and published in Spain in 1639 The author, an August mían monk named 
Calancha, of Lima, Peru, urote "A tree grows which they call 'the fever tree' 
in the country of Loxa, uhose bark, the color of cinnamon, is made into powder 
amounting to the weight of two silver coins and given as a beverage, cures the 
fevers and the tertians, it has produced miraculous results in Lima " A 
variety of colorful and fanciful versions of the discovery of the fever bark 
exists A popular and persistent version is that the bark was employed in 1638 
to treat Countess Anna del Chinchón, wife of the viceroy to Peru, and that her 
miraculous cure resulted in the introduction of cinchona into Spain in 1639 
for the treatment of ague There is no evidence that the countess ever used 
the bark, yet for many years the drug was called 'los Polvos de la Condesa' 
However, the viceroy did bring a large shipment of cinchona bark to Spain By 
1640, the drug was being employed for fevers in Europe Its use was first men-
tioned in European medical literature in 1643 by a Belgian physician, Herman 
van der Heyden 
The term cinchona was chosen by Linnaeus (who accidentally misspelled it) 
for the genus of plants yielding the drug Although this term is probably 
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derived from the name of the countess whose alleged cure led to its wide use, 
some believe that it comes from a word of Incan origin, 'kinia', which means 
'bark' The Jesuit fathers were the main importers and distributors of cin-
chona bark m Europe, and the name 'Jesuit Bark' soon became attached to the 
drug It was sponsored in Rome chiefly by the eminent philosopher Cardinal de 
Lugo, hence the drug there came to be called 'Cardinal's Bark' The conserva-
tive medical groups viewed the new antipyretic with disdain because its use 
did not conform to the teachings of Galen Others looked upon it with suspi-
cion because the Jesuits used it For these reasons, the drug was dispensed 
for many years predominantly by charlatans and in the form of secret remedies 
The first official recognition of cinchona bark came in 1677, when it was 
included in an edition of the 'London Pharmacopoeia' as 'Cortex Peruanus' 
This early inclusion probably renders quinine the drug with the oldest pharma-
copoeial history For almost 2 centuries the bark was employed for medicine as 
a powder, extract, or infusion In 1820, Pelletier and Caventou isolated qui-
nine and cinchonine from cinchona bark, and the use of the alkaloids as such 
gained favor rapidly 
Lntil the third decade of the present century, the cinchona alkaloids repre-
sented the sole chemotherapeutic agents for the specific treatment of malaria 
In the following years the use of quinine as an antimalarial was brought to a 
low ebb, a host of new synthetic antimalarials was developed starting from the 
chemical structure of quinine as a 'lead', especially when in the course of 
World War II quinine became scarce to the Allies Many of them were more 
potent and less toxic than quinine, which exhibits myriads of more or less 
serious side-effects at the blood and tissue concentrations required for anti-
malarial activity Indeed, quinine affects such a large variety of biological 
systems that it has been called a 'general protoplasmic poison', which 
appraisal, with a few reservations, is highly correct It is toxic to many 
bacteria and other unicellular organisms such as trypanosomes, infusoria, 
yeast, spermatozoa and certain stages of development of the four Plasmodium 
species, which are the causative agents of malaria in man 
In the sixties, quinine, alone or m combination therapies, made its come-
back as an antimalarial because of the prevalence of strains of Plasmodium 
Falciparum that had acquired multiple resistance or insensitivity to many or 
all synthetic antimalarial drugs in certain parts of the world The lack of 
development of such resistance to quinine is ironic in view of the thousands 
of compounds that have been synthesized in an attempt to free the malaria 
patient from dependence on this relatively toxic natural product 
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Other (raro) current applications of quinine are itb employment as a reliev­
er of recumbancy leg muscle cramps (night cramps), and its occurrence as an 
additive of doubtful benefit in pick-me-ups and tonics 
In the sixties, the soft drink industry discovered quinine as a bitter prin­
ciple that could be used for the flavoring of carbonated soft drinks and tabic 
waters like the well-known 'bitter lemon' and 'tonic' which may contain sever-
il dovTiis of milligrams of the drug per liter of beverage In recent years the 
search for bitter agents that may substitute for the toxic alkaloid in soft 
drinks has begun For the time being, its utilization in soft drinks labels 
quinine as a non-prescription, mass-consumed luxury drug Consequently, qui­
nine kinetics in healthy subjects, which significantly differs from those in 
malarious patients with clinical symptoms, should be investigated 
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BRIEF SCOPE OF THE PRESENT DISSERTATION 
Nicotine 
• Investigation of the suitability of nicotine retention in smoked-out 
cigarette filters as a marker of mouth-level nicotine intake by smokers 
• Investigation of tne absolute intake of nicotine and carbon monoxide by 
habitual smokers of filter-tipped cigarettes 
• Comparison of the yield of nicotine and carbon monoxide in human and in 
machine smoking of filter cigarettes 
• Comparison of cigarettes with conventional and with ventilated filters 
with regard to their yield of the above compounds to smokers 
Caffeine 
' Investigation of caffeine pharmacokinetics after intravenous and oral 
administration to healthy volunteers 
• Comparison of rate and extent of gastrointestinal caffeine absorption from 
coffee and from tea 
• Investigation of paraxanthine pharmacokinetics after intravenous and oral 
administration in healthy volunteers 
• Pharmacokinetical comparison of caffeine and its main metabolite paraxan-
thine 
• Determination of the fractional conversion of caffeine into paraxanthine 
Quinine 
" Investigation of quinine pharmacokinetics after intravenous and oral 
administration to healthy Caucasian volunteers 
• Determination of quinine bioavailability in the most frequently adminis-
tered oral formulation the sulphate salt in a gelatine capsule 
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GLOSSARY OF PROFESSIONAL TERMS, ABBREVATIONS, AND SYMBOLS 
A(U)X 
AUC 
AUC 
I V 
AUC. 
AUcJ 
BW 
c 2 4 
CAF 
ch. 
c i g . 
CL 
CL 
CL 
г 
CO 
CO , 
a l v 
?.COHb 
fCOHb 
C O . 
cone. 
c o n v e n t i o n a l 
cot 
c o t i n i n e 
c o t i n i n e - D 2 
C ( t ) 
CV 
D 
D , D. 
or IV 
D ( t ) , D(s ) 
D 
DL,CO 
AX 
Д
г е 1 
symbol of the convolut ion o p e r a t o r ( s e e appendix I I ) 
i n d i c a t i o n of temperature: number of degrees cent igrade 
Area Under the X(t) v s . t ime curve: A(U)X = I X ( t ) dt 
Area Under the C(t) v s . t ime curve; zero s t a t i s t i c a l moment 
AUC a f t e r ora l admin i s t ra t ion 
AUC a f t e r intravenous a d m i n i s t r a t i o n 
AUC u n t i l the f i n a l ( c o n e , t ime) data po int at t = Ζ 
body weight 
average circadian (24 hrs) plasma concentration 
caffeine 
chapter 
cigarette 
total plasma clearance (= V .) 
metabolic plasma clearance (= V ,) r
 me 1 
renal plasma clearance 
carbon monoxide 
CO concentration in expired alveolar air 
percentage of hemoglobin monomers occupied by CO 
fraction of hemoglobin monomers occupied by CO 
cardiac output (= V ) 
(plasma) concentration 
non-ventilated, non-perforated (filter cigarettes) 
cotinine (subscript) 
(-)-cotinine: main nicotine metabolite 
4',4'-didcutero-(-)-cotinine 
drug plasma concentration as a function of time 
coefficient of variation; relative standard deviation 
input or dose; dose of nicotine reaching the oral cavity of the 
smoker 
oral dose, intravenous dose 
input rate or dosage rate function in time and Laplace domain, 
respectively 
constant value of the input function D(t) 
amount of carbon monoxide absorbed into the pulmonary blood 
(magnitude of) change of the value of quantity X 
relative deviation of f and f
n
i 
EL ,. 
cot 
ESTD 
F' 
Fl, F2, 
F3, F4 
fD· V 
M 
F(t) 
F(s) 
f
vol,X 
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GI 
G(L)C 
h, hr 
h 
a 
Hb 
H(t) 
H(s) 
HPLC 
ID 
ISTD 
ι ν 
к 
l 
MAT 
MDT 
extraction ratio, fraction of systemic drug eliminated during a 
single circulatory transit 
elimination rate of cotinme 
external standard 
absolute nicotine retention in cigarette filter (cf D and 
R ), availability as estimated by plain AUC ratio (cf h ) 
nie J ' v a 
systemic availability as estimated by AUC ratio, corrected for 
individual changes In drug disposition rate 
codes of the four conventional filter cigarette brands 
studied in this thesis 
measured molar fractions of cotinine-D2 in a smokers' plasma 
sample and its duplicate, respectively 
systemic availability of nicotine inhaled with tobacco smoke 
fraction of a parent drug that is converted into a particular 
metabolite 
rest-of-body transport function, closed-loop feedback transport 
function (cf H(t) and ψ(Ο) 
rest-of-body transfer function, closed-loop feedback transfer 
function (cf H(s) and ψ(8)) 
fractional volume of gas X 
gram, gravitational acceleration at sea level 
gastrointestinal 
gas (liquid) Chromatograph(ic) 
hour 
systemic availability as estimated by numerical deconvolution 
(cf F) 
hemoglobin 
heart-lungs transport function, closed-loop forward transport 
function (cf F(t) and Ψ(ΐ)) 
heart-lungs transfer function, closed-loop forward transfer 
function (cf F(s) and i/i(s)) 
high-performance liquid Chromatograph(ic) 
internal diameter 
internal standard 
intravenous 
power of time in a pharmacokinetical gamma function 
liter 
mean absorption time (= TH ) 
mean dosage time (= TD) 
MedAT 
MET 
min 
MIT 
ModAT 
MRT 
MS-SIM 
мтт 
m e 
NDIR 
NSD 
N 
re 
P. PP 
Ρ 
Ρ о 
ppm 
PX 
Ψ(ί) 
ФЫ 
Q 
Q (t) 
SD 
SIM 
SOC 
SPE 
t 
topography 
t, 
Ί 
median absorption time 
mean (urinary) excretion time 
minute 
(in general) mean input time (MIT = MDT + MAT in case of oral 
dosage, IIT = i · infusion time in case of ι ν infusion, MIT = 
0 in case of pulse ι ν injectionj 
modal absorption time 
Mean (bodj) Residence Time 
mass spectrometry - selective ion monitoring 
mean (body) transit time 
nicotine (subscript) 
non-dispersive infra red 
nitrogen-sensitive detector or - detection 
average number of body circulations 
page, pages 
type I error probability (of rejecting the null hypothesis 
while it is true) 
per os, peroral 
parts per million 1 ppm = a partial volume of 10 
paraxanthine (main caffeine metabolite) 
total body transport function, probability density distribution 
of body residence times 
total body transfer function, the Laplace transform of φ(ί) 
quininp 
amount of quinine renally excreted at time = t 
coefficient of correlation 
analytical recovery of a drug 
relative retention of nicotine in the cigarette filter R = 
0
 nie 
F/(F + D) 
registered trade mark 
second, or transform variable of time m the Laplace domain 
standard deviation 
selective ion monitoring 
steroid oral contraceptives 
solid phase extraction 
time 
of smoking in this thesis synonymous with smoking technique 
half-life of plasma elimination of a drug 
TAUC area under the time'concentration vs. time curve: 1 statisti­
cal moment 
T'AUC area under the squared-time'concentration vs. time curve: 2 
statistical moment 
ТВ theobromine (minor caffeine metabolite, also occurring in 
chocolat, tea and coffee) 
TP theophylline (minor caffeine metabolite, also occurring in 
minute amounts in tea) 
TX mean transit time of the function X(t): TX = 1 t»X(t)dt / AX 
τ exponential time constant occurring in the equation C(t) = 
A . e " ^ 
θ times of urine voiding 
u time of last oral data point included in numerical deconvolu-
tion calculations of h , MAT, MedAT, and ModAT 
a 
UFR. urine flow rate (in the first χ hours following administration) 
UV ultra violet 
V volume 
V volume differentiated with respect to time: flow 
VI, V2 codes of the two ventilated filter cigarette brands studied in 
this thesis 
V B total blood volume (= 0.08 t/kg body weight in man) 
V. total blood flow; cardiac output (= CO.) 
V. apparent volume of distribution 
V . total plasma clearance (= CL) 
V metabolic plasma clearance (= CL ) 
mei r m 
V, hepatic blood flow 
VR ventilation rate (% of vent air in the mainstream of the smoke) 
VR , VR . nominal (maximum) and minimal ventilation rate of a ventilated 
nom min 
filter cigarette, respectively 
VRT Variance of (body) Residence Times 
vs. versus 
VX variance of transit times of the function X(t): 
VX = U t2«X(t) dt) / ΑΧ - (TX/ΑΧ)2 
WSS summation of weighted squared deviations of concentrations 
SECTION I 
PHARMACOKINETICS: A SYSTEMS DYNAMICS APPROACH 
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Chapter 1 
PHARMACOKINETICS, A SYSTEMS DYNAMICS APPROACH. 
1.1 INTRODUCTION 
The human body may be considered as a dynamical system. It is not only 
reacting to inputs froa the outside world, but it is also a self-organizing 
system, to some extent controlling its input and even controlling its environ­
ment. 
Obviously, a large number of linear and nonlinear feedback control sys­
tems regulating posture, movements, blood pressure, etc. is Involved. To 
understand such a complicated system, it is logical to apply knovledge gained 
in systems dynamics and control theory. Recent developments in the applied 
mathematics of dynamical systems may greatly facilitate the study of the 
2 3 behavior of the body and its responses to the input of drugs. ' 
1.2 DYNAMICAL SYSTEMS THEORY OF BODY FUNCTIONING 
In systems dynamics, the body can be characterized by a large number of 
4 
state variables: the state vector X. Depending on the type of study one does, 
one may consider various state variables since it is impossible to consider 
all state variables at the same time. State variables may be the blood pres­
sure in the aorta, the core temperature, the autonomic drive to the intestine, 
the tension in the sensors of a muscle, the degree of muscle contraction, the 
hypothalamic drive on the growth hormone of the hypophysis, etc. See figure 1. 
The future state of the system depends on the present state, the memory 
of the system, the input and the time. The change in the state variables is 
therefore a function of the state X, the time T, the memory M, and the input 
I: 
І = 7(X,T,H,T) 
Input State variables : Χ 
Blood pressure Χ ι 
Core t e m p Χ 2 
Insuline cone X3 
Outpu 
FIGURE 1 Schematic presentation of the body as a dynamical system Many thou­
sands of state variables together may fully characterize the entire body 
behavior Such a aultidimensional dynamical system would be impossible to 
study were it not that attractors arc involved by which the actual behavior is 
of a much lower dimension 
This relationship may be highly nonlinpar so that the differential equation 
cannot be solved by classic methods, but new ways of analysis have been devel-
j 2,3,5 
oped 
Although the system is of an extremely high dimension, it behaves as a 
relatively loi* dimensional control system This implies that attractors are 
involved In the course of time, the systems settle down to point attractors, 
3 
periodic attractors Cosci11ation), or so-called strange attractors 
1 3 THE BEHAVIOR OF PHYSIOLOGICAL SYSTEMS IS DOMINATED BY 
ATTRACTORS 
The multidimensional state space of a living system is dominated by 
asymptotic behavior of much lower dimension Attractors may be considered as 
low dimensional subsets of the state space to which its behavior quickly set­
tles down 
In this way, the dynamical system can be visualized by its phase por­
trait, that is, the state space of the systems can be divided in basins, which 
are the areas of influence of its attractors separated by lines of bifurcation 
3,5 
or séparatrices 
2 
The best known attractor is the point attractor. It is the steady state 
3 
of a system. Garfinkel recently pointed out that thinking in physiology has 
been dominated by point attractors; so students in medical schools are still 
taught the importance of homeostasis, whereas reality is much more complicat­
ed. 
Periodic attractors are the basis of oscillation, which is abundant in 
biology (ECG, EEG, etc.). The cyclic behavior of dynamical systems on basis of 
periodic attractors is reasonably well understood. 
The interest now is on aperiodic, chaotic, or strange attractors. A nice 
clarification has been given by Hofstadter. Details can be found in an arti­
cle by Abraham and Shaw and by Ott. 
1.4 DYNAMICAL SYSTEMS THEORY IN PHARMACOKINETICS 
In pharmacokinetics one may often disregard a large number of the state 
variables of the system, since they are irrelevant for the understanding of 
the disposition of drugs in the body. The relevant state variables in pharma­
cokinetics are the concentration of drugs in the aorta, the central venous 
pool, the liver sinusoids, etc. The differential equation may even be a linear 
8 
one: 
X(t) = A«X(t) + B«I(t) 
where X(t) is the state vector, I(t) the input vector, and A and В matrices. 
If there is linearity, the differential equation can be solved: 
X(t) = •(t)«X(0) + «(t) * B'I(t) 
The further state behavior is completely determined by the state transition 
matrix $(t), the initial state and the input. Also the output of the system is 
uniquely described. The attractor of the system is a point attractor so that a 
constant input always leads to a steady state situation. 
For a better understanding of the systems dynamics approach in pharma­
cokinetics and the implications of various input functions, we will first con­
sider the subsystems of the body, which are the individual organs and tissues. 
3 
1 5 SYSTEMS DYNAMICS OF SUBSYSTEMS 
In contrast to the total body system, the subsystems are relatively 
homogenous, therefore, only a few state variables fully characterize those 
systems 
1 5 1 A Drug Transport in Tissues and Organs 
When a drug is injected into the blood supply of a tissue or organ, 
the Individual drug molecules may pass che tissue via quite different routes 
The transit time, that is, the time from entry to exit for the individual 
molecules depends on the length of the pathway and whether or not the 
molecules enter cells surrounding the blood vessels and remain there for some 
time Some molecules may leave the tissue already after a few seconds whereas 
others may have a much longer transit time 
Figure 2 is an illustration of a two-dimensional network of a part of 
9 
the wing of a bat It may be seen from this two-dimensional network that even 
drug molecules that do not leave the lumen of the blood vessels may have quite 
different transit times as some molecules may even temporarily proceed in the 
wrong direction. Obviously, a much larger variation may occur in all mammalian 
organs and tissues as the capillary network is mostly three-dimensional and 
the bloodflow is not the same all the time. 
1 5 2 В The Density Function of Transit Times 
With regard to drug transport, a tissue or organ may be characterized 
by a density function of transit times This will be a continuous distribution 
function, since even the slightest amount of drug (say 1 )ig) consists of a 
huge number of molecules (more than 10") For each subsystem, therefore, a 
density function of transit times is the characteristic transport function 
which dictates what occurs on the venous site when drug is offered to the 
arterial site See figure 4 
Figure 3 is an illustration of the output concentration of bromfluo-
rescein when given by a pulse injection to a lung lobus of a dog The input 
pulse is dispersed by the subsystem analogous to the dispersion in a liquid 
Chromatograph In general, there is a delay or lag-time, a steep rise, a peak, 
and a decline See figures 3 and ¡t 
4 
Te tenute 
FIGURE 2. Two dimensionai capil-
lary network of part of the wing 
of a bat.* ño]ecuJ es entering 
at the arterial site may pass the 
network via different pathways 
In addition, they may leave the 
capillary and remain m the cells 
surrounding the capillaries. Con-
sequently the transit time of the 
molecules will be distributed ac-
cording to a certain density func-
tion. A realistic density function 
for this system is shown in figure 
4. (From Nicoli, P.A. and Webb, 
R.L., Annals S.Y. Acad. Sci. 46 
(1946) 697. Uith permission). 
Obviously, when a drug is given as a very small pulse, all drug 
molecules enter the system at the same time and the output curve is directly 
proportional to the density function of transit times The transport function 
of a subsystem may therefore be regarded as the unit impulse response of that 
subsystem 
As an abstraction of its shape, the density function of transit times 
of a subsystem can be characterized by the modal transit time (ModTT; the time 
of peak occurence), the median transit time (ModTT, the time at which half of 
the molecules have passed), and the mean transit time (MTT, the sum of all 
individual transit times divided by the number of molecules leaving the sub-
system) See figure 4 In addition, the volume of the subsystem (V), the 
bloodflow though it (V), and, in case of elimination, the extraction ratio (E) 
are of importance 
5 
Relative dye concentration 
arter iole 
time of injection sec 
FIGURE 3 Arterial concentration input function and the venous concentration 
output function of a fluorescent dye m a part of the lung The mean transit 
time is ± 3 sec (Reproduced from Uagner, Ы W. et al , Science 218 (1982) 379 
With permission). 
FIGURE 4 Density function of transit times F(t) and its integral, the proba­
bility function P(t) In this case the modal transit time is 7 sec, the median 
transit time is 10 sec, and the mean transit time is 12 sec Some molecules 
may have very large transit times, which have a considerable influence on the 
mean transit time 
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In a subsystem, the central volume principle requires that the volume 
equals the the product of the flow and the mean transit time This principle 
is generally applied in circulation research 
1 5 3 С Flow Vessel Analog of a Tissue 
A flow vessel is a reasonably good analog of a tissue or organ See 
figure 5 (left) If the contents of the vessel are thoroughly mixed, the drug 
concentration is the same in all parts of the vessel As a result, the 
decrease m the concentration following a pulse input at the entrance is pro­
portional to the concentration in the vessel This implies that the transfer 
function is exponential See figure 5 (right) 
F(t) = (1/τ) e " ( t " T W T and F(s) = e" T s / (st + 1) 
where τ is the time constant and Τ is the delay The mean transit time of the 
flow vessel equals the time constant It is interesting to note that the 
median transit time equals the half-life, while the modal transit time equals 
the delay. 
In the actual m vivo situation, the rise will be less steep and the 
decline not exactly exponential The flow vessel is, however, a good model of 
a tissue or organ 
1 6 C O N T R O L SYSTEMS DYNAMICS OF A SUBSYSTEM 
A subsystem is fully described by its transport function F(t), which is 
in fact a density function of transit times Control systems theory can be 
used to understand the input-output relations See figures 2, 5 and Table I 
According to conventions in systems dynamcis, the input and the output can be 
considered in the time domain as well in the Laplace s-domain The transport 
function F(t) in the time domain corresponds to the transfer function F(s) in 
the Laplace s-domain See Table I 
The relationship between the input function D(t), which is a dosage flow 
of drug (e g , in yg/min), and the output function C(t), which is the concen-
7 
Frequency(1/mln)-
050
Ί 
FIGURE 5. (Top left) Block diagram of a subsystem with simple input and simple 
output. (Bottom left) A good example is a flow vessel. The volume and the 
flow, provided that mixing is efficient, fully determine the subsystem behav­
ior. (Right) Density function of transit times of an ideal flow vessel. This 
function is monoexponent ia1, so its median transit time equals the half-life 
time while the mean transit time is 1/ln 2 - 1.44 times the half-life. In this 
example the ПТТ = TF = 2 s. 
tration in the venous blood leaving the subsystem (e.g., in yg/rat), is gov­
erned by the transport function F(t) and the bloodflow (V): 
C(t) = (l/V) D(t) * F(t) and F( S) = (1/V) D(s) · F(s) 
8 12 
where * is the symbol of the convolution integral. See Table I. * 
If elimination occurs in the subsystem, e.g. as in the liver and the 
kidneys, the extraction ratio is also involved. See Table I. In general, the 
output is the convolution of input function and the transport function in the 
time domain, and merely the product of input function and transfer function in 
the Laplace domain. 
The transport function (that is, the density function of transit times) 
may resemble a log normal distribution, a gamma function, a Poisson distribu­
tion, or a sum of exponentials. The analysis is obviously best if one needs 
not to take into account what kind of function is involved. This implies that 
integral analysis, using the entire curve, is of advantage. 
8 
Table t 
SYSTEMS DYNAMICS fN A SUBSYSTEM^ 
The systems equation 
Laplace domain У¡thout extraction With extraction 
C(.) - Ш F(i) Cd) - Ш- • (1-Е) · F(s) 
\ \ 
C( t) . £ M · (1-Е) F(t) - - U ^ - ƒ ' D(t-A) · FU) · dt 
\ VB 0 
where *" is the operator symbol of the convolution integral 
Analysis 
*— AC = ^  · AF AC - H • (1-Е) · AF 
Time domain 
V
B 
AUC - d ? 5 e AUC 
VB 
Mean times 
TC * TO + TF 
Variance 
VC - VO + VF 
Volume of distribution 
v - v B 
VB 
dose 
VB 
• MTT 
• (1-Е) 
where 
Note: D(t) is the dosage input function ( e g . In mg/h), F(t) is the 
subsystem transport function which is the density function of transit 
times, V is the blood f Ion, E the extraction ratio For the explanation 
of the other symbols, see Table II The symbol "A" in AC, AD, and AF 
stands for Area under the C(t), D(t) and F(t) curve In analogy, the 
"T" and the "V" stand for the mean Time and its Variance, respectively, 
of the functions C(t), D(t) and F(t) 
а 
input dobige flou into the subsystem Output dosage flou out of the 
subiystem Unit of both input and output e g , mg/h The output equals the 
blood flow through the subsystem it/h) times the concentration m the blood 
leaving the Subsystem (mg/l) 
1 6 1 A Analysts of Input-Output Relations 
In systems a n a l y s i s , we use the s t a t i s t i c a l moments as a u s e f u l type 
13 14 
o f i n t e g r a l a n a l y s i s , d i s r e g a r d i n g the shape of the funct ions involved ' 
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Table II 
ANALYSIS OF TRANSPORT AND TRANSFER FUNCTIONS BY STATISTICAL 
MOMENTS 
Function, 
in the time domain F(t), in the Laplace domain Fis) 
Definition of the к general moment: 
nv - Г t k · F(t) · dt 
к о 
For a density function of transit times: 
m - 1 (the area) m, • TF • MTT (mean transit time) 
о 1 
or the expected value E(F(t)) 
Definition of the к central moment: 
U. = Г (,X-m.)k C(t) -dt 
к g ' 
For a density function of transit times: 
U - 1 μ - 0 μ, · VF - the variance 
Symbols used in the text : 
Areas 
AF - Lim F(s) - ƒ F(t) · dt 
Неап С ime 
Variance 
T F . . L i m
 d
 -
 l n F ( 5
> . Г t · F(t) · dt/AF 
s»0 ds 0 
V F . L i m Ч
2
 •
 l n , :
'
s
> . ƒ-
 t
2
 .
 F(t) . dt/AF - TF2 
»*0 ds2 0 
See Table I. We then obtain directly the area under the curve of the func-
tions, the mean times, and their variance. There is a simple relationship 
between the moments and the so-called final value theorema of the Laplace 
13 15 transforms. ' See Tables I and II. 
Whatever the input function D(t) may be, its area equals the total 
dose administered. The mean time of the input function is the mean time for 
the dose to enter the subsystem. Obviously, the mean input time is zero if the 
dose is given as a short lasting pulse. 
10 
ι: iH(0:1/s 
1.6η 
1.4-
1.2-
1.0-
0.8-
0.6-
0.4-
0.2-
\ 
Veto 
V x 
1 1 1 1 1 1 I1 
FIGURE 6. The influence of various types of input functions on the output of a 
subsystem. (Top) The input is a pulse or Dirac Delta function. This implies 
that all the molecules enter at the same time so that the output is directly 
proportional to the transport function so convolution reduces to multiplica­
tion. (Middle) The input is a step function or constant infusion. The output 
is the Integral of the input function, so the convolution integral reduces to 
a simple integration. (Bottom) Any input function. As a result the output is 
the convolution integral of the transport function and the input function. 
The area under the transport function F(t) is obviously equal to unity 
as is the case in a density function, because the integral is the probability 
function. The mean time of the transport function is the mean transit time of 
the subsystem. 
The variance of the functions D(t) and F(t) is the variance of the 
mean input time and the mean transit time, respectively. 
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Table III 
SPECIAL INPUT FUNCTIONS INTO A SUBSYSTEM 
General equation 
C(s) > ^ - (1-Е) · F(s) »nd C(t) - ^ І І · (1-Е) F(t) 
в в 
1) Pulse input (D(t) = D'b(t)) 
C(s) = — · (1-Е) · F(s) C(t) = -Я • (1-Е) F(t) 
VB VB 
2) Step function input (D(l) = D) 
C(s) = - · ^ ^ - F(s) C(t) = - Л (1-Е) ƒ' F(X) dA 
5 VB VB 0 
Steady state situât ion (f*~) 
C(») . -1. . (1-Е) 
VB 
Note: i(t) = tne Dirac delta unit impulse function, D = the constant step 
function input rate, €(-) = the concentration at steady state 
1 6 2 В Special Input Functions to a Subsystem 
The Dirac б-pulse A pulse injection is a special input, since in 
that case all the molecules enter the subsystem at the same moment The output 
then is directly proportional to the transport function This implies that the 
convolution operator then reduces to a proportionality See figure 6 and Table 
III The proportionality factor is the area under the output (concentration) 
curve So, the transport function F(t) can be calculated simply by dividing 
the output conrrntration by its area under thr curve following a pulse injec­
tion 
The step function input A constant infusion or step function is also 
a special input It may be regarded as a sequence of of pulse injections of 
equal size applied at regular time intervals The convolution operator then 
reduces to a normal integration See figure 6 and Table III If the constant 
infusion is continued over a sufficient long period of time, that is, long 
with respect to the mean transit time, the output concentration is also con­
stant and equal to the quotient of the constant dosage flow (that is, the 
input rate) and the bloodflofc See Table III Obviously, if extraction occurs, 
the output would be lowered by a factor equal to (1-Е) since only that frac­
tion passes the subsystem intact Since the central volume principle holds, 
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the amount of drug in the tissue during steady state is also constant and is 
equal to the product of the dosage flow and the mean transit time See Table 
III 
Any input system The input system in general can be dissected in a 
number of injections of different size given in succession The output of each 
injection is proportional to the dose and has the shape of the transport func­
tion The overall result is the superposition of all these curves, which in 
fact is the convolution integral 
1 6 3 С The Output in the Steady State 
Depending on the dynamics of the transport function, the steady state 
will be reached rapidly or more slowly The dynamics of small, highly vascu­
larized tissues are fast as reflected by a small MTT of seconds or so that the 
output of such a tissue practically follows the input and steady state is 
reached very rapidly The dynamics of poorly vascularized tissues are much 
slower, in the order of several minutes, and their output will not readily 
follow input variations 
The dynamics of individual tissues may vary greatly, but their dynam­
ics are, in general, much faster than the kinetics of drugs in the entire sys­
tem The mean transit time of drugs in tissues and organs is from several sec­
onds to several minutes, whereas the mean residence time of drugs in the body 
is in the order of a few hours to many hours Obviously, for the total system 
it is of great importance how the various subsystems as the organs and tissues 
ι 49 
are arranged See handbooks of anatomy, e g , Gray s 
1 7 THE A R R A N G E M E N T OF SUBSYSTEMS 
In principle, the subsystems may be arranged in series or in parallel 
The output of such an arrangement may be fed back as input to the system 
(closed-loop system), or it may not be fed back (open-loop system) For rea­
sons of simplicity, we will restrict ourselves here to two subsystems with 
transport functions F (t) and F (t) For more complicated arrangements, see 
handbooks such as Di Stefano et dl 1 2 
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FIGURE 7 Arrangement of subsystems m the time (t) domain (Top) Two subsys­
tems m series In the Laplace or s domain, the overall transfer function is 
the product of the two transfer functions (Middle) Two subsystems m paral­
lel In the Laplace domain the overall transfer function is the weighted sum 
of the two tranfer functions The weighing factor is the blood flow through 
each of the subsystems (Bottom) A subsystem with positive feedback arrange­
ment The output is fed back to the input site The overall transfer function 
is typical for a positive feedback control system 
1 7 1 A Subsystems in Series 
If two subsystems are connected in series, the output of the first is 
input to the second See figure 7 (Top) Consequently, the overall transport 
function is the convolution of the Luo transfer functions of the subsystems 
Fit) = FjCt) * F2(t) 
The flow to the two subsystems is equal, so that the overall system equation 
can easily be Britton down See ГаЫо I\ If a pulse injection is given to the 
first system, there is dispersion in the first, while the second system causes 
14 
a further dispersion. See figure 8. Obviously, the mean transit time of the 
total system equals the sum of the mean transit times of the two subsystems, 
and the delays in the subsystems add to a total delay. 
Frequency ( 1/ mm) -
10 
Frequency(1/min)log scale -
1 Oi 0 10 
0.08 
0 0 6 
0.04 
0 0 2 
0 
\ 
\ 
\ , \ ¿ 
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F ( l ) . 
^ 3 
ϊ><1 
-ç (t-T)M 
^ r f e 
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6 β 
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0 1 0 
0 0 6 
аоб 
0 01 
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2.F[i)»F(l>e1c 
\ _ attrae tor 
мхптаіюп 
FIGURE 8. (Top left) Individual monoexponential transfer functions F (t) and 
FJt) with time constants of 1 and 4 min, resp. (Top middle) The same fune 
tions on a log scale. (Bottom left) The result of the arrangement of F.(t) and 
FJt) in series (cf. figure 7, upper panel) and in parallel (f = 0.8, f = 
0.2; cf. figure 7, middle panel). Note the great difference in the two curves. 
(Bottom middle) The same functions on a log scale showing that the two time 
constants of 1 and 4 mm still dominate the overall curves. 
(Top right) The forward path and the first five recirculations of the feedback 
arrangement (cf. figure 7, lower panel; τ here equals 10 s and Τ is 4 s). The 
curves grow flatter and the delays are added. (Bottom right) The overall out­
put is the superposition of all the individual curves. Note that after initial 
slight oscillations the curve attracts to a fixed point simply because recir­
culation mixing occurs very rapidly. 
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Table IV 
ARRANGEMENT OF SUBSYSTEMS 
Cenerai ьу sLemb iqujt юпь 
c ( s ) = Dili . F ( s ) c ( t ) = D U I F ( t ) 
V v 
/ƒ Two subsytcmv ¡n scrips 
F(s) = Fjls) • F2(s) F(t) - F j d ) F2(t) 
Лпаіуыь 
Лгеяь 
A C = AD . A A _ dose 
V 1 2 V 
fienn 11 mes 
TC = TD + TF1 + TF 2 MTT = TF1 + TF 2 
Z] Two bubsystems in parallel 
F(s) = ί,Ρ,ίβ) + f 2F 2(5) F(t) = fyfyM + f 2
F 2 ( t ) 
Analysis 
Areas 
(f,
 +
 F2) - 1 
AC - ^  (f.AF.
 +
 f/F.) = d - ^ 
y 1 1 2 ¿ \j 
Mean times 
fl T Fl A F1 + f2 T F2 A F2 
TC = TO + • ^-^ = TD + f.TF, + f.TF. 
r AF, + f2AF2 ' ' 2 2 
Note A\ nnd T\ dtnotc Lhr nrea nnd the moan time of the function X(t), 
'cpect η p]y \it> = CI.L), 0(4). F ft) or F it) 
1 7 2 В Subsystems in Parallel 
The input is divided over the two subsystems simultaneously dependent 
on their relative flows The total transfer function is the weighted sum of 
the transfer functions of the subsystems 
F(t) = fjFjCt) + f 2F 2(t) 
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Table IV [continued) 
ARRANGEMENT OF SUBSYSTEMS 
3] A subsystem m positive feedback arrangement 
Laplace domain Time domain 
First pass 
C I O = 0M · F(s) C.U) = * Ш - F ( t ) 
Second pass. 
C,(s) - Щ і . F(s) · F(s) C-(t) - Ц^- F(t) ·= F., , ( t ) .. 
r« B B 
f7 pass ' 
С (s) . °¿± i - F(s)n С ( t ) - Ш- F i t ) · F U ) * . . . . 
в
 n
 в 
Summation of all passes: 
CU) = Ц^- · — Щ - dt) » c.U) + c,(t) + 
VB 1 - Fis) '
 2 
Attractor following a single dose D: 
CU") - — · 
\ M T T 
Note: 1) In case no elimination occurs, a steady-state level is reached 
following a single dose, so the attractor is a point attractor. 2) The 
equation after one pass equals the open-loop or general systems 
equation. 
where f. and f are the fractions of the flow for the two subsystems. The 
overall systems equation is given in Table III. The mean transit time Is also 
the weighted sum of the transit times of the two subsystems. 
An example is given in figure 8. For instance, if both F^Ct) and F.(t) 
are mono-exponential transfer functions, the overall transfer function is 
biexponential. 
1.7.3 C. Subsystems in Feedback Arrangement 
If the output of a subsystem is fed back to the system again, the next 
output is again the result of a convolution operation. Repetitive passages 
through the subsystem causes progressive dispersion. See figure 9. In this 
figure, a pulse is given to the system showing an exponential dispersion dur­
ing the first pass. It is like feeding back the output of a liquid chromato-
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graph to the input The progressive dispersion results in a constant concen-
tration after many recirculations See bottom of figure 9 This is the attrac-
tor of the recirculation system following a single input See Table IV (con-
tinued) 
It is obvious that if, during a single pass, some degree of extraction 
occurs, thi point attractor uill be zero as finally the drug has left the sys-
tPID 
1 8 SYSTEMS DYNAMICS OF THE TOTAL B O D Y 
The behavior of the total body system depends on the behavior of the 
subsystems and anatomical organization of the subsystems See figure 9 
1 8 1 A Anatomical Organization of the Subsystems 
The various organs and tissues of the body that receive arterial input 
are in essence arranged in parallel The liver is an exception, since it is in 
series with the small intestines See figure 10 According to control systems 
8 12 
theory, ' the overall transfer function of a system consisting of subsystems 
arranged in parallel is an addition of the individual subsystem transfer func-
8 12 
tions The transfer function of subsystems in series are to be multiplied ' 
We have grouped together all tissues and organs that receive arterial 
input, uhile the gut and the liver in series is considered as one subsystem 
See figure 11 The heart-lung system is considered as a separate subsystem 
that is arranged in series with the rest of the body See figure 11 If one 
injects a drug into the vena cava, molecules first pass the heart-lung system 
So, if one observes the concentration in the aorta, one sees the dispersion or 
distortion brought about in the heart-lung system The drug molecules then 
pass on to the rest of the body, again being dispersed Still observing in the 
aorta, one sees after some time again the dispersed concentration or distor-
tion after the second pass through the heart-lungs In essence, one sees the 
result of several recirculations The concentration, however, finally dies out 
as during each pass through the body a certain fraction of drug is eliminated 
This fraction is called the extraction ratio In general, extraction occurs 
not in the heart-lung system, but in the rest of the body in which the liver 
18 
brain 
muscle 
skin 
FIGURE 9. Semischematic anatomical arrangement of organs and tissues with 
their blood supply. The system is 'viewed' by measuring the concentration of a 
drug in the blood of the aorta or some peripheral venous observation sites. 
and the kidneys are included. The observed concentration of drug in the aorta, 
when a drug input function is given to the vena cava, is therefore the sum of 
a series of convolutions because of the recirculations. The sum of the prod-
ucts reduces to a simple equation showing a positive feedback system. In fact, 
conventions of control systems theory immediately let one write down the total 
systems equations of the systems of figure 12. See Table V. 
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FIGURE 10. Diagram of the 
sues and organs. Most tissues receive arterial blood and are therefore 
arranged m parallel. The blood leaving these tissues is pooled in the vena 
cava from which it flous to the heart and the lungs. The lungs are therefore 
in series with the tissues of the rest of the body. An overall system equation 
can easily be derived, (from Van Rossum, J.M. et al., Pharmacol. Ther. 21 
(1983) 77. With permission). 
FIGURE 11. Reduced block diagram of the body. All the tissues that are 
arranged m parallel have been grouped together. In essence this results in a 
simple positive feedback arrangement with the lungs (transport function H(t)) 
in the forward path and the organs and tissues of the rest of the body (group 
transport function F(t)) in the feedback path. 
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Table V 
THE posmve FEEDBACK BODY TRANSFER FUNCTION * 
Syst ees equation 
Laplace domain 
1 1
 VB 1 - (1-Е) · F(s)H(s) V e | 
Mhere; 
E · H(s) 
ψ(ί) 
1 - (1-£) · F(s) H(s) 
Tine dora in 
C(t) - ^ - *K-(t) 
V
el 
Analysis 
Areas 
АО AH dose _ dose 
AC 
#елп tines 
VB t - (1-Е) • AF · AH VB · E V e | 
TC - TO • TK> - TD • HAT 
where : 
MRT - ΤΗ • ΗΤΤ • ^ - ^ - — - TF 
E E 
and: 
ΗΤΤ - TF • ΤΗ 
Note: +(s) · tbc normalized overall positive feedback transfer function. t(t) 
s
 the total body transport function, i.e., density function of residence 
times. Í1TT s the body mean transit time, i.e., the mean time for a 
single pass. ПЯТ * cAc body mean residence time. V. - the cardiac 
output. E « the extraction ratio. V . « the clearance. 
m 
Input: dosage flou directly into the nixed venous pool. Output: drug flou 
through the aorta » cone, in the aorta times V . 
It may be emphasized here that the study of pharmacokinetics essen­
tially deals with the result of the recirculations. Circulation research 
mainly aims at the study of the density functions of transit times of individ­
ual organs and tissues or the total system. The circulation times of the tis­
sues and organs is of the order of seconds to minutes, whereas the time con-
21 
stants of the residence of drugs in the body are in the order of hours to 
days In accordance, data sampling in pharmacokinetics is not frequent, in 
contrast to data sampling in circulation research 
Table VI 
THE TOTAL BODY POSITIVE FEEDBACK CONTROL SYSTEM OF DRUG 
DISPOSITION 
His) The forward path transfer function 
F(s) The feedback path transfer function 
F(s)'H(s) The open-Joop or single pass transfer function 
FCtl'IKt) The transport function governing я single transit through 
the body It therefore is a density function of body 
transit times 
" Symbol for the convolution integral 
lf(s) The closed-loop transfer function governing the 
l-(l-E),F(s)*H(s) repetitive transit through the body 
1JE The steady-ïtate error of the closed-loop feedback system 
ty(s) The normalized closed-loop transfer function (normalized 
by multiplication with E) 
$(t) The transport function governing repetitive transport 
through the body It therefore is a density function of 
body residence times 
E The extraction ratio, ι e , the fraction of drug 
elimmatcd during a single pass 
V- The cardiac output 
1 8 2 В The Feedback Control System 
The output of the aorta is fed to the rest of the body with transfer 
function F(t), while its output is again is again fed back to the mixed venous 
pool The result is a positive feedback with a forward transfer function H(t) 
and a feedback transfer function F(t) The two in succession give the open-
loop transfer function governing a single pass through the entire body See 
Table VI In essence, this is a density function of body transit times 
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The closed-loop transfer function is the combination of F(t) and H(t) 
according to a positive feedback control system. See Table VI. From this 
equation, ue derive the overall body transfer function by normalizing so that 
it, in fact, becomes a density function of residence times. The steady-state 
error of this positive feedback control system equals 1/E, so that the error 
is larger when the extraction is smaller. Needless to say, if the error is 
zero, the positive feedback system blows itself up. 
1.8.3 C. The Total Body Transport Function Y U ) 
The total body transfer function is essentially a normalized positive 
feedback transfer function. Ve prefer not to include the cardiac output in the 
overall transfer function. As remarked, it is a normalized function obtained 
by multiplying the closed-loop transfer function with the extraction ratio E 
and at the same time multiplying the cardiac output in the numerator with E. 
The reason for this is that the so-called steady-state error constant of the 
feedback equation is 1/E. For definition of error constants in feedback sys-
tems, see d'Azzo and Houpis. Using the definition of the clearance (V , = 
VR»E), the overall positive feedback transfer function of Table VI can be 
rewritten and transformed back to the time domain. See Tables V and VI. 
The overall body transport function has the dimensions of a statisti-
cal density function and can be defined as a frequency distribution of resi-
dence times. The concentration in the aorta is the convolution of input func-
tion and this body transport function *(t). See Table V. 
The body transport function can be calculated by deconvolution of the 
concentration (output) curve with the input function if the latter is known. 
As mentioned before, in case of pulse injection directly into the vena cava, 
all molecules enter the system at once. Consequently the output concentration 
is directly proportional to the transport function. The proportionality factor 
is (dose)/V , , which equals the area under the concentration curve. So, from 
el 
plasma concentration curves following a rapid bolus injection, the body trans-
port function can be obtained by dividing the concentration data by the AUG. 
An example will be given in figure 14. 
Often plasma concentration profiles following i.V. administration can 
be fitted to a sum of (1, 2, or 3) exponentials, so that then also the trans-
port function can be described by a sum of exponentials. It should be realized 
that the largest errors are made during the first minutes after injection 
because the first pass through the heart-lungs is very fast, while there is 
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FIGURE 13. Output concentration curves of drugs with the saste feedforward and 
feedback transfer functions as those of figure 12, but with varying extraction 
ratios E. The concentration during the first few minutes has been left out. 
The slope of decay of the various curves strongly depends on the extraction 
ratio. 
FIGURE 12. (Top) Theoretical transport functions of the heart-lungs (feedfor­
ward, H(t)) and of the rest-of-the-body (feedback, F(t)), as well as the open 
loop feedback transport function (after one whole circulation, (1-Е) 
F(t)*n(t)). 
(Hiddle) The forward path B(t) and the first ten recirculations »hieb 
show an increasing degree of dispersion and progressive extraction. Finally 
the curves reduce to zero (in contrast to the corresponding curves for a feed­
back system without extraction, where the curves attract to a fixed value > 0, 
see figure 8, top right). 
(Bottom) The observed concentration curve (output) is the superposi­
tion of the forward path and all the recirculations (cf. figure 8, bottom 
right). It is a highly damped oscillation. Irrespective of the type of S(t) 
and F(t) functions, the result is largely a biexponential decay curve except 
for the first few minutes or so. 
The frequency scales (abscissas) are proportional to concentration 
(output) scales by a factor WC, the Area Under each Curve (see § 1.8.6.-1). 
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still a delay of some seconds The plasma concentration curve should start at 
zero concentration in any case Extrapolation to zero time therefore has lit­
tle meaning The so-called zero time concentration will strongly depend on the 
number of data points shortly after injection In fact, it is the concentra­
tion at the modal transit time of the pulmonary system Consequently, the cal­
culation of the so-called central volume of distribution, as usually done in 
compartmental kinetics, is of little meaning 
1 8 4 D Dependence of the Body Transport Function on Forward and 
Feedback Transfer Functions 
If one 'observes1 the output by looking at the concentration in the 
aorta, the first pass is due to dispersion in the heart-lung system (figure 12 
upper panel) The second pass includes convolution of Hit)1F(t) 'H(t), while 
only a fraction (1-Е) will be seen the second time The following passes show 
progressive dispersion and progressive reduction due to repetitive extraction 
(figure 12 middle panel) The observer in the aortn sees a cumulation of the 
first and next passes through the body (figure 12 louer panel) This cumula­
tive curve relates to an overdamped oscillation It approaches zero, because 
there is diminuation Готраге figure 12 (middle and lower panel) to the right 
panels of figure 8 
Except for the initial oscillations, the curve very much resembles a 
biexponential curve In fact, the shape of the forward and feedback transfer 
functions is not critical with respect to the shape of the entire output curve 
except during the first minutes after ι ν injection Consequently, pharma­
cokinetic experiments provide little information on the forward and feedback 
transfer function The importance of recirculation in pharmacokinetics has 
18 19 20 
been emphasized by Vaughan and Cutler ' 
1 8 5 E Dependence of the Body Transport Function on the Extraction 
Ratio 
It is obvious that if the extraction were complete, no recirculation 
would occur, and the output would be equal to the first pass through the 
heart-lung subsystem If, on the other hand, the extraction were zero, the 
drug would recirculate the whole life span of the body It is evident that the 
extraction ratio strongly influences the profile of the body transport func-
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tion This influence is shown in figure 13 The extraction ratio has a greater 
influence than the profile of the forward and feedback transfer functions 
because the extraction ratio determines the average number of recirculations 
1 8 6 F Analysis of the Body Transport Function 
As for the analysis of subsystems, statistical moments are the methods 
of choice for the analysis of the system's transport function since they are 
integral methods using the entire plasma concentration curve The analysis is 
therefore independent of fitting data co a sum of exponentials or other poly­
nomials 
1 Areas The areas under the plasma curve (AC or AUC) equals the 
areas under the input and transport functions according to the system equa­
tions (see Table V) Realizing that the area under a density function equals 
1, the AUC equals the dose divided by the clearance It is also evident that 
if one estimates the AUC of the first pass through the pulmonary system, the 
AUC then equals the dose divided by the cardiac output 
2 Mean Times The mean times are calculated from the concentration 
curve and equal the sum of the mean time of the dose to enter the system and 
the mean residence time of the drug molecules in the system 
The mean residence time is composed of the mean times to pass the pul­
monary system and the mean number of recirculations (N ) through the entire 
body The mean number of recirculations depends merely on the extraction ratio 
(Ε) N = (1-E)/E A mean number of recirculations of 25 means that on the 
average, the molecules pass the system 25 times, but some molecules may be 
eliminated already at the first pass while others may make more than 100 tran­
sits through the body The mean residence time is therefore largely dependent 
on the mean transit time through the body and the average number of recircula­
tions See Tables V and VII В 
Approximately, the MRT equals the MTT divided by the extraction ratio 
This approximation is correct if the extraction ratio is small, as is the case 
for most drugs See Table VII С The mean transit time of phenazon is in the 
order of 10 mm, the extraction ratio about 0 7 % and the mean residence time 
about 15 h The MTT of aminophenazon is also in the order of 10 min, but its 
extraction ratio is about 7% and therefore its MRT is about 5 h 
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Table VII A 
PHARMACOKINETIC SYSTEM PARAMETERS 
cardiac output MIT = mean input time 
extraction ratio N = average number of recircuJations 
clearance V , = volume of distribution 
dss 
mean body transit time ttFT = mean body residence time 
mean absorption time h = bionvailnbility (absorbed fraction) 
1.9 PHARMACOKINETIC SYSTEMS PARAMETERS 
Irrespective of the fitting procedures used on the plasma concentration 
curve, the area under the curve (AUG) and the area under the time-
concentration curve (TAUC) can be obtained either by applying numerical inte­
gration methods or by analytical integrations to which the data have been fit­
ted. In fact, the AUG and TAUC are analogous to the sLatistical moments used 
to characterize statistical distribution functions. 
When the drug is given by i.v. or pulse injection, the plasma concentra­
tion is directly proportional to the body transport function or density func­
tion of residence times. The moment calculations applied to the plasma concen­
tration curve is therefore a logical way of calculating kinetic systems 
parameters. See Tables V and VII В. The total body clearance is directly 
related to the dose and to the AUG. The mean residence time is by reasonable 
approximation equal to the quotient of TAUC and AUG. 
The cardiac output in general cannot be obtained simultaneously, but 
could be obtained with conventional methods such as thermodilution or i.v. 
indicator dilution methods. The recently developed noninvasive laser Doppler 
methods and NMR techniques allow cardiac output determination on a larger 
scale. This will be very important for a better understanding of pharmacoki­
netics. For the moment, simultaneous cardiac output and pharmacokinetic mea­
surements are lacking. The combined methods would also deepen the insight into 
the pathology of the circulation for which the MTT is a good indicator. 
If the cardiac output is known, the extraction ratio and the body mean 
transit time can be found. The steady-state volume of distribution is approxi­
mately the product of clearance and mean residence time. 
E = 
Kr 
MTT -
MAT = 
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Table VII В 
RELATIONSHIPS BETWEEN PHARMACOKINETIC SYSTEM PARAMETERS 
By definition Ve¡ = E'V
в
 Р ^ = ІГТТ
 B N^ = (l-E)IE 
Approximately, j/ E is Jess than JOi 
HRT = HTT/E V. = V '«¡Π· N = UE dss e] re 
System parameters derived from concentration data foJJowing an intravenous 
pulse injection In genera] 
ШС = ! C(t)'dt TAUC = ! fC(t)'dt 
о о 
Т
г
М1С = 1 t7'C(t)'dt 
о 
-t/T 
If C(t) can be fitted to a sum of exponentials C(t) = Σ A 'e 
AUC = Ι Α · τ TAUC = Ι Α · τ ' T'AUC » 21 Α · τ * 
1 1 1 1 1 1 
If C(t) can be fitted to a sum of gamma functions (where к. с <·!,'*>) 
к -£/т 
C(t> = I A (tl\ ) 1'e J Я1С = Ι Α ·τ 'Tik +1) 
TAUC = Σ Α · τ '»rCft +2J Г'А/С = Σ Α · τ ' « r f * + j ; 
1 1 1 1 1 1 
Always HRT = TAUC/AUC VUT = Τ1 AUC/AUC - (TAUC/AUC)2 V , = D/AUC 
el 
and provided that the cardiac output is known 
E = V
e]/VB MTT = E'HRT *(t) = C(t)IAUC 
The system parameters of a number of drugs have been given in Table VII 
С The shortest mean body transit time is found to be in the order of 1 min 
The MTT correlates with the volume of distribution Drugs having a large vol­
ume, as many psychopharmacologiral agents, also have a relatively long MTT of 
0 5 h ( e g , nicotine, codeine, methadon) For most drugs, the mean residence 
time is many hours because of a considerable number of recirculations 
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Table VII С 
PHARMACOKINETIC SYSTEM PARAMETERS OF SOME DRUGS IN MAN 
Drug 
Fluorouracil 
Warfarin 
Sulfinpyrazone 
Thiamphemcol 
Theophylline 
Prazosin 
Phenazon 
Ammophenazon 
Proquazon 
Paracetamol 
Phenacetm 
Terbutaline 
Nicotine 
Pindolol 
Butobarbital 
Lornetazepam 
Caffeine 
Dexamphetamine 
Codeine 
Meperidine 
Methadon 
Fentanyl 
Buprenorphine 
Pentazocine 
Quinine 
Cotmme 
V
el 
l/h 
65 
0 
1 
9 
3 
10 
2 
22 
43 
19 
66 
14 
77 
IS 
1 
11 
7 
21 
45 
57 
S 
37 
54 
32 
8 
3 
32 
17 
42 
54 
4 
17 
7 
3 
8 
08 
4 
15 
1 
6 
Note The cardiac output 
HPT 
h 
0 15 
40 
6 5 
2 6 
7 9 
2 8 
14 5 
1 94 
1 9 
3 2 
1 4 
5 4 
2 4 
2 9 
54 
10 5 
6 5 
9 8 
4 
3 7 
30 
3 8 
2 
1 2 
12 0 
14 5 
V B u a s 
Vdss 
t 
9 8 
12 8 
7 6 
24 5 
28 
29 
32 
44 
82 
63 
89 
75 
183 
55 
58 
120 
46 
210 
182 
209 
240 
141 
90 
96 
97 
52 
assumed 
E 
τ 
22 
0 16 
0 39 
3 14 
1 16 
3 47 
0 7 
7 6 
14 
6 4 
22 
4 7 
2 5 
6 3 
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2 0 
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15 
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This thesis 
1 10 C A L C U L A T I O N OF THE BODY TRANSPORT FUNCTION 
The p r o f i l e of t h e body t r a n s p o r t f u n c t i o n ifi(t) can be c a l c u l a t e d from 
t h e plasma c o n c e n t r a t i o n , prov jded t h i t t h e i n p u t f u n c t i o n i s k n o u n , and t h e 
t r a n s p o r t f u n c t i o n from a p p l i c a t i o n s i t e t o mixed venous p o o l ( s e e §1 11) may 
30 
be neglected The latter is obviously the case for ι ν injections directly 
into the vena cava, but also for injections in an arm vein except for drugs 
with very fast dynamics 
Since the output concentration is a convolution of input function and 
body transport function, the latter can be found by the inverse operation 
t/ecomOVution 
iKt) = V . C(t) < D(t)"1 or *(s) = V , C(s) / D(s) 
el el 
In general, the transport function can be obtained by a numerical deconvolu-
tion procedure either by using matrix division methods or by first transform­
ing C(t) and D(t) into the Laplace or Fourier domain, dividing the functions 
CCs^DCs), and then transforming the result back to the time domain Several 
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numerical deconvolution methods have been reported ' 
If the input function is the Dirac delta pulse, the output is directly 
proportional to the transport function Consequently, the inverse operation 
deconvolution is equal to division This implies that in case of ι ν injec­
tion of the drug, its transport function in the injected volunteer can be cal­
culated by dividing the observed concentration vs time profile by the area 
under it (AUG) 
If the concentration vs. time profile after ι ν injection of the drug 
can be described satisfactorily by an analytical expresssion, a similar ana­
lytical expression is easily derived for ψ(ΐ) For example, if the profile can 
be fitted to a sum of exponentials 
ж -t/τ 
C(t) = Σ A «e 
ι ι 
then the body transport function ψ(ΐ), by definition, is found as 
ш -t/\ m 
i(.(t) = Σ Α · β / Σ Α τ 
1 1 1 1 1 
If the same dose of the drug with the above ψ(ί) were to be adminis­
tered by constant ι ν infusion over a period Τ to the same volunteer, it can 
be shown that its concentration vs time profile during and after the infusion 
would fit to 
m -t/1! 
C(t) = Σ (Α τ /Τ)·(1-β ) , and 
ι ι ι 
-Т/т, -Ct-T)/T 
C(t) = Σ (Α τ /Τ)·(1-β )'e 
1 ι ι 
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respectively Hence iMt) is also computable from the concentration vs time 
profile during and following constant ι ν infusion of the drug The results 
of this procedure in calculating ψ(ΐ) of quinine in a healthy female volunteer 
is shown in figure 14 
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FIGURE 14 (Top left) Venous concentration curve of quinine following a known 
input (here ι ν infusion) in a human subject (Bottom left) Total body 
transport function of quinine as calculated from the upper profile (Top 
right) Venous concentration curve m the same subject following an unknown 
input via the GI tract after ingestion of a capsule containing a quinine salt 
(Bottom right) Input function from GI tract into the venous pool calculated 
from the output following oral dosage and the total body transport function 
(Reproduced from Teeuwen, И W A et al , in preparation) 
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1 11 INPUT FUNCTIONS AND APPLICATION TRANSPORT FUNCTIONS 
As the overall body transport function is the characteristic function, 
fully dominating what the output will be for a given input, knowledge about 
the transport function is important in order to calculate what the output will 
be when various inputs are offered (convolution), or it can be used to calcu-
late the input function giving rise to an observed output (deconvolution) 
1 11 1 A Input Functions at the Application Site 
In general the input function D(t) is not offered directly to the 
mixed venous pool, but at some application site which may be a peripheral 
vein, the skin, the GI tract, a muscle, the respiratory tract or any other 
location This implies that a transport function H (t) has to be included in 
the systems equation which determines the transport from application site to 
Da(t) t 
input 
^ « . n i . V ^ » . 
Ha(t) 
„ „ _ . · * - . 
¡ (venous 
! pool) ! .r\ . 
i Ί 
L· . 
I 
H(t) 
heart-lungs 
Fit) 
body 
(aorta) 
— V _ . 
F 0 ( t ) 
> . . . . ! . _ _ —/J . 
CCI)
 | 
output 
FIGURE 15 Realistic block diagram of the body transport function with input 
not into the venous pool but rather at an application site, and with ou put 
observation not m the aorta but rather m a peripheral vein Two additional 
transport functions (И (t) and F (t)) are involved See also figure 11 and 
Table VIII 
venous pool See figure 15 
The area under this function AH may be less than unity if some drug 
is lost during this transport (incomplete absorption) In fact, AH is 
the biological availability It will also take some time to pass the H (t) 
function as indicated by a mean absorption time MAT 
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The output is, in general, not measured in the aorta but in a periph­
eral vein or at some other observation site See figure 15 Therefore, again a 
transport function F (t) has to be included describing the transport from aor­
ta to this observation site Often this function is very fast with respect to 
the total body transport function Ψ(ί), so that it may be neglected 
The general systems equation, then, has to be extended with H (t) and 
F (t), but the principles as discussed before remain valid See Table VIII 
о 
1 11 2 В. The Intravenous Input Function 
If drugs are not injected into the vena cava, but into a vein of the 
arm, the application transport function H (t) is short A pulse input function 
is, however, already dispersed or distorted to some extent when the drug 
reaches the the vena cava or mixed venous pool The additional transport func­
tion governing transport from injection site to mixed venous pool has no 
influence on the positive feedback body transport function, except that when 
very fast processes are observed, as m the first passes through the heart-
lungs , these may cause great errors m the output 
During passage from injection site to mixed venous pool, in general 
no drug is lost (h = 1) so that from the analysis by statistical moments, the 
clearance still can be calculated The mean time from injection site to venous 
pool is in the order of seconds so that this trdnsport function often may be 
neglected Consequently, the очегаіі body transport function can be obtained 
most easily from ι ν drug application 
The input functions usually applied by the ^ ν route are the pulse 
or bolus injection and the step function or constant ι ν infusion 
Pulse injection The output concentration is directly proportional to 
the convolution of H (t), ψ(ΐ) and and F (t), or approximately to iKt) alone, 
а о 
neglecting H (t) and F (t) This approximation is certainly allowed for the 
plasma concentration with a large mean residence time, but large errors may 
occur for the fast time constants of the curve, that is, just after injection 
Intravenous infusion The output concentration is the integral of the 
convolution of H (t), *(t), and F (t) Since H (t) and F (t) may be neglected, 
in fact, the output is simply the integral of the transport function Ψ(0 If 
the infusion is continued long enough, a stead>-state output concentration is 
obtained since the area under ψ(0 is one bee Table VIII 
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Table Ш 
SYSTEMS DYNAMICS OF DRUG APPLICATION IN GENERAL 
Systems equation 
Laplace s-domam 
C O . "¿Ill . H (s) H(s) · F (s) 
C ( S )
 V„ "a'5' , - (1-Е) · F(s)H(S)
 0 
D (s) 
V
el 
Time domain 
• Hjs) · ψ(5) · F0(s) 
D (t) 
Analysis 
Areas 
C(t) = -? - Η (t) ' ψ(ΐ) F (t) 
el 
AD dose 
Пеап times 
AC = -г-=- -АН · Αψ · AF„ = : 
V , a 0 ν 
el el 
TC - TD + TH + MRT + TF. 
а О 
TC =• MIT + MRT 
Intravenous input functions 
H (t) - H (t) and h = 1 
a) Pulse or bolus (D(t) = D'b(t)) 
C(t) = Д - · H (t) - ψ(0 = Д - · ψ(0 
V . ' V . 
el el 
b) Step function or constant rate infusion (D(t) = D) 
C(t) - т^- ƒ' ψ(λ) · dX 
V . 0 
el 
Steady state (f*-) _ 0 
5 5
 " V , el 
Note: 6(t) = the Dirac delta pulse function, D = the constant step function 
input rate (mg/h) 
Input drug dosage flow at applicai ion site Output drug dosage flou along 
obsen at ion sitr = cone m the blood at observation site times the blood 
f low 
From concentration curves during and after infusion, it is relatively 
еаьу to calculate the body transport function See figure 15 and the previous 
paragraph 
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1 1 1 3 С The Transport Function of the Respiratory Tract 
Inhalation of drugs is a common practice in anaesthesiology and in 
the treatment of asthma and bronchitis In addition» smoking of tobacco is 
aimed at input of nicotine via the lung alveoli 
The bronchi receive blood from thp general circulation and deliver 
back to the general circulation The alveoli are in the pulmonary circulation, 
while the bronchioli receive blood from the left heart and deliver blood to 
the pulmonary circulation This implies that drugs applied to the respiratory 
tract may reach different parts of the circulation via two major routes (fig­
ure 16) The relative importance of the two routes largely depends on the 
physico-chemical properties of the drug (e g , state of aggregation), its 
pharmaceutical formulation (e g , dispersion grade of aerosols) and on the 
D (t) 
input 
1 
H L A ( t ) 
H L B ( t ) 
fv 
> 
enousl 
pool) 
<• , 
J • 
1 + 
1-Е) 
H i t ) 
F ( t ) 
" 
aorta) 
Foil) 
output 
C(tî 
FIGURE 16 Blockdiagram of the body while the input is directly into the res· 
piratory tiact The application site transport function HT(t) is a composite 
of transport via the alveoli (N .(t)) and via the bronchi (H7fì(t)) 
depth and cturation of inhalation 
In general, a fraction f. is absorbed in the alveoli and small bron-
chioli and transported to the aorta» this absorption and subsequent transport 
is characterized by the transport function H (t) The absorption via the 
alveoli may be very rapid, such that drugs given to the lungs may reach the 
aorta even faster than following ι ν injection due to bypass of the H(t) 
transport function (figure 16) 
Another fraction f_ ma> be absorbed relatively slowly via the tra-
chea, the bronchi and the bronchioli, this absorption and transport being 
characterized by the function H.-Ct) Consequently, the overall transport 
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function Hr(t) from application site to venous pool contains tup ternjs. The 
overall systemic availability h equals the summation of f and f^ (in this 
thesis, fT = f. + f will be the symbol of total systemic availability of 
Ij A D 
nicotine in the respiratory tract, reserving h as the symbol for GI tract 
systemic availability). 
The nicotine intake by cigarette smoking mainly occurs via the lung 
alveoli since the major part of nicotine in cigarette smoke is associated to 
aerosols, and since the particle size of cigarette smoke aerosols in general 
is very small (about a few tenth of a ym on the average). The complementary 
(minute) part of nicotine in cigarette smoke is vaporized and is deposited 
completely in the deep airways. The transport function HT.(t) is very fast for 
nicotine; indeed an inhaled dose of nicotine reaches the aorta (and the brain) 
24 faster (7 sec) than a dose injected in an arm vein (14 sec). It is argued 
that habituation to nicotine is a dependence on high nicotine boll in the 
24 brain. If this is true, cigarette smoking is able to produce habituation by 
the grace of the low-dispersion respiratory tract transport function. Almost 
any other route of nicotine administration (including the oral route used in 
case of nicotine chewing gum) would be characterized by slower dynamics and 
consequently would produce more dispersed low-peaked nicotine bumps in the 
cerebral blood vessels. 
Cigarettes are smoked taking a number of puffs in rapid succession 
(ca. 10 per cigarette), while the interval between the cigarettes may vary 
considerably. As the dynamics of the application transport function HT.(t) are 
rapid as stated before, the nicotine concentration in the blood (the output) 
rises with every puff of cigarette smoke (the input or dosage). Since the 
body transport function of nicotine (governing nicotine disposition) is very 
fast as well, the output rapidly decreases if the input is zero for a while. 
So, nicotine output follows nicotine input, and there is a rise and fall in 
the nicotine concentration with every cigarette. See figure 17. 
The time course of nicotine's principle metabolite cotinine however 
is heavily damped due to the slow disposition kinetics of this metabolite, 
once formed. The metabolic input (formation) function is dealt with in § 1.13. 
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FIGURE 17. Plasma concentration curves of (o) the parent drug nicotine and (*) 
its major metabolite cotinine over 24 h m a regular steady smoker. Every 
arrow denotes the (time of) smoking of a single cigarette. The input- and 
transport functions of nicotine are both fast, and consequently
r
 nicotine out­
put rapidly follows its input. On the other hand, the transport function of 
cotinine is very slow. Therefore cot mme output does not follow nicotine 
input, but rather averages it. (From Teeuwen H.W.A., unpublished data). 
1.12 ANALYSIS OF INPUT FUNCTIONS AND APPLICATION SITE 
TRANSPORT FUNCTIONS 
Once the body transport function is known by calculation from a mea­
sured output following л known i.V. input, unknown input functions can also be 
calculated as well as the transport function from application site to venous 
pool. The general equation is fsee Table IX): 
C(t) = (1/V ,) D(t) ··' H ft) -' +(t) ··- F (t) 
e i a о 
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So, if 4>(t) is known, D(t)*H (t) can also be obtained An example is given for 
the oral intake of a capsule of quinine in figure 14 The results show that 
this function is certainly not of a monoexponentlally decaying type as sug­
gested by classic compartmental pharmacokinetics There is quite a variation 
in the transport rate of quinine from the GI tract to the venous pool in dif­
ferent individuals 
1 12 1 A Analysis of the Application Function H (t) 
From Input-output studies with known ψ(ΐ), one still does not have 
D(t) or H (t) separately, but rather their convolution (see figure 14, bottom 
right) If, however, D(t) is reduced to a pulse, the general solution reduces 
to 
C(t) = (1/V
el) D · Ha(t) * *(t) 
This implies that H (t) then can be calculated from the output concentration, 
provided that $(t) has been determined using (analytical or numerical) decon-
volution The analysis is summarized in Table IX using Laplace transforms 
Examples of momentary (pulse) input functions are the intramuscular 
injection of a small volume solution, or the oral administration of a solution 
of a drug In both examples the drug is brought practically directly without 
losses to the application site, where the function H (t) takes over 
1 12 2 В Analysis of the Input Function by Eliminating the Transport 
Function 
The input function of an oral tablet or capsule can be calculated by 
a deconvolution operation on the output concentration of that tablet and a 
solution of the drug This implies that in the two experiments, the H (t) is 
expected to remain the same In essence, the H (t) is not separated from Φ(ΐ) 
So, by measuring the output of a solution, one calculates H (t)''r4>(t) A decon­
volution operation on the output following the tablet using the previously 
found H (t)**(t) directly gives D(t) 
If one measures the output concentration following the oral intake of 
a tablet and a retard preparation, obviously deconvolution does not give the 
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Table IX 
ANALYSIS OF APPLICATION TRANSFER FUNCTIONS AND INPUT FUNCTIONS 
A Analysis of the appiication transfer function H (s). 
Systems equation (Laplace do/nam); 
after pulse intravenous input · after pulse input at application site: 
H . ( s ) H ( s ) 
С. (s) = D b ) · - ! · iMs) · F (s) С (s) - D (s) · -4 · iMs) - F (s) 
i i y о a a y о 
el el 
where D (s) = D, И (s) = 1, and D (s) = D . i l a s 
Intra-individua] variabiJity of V ., ty(s), and F (s) is neglected. 
el о 
Analysis of И (s) from ι.v. input and pulse input at application site: 
С » η H (s) 
С,(s) D. 
bioavailability : mean absorption time: 
AUC D 
AUC. D 
TH = TC - TC. 
B. Analysis of the input function D (s) of a retard preparation. 
Systems equation (Laplace domain) 
after pulse input of a solution (D .(s) = D ,): 
H (5) a,sor ' a,sol' 
c
, .„И
5
' =
 D
, «„i<s> · -2 - v(s) · F (s) 
a. sol a. sol ν/ о 
V
el 
after input of a particular retard préparât ion : 
H (s) 
С (s) = D (s) • -4 · ifs) · F (s) 
a,ret a,ret ι/ о 
el 
Intra-individual variability of V ., i>(s), F (s) and H (s) is neglected. 
el о a 
Analysis of D (s) from a dose as a solution and a dose as a retard 
a, ret 
preparation. С (s) 
D (5) . .iiiet D 
a,ret г (s) a,sol 
a,sol 
absorbed dose. mean dissolution time: 
A U C
r e t TD = TC - TC , 
D = D · a,rei a,ret a,sol 
a.ret a,sol дис 
sol 
es TD . = 0 
a,sol 
input of the retard preparation. It does, however, provide a good measure of 
the relative performance of the two formulations. Again it is not necessary to 
know the body transport function nor the application site transport function 
as may easily be concluded from the systems equations in the Laplace domain. 
See Table IX. 
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It must be realized that it is not always possible to perform the 
analysis since it may occur that the application transport function is differ­
ent for the tuo pharmaceutical dosage forms that are compared For instance, a 
solution may pass immediately from stomach to duodenum, whereas the retard 
tablet may distribute over a different part of the GI tract 
1 13 THE METABOLIC INPUT FUNCTION 
Most drugs are transformed in the body into metabolites which may have 
pharmacological activity With regard to a metabolite concentration profile, 
the parent drug concentration is input to the metabolite transport function 
See figure 1Θ The system equation for the parent drug and metabolite is given 
in Table X It is evident that the two transport functions are in series Con­
sequently, the metabolite curve is more dispersed than the concentration curve 
of the parent drug 
Three types of interrelationship between the transport functions of 
parent drug and metabolite may be discerned 
* If the dynamics of the metabolite is much faster than the dynamics of the 
parent drug, there is practically no further dispersion and the profile of 
the metabolite is identical to that of the parent drug An example is the 
kinetics of trichlorethanol and its glucuronic acid metabolite 
• The dynamics of the metabolite is much slower than the dynamics of the 
parent drug Then the dispersion by the metabolite is so large that the 
curve of the parent drug may be considered as a pulse The profile of the 
metabolite curve is very much flatter An example is found in nicotine and 
its major metabolite cotinine As we saw in §1 11 C, in cigarette smoking 
nicotine output follows its input practically without delay as a conse­
quence of the fast dynamics of the application transport function HT(t) 
(governing alveolar nicotine absorption) and the body transport function 
*(t) (governing nicotine disposition) There is a rise and fall in the 
nicotine plasma concentration with every individual cigarette smoked (see 
figure 17) The body transport function of cotinine, however, is slower so 
that the cotinine output concentration cannot follow the input variation 
of nicotine Instead it averages the intake variation of nicotine In this 
respect, the cotinine plasma level is a valuable tool to estimate the dai­
ly intake of its parent nicotine in tobacco smokers 
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FIGURE 18 Feedback diagram for the parent drug and its major metabolite When 
observing the metabolite concentrât ion, the concentration (output) of the par-
ent drug acts as input to the metabolite system, operated on by the transport 
function of the metabolite. Hence, the two transport functions (of parent and 
metabolite) are arranged in series. See Table X 
The dynamics of the parent drug and the metabolite are very much the same. 
The metabolite curve is more, but not much more dispersed than the curve 
of the parent drug, and assumes a typical convex 'garama' shape. After 
approximately two times the common MRT of both compounds, the curves of 
parent and metabolite roughly parallel each other An example is found in 
caffeine and its main metabolite paraxanthine (figure 19) 
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Table Χ 
CONTROL SYSTEMS DYNAMICS OF DRUG METABOLISM 
Systems equation 
In Laplace s-domam : 
HJs) H U Í H r , ( s ' 
С (s) = D ( s ) · -? ^ • E - f - F f s ) ϋ - F ( s ) 
mv ' a v B l - ( 1 - E ) - F ( s ) H ( s ) m 1-(1-E ) - F ( s ) H (s) "" 
В m m m 
H ( s ) 
С (s) = D ( s ) · f · ψ ( 5 ) · F ( s ) · ψ,η(5) · F ( s ) 
"i a y m mo 
me I 
where 
ψ ( 5 ) L H i l ] and ψ (s) ^-^ 
1 - ( 1 - F ) - F ( s ) H ( s ) Ψ* *-l*-tJ'*J*)HJ*) 
m m m 
In tjme domain: H ( t ) 
с (t) = olt) * -A— · ψ(ι) -· f · F(t) * ψ ί ι ) * ТЫ 
m a u m m mo 
л ι " ^ ' 
Analysis 
Areas : AH . „ ._
 c AH - A F a A H ' A F ' E , m mo AC • AD · -— · · f 
m a
 V 0 I - ( 1 - E ) - A F - A H m I - { î - E )*AF -AH m m m 
AC · *°™ · f · f 
m y a m 
Mean times : "^ ' 
TC - TD + TH + Τψ + TF + Τψ + TF 
m a a m o 
where: and: 
Τ ψ = MRT - ΤΗ + — - MTT Τ ψ - ИНТ = ΤΗ + · МТТ 
f m m m [ гг 
npproximntely: m 
TC = MAT + MRT + MRT 
1 . 1 4 C O N C L U S I O N S 
The body is a dynamical system whose future state depends on its 
present state and inputs to the system. In pharmacokinetics, only a limited 
number of state variables are sufficient to characterize the system behavior. 
In general, point attractors dominate the kinetics. 
The various organs and tissues may be considered as subsystems. Their 
kinetic behavior is fully characterized by density functions of transit times 
and their bloodflow. 
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Table X (continued) 
CONTROL SYSTEMS DYNAMICS OF DRUG METABOLISM 
Special input functions of the parent compound 
1) ι ν pulse infection (D(t) = D'ò(t), h = 1. H (t) fast) 
a a 
С ( t ) - Д - · ψ ( 0 f • F ( t ) l i ( t ) F ^ l t ) 
m w m m mo 
el 
2) ι ι constant rate infusion (Dft) = D, h = 1, H (t) fast) 
a a 
С (t) = — 5 - · f S1 ψ(0 F(t) * ψ (t) ·· F (t) · dt 
m y m Q m mo 
mei 
Steady state (f*-) 
D * f 
CJP") V . 
mei 
Note' All metabolite parameters bear a subscript "η" f is the fraction of 
the paient compound converted into the particular metabolite 
в 
Parent drug (P) input Ρ dosage flou at application site 
Ρ output Ρ dosage flow along the observât ion site = Ρ blood cone times the 
blood flou 
ttetabol ite (Ν) input met aboi ic conversion rate of Ρ into H, dosage flou of 
Η out of the converting organs and tissues 
H output H dosage flow along the observation site = H blood cone times the 
blood flow 
The total body is an arrangement of the subsystems according to a posi­
tive feedback control system The open-loop feedback transport function is a 
density function of body transit times, while the closed-loop transport func­
tion is, m essence, a density function of residence times 
The important pharmacokinetic system parameters are the mean body resi­
dence time, the cardiac output, the extraction ratio, the total clearance, and 
the apparent volume of distribution 
The overall body transport function can be found from measuring the 
output concentration when applying a known input function using deconvolution 
methods Unknown dosage input functions to the body, either by oral intake, 
intramuscular injection, inhalation or otherwise, can be found from measuring 
the output concentration of such an unknown input after first obtaining the 
body transport function 
Since the body transport function is fixed for a given individual and a 
given drug in a short period of time, a required output can only be obtained 
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FIGURE 19 (Top left) Venous concentration curve of paraxanthine (mam metabo­
lite of caffeine) following a known input (here ι ν infusion) in a human 
subject (Bottom left) Total body transport function of paraxanthine as calcu­
lated from the infusion profile (Top right) Venous concentration curve m the 
same subject following an unknown metabolic input after an ι ν dose of the 
parent compound caffeine The venous caffeine concentration curve is shown as 
well (Bottom right) Metabolic input function of paraxanthine by caffeine 
biotransformation, as calculated from the output following caffeine dosage and 
the paraxanthine transport function Note the analogy with figure 14 (Repro­
duced from Teeuwen, HUA et al , m preparation) 
by devising the correct input function Computational experiments may be help­
ful to design the adequate dosage form and schedule to fulfill such require­
ments 
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2 1 SUMMARY 
A rapid and sensitive capillary gas-chromatographic method with 
nitrogen-sensitive detection is reported for the simultaneous analysis of 
nicotine and cotmme levels occurring m the plasma, saliva, and urine of 
regular tobacco smokers The proposed assay has a linear output, has satis­
factory accuracy over the range of concentrations of both amines encountered 
m active smokers, and has also been succesful in the analysis of the urine 
samples of passive smokers Its lower limit of sensitivity is 0 2 ng of nico­
tine and 0 5 ng of cotinme per ml of plasma or saliva or per 100 yî of urine 
The beneficial characteristics of the presented method were achieved by 
the combination of solid phase extraction of 0 1 - 1.0 ml of fluid specimens, 
capillary column gas chromatography uith splitless injection and nitrogen sen-
sitive detection, and the use of separate, structurally analogous compounds as 
internal standards for nicotine and cotinme The suitability of the assay is 
shown by plasma concentration-time curves of nicotine and cotmme m a steady 
smoker during a 24 hours period 
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2 2 INTRODUCTION 
Concomittant with the increasing public awareness of the relationship 
existing between the active intake, and maybe the passive intake as well, of 
tobacco and tobacco smoke constituents, and the chance of developing a 
tobacco-use related disease, the measurement of nicotine and its major phase-I 
metabolite cot mine in body fluids has gained increased attention in the past 
two decades 
Nicotine is the most abundant and the most potent pharmacological agent 
in tobacco and tobacco smoke It is the primary, though not the only reason 
why people consume tobacco and it may contribute to causation of some of the 
diseases that are related to the use of tobacco requisites. The nicotine 
delivery of the cigarette to the smoker must be the limiting factor in the 
rate of nicotine self-administration by smokers [1] While regulating his 
nicotine input rate, the smoker at the same time co-regulates the input rate 
of the smoke constituents other than nicotine present in both the particulate 
phase (water, 'tar') and the gaseous phase (e g , carbon monoxide) of the 
smoke 
Methods reported for the assay of nicotine and cotinine in biological 
material cover a large field of analytical techniques A qualitative mass 
spectrometncal assay has been published by Horning et al [2] Radioimmunoas-
says [3-11] and a related procedure [12] have been reported but are very cum-
bersome and therefore inappropriate when large amounts of samples are to be 
analyzed High-performance liquid chromatographic techniques employing detec-
tion by li V -absorbance [13-15] typically are not sensitive enough to cover 
the range of concentrations below approximately 50 ng/roU of sample, so their 
use is restricted to urine samples of active smokers 
Gas chromatographical (GC) methods on the other hand can be rendered 
very rapid and sensitive A large variety of GC methods has been reported for 
the analysis of nicotine and cotinine in biological fluids using flame ioniza-
tion detection (FID) [16-19], electron capture detection (ECD, after derivati-
sation) [20], nitrogen phosphorous detection (NPD) [21-29], and detection by 
mass spectrometry combined with the facility of selected ion monitoring 
(MS/SIM) [29- 33) 
In the analysis of nicotine and cotinine by GC, the following parameters 
must be tuned deliberately sample volume, extraction procedure, choice of 
internal standards, type of column, injection mode, isothermal or temperature-
programmed elution, and sensitivity and specificity of the detector These 
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important considerations will now be discussed in some detail while comparing 
published methods 
Sample volume Except for urine, the available sample volume in general 
Is limited, especially so when the sample source is a baby or a small labora-
tory animal, or when repetitive sampling from a single subject is intended, 
e g in the course of a pharmacokinetic experiment Reported methods require 
non-urine sample volumes that range from 10 mt [30] to 100 \il in the 
mlcromethods developed by Feyerabend and Russell, and Curvali et al [23,27], 
or even to 50 pi [32] Most methods require 1 ml of plasma 
[17,19,22,25-28,33] A comparable quantity is the requirement of 1 g of tis-
sue by Thompson et al [29] 
Extraction An extraction procedure should recover nicotine and cot mine 
simultaneously and completely from plasma, urine and other relevant biological 
materials m a single and rapid extraction step, at the same time separating 
the two amines and their internal standards from the bulk of the potentially 
interfering endogenous fluid constituents in order to create beneficial condi-
tions for the subsequent chromatographical run Unfortunately, the vast major-
ity of the published nicotine and cotinine assays involve extraction proce-
dures that fail to meet one or more of these criteria 
The most commonly encountered handicap is a multiplicity of liquid 
extraction steps that can grow to unworkable proportions Three reasons may be 
conceived to introduce more than one extraction First, analyte recovery may 
be enhanced by extracting a sample with a few small portions of extraction 
solvent, rather than extracting it with one big portion [16,19,21,22,30-32] 
Second, extraction of the alkaloids and their standards in an organic 
solvent under alkaline conditions may be preceded or followed by an acidic 
extraction of the sample to remove weakly acidic or neutral interferences 
[19,20,22,23,25,26,29,31,32] In case the acidic extraction follows the alka-
line one, a third extraction is needed to finally tranfer nicotine and coti-
nine into a non-aqeous milieu, suitable for evaporative concentration and 
injection into a gas Chromatograph In spite of their complexity, the degree 
of clean-up realized with these acidic-alkaline or alkaline-acidic-alkaline 
extractions is likely to be questionable, witness the fact that the authors of 
only two assays involving these extraction sequences stated that their assay 
was fit to urine analysis [23,26] 
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The third reason for the performance of more than one liquid extraction 
step is the separate extraction of nicotine and cotinine in those methods 
claiming to be applicable to the analysis of both amines, using different 
extraction solvents [16,26,22,29] Most frequently, nicotine and cotinine are 
extracted in diethyl ether and dichloromethane, respectively Dichloromethane 
appears to be the only solvent in which both nicotine and cotinine may be 
extracted simultaneously and to a good extent Kogan et al , Curvali et al , 
and Davis [25,27,28] utilized it as an extraction solvent, combining it with 
NPD Kogan cum suis [25] employed a packed column and a three-step plasma 
extraction procedure of the alkaline-acidic-alkaline type For Curvali and 
co-workers [27] and Davis [28] who employed capillary columns, a single-step 
extraction sufficed Neither of these three assays was stated to be suited to 
urine analysis by the authors 
It is obvious that multiple extraction steps may give rise to low recov-
eries of the analyte(s) and so to reduced sensitivity and accuracy of the 
assay Compensation for the extraction losses may be found in bulky sample 
volumes [16,19,21,23,30,31] In addition, lengthy extraction procedures are 
counterproductive and promote interference from extraneous nicotine as stated 
by Curvali et al [27] 
As an alternative, Stehlik et al [18] and Kyerematen et al [15] iso-
lated nicotine and cotinine from biological materials by making use of selec-
tive adsorption of both amines onto the stationary phase of a disposable 
extraction column This type of extraction is known as 'solid phase' extrac-
tion (SPE) SPE m our laboratory has proven to be a very powerful extraction 
technique In accordance with our experience, both Stehlik and Kyerematen suc-
ceeded in extracting nicotine and cotinine simultaneously, with good recovery 
and with a sufficient degree of clean-up in a single extraction step from 
urine The extraction procedure of Kyerematen can be applied without modifica-
tions to plasma as well, but that of Stehlik is modified for plasma and 
involves three steps We set it our goal to develop a SPE-procedure applicable 
without any modifications to the GC-analysis of nicotine and cotinine in both 
plasma and urine 
Internal standards Jacob et al [26] were critical of the use of quino-
line and lidocaine as internal standards (ISTDs) for nicotine and cotinine 
They observed a large variability in the peak height ratio of nicotine to 
quinoline analyzing identical samples, and suggested that this variability was 
due to different relative losses of nicotine and its ISTD during sample work-
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up and/or during gas chromatography In general, they recommended the use of 
structural analogs as ISTDs, because their similar physico-chemical properties 
garantee similar relative losses in the course of the analysis procedure 
As a consequence, dual internal standards should be used for nicotine 
and cotmine, for the physico-chemical properties of these two compounds dif­
fer widely 
Qu ino line, chlorphentermine, ketamine, modal ine, N-ethyl-normcotine, 
N-n-propyl-nornicotine, N-methyl-anabasine, nicotine-5,5'-Ό„, and 
N-'H.C-normcotine have been used as nicotine-dedicated ISTDs [16,18-23,26-29, 
31,32] Lidocaine, lignocaine, phemramine, N-(2-methoxyethyl)-norcotinine, 
2'-oxy N-methyl-anabasine, N-ethyl-norcotinine and N-3H C-norcotmine have 
been reported as ISTDs dedicated to cotmine [16-18,22,26-29,33] Furthermore, 
Kogan and co-workers employed ketamine as an ISTD for both nicotine and coti-
nine [25] Kalkman et al added their 'internal' standard quinoline after 
extraction of nicotine [30], implicating that the standard cannot correct for 
analyte losses during the extraction The authors therefore should have called 
their standard an external standard Grubner, First and Huber do not use any 
standard at all [24] 
The degree of structural analogy existing between analyte and ISTD in 
the various assays ranges from poor (first three nicotine and cotmine stan­
dards mentioned) to excellent (isotope-labeled analogs) However, use of these 
labeled analogs restricts the spectrum of applicable detection techniques to 
the expensive mass spectrometer 
Chromatography Gas chromatographical separation of nicotine and/or 
cotmine, standard(s), and endogenous compounds evoking a detector response 
may be achieved with packed [16,17,19,20-26,32] and with capillary open tubu­
lar columns [18,27-29,31,33] Also, gas chromatography may be performed 
isothermally [16,17,19-26,30,32] or with oven temperature programming [18, 
27-29,31,33] 
Isothermal runs have the advantage of yielding stable base lines without 
noise and drift, a condition that fosters sensitivity and accuracy especially 
when employing packed GC-columns For capillary GC, isothermal operation 
implicates split injection and a concomittant decimation in sensitivity 
because of the loss of typically more than 90% of the injected materials 
through the split vent As a consequence, there are many assays combining 
isothermal operation with the use of packed columns [16,17,19-24,26,30], 
whereas only a few combine it with capillary columns [27,31] 
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Oven temperature programming on the other hand offers the advantage of 
eluting both nicotine and cotinine within a relatively short period of time 
In temperature-programmed capillary GC, one has the option of avoiding sensi-
tivity decimation and at the same time substantially increasing peak resolu-
tion by using the splitless injection mode The injection conditions in this 
case should be chosen deliberately so as to optimally benefit by the so-called 
'cold trap' and the 'solvent effect' irechamsms of analyte reconcentration in 
narrow bands at the head of the capillary column [34] The chromatographical 
strategy in the analytical methods proposed by Thompson, Stehlik, Daenens and 
their respective colleagues, and by Davis [18,29,33,28] is based on the latter 
cons iderat ions 
All isothermal methods referred to, as well as one with temperature pro-
gramming, that are reported for the analysis of both nicotine and cotinine 
[16,22,26,27,29] elute the two amines in parallel chromatographical runs using 
two separate chromatographs, each operating at the conditions specific to the 
determination of the individual analyte With the exception of the Curvali 
method [27], these methods involve separate extraction procedures as well for 
nicotine and its main metabolite, so that actually these assa> procedures 
[16,22,26,29] are composed of two distinct analytical methods that start from 
the same sample and employ the same type of equipment, rather than constitut-
ing truely a single and simultaneous assay Both simultaneous extraction and 
chromatography is accomplished only by Davis [28] and by Stehlik cum suis 
[18] 
Summarizing, it may be stated here that all methods reported for nico-
tine and/or cotinine assay in biological fluids known to us are afflicted with 
some kind of drawback It is not amazing that Davis in his article [28] 
noticed that there had been no reports specifically mentioning automated sam-
ple injection in the determination of nicotine and cotinine The majority of 
the work-up procedures is so laborious that the number of extracts that can be 
produced in the course of one working day is hardly worth while to involve an 
automatic injector in their chromatographical analysis 
This paper for the first time describes an assay procedure requiring 
only a single extraction step which without any modifications can be applied 
to extract nicotine and cotinine rapidly, simultaneously and nearly quantita-
tively from plasma, saliva and urine The assay furthermore resolves nicotine 
and cotinine from a single injection within 10 minutes, and is sensitive 
enough to be applied to the urine of passive smokers 45 samples can be 
extracted and run chromatographically by a skilled analyst in a single 8 h 
working day 
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These characteristics are accomplished by combining solid phase extrac-
tion work-up with high resolution gas chromatography, oven temperature pro-
gramming, splitless injection and nitrogen-phosphorous detection 
2 3 MATERIALS AND METHODS 
Glassware All glassware for sample storage and for the extraction pro-
cedure was cleaned by leaving it overnight in concentrated nitrous acid, wash-
ing it consecutively with hot tap water and ethanol, and drying it in an oven 
at 60° The glassware was subsequently silanized by exposing it to a 4% 
dichloro dimethyl silane solution in toluene, which was left in it overnight 
or for at least 3 h It was then washed with ethanol and briefly dried in an 
oven at 60' When not in use, it was stored in dust-free and air-tight boxes 
Laboratory and personnel An interdiction to smoke in the analytical 
laboratory was issued one year before the first authentic samples were ana-
lyzed The analyst and the blood sampler were chosen non-smokers 
Chemicals and solvents (-)-Nicotine was purchased from Merck, Darm-
stadt, West-Germany, (-)-cotinine from Sigma, Saint Louis, USA, nikethamide 
from Janssen Chimica, Beerse, Belgium ß-mcotyrine was a kind gift from Dr 
Th Darby of the Department of Pharmacology, University of South Carolina 
(Columbia, S С , U S A ) These four compounds, whose structural formulas are 
shown in figure 1, were purified by double distillation under nitrogen before 
use A purity of > 99% was thus achieved, as revealed by gas chromatography 
and mass spectroscopy The compounds were stored dark at -20' in desiccators 
under reduced (nitrogen) pressure to prevent oxidation, degradation and con­
tamination 
Every bottle of the following solvents was checked individually on the 
presence of nicotine contamination by gas chromatographical analysis described 
herein ethanol (ρ a grade, Merck), methanol (p a grade, Merck), propyl 
acetate (p a grade, Janssen Chimica) and toluene (technical quality, Boom, 
Meppel, The Netherlands) A 0 05 M solution of disodium tetraborate (Janssen 
Chimica) in tap water was buffered to pH = 9 0 by adding a few drops of con­
centrated nitrous acid (Merck), an aliquot of 10 mi of the buffer was checked 
on the presence of nicotine by solid phase extraction followed by gas-
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FIGURE 1 Structural formulas of the two analytes and their internal standards. 
chromatographical analysis (see 'Procedure') The solvents and the buffer 
solution were rejected if more than 1 ng of nicotine was found in the 10 m£ 
aliquot 
Instrumentation The gas-chromatographical analyses were performed on a 
Hewlett Packard model 5890 instrument, equipped with a split/splitless liner, 
a splitless insert (79 χ 2 mm ID), a HP fused silica capillary column (12 5 m 
χ 0 20 mm ID) wall-coated with a dimethyl silicone phase (phase ratio = 150) 
and a nitrogen-sensitive detector containing a rubidium bromide crystal 
Detector gas flow rates were 3 0, 75 and 30 mî/min for hydrogen, air and make-
up helium, respectively The linear velocity of the helium carrier gas through 
the column was 42 cm/sec, achieved with a column head pressure of 1 0 Bar The 
injection port and the detector were operated at temperature of 200° and 300', 
respectively 
Sharp peaks with minimal tailing were obtained by splitless injection of 
propyl acetatic sample extracts at an oven temperature of 60', followed after 
30 sec by activation of the septum purge (1 5 ml/min) and a rise of the oven 
temperature at 70°/min to 140°, then at 50/min to 155°, and finally at a rate 
of 30a/min to 200° The latter temperature was maintained 45 sec in case of 
plasma or saliva analysis or 90 sec in case of urine analysis Subsequently 
the oven was allowed to cool down back to 60° 
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Plotting of the chromatograms was carried out by a flow chart recorder 
(model BD-8, Kipp & Zonen, Worms, The Netherlands). Electronic peak integra­
tion was performed by a Hewlett Packard 21 MX Lab Auto System. A Texas Instru­
ments data terminal (model 700 ASR 'silent') read the integration options and 
printed out the reports. 
Procedure. After thawing, the samples were vortex-mixed and centrifuged 
for 5 min at 1000 g. A 1 mt plasma sample or 100 \it urine sample was pipetted 
into a test tube followed by aliquots of the appropiate internal standard 
solutions (see: 'Calibration') and 1 mi of borax buffer (pH = 9). The contents 
of the tube were mixed well and then were passed under suction (flow rate 
about 0.5 ml/min) through a C2 solid phase extraction (SPE) column containing 
100 mg of ethyl-silica sorbent (JT Baker, Phillipsburgh, USA). The SPE-column 
had been preconditioned by a 2 mt methanol wash and a 2 ml borax buffer wash. 
TM S 
A Baker 10 -SPE vacuum manifold allowed 10 samples to be extracted at one 
time. 
After passage of the sample, the SPE-column was washed twice with a 2 ml 
portion of distilled water and once with 100 ill of an aqueous methanol (602) 
solution. Then it was dried thoroughly under air suction for 5 min. Nicotine, 
cotinine and their ISTDs were desorbed under gravity from the SPE-column with 
500 μ£ of methanol. The eluates were caught in conical 1 mt vials. The 
methanol was evaporated at 45' under a gentle stream of dry nitrogen in 30 
min. It was exchanged with propyl acetate by addition of 20 ill at the start of 
the evaporation, which was terminated at a residual volume of 10 μ!. A 0.75 vl 
aliquot was injected into the gas Chromatograph. 
Calibration. Blank plasma was obtained from nonsmokers working in a 
smoke-free environment. Blank urine was obtained from a 5 years old boy whose 
parents were both non-smokers. No cotinine could be detected in these fluid 
pools; nicotine levels were less than 0.3 ng/mt in both plasma and urine. 
Nicotine levels found in dog or goat plasmas or even in tap water were similar 
in magnitude and ranged from 0.1 to 0.5 ng/ml. Probably these specimens do not 
contain nicotine but are contaminated with it during the assay procedure. 
Stock and working standard solutions of nicotine, cotinine, and their 
respective ISTDs ß-nicotyrine and nikethamide were prepared in borax buffer 
(pH = 9) and stored at 4" in the dark. They were refreshed every 5 working 
days. 
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10 plasma or urine calibration standards were prepared Blank plasma (1 
ml) bas spiked with 50 ng of fi-nicotyrine and 250 ng of nikethamide as ISTDs 
and with 0 (0) - 5 (40) - 10 (80) - IS (120) - 20 (160) - 25 (200) - 30 (250) 
- 40 (300) - 50 (350) - 60 (400) ng of nicotine and cotinine (spiked amounts 
of cotinine given in brackets) Blank urine (0 1 rat) was spiked with 100 ng of 
both ISTDs and with equal amounts 0 - 10 - 20 - 30 - 40 - 50 - 62i - 75 - 87І 
- 100 ng, of nicotine and cotinine The standard samples were taken through 
the extraction and chromatography procedure in the normal way 
Calibration points were generated by plotting the amounts of nicotine 
and cotinine in the standard sample versus the peak area ratio of nicotine to 
B-nicotyrine and cotinine to nikethamide, respectively Nicotine and cotinine 
concentrations in authentic samples were calculated according to the linear 
least squares regression line through the nicotine or cotinine calibration 
points 
Extraction and overall recovery Each sample of three groups of ten 
blank plasma samples (1 mi) was spiked with 50 ng of fi-nicotyrine and 250 ng 
of nikethamide Group I was also spiked with 25 ng of nicotine and 250 ng of 
cotinine After the three groups of samples had been taken through the extrac­
tion procedure, the ten samples of group II were still spiked with 25 ng of 
nicotine and 250 ng of cotinine as methanolic solutions The three groups of 
samples uere then taken through the concentration procedure The samples of 
group III then were spiked with 25 ng of nicotine and 250 ng of cotinine as 
propyl acetatic solutions 
The mean peak area ratio of nicotine / ß-nicotynne and of cotinine / 
nikethamide were determined in each of the three groups of samples The 
extraction recoveries of nicotine and cotinine were calculated by dividing the 
mean peak area ratios in group I by the corresponding ones in group II Simi-
larly, the mean ratios in group I divided by those in group III yielded the 
total recoveries of nicotine and cotinine Total recoveries were determined 
both at a residual evaporation volume of 50 y£ and at the usual volume of 10 
li£, by injection of an aliquot of the group I samples at both these residual 
volumes and subsequent division of the resulting mean peak area ratios by the 
corresponding figures in group III 
Extraction and overall recovery of nicotine and cotinine in 0 1 mi urine 
samples were determined using the same strategy, spiking the samples with 100 
ng of each of the standards and adding 50 ng of both nicotine and cotinine to 
the sample groups at the appropriate stages of work-up 
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The extraction and evaporation recoveries of the standards fl-nicotyrine 
and nikethamide from plasma and urine samples were estimated by inversion of 
the strategy nicotine and cotinine were used as ISTDs for (l-nicotyrine and 
nikethamide, respectively, and the latter two compounds were added at the var-
ious stages of work-up 
2 4 RESULTS AND DISCUSSION 
Contamination Extraneous nicotine present in the atmosphere, in sol-
vents and reagents, and on the surface of glassware, apparatus and the skin of 
the venipuncturist or analyst may be incorporated into the biological samples 
and thus falsely elevate nicotine levels in these samples This elevation has 
been minimized by precautions like the issue of a smoke interdiction in the 
analytical laboratory, the appointment of a non-smoking blood sampler and ana-
lyst, the meticulous cleaning of all glassware followed by the application of 
a anti-adsorptive dimethylsilyl coating on its inner surfaces, and the avoid-
ance of all unnecessary contact between the sample and plastic, metal, and 
uncoated glass surfaces Furthermore the total work-up of the samples was per-
formed in a fume-hood, and all reagents and solvents were checked for their 
purity 
It thus has been possible to reduce the nicotine concentrations of 
'blank' plasma and urine samples (and the y-intercepts of nicotine regression 
lines) to a value below 0 5 ng/mt (see 'Calibration') For urine samples con-
tamination with extraneous nicotine is less of a problem though, since at 
least in 'active' smokers the level of contamination is only a minute fraction 
of the true nicotine level of the samples Since tobacco smoke contains only 
traces of cotinine whereas biological fluids of smokers contain relatively 
much of it, no contamination problems whatsoever exist in cotinine analysis 
Extraction and overall recovery Extraction using ethyl-silica ('C2') 
solid phase extraction columns under the conditions described resulted in an 
almost quantitative extraction of both nicotine, cotinine and their ISTDs from 
human plasma and urine (see Table I) 
The extraction recovery of all compounds from urine appears to be 
marginally greater than that from plasma, which could be due to a slight 
extent of plasma protein binding of the compounds In the range of concentra-
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TABLE I EXTRACTIOU AND OVERALL RECOVERIES FROH HUMAN PLASMA AND URINE 
Matrix Compound 
Plasma 
Urine 
nicotine 
ß-mcotyrine 
entmine 
nikethamide 
nicotine 
$-nicotyrine 
cot in me 
nikethamide 
Extraction 
recovery (%) 
96 t i 
96 + 5 
98 + 4 
98 t 3 
99 ± 4 
100 + 4 
101 + 3 
100 ± 3 
Overall " 
recovery (Z) 
93 t 5 
94 + 5 
98 ± 4 
98 ± 4 
96 + 4 
97 + 3 
99 + 2 
99 + 3 
ft? 
for a residual evaponzation volume of 50 μί 
for a residual evaponzation volume of 10 yi 
Overall s v 
recovery (%) 
75 + 7 
77 t 6 
98 t 4 
96 + 4 
78 + 6 
80 + 7 
99 ± 3 
98 t 3 
tions normally encountered in smokers' plasmas, and at pH = 7 4, nicotine is 
bound to plasma proteins for 4 9 ± 8 0 % [35], whereas colmine exhibits a 
bound fraction of 6 0 ± 3 5 % [36] We have not been able to trace the 
protein-bound fractions of ß-nicotynne and nikethamide in the literature 
The plasma extraction recoveries of nicotine and cotinine are slightly 
greater than their free fractions in plasma The difference might be explained 
by assuming that a slightly greater fraction of both amines is free at the pH 
of extraction (pH = 9) than at the physiological plasma pH (= 7 4) Alterna-
tively, part of the protein-bound nicotine and cotinine molecules may move 
from the binding sites on the proteins to the competing sites on thp extrac-
tion sorbpnt during passage of the plasma proteins through the SPE-column 
[37] 
During the concentration step following extraction, approximately 20% of 
nicotine and its 1STD occur are lost, whereas the recoveries of the less 
volatile cotinine and its ISTD are hardly affected by the concentration proce-
dure (Table I) Nicotine and ß-nicotyrine are lost mainly in the tail of the 
concentration step, from 50 y£ to 10 y£ Nevertheless we decided to maintain 
10 iii as a residual volume in the procedure because the factor 5 In volume 
reduction achieved in the tail of the concentration step is accompanied by a 
sensitivity gain that easily outweighs the 20% evaponzation losses of nico-
tine and ß-nlcotyrine 
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Despite the incomplete recovery, the accuracy data for nicotine in the 
proposed method are beneficial by the grace of its equally volatile ISTD, 
which is recovered to practically the same, incomplete, extent (Table I) The 
importance of similarity m physico-chemical properties (volatility) between a 
compound and its ISTD thus Is demonstrated, as is the necessity to employ dual 
internal standards for nicotine and cotinine Like nicotine, B-mcotyrine is a 
tobacco alkaloid However, its abundance in tobacco and tobacco smoke is 
infinitesimal, justifying its use as an ISTD m this assay method We have not 
been able to detect smoke-derived ß-mcotyrine in human plasma or urine so 
far Trace quantities (= 1 ug) were found in cigarette filters 
Gas chromatography and sensitivity The specificity and the sensitivity 
of the nitrogen-phosphorous detector for compounds containing atoms of these 
elements is very suitable for an accurate estimation of even small concentra-
tions of nicotine and cotinine in biological fluids The detection limit at a 
signal to noise ratio of S corresponds with a splitlessly injected quantity of 
about 5 pg of nicotine and 15 pg of cotinine, which quantities in turn corre-
spond to minimum detectable amounts of 5 0 1 ng of nicotine and 0 2 ng of 
cotinine per ml of plasma or per 0 1 mi of urine 
Considering that the simple single-step extraction procedure described 
herein provides a limited degree of sample clean-up, the gas chromatographical 
analysis following it should have a high resolving power Excellent resolution 
was obtained by using a short (12i m) dimethyl silicone-coated capillary col-
umn combined with splitless injection under well-chosen values of critical 
parameters like inner insert volume (0 25 ml), carrier gas flow (0 8 mt/min) 
and purge activation time (30 s), an injection port temperature (200°) high 
enough to vapounze injected analytes and standards, but low enough to prevent 
their decomposition and prohibit the vapourization of compounds which could 
interfere in the chromatograms 
Figure 2 shows some representative chromatograms of plasma and urine 
extracts The peaks are symmetrical and well-resolved, widths at half-height 
varying from 1 sec for nicotine to 3 sec for cotinine The retention times are 
3 0 - 3 8 - 4 5 - 5 7 m m for nicotine, the ISTDs U-mcotyrine and 
nikethamide, and cotinine, respectively Caffeine is unintentionally detected 
at 6 5 m m The chromatographical runtime including the cooling time of the 
oven (200° •* 60') comes to 9 5 m m for a plasma extract and 10 m m for a urine 
extract Though no examples are shown, chromatograms with a similar appearance 
are obtained for the clear supernatant resulting from centrifugation (5 mm, 
1000 g) of human saliva 
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FIGURE 2 Chromatograms of (a) a plasma extract from a casual smoker after 24 
hours of smoking abstinence_, (b) idem, after smoking 14 cigarettes m 8 hours, 
(c) a morning urine extract from a 7 years old boy exposed to the smoke of 36 
cigarettes smoked by his parents during the preceding dayt and (d) a urine 
extract from a package-a-day smoker Peaks 1 = nicotine, 2 = b-mcotyrme 
(ISTD ) , 3 = nikethamide (ISTD ) , 4 = cot mme, 5 = caffeine Concentrations 
of nicotine I cotmine (a) 0 5 / 120 (b) 37 / 390 (c) 21 / 18 (d) 250 f 265 
ng/mt Attenuation (a f ь ) (a) and (b) 250, (c) 125, (d) 1000 (·10~Χ2) 
After injection of about 100 extracts, deterioration of chromatographic 
separation occurred as a result of the formation of carbonaceous deposits on 
the interior surface of the insert and in the column head In such an event, 
the polluted insert was replaced by a spare one, cleaned in chromic acid, 
rinsed in various solvents, and deactivated (see 'Glassware') In addition, 
20 cm of the column was broken off at the injector end and the column was re­
inserted into the injection port The column length of 12^ m reported here was 
in fact the mean of an initial length of 15 m and a terminal length of 10 m 
At this minimal length, the nicotine peak sometimes showed overlap with nearby 
endogenous peaks 
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plasma cone (ng/ml) 
FIGURE 3 Concentration profiles of nicotine (о) and cotmine С') m the plas­
ma of a steady smoker during 24 Ars. Each bottom triangle denotes the (time 
of) smoking of a single cigarette. 
The longevity of the collector bead was determined by the deposition 
rate of silicone particles originating from the column ('silicone bleed'). On 
the average a collector being in almost daily use lasted 6 months, which is 
equal to the maximum lifetime stated by the manufacturer 
Nicotine and cotinine plasma concentrations were determined over a 24 h 
period in a moderate smoker of a non-ventilated filter-tipped cigarette brand 
(13 mg of tar, 1.0 mg of nicotine) according to the proposed analytical 
method. Before analysis, the samples had been stored for 2 months at -20°. The 
concentration profiles are shown in figure 3. 
Accuracy Detector response is linear over the entire range of nicotine 
and cotinine concentrations added to the calibration standard samples. Corre­
lation coefficients of the calibration curves are between 0.990 and 0.999 
(average coefficient. 0.994). Calibration curves from day to day have repro­
ducible slopes that approximately equal the reciprocal of the spiked amount of 
ISTD, expressed in nMoles. This is an indication that the detector response to 
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TABLE 11 REPRODUCABILITY AND ACCURACY OF THE PROPOSED ASSAY 
FOR 1 HL SPIKED PLASMA SAtlPLES OR 0 1 ML SPIKED URINE SAMPLES 
CV = coefficient of variation 
Compound 
nicotine 
cotinme 
nicotine 
cotinme 
Spiked 
cone. 
ng/ml 
1 
2 
5 
25 
60 
5 
25 
50 
100 
250 
400 
50 
100 
200 
500 
1000 
50 
100 
200 
500 
1000 
Observed 
cone. 
ng/ml 
1.4 
2.2 
5.3 
25 4 
59 3 
5 2 
24.0 
48.3 
103 0 
246 9 
408.1 
51.1 
101.6 
208.7 
490 2 
983.0 
53.5 
100 4 
194.4 
512 7 
1025.8 
Standard 
deviation 
ng/ml 
0.2 
0.3 
0.1 
1.0 
1.1 
0 6 
1.6 
1 7 
2.8 
4.9 
6 1 
1.2 
2.5 
4.0 
9.3 
19.7 
6.8 
8.3 
8.6 
12.8 
19.5 
CV 
I 
(n=5) 
16.8 
13 6 
2.5 
3.9 
1.9 
11.5 
6.5 
3.5 
2.7 
2.0 
1.5 
2.3 
2 5 
1.9 
1.9 
2.0 
12 8 
8 3 
4.4 
2.5 
1.9 
nicotine and cotinme is comparable with the response to their respective 
ISTDs The mean intercept of successive cotmine regression lines is not sig-
nificantly different from zero, that of successive nicotine regression lines 
can be kept as low as a few tenth of ng of nicotine per ml of plasma or per 
0 1 ml of urine if the given procedure for the cleaning and silanizing of 
glassware is applied uncurtailed To reduce carry-over owing to the adsorption 
of nicotine and cotinme in the syringe, the latter was rinsed in vials con-
taining 10 ml of 2-propanol and 1 5 ml of concentrated ammonium hydroxide 
between injections 
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Reproducability characteristics were acquired by spiking blank 1 ml 
plasma samples and 0 1 ml urine samples with the usual amounts of ISTDs (see 
'Calibration') and with nicotine and cotinine to give samples of different 
concentrations within the range 1 - 60 ng of nicotine and 5 - 400 ng of coti-
nine per ml of plasma, and within 50 - 1000 ng of both nicotine and cotinine 
per ml of urine Five samples at each concentration were prepared and ana-
lyzed At each concentration the mean and the standard deviation of the 
observed concentration and the coefficient of variation (CV) was calculated 
The values are displayed m Table II The results show that plasma concentra-
tions of nicotine ä 2 - 5 ng/rol, plasma levels of cotinine > 5 - 25 ng/ml, and 
urinary concentrations of both alkaloids exceeding 50 - 100 ng/ml are measur-
able with a CV of = 10% or less These concentrations nicely cover the range 
of nicotine and cotinine levels occurrnng in moderate smokers (e g , see fig-
ure 3) 
2 5 CONCLUSIONS 
For the first time an assay procedure is described for the simultaneous 
analysis of nicotine and cotinine which 1) requires only one extraction step 
in which both alkaloids are extracted rapidly and nearly quantitatively, which 
2) is applicable to plasma and urine without modifications, and which 3) sepa-
rates both alkaloids from each other and from endogenous plasma and urine con-
stituents in a single and short gas-chromatographical run 
These qualifications were achieved by combining solid phase extraction, 
high resolution capillary gas chromatography, splitless injection, and 
nitrogen-specific detection The rigorous exclusion of extraneous nicotine and 
the structural analogy and resultant analogy in physico-chemical characteris-
tics existing between nicotine, cotinine and their respective internal stan-
dards also contribute to the reliability of the method 
In our laboratory the method is being used routinely to determine the 
pharmacokinetics of nicotine and cotinine and to estimate the nicotine intake 
of 'active' and 'passive' smokers More than 1000 samples have been analyzed 
for nicotine and cotinine so far by the procedure described 
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Chapter 3 
ESTIMATION OF THE NICOTINE CONTENT OF CIGARETTE 
FILTERS AND GLASS FIBRE ('CAMBRIDGE') FILTERS 
Harald W A Teeuwen and Ronald J W Aalders 
Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Mathematics, University of Nijmegen, Ρ О. Box 9101, 6500 ЯВ Nijmegen, 
The Netherlands. 
3 1 INTRODUCTION 
A sample preparation procedure composed of crushing, ultrasonic vibra­
tion, and filtration vas combined with a shortened version of the GC-NSD pro­
cedure presented m the previous chapter to quantify nicotine in filters of 
man-smoked and machine-smoked cigarettes, and in glass fibre ('Cambridge') 
filters used for trapping mainstream smoke aerosols during machine smoking. 
The mainstream smoke is that part of the smoke that is generated during 
a puff and is subsequently drawn through the cigarette and its filter by suc­
tion applied to this filter by the smoker or the smoking machine Part of the 
aerosols containing water, dry smoke condensate ('tar') and nicotine (which 
occurs almost completely associated with aerosols in the (slightly acid) 
cigarette smoke) is deposited in the cigarette filter. In human smoking, the 
complementary part of these substances is delivered to the smoker's mouth, 
together with the gaseous phase of the mainstream smoke which is virtually 
unaffected by most commercial cigarette filters. In machine smoking, the main­
stream smoke may be deprived of its remaining aerosols by filtering it through 
a 'Cambridge' filter, trapping more than 99% of the particles by weight After 
filtration, the particle phase and the remaining gaseous phase of the smoke 
may be separately analyzed for their substance composition. 
A quantitative analysis procedure for nicotine in cigarette filters will 
now be described In addition, a slight modification of the assay, rendering 
it applicable to analyze 'Cambridge' filters for their content of the alka­
loid, is given in a note at the end. 
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3 2 MATERIALS A N D M E T H O D S 
Materials A household blender/mixer (Moulinex model Moulinette 643 S, 
France) was purchased locally Cellulose acetate filters (diameter 2 5 cm, 
pore diameter 0 45 ym) were obtained from Schleicher & Schuil, Dassel, West" 
Germany Single-use polypropylene 2 ml-synnges ('Monoject') were from Bally-
money, Northern Ireland The ultrasonic bath was a Somcor model SC-120T (Sen­
icor Instrument Corp , New York) The origin of the chemicals and the other 
materials is specified in the section 'Materials and Methods' of Chapter 2 
Standard solutions Solutions of nicotine (30 mg/i) and of fi-nicotyrine 
(250 mg/E) were made up in propyl acetate If stored at 4° protected from 
light, their stability sufficed to be used for at least two weeks 
Procedure To ensure the highest accuracy, the cigarette butts to be 
analyzed were stored in air-tight bottles in the dark at room temperature by 
the subjects themselves and later in the laboratory The 10 butts selected for 
analysis from the daily pools collected by the subjects had a tuft of unburnt 
tobacco occluding the distal end of the filter, and they were free of lipstick 
stains as a potential source of substances interfering with the gas-
chromatographic analysis [1] Furthermore the mean length of the selected 
butts coincided with the mean length of the butts rejected for analysis Butts 
originating from the 16-day collection period of each subject were processed 
within-da> according to the following directives 
After removal of ashes and residual unburnt tobacco, the filters of the 
10 selected butts were crushed in a household blender for 30 sec The result­
ing mount of filter fibres was quantitatively transferred into an Erlenmeyer 
flask containing 100 ml of methanol The flask was stoppered and its suspended 
contents were subjected to ultrasonic vibration for 30 min Part (5-7 ml) of 
the suspension was filtrated through a cellulose acetate filter (pore diameter 
0 45 pm) A 25 pi aliquot of filtrate was pipetted into a 1 ml vial, to which 
an equal volume of the fi-nicotyrine standard solution was added as an external 
standard The contents of the vial were diluted with 600 yl of propyl acetate 
and thoroughly mixed Part (0 4-0 6 μΐ) of the mixture was injected under the 
conditions described in Chapter 2 ('Instrumentation') However, the GC oven 
temperature program was cut off at 152° after elution of the compound appear­
ing latest, which is the ESTD (R = 3 8 min) As a blank control sample, ten 
filters of unsmoked cigarettes of the same brand were processed analoguously 
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Calibration. Seven standard samples were prepared by transferring 0 - 1 0 
- 2 0 - 3 0 - 4 0 - 5 0 - 6 0 μί volumes of the nicotine standard solution into 1 
mí-vials. Addition of the ESTD and propyl acetate to these standard samples 
and their gas-chromatographic analysis were carried out as specified in the 
previous paragraph. A calibration curve was constructed by plotting the 
nlcotine/ESTD peak area ratio (Y) versus the amount of nicotine present in the 
standard sample (X). A handcalculator program calculated the slope 'a' and the 
intercept 'b' of the regression line (Y = aX + b) of the calibration curve. 
The absolute amount of nicotine (F ) in 10 filters giving rise to a 
uncorr
 β β 
peak area ratio 'y' can be shown by trivial calculation to average: 
F = 400 (y - Ь)/а (vg/filter) 
uncorr 
The nicotine amount in unsmoked cigarette filters (F ) is calculated the 
iinsm 
same way. The gross nicotine retention in filters of smoked cigarettes 
(F ) is corrected for the amount of nicotine present in unsmoked filters 
uncorr 
to yield the average amount of nicotine in the filters, deposited there by the 
act of smoking (F): 
F = F - F (vg/filter) 
uncorr unsm 
Throughout this dissertation, amounts of nicotine stated to be present in 
cigarette filters are corrected for nicotine present in these filters before 
smoking. 
Nicotine filter retention as a function of storage time. To obtain an 
Indication of the rate at which nicotine is lost in filter butts during stor­
age, we requested a smoker consuming 25 - 30 cigarettes/day to collect her 
smoked-out butts. Butts were gathered during a period of 16 consecutive days; 
daily saved butts were pooled in 50-mt brown polypropylene pots with a screw-
cap and stored in the way indicated in the beginning of this section. 
At the 17 day from the 16 portions of butts, two groups of 10 butts 
were selected having estimated equal average length, a tuft of unburnt tobacco 
at the distal end, and no sign of lipstick stains. The first group of 10 butts 
was analyzed on this very 17 day; the other group of 10 butts was carefully 
placed back into the screw-capped pots and was not analyzed until 14 days lat­
er (at the 31 day). The results of the analyses were compared. 
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3 3 RESULTS AND DISCUSSION 
Chromatography Figure 1 (a and b) displays chromatograms of 20 
cigarette filters, selected from a total of 31 butts pooled by the volunteer 
at the 7 day of his collection period One group of 10 butts was analyzed 
for its nicotine content when 10 days old, the other group of again 10 butts 
was analyzed 14 days later Thi chromatograms do not differ, except for the 
ratio of nicotine to ESTD which is slightly smaller for the older group of 
butts Figure 1 с shows that the amount of nicotine present in filters of 
unsmoked cigarettes of the same brand is relatively small, though not negligi­
ble 
The chromatograms have a clean appearance A minor unidentified peak is 
visible between the peaks of nicotine and the ESTD The unknown peak consti­
tutes a contaminant of the ESTD-solution, its identity probably being N-methyl 
myosmine (suggested by mass spectrometry) 
The retention times are 3 0 m m for nicotine and 3 8 m m for the ESTD 
ß-mcotyrine The peaks are very well resolved, peak widths at half-height 
varying from 1 sec (nicotine) to 2 sec (ESTD) 
Filters of smoked cigarettes of the brands investigated in the course of 
this research were found to contain 0 4 - 3 0 mg of nicotine, depending on 
brand and smoking technique, whereas unsmoked filters typically contained 20 -
40 ]ig of it The latter amount probably is deposited in the filter by inward 
diffusion of nicotine migrated from the tobacco adjacent to the filter 
Although the ESTD ft-nicotynne is a tobacco alkaloid itself, it occurs 
only m trace quantities of a few micrograms or even ]ess in filters of smoked 
cigarettes Therefore its use as an external standard in this analytical 
method is validated 
Accuracy Correlation coefficients of regression lines varied from 
0 990 to 0 999 (average 0 996) The total recovery of nicotine in this method 
solely depends on the efficacy of detachment of nicotine from the crushed fil-
ter fibres in methanolic milieu, which probably is complete The working-up 
procedure does not include extraction or evaporation steps in which detectable 
losses could take place Another factor that might give rise to nicotine loss-
es is the transfer step of the crushed filter fibres into the flask containing 
100 ml of methanol However, an experienced analyst will recover more than 99% 
during transfer 
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FIGI/RE 1 Chromatograms of cigarette filters (a) a set of 10 smoked-out fil­
ters, collected by a smoker at the 7 day of a 16-day collection period, and 
analyzed when they were 10 days old, (b) another set of 10 filters, collected 
by the same smoker at the same day, analyzed when they were 24 days old, (c) 
10 filters of unsmoked cigarettes of the same brand Peaks 1 = nicotine, 2 = 
contaminant, 3 = ESTD ($-nicotyrine) The nicotine peak in chromatogram (b) is 
slightly lower than m (a), Indicating a small nicotine loss having ocurred 
between the 10C and the 24С day of storage (-4 3 %, cf Table I) 
The coefficients of variation (CV) could not be determined, because each 
set of ten smoked-out filters is unique and hence can only be analyzed once 
An alternative strategy of spiking unsmoked filters with equal amounts of 
nicotine was assumed to lead to artifacts as a result of the inevitable inho-
mogeneity of nicotine distribution in the filter volume and because of the 
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non-reproducible amount of nicotine already present in filters of non-smoked 
cigarettes Therefore this strategy was rejected 
Nevertheless, the CV may be 2 5 % at most, 2 5 % being the CV determined 
for the analysis of nicotine at high concentrations in biological fluids We 
feel that this estimate is realistic, because 
• the recovery of nicotine is more reproducible and higher in filter analy-
sis than in the analysis of biological fluids, and 
• analytical methods in general tend to be more precise with the amount of 
material to be analyzed 
The concentration of nicotine in the methanol suspension of crushed filters 
(typically SO ug/mí) exceeds that in blood plasma (typically 20 ng/m£) by 
three orders of magnitude 
Nicotine filter retention as a function of storage time As filter butts of 
smoked cigarettes age, they desiccate The 'desiccation' process in a broad 
sense applies both to the water content and to the nicotine content of the 
filter 
Nicotine is lost from the filter through chemical degradation, evaporation 
('sublimation'), and maybe fotolytic decomposition The rate of the latter 
process may be effectively reduced to zero by storing the filters in the dark 
Evaporation is minimized by storing the filters in an air-tight flask at tem-
peratures not higher than ambient Moreover, evaporation is retarded if the 
butt contains a residual tuft of tobacco sealing the distal end of the filter 
The desiccation process in butts stored under the above-mentioned optimal 
conditions was investigated as a function of time as described under 'Materi-
als and Methods' Figure 2 shows the results of the first analysis, whereas 
Table I compares the results of the first and the second analysis 
The agreement of the results of the first and the second analysis is clos-
er than 10 %, in spite of desiccation and notuithstanding the fact that each 
portion of butts must be considered to be unique It may be concluded that 10 
cigarettes are a good random check to determine the daily average nicotine 
butt content The nicotine content of individual cigarette butts must be sus-
pected to vary considerably though, as does the average content from day to 
day (figure 2) 
The rate at which nicotine disappears from these butts appears greatest in 
the first five days of butt storage, it amounts to some 6 % (1 2 % per day) of 
the amount present in the filters We associate this rapid loss with nicotine 
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Average cigarette filter nicotine content (MC) 
1 2 3 4 5 6 7 β 9 10 11 12 13 U 15 16 mean 
experimental day ί SD 
FIGURE Ζ Daily average of the nicotine content of 10 butts of filter 
cigarettes, smoked and collected by a smoker during 16 consecutive days For 
each of the 16 days a representative check of 10 smoked filters was taken and 
collectively analyzed at the 17 day The last bar shous the mean filter 
nicotine content (± SD) in the whole period Vote the large differences in 
nicotine content from day-to-day, which likely correspond to proportional dif­
ferences m smoking technique 
evaporation from superficial areas of the filters In the weeks thereafter, 
nicotine is lost at a slower rate, presumably from deeper layers of the fil­
ters (0 3 - 0 4 % per day) 
These figures are comparable to the 13 % average nicotine loss reported in 
reference [2] for 62 portions of 10 butts of ventilated filter cigarettes 
stored for a period of 14 days 
The mean age of the butts saved by our volunteers in the course of a phar­
macokinetic investigation of the nicotine intake by human smokers came to 9 
days As a tentative conclusion on the basis of the available data (Table I), 
we expect a mean percentage of approximately 7¿ % of nicotine to be lost from 
the butts during storage 
The nicotine intake per cigarette at mouth-level (D) and at blood-level 
(D«f ), and the nicotine intake rate (D) given elsewhere in this thesis were 
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TABLE I LOSS PERCENTAGES OF NICOTINE IN CIGARETTE FILTERS AS A FUNCTION OF 
STORAGE TIHE 
Butts collected by the smoker at the (17-ι)Ζ day (i = 1,2, 16) of the 
16-day collection period were analyzed at an age of ι days1, and 1+14 days2, 
if assigned to 'short' and 'prolonged' storage groups, respectively 
Butt age1 Butt age1 Loss' Butt age1 Butt age1 Loss' 
days days Ζ days days Ζ 
1 
2 
3 
4 
5 
6 
7 
a 
15 
16 
17 
18 
19 
20 
21 
22 
-9 2 
-7 8 
-6 5 
-5 4 
-4 0 
-3 0 
-3 5 
-2 1 
9 
10 
11 
12 
13 
14 
15 
16 
23 
24 
25 
26 
27 
28 
29 
30 
+1 6 
-4 3 
-4 3 
-о г 
+2 9 
+3 0 
-4 1 
+1.0 
1
 Age of short-stored group of butts at analysis (analysis result F mg) 
1
 Age of longer-stored group of butts at analysis (analysis result F mg) 
' Calculated as {(F - FJ/Fj) · 100% 
not corrected for this loss, because we felt that the body of available data 
on nicotine losses from the stored butts uas too limited The listed values of 
the former-mentioned intake quantities therefore are slight underestimations 
Unfortunately, a more profound investigation of the rate of the nicotine loss 
procebs was not feasible because of lack of time 
3 4 NOTE ON THE ANALYSIS OF GLASS FIBRE FILTERS 
The analytical procedure for estimating nicotine amounts trapped on 
'Camb'idge' glass fibre filters is essentially as described in the Dutch stan­
dard SEN 1382 [3] and is comparable to the one used to estimate the amounts 
deposited in cigarette filters 
The particulate matter in the mainstream smoke of 10 cigarettes smoked 
on a machine is deposited on a 'Cambridge' filter The glass fibre filter is 
removed from the holder and immersed in 100 mi of methanol Particulate matter 
deposited on the inner walls of the holder is wiped off using a pair of tweez-
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ers with half a clean, folded 'Cambridge' filter, which is then also immersed 
in the methanol. The Erlenmeyer flask containing the filters and the methanol 
is shaken for 15 min. It is then stored overnight. An aliquot sample of the 
supernatant liquid is used for analysis as described in § 3.2 after filtra-
tion. A blank is prepared by the same procedure using one and a half clean 
'Cambridge' filter. 
3.5 CONCLUSIONS 
The method presented here for the estimation of the absolute retention 
of nicotine in filters of smoked cigarettes is rapid and precise. It is well-
documented with respect to the way in which filter-tipped butts should be 
stored in order to minimize nicotine losses from them pending analysis. An 
indication of the relative nicotine loss rate from the filter butts as a 
result of storage for a period up to one month has been given. Analytical 
results are only slightly affected by a storage time of 9 days. 
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Chapter 4 
CAPILLARY GASCHROMATOGRAPHIC - MASS SPECTROMETRIC 
- SELECTIVE ION MONITORING METHOD FOR MEASURING 
RELATIVE LEVELS OF COTININE AND ORALLY ADMINISTERED 
COTININE-D2 IN SMOKERS' BLOOD PLASMAS 
Harald W A Teeuwen and Ronald J W Aalders1 
Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Mathematics, University of Nijmegen, Ρ 0 Box 9101, 6500 HB Nijmegen, 
The Netherlands 
4 1 INTRODUCTION 
While designing the investigation of nicotine intake of human cigarette 
smokers, the need arose for an analytical method that would enable us to sepa­
rately detect nicotine's principal metabolite cotmine and a deuterium-
labelled cotmine analogue 4',4'-dideutero cotmine (cotmme-DZ) in smokers' 
plasmas We synthetized the latter cotinme analogue with the intention to 
administer it perorally to our experimental smokers In order to reveal a basic 
pharmacokinetic parameter (total clearance), which Is identical for cotimne-
И2 ('native' cotmine) and for cotmine-DZ 
In this thesis a capillary column gas chromatographic method with 
nitrogen-sensitive detection is described for the analysis of nicotine and 
cotmine m biological fluids By its very nature, a nitrogen sensitive 
detector cannot distinguish between a molecule and the same molecule provided 
with an isotopie lable To attain our goal, we replaced nitrogen-sensitive 
detection by mass spectrometry (MS) with the facility of selected ion monitor­
ing (SIM) As the method is not aimed at nicotine analysis, it became feasible 
1
 Present address Turmac Tobacco Co , Ρ 0 Box 12, 6900 AA Zevenaar, The 
Netherlands 
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Co speed up Lhr GC oven temperature program as well 
The resulting method does not employ an internal or external standard. 
Hence relative concentrations of cotinme and cotinine-D2 are measured. Stated 
differently, the concentration ratio of cotinme and cotinine-D2 is determined 
rather than the absolute concentrations of these compounds. The latter are 
calculated by combining the relative concentrations obtained by the presently 
described CC-HS-SIH method with the total cotinme concentration (the sum of 
the concentrations of cotinme and cotinine-D2) as analyzed by CC-NSD. This 
way of combining analytical data obtained by CC-NSD and GC-MS-SIM departs from 
the virtually identical physico-chemical properties of cotmme-HZ and its 
deuterated counterpart, particularly qua lonizability, and pattern and effi-
ciency of fragmentation. We now proceed to describe the CC-HS-SIH method 
A 2 MATERIALS A N D METHODS 
Glassware, laboratory and personnel The procedure followed to obtain 
clean silanized glassware free of cotinme was outlined before Again, a non-
smoking analyst (R.A ) performed the analyses in a smoke-free laboratory 
Chemicals and solvents The reader is referred to the honranyroous sec-
tion in chapter 2 for the origin of the bulk of the chemicals and solvents 
4',4'-dideutero cotinme was synthesized in eight steps departing froni nico-
tinic acid and pyrrolidone according to a procedure outlined in Appendix I of 
this thesis. It was found to be Ì 99% chemically pure by spectrometncal tech-
niques (UV, IR, 'H-NMR) solely, or combined with chromatography (reversed-
phase HPLC with UV-detection at 254 and 280 nm, GC-NSD, GC-MS). 
Instrumentation. The analyses were performed on a Hewlett Packard Model 
5790 gas Chromatograph equipped with a split/splitless capillary injector, a 
splitless liner and a fused silica capillary column (17.5 m χ 0.20 mm ID) 
wall-coated with a dimethyl silicone liquid phase (phase ratio = 150, Hewlett 
Packard) The gas Chromatograph was coupled to a Hewlett Packard Model 5970 
quadrupole Mass Selective Detector by insertion of the capillary column into 
the GC-MS interface at a distance of less than 1 mm from the ion source block. 
The gas Chromatograph and the mass selective detector were connected to a HP 
9816 terminal/data system with implemented peak integration software. 
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The GC-MS system was operated at the following temperatures: injection 
port: 250', interface and ion source block: 270°, oven temperature: 75" dur-
ing injection, at 30 sec after injection followed by a semi-ballistic raise to 
ISO', a further raise at a rate of 20°/min to 220', and finally a raise at 
64'/rain to 250°, which oven temperature was held for 1.5 - 2.5 min in case of 
a plasma sample and for 2.5 - 4.5 min in case of a urine sample. The precise 
dwelling time at 250' depended on the occurrence of late-eluting endogenous 
peaks in the samples, this occurrence varying between subjects. 
The mass spectrometer was operated with an electron ionization voltage 
of 70 V and an accelerating voltage of 1800 V. The source pressure varied 
from 4*10 to 6·10 Torr with the GC oven temperature. The carrier gas pres-
sure drop amounted to 1.0 Bar, resulting in a carrier gas (helium) flow rate 
of 0.5 mî/min. The make-up gas (helium) flow rate was 25 mt/min and the purge 
flow rate was 2 mt/rain, except in the 30 sec during and following injection of 
a sample. 3 μί samples were injected in the splitless mode. 
Prior to the beginning of a series of measurements, the ion source and 
the mass analyzer voltage settings were optimized to monitor the precise 
weight of the cotinine and cotinine-D2 base peaks (m/z = 98 and 100, respec­
tively) . For this purpose a volume of 3 yt propyl acetate containing about 50 
ng of both cotinine and cotinine-D2 was injected into the GC-MS system. Six 
mass channels of 0.05 u difference around the theoretical mass value were mon­
itored. Peak integration in each channel yielded the channel showing the 
highest intensity. The mass of the most intense channel in the 98 u-range was 
taken as the cotinine base peak, that in the 100-u range as the cotinine-D2 
base peak. 
Solid Phase Extraction Procedure. The extraction procedure is identical 
to the procedure described in chapter 2 for the GC-NSD method. In practice, 
extracts of each sample containing both cotinine-H2 and deuterated cotinine 
were divided in two. One aliquot was chromatographed with GC-NSD to determine 
its nicotine and (total) cotinine concentration, whilst the other aliquot was 
injected into the GC-MS combination to determine the ratio of the cotinine-H2 
and cotinine-D2 concentrations. 
Total recovery and accuracy. The total recovery of cotinine-H2 in the 
above-mentioned extraction procedure is listed for various cotinine concentra­
tions in Table I of chapter 2. On the basis of the structure identity existing 
between the two cotinines and the ensuing virtually identical physico-chemical 
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characteristics of the two compounds, their recovery data must be expected to 
be identical as well 
The accuracy and reproducability of the described method were not deter­
mined a prion An indication of the reproducability of the method in plasma 
was acquired afterwards by comparing analysis results of duplicate samples 
from our experimental volunteers Be f
n
 and f-i the measured molar fractions 
of cotinine-D2 in a particular plasma sample and its duplicate, respectively, 
then the relative deviation Δ , of the two measurements is defined as 
rel 
Л
ге1 = {І£В- V 1 ' ( fD + V » ' 100* 
& , was studied in three cotinine-D2 plasma concentration ranges [0, 50>. 
rel 
[50, 100> and [100, -»> ng/mt The concentration of nicotine-derived cotinine 
in our smoking subjects always was in the latter range, mostly having a value 
in between 200 and 350 ng/m£ 
A 3 RESULTS AND DISCUSSION 
Mass spectrometry Mass spectra of cotinine-H2 and cotinine-D2 are pre-
sented in figure 1 The integer base peaks of cotinine-H2 and cotinine-D2 are 
98 and 100, respectively, these fragment masses corresponding to the (mono-
lonized) pyrrolidine moieties of the cotinine molecule The mass mantissa as 
determined by the procedure described in the section 'instrumentation' was 
found to be identical for both cotinine species at any time, as is to be 
expected from the mass difference between hydrogen and deuterium, which equals 
unity up to 0 01 u The mantissa mostly amounted to 05 , sometimes however to 
00 or to 10 
Chromatography Typical plasma chromatograms of a steady smoking vol-
unteer are shown in figure 2 The (coinciding) peak of cotinine-H2 and 
cotinine-D2 has a retention time of 3 2 - 3 3 m m and a peak-width at half-
height of about 10 sec under the conditions specified 
It may be inferred that most of the chromatogram run time is used to 
elute numerous endogenous peaks, which are present in both chromatograms of 
both selected ions (figure 2c/d), most notably in the mass 98 chromatogram 
(figure 2c) The time interval of cotinine elution ( 3 1 - 3 5 rain), however, 
is not significantly occupied by endogenous peaks 
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FIGURE i. Mass spectra of (a) cotinine-HZ and (b) cotlnine-D2. Base peaks cor­
respond to the mass of the S-membered (pyrrolidine) rings. Hasses of the 
molecular ions are also clearly discernible. Structures of intact soléenles 
and base peak fragments are shown. 
The proposed GC-MS-SIM analytical method is reasonably rapid, the time 
interval between injections being 14 minutes. Due to the adverse heat capaci-
ty characteristics of the GC-oven, approximately half of the runtime is needed 
to cool the oven from 250* down to 75'. 
An example of cotinine plasma profiles determined with the aid of the 
presently described assay is given is figure 3. Though no examples are shown, 
the reported method is also valid to determine the cotinine species composi-
tion existing in saliva and urine of smokers after ал oral dose of cotinine-
D2. 
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FIGURE 2 Chromatograms showing total abundance of the masses 98 and 100 in 
(a) blank human plasma and (b) m the plasma of a smoking volunteer obtained ± 
I h after ingestion of 5 3 mg of cotinine-D2 Separate abundances of mass 98 
and mass 100 m the plasma of chromatogram (b) have been indicated m chro­
matograms (c) and (d), respectively 
Accuracy and sensitivity An indication of the accuracy of the present 
analytical method was obtained by comparison of analysis results of duplicate 
samples The relative deviation Δ . of 96 duplicate measurements, spread over 
three cotinine-D2 concentration ranees, is shown in Table Ι Δ , is seen to 
0
 rel 
increase as the cot mine-D2 concentration decreases, cotinine-H2 meanwhile 
assuming a high steady-state value (200 - 350 ng/m£) In the lower part of the 
0 - 5 0 ng/mll range the method is less accurate, Δ . probably being higher 
than 10% The low accuracy at these low cotinine-D2 levels is due to the rela­
tively low sensitivity of the mass spectrometer as a cotinine detector To 
compensare for reduced accuracy, duplicate plasma samples taken 24 hours after 
cotinine-D2 administration (figure 3) often were run twice on the GC-MS 
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FIGURE 3 Plasma concentration vs time profiles of (о) nicotine, (') coti­
nine, and (χ) cotmine-DZ in a steady smoker as determined over a 24 hrs peri­
od by GC-NSD and GC-MS-SIH Bottom arrows denote the (time of) smoking of sin­
gle cigarettes A 5 Э mg dose of cotmme-DZ was administered to the smoker 
per os m a gelatine capsule at 9 00 a m 
4 4 CONCLUSIONS 
A gas chromatographic mass spectrometnc method employing selective ion 
monitoring, preceded by solid phase extraction of the sample, has been devel­
oped to analyze the relative concentrations of nicotine-derived cotinine 
(cotinine-H2) and a dideuterated cotinine species (cotinine-D2) given by mouth 
in the body fluids (mainly blood plasma) of smoking volunteers 
The relative deviation of duplicate analyses is less than 10% at coti­
nine concentrations greater than about 25 ng/m£ It shares its working-up pro-
cedure with the GC-NSD method described elsewhere in this dissertation , and 
was combined with the latter method to reveal the absolute concentrations of 
cotini.ne-H2 and cotinine-D2 in smokers' plasmas 
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TABLE I RELATIVE DEVIATION OF PS DUPLICATE PLASMA ANALYSES OF THE C0TININE-D2 
MOLAR FRACTION 
Δ . = relative deviation of duplicate samples, η = number of plasma samples 
m the specified concentration range 
lcotinine-D2] (ng/mt)* 0-50 50-100 2 100 
Δ , (mean ± SD) (Ζ)1 7.2 + 2.6 3 4 t 1.0 2 2 ± 0.5 
rel 
π' 24 49 25 
1
 Concentration range of cotinine-D2 The concentration of cotinine-H2 exceeds 
100 ng/ml, 
2
 Δ j = {\fD - fD,\ I (f + fD,)) · 100%, where /^ and f , are duplicate mea­
surements of the molar fractions of cotinine-D2 m each sample, 
5
 Σ η = 9S. The plasma samples were taken from 7 volunteers (smokers of 
cigarette brand F2) participating in experiments aimed at determining nicotine 
intake by human cigarette smokers 
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Chapter 5 
RAPID AND SENSITIVE GAS CHROMATOGRAPHIC 
DETERMINATION OF CAFFEINE IN BEVERAGES AND 
BIOLOGICAL FLUIDS 
Harald W.A. Teeuwen, Eric L. Eibers, Jacques M. van Rossutn, 
* 
and Robert M.M. Maes 
Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Mathematics, University of Hijmegen, P.O. Box 9101, 6500 ΠΒ Nijmegen, and 
Netherlands Institute for Drugs and Doping Research (N.1.D.D.R.), State 
University of Utrecht, Vondellaan li, 3521 GE Utrecht, The Netherlands. 
5.1 SUMMARY 
A gas chromatographic procedure has been developed for the determination 
of caffeine in plasma, saliva and xanthine beverages. Using a 75 cm column 
packed with OV-17 and nitrogen-phosphorus selective detection, a suitable lim­
it of analysis (coefficient of variation (CV) = 10.2 %) of 50 ng/mi in plasma 
starting with a sample volume of 1 mt was obtained. Within-dây CVs at caf-
feine concentrations of 0.1 - 0.5 - 2.0 - 7.5 - 15.0 Vg/ml in plasma were 7.7 
- 5.6 - 4.8 - 3.8 - 3.4 %, respectively. The limit of detection, defined as 
the injected quantity of caffeine giving rise to a signal to noise ratio of 2 
is 40 pg caffeine, corresponding to a plasma concentration of 1 ng/ml. 
The procedure involves addition of the internal standard 7-pentyl theo-
phylline and alkaline extraction of the sample with dichloromethane. The 
described method rivals any gas-chromatographic analysis procedure published 
so far in rapidness and accuracy. 
Plasma and saliva caffeine concentrations were determined in a healthy 
male volunteer swallowing 400 ml of coffee. The calculated pharmacokinetic 
parameters, assuming complete caffeine absorption from the G.I. tract, agree 
with previously published values. 
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5 2 INTRODUCTION 
Caffeine is an alkaloid occurring in plants distributed widely through-
out the uorld Its consumption by man, almost exclusively as beverages of var-
ious kinds, reaches back to the Paleolithic and has unflagglngly continued 
until the present day The dailj pcr-capita intake of caffeine In the United 
States is estimated to average above 200 mg m recent times, 90% of this 
amount resulting from drinking coffee [1] It is expected that Western Euro-
pean figures on caffeine consumption are in close agreement with the American 
ones So, on a molecular basis, caffeine after ethanol probably occupies the 
second highest position on the list of mass-consumed pharmacological agents in 
Western Society 
Undoubtedly, the popularity of caffeine beverages depends on its stimu-
lant action on the central nervous system resulting in the wellknown effects 
of elevating mood, decreasing fatigue and increasing performance Although 
caffeine is a potential drug of abuse (for a review of caffeine abuse see 
Gilbert, [2]), cases of abuse are rare Furthermore, caffeine has a low toxic-
ity, is relatively inexpensive and, if withdrawn, its absence implements only 
a mild abstinence syndrom Therefore caffeine consumption does not constitute 
a significant medical or social problem and, unlike that of e g alcohol or 
tobacco, never has been the subject of governmental prevention campaigns 
focussed on especially adolescents Significantly, 'teetotalism' does not ban 
the teetotaller from enjoying coffee and caffeine 
Altogether, it looks much like the morning cup of coffee or tea will 
remain part of the Western dietary habit for a long time to come, an expecta-
tion that stresses the need for further investigations into the intake, the 
pharmacokinetics, metabolism and pharmacodynamics of caffeine 
As the initial stage of such an investigation, we developed several ana-
lytical methods for the assessment of caffeine and its metabolites m a 
variety of matrices We here report a sensitive and specific gas-liquid chro-
matographic method for caffeine analysis in human plasma and saliva and in 
xanthine beverages including coffee, tea, cola-flavored softdrinks and cocoa 
This GLC method has the shortest runtime but one ever published for an analyt-
ical caffeine method and hence is very convenient for the routine analysis of 
large amounts of samples The described method was put to the test in a phar-
macokinetic pilot experiment 
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5 3 MATERIALS AND METHODS 
Standards and reagents Caffeine (CAF) and theophylline (TP), both as 
the monohydrate, and tetrabutylammonium hydrogen sulphate (TBA'HSO.) were pur­
chased from Janssen Chimica, Beerse, Belgium Pentane, ethanol, 
dichloromethane, and sodium hydroxide (Merck, Darmstadt, F R G ) were of ana­
lytical grade 1-Jodopentane (Merck) was of synthetical grade 
A CAF stock solution in ethanol (1 mg/mt) was diluted to prepare refer­
ence solutions of 100, 25, 5, and 1 ug/rai The solutions were stable for at 
least 1 month when stored at 4' 
Synthesis of the internal standard 7-pentyl TP (7p-TP) was used as an 
internal standard (ISTD) and was synthesized by extractive alkylation of TP 
according to the directives given by Sonati et al [3] To each of twenty 10 
mi tubes 100 vi of a TP solution in ethanol (1 g/i) was added After evapora­
tion of ethanol (50°, dry nitrogen), 22 55 mg TBA'HSO, dissolved in 2 5 ml 0 1 
N NaOH, 2 5 ml CH.C1, and 0 5 ml 1-Jodopentane were subsequently added The 
tubes were tightly closed with a PTFE screw-cap and shaken for 1 h at 50° in a 
horizontal position After cent r if ligation (5 min, 1000 g) the (lower) organic 
phases were transferred into fresh tubes and evaporated under dry nitrogen 
(40°) The dry residues were dissolved in 2 mi of pentane and left in an 
ultrasonic bath for 10 min After centrifugation the clear pentane solutions 
were transferred to 20 new tubes and the pentane was evaporated The residues 
were each taken up in 5 mi of ethanol to reach a concentration of approximate­
ly 26 pg 7-pentyl TP per ml (assuming the reaction yield is 100 %) The 
ethanolic solutions were pooled, the 100 ml pool sufficed for a thousand 
assays and was stored at 4° 
Gas Chromatograph and nitrogen-phosphorus selective detection A 
Hewlett Packard model 5710 gas Chromatograph equipped with a nitrogen-
phosphorus selective detector was used The glass column (75 cm χ 3 mm ID) was 
degreased by slowly leading a 80 ml boiling water-toluene (v/v = 50/50) mix­
ture through it Subsequently it was dried thoroughly, sylilated, and packed 
with 5% OV-17 on Gas-Chrom Q, 80-100 mesh The packing was prepared by mixing 
Gaschrom Q coated with 10% OV-17 and with 3% OV-17 (Applied Science Laborato­
ries Ine , Pensylvania, USA) in the ratio 2 5 The packing was deactivated 
by 5 injections with 3 μΐ N,0 bis trimethylsilyl trifluoroacetamide (BSTFA, 
Pierce, Rockford, Illinois, USA), each injection time-spaced by 15 min During 
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deactivation, helium was led through the column at a flow of 5 mi/min at an 
oVen temperature of 100e. 
Operating conditions were as follows: injection port temp. 250', oven 
temp. 220°, detector temp. 300°, detector voítage 16 V, helium (carrier) flow 
rate 30 mt/min, hydrogen flow rate 3,0 ml/rain, air flow rate 50 mt/min. 
The detector output signal was led to a flow chart recorder (Model BD 8, 
Kipp & Zonen, Wormer, The Netherlands) and via an analog/digital converter 
(Model 1B652 A, Hewlett Packard) to an electronic peak integrator (Model 
Silent 700 ASR, Texas Instruments). 
Procedure. An aliquot of 100 \¡t of the ISTD solution was evaporated to 
dryness at 50° in a 10 ml test tube. Subsequently the sample to be analyzed, 
being either a 1.0 mi plasma or saliva sample or a beverage sample diluted 50 
- 200 times to 1.0 mt with aqua dest, was added, followed by 50 yt 2 N NaOH 
and 7 mt of dichloromethane. The tube was then closed with a screw-cap and 
shaken for 10 min. After centrifugalion (10 min, 1000 g) the organic layer was 
transferred into a clean tube and evaporated to dryness under a gentle stream 
of nitrogen at 40". The residue was reconstituted in 50 μί of pentane. 2 vl 
allquots were injected into the gas Chromatograph. 
Calibration was accomplished by using the procedure on prepared water or 
blank plasma standards to which known amounts of CAP had been added. Water 
standards were prepared in case of saliva or beverage analysis. Blank human 
plasma was supplied by the volunteer subjects after an abstinence period pre­
ceding each experiment. Before analyzing beverage samples or subjects* plasma 
or saliva samples, the plasma or water standards were analyzed and the peak 
areas of CAF and the 1STD were measured. A calibration curve was prepared by 
plotting the peak area ratio of CAF to the ISTD against the CAF concentration. 
A handcalculator programme calculated the regression line of the calibration 
curve. The beverage samples or the subjects' plasmas or salivas were then ana­
lyzed and the CAF to ISTD peak area ratios were determined. The CAF concentra­
tion in each sample was calculated according to the regression line. 
Reproducability and recovery. The reliability of the method was tested 
by applying the procedure to В prepared 1 mi plasma or water samples spiked 
with 0.10 - 0.50 - 2.0 - 7.5 - 15.0 yg CAF. Mean values, standard deviations 
and ranges of the measured concentrations were determined. Coefficients of 
variation (CV) were obtained by dividing the standard deviation by the corre­
sponding mean value for each concentration. Recoveries of CAF and its ISTD 
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were determined by injecting known aliquots of standard solutions of both com-
pounds directly into the GC and comparing the resulting peak areas of each 
compound to those obtained after injection of worked-up samples 
Pharmacokinetic pilot experiment A healthy male non-smoking volunteer 
(23 years, 68 kg) who had abstained from coffee, thea, cola beverages, cocoa 
and chocolat products for 60 hours preceding the experiment was given 200 mt 
of freshly brewed coffee ('Zilvermerk', Douwe Egberts, Joure, The Netherlands) 
in a cup The volunteer emptied the cup in 8 minutes, taking a draught every 
minute (time of the first draught was taken t = 0) The first blood sample was 
taken at t = 10 m m Then the subject drank another 200 mi coffee in 8 
draughts, starting at t = 11 min Further blood samples were taken at t = 21 -
29 - 37 - 46 - 55 min and at t = 1 1 - 1 3 - 1 8 - 2 8 - 4 3 - 6 8 - 12 4 -
23 4 hours After the second cup of coffee, the subject was asked to brush his 
teeth thoroughly 1 5 mí saliva samples were produced a t t = 1 0 - 1 5 - 3 2 -
4 0 - 5 6 - 8 3 - 14 9 - 25 7 hours Saliva production was not stimulated 
Blood and saliva samples were centnfuged for 10 min at 1000 g The plasma 
samples and the clear salivary supernatant were stored at -20° Five coffee 
samples (5 μ£) , taken from each of the volunteers two cups of coffee, were 
diluted to 1 mi with distilled water and frozen at -20° pending analysis 
Analysis of all samples was performed two days after termination of the exper­
iment 
5 4 RESULTS 
Chromatography Figure 1 shows typical chromatograms of plasma, saliva 
and (diluted) coffee extracts CAF (peak 2) is well separated from the ISTD 
(peak 3) and from a contaminant present in the ISTD solution (peak 1) The 
retention times are 0 9 m m for this contaminant, 1 4 m m for CAF and 2 7 m m 
for ISTD No other peaks of significant size are present in the chromatograms 
of either plasma, saliva, or beverage extracts The runtime is as short as 3 3 
m m The limit of analysis, defined as the lower concentration-limit that can 
be analyzed with a CV < 10%, is 50 ng/rat 
Accuracy and recovery Table I lists spiked concentrations and mea­
sured concentrations together with their range and CV for a variety of CAF-
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FIGURE 1 Chromatograms of (a) a plasma extract from our pharmacokinetic pilot 
subject after a 60 h abstinence period from all CAF-contammg beverageSj food 
and medications, (b) a plasma extract from the same subject at t = 6 S h in 
the pilot experiment, the CAF concentration being 1 6 vg/ml, (c) a saliva 
extract from the subject after the 60 ft abstinence period, and (d) an extiact 
from the coffee after 200 times dilution, the resulting CAF concentration 
being 1 9 vg/ml Peaks 1 = unidentified contaminant present m the ISTD stan­
dard solution, 2 = CAF, 3 = ISTD (7-penty] theophylline) 
concentrations in plasma and water Measured values correlate within at most 
6% with the spiked values The CV is as low as 1 9 % at a plasma CAF concen­
tration of 15 0 pg/m£ The detection limit, defined as the injected amount of 
CAF yielding a peak signal to noise ratio of 2, is about 40 pg CAF, corre-
sponding to a plasma concentration of 1 ng/mft 
The correlation coeffient г averaged 0 9990 for an 8-point plasma 
regression line, 1 mi blank plasma or water samples being spiked with 0 - 0 5 
- 1 0 - 2 0 - 5 0 - 8 0 - 10 0 - 15 Oiig CAF The lowest r value obtained m 
one month of almost daily analysis was 0 9971 We are unable to give a general 
equation for the regression line, because the slope of this line depends on 
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TABLE I REPRODUCABILITY AND ACCURACY OF THE PROPOSED ANALYTICAL 
PROCEDURE AT VARIOUS CONCENTRATIONS OF CAFFEINE IN PLASMA AND WATER 
R = recovery, CV = coefficient of variation, η = number of assays 
Spiked Measured Range of CV R η 
cone cone cone 
mg/l mg/l mg/l Ζ 2 
Pi­
va 
asma 
ter 
0 
0 
0 
2 
7 
15 
0 
0 
0 
г 
7 
15 
050 
100 
SO 
00 
50 
00 
050 
100 
50 
00 
50 
00 
0 
0 
0 
Ζ 
7 
15 
0 
0 
0 
1 
7 
14 
048 
096 
49 
04 
53 
15 
047 
106 
52 
95 
80 
75 
0 041 • 
0 088 • 
0 44 • 
1 91 • 
7 15 • 
14 66 • 
0 040 • 
0 090 • 
0 43 • 
1 81 • 
7 34 • 
14 34 • 
• 0 057 
• 0 109 
• 0 55 
• 2 12 
• 7 95 
• 15 70 
• 0 55 
• 0 121 
• 0 59 
• 2 14 
• 8 09 
• 15 25 
10 
7 
5 
4 
3 
1 
9 
9 
7 
5 
4 
1 
2 
7 
6 
8 
8 
9 
1 
2 
7 
0 
3 
9 
101 
98 
94 
97 
92 
89 
103 
99 
96 
97 
91 
91 
5 
2 
7 
9 
9 
3 
0 
2 
4 
1 
0 
9 
8 
8 
8 
8 
a 
8 
8 
8 
a 
8 
8 
8 
the concentration of the ISTD solution and hence on the efficiency of the syn­
thesis reaction, which varies somewhat between batches Additionally, the 
slope of successively obtained regression lines using one particular batch 
gradually increases some 20 X in the course of 4 - 6 weeks, the increase must 
be due to slow decomposition of the internal standard solution 
It was ascertained that no decomposition products interfered with the 
CAF-peak In fact, no decomposition peaks at all were observed after injection 
of an aliquot of the ISTD solution, no matter the age of the latter It is 
unlikely that peak 1 in the chromatograms of fig 1 originates from an ISTD 
decomposition product Peak 1 is already present in chromatograms of the ISTD 
solution immediately after synthesis of the ISTD, and its relative height to 
the ISTD peak doesn't increase or decrease significantly with aging of the 
solution It was ascertained as well that the three dimethylxanthine metabo­
lites of CAF did not co-elute with their parent compound, which would give 
rise to falsely elevated CAF concentrations Paraxanthine, theobromine and TP 
were retained on the GC column after injection under operating conditions 
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FIGURE 2 Plasma ( ) and saliva (o) caffeine concentration versus tine curves 
m the pharmacokinetic pilot subject, after swalloitmg a 400 ml-volume of 
freshly brewed coffee containing 153 mg of CAF 
The CAF recovery averaged 87 9 - 103 0 % depending on its concentration 
and the matrix, the recovery of the internal standard 9 1 3 1 6 8 % in plasma 
and 93 1 ± U 1 % in water (Table I) The tendency of the CAF recovery to 
diminish uith increasing CAF concentration could reflect a limited solubility 
of CAF in the extraction fluid dichlororaethane However, this tendency was too 
weak to produce marked nonlineanties in calibration curves in the CAF concen-
tration range from zero to 7i vg/mi The latter range normally covers the con-
centrations occurring after intake of up to 300 mg of CAF 
Pharmacokinetic pilot experiment The mean CAF concentration in the cof-
fee drank by the volunteer was found to equal 384 ± 23 mg/l (mean ± SD, n=10) 
There was no significant concentration difference between the coffee in first 
and in the second cup, indicating that the rate of a possible thermal decompo-
sition reaction of caffeine in freshly brewed coffee is too slow to be of 
importance in the 11 minutes time interval that separated the consumption of 
the two cups 
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The total CAJ dose in the 400 mt volume of coffee ingested by our volun­
teer thus amounted to 153 ± 9 rag The CAT concentration vs time curves in the 
volunteer's plasma and saliva are given in figure 2 Absorption is seen to be 
rapid (k . = 3 54 h ), the plasma CAT concentration reaching its top 1 h 
after the first draught The plasma elimination half-life t, is 3 8 h and 
the area-under-the-curve is 28 7 rag h/i The mean body residence time of caf­
feine molecules equals 5 75 h Assuning complete absorption of CAF from the 
gastro-intestinal tract [4,5] total clearance is 5 34 1/h and the distibution 
volume of CAF is 30 7 I in this subject These values are consistent with the 
findings for healthy men in earlier investigations 14,5,6], in which analyses 
were performed with HPLC methods 
The saliva curve almost parallels the curve, its angle of decline is a 
little greater, reflected in a somewhat shorter saliva half-life compared to 
that in plasma t, = 3 6 h The mean saliva/total plasma caffeine concentra-
* ι S 
tion ratio between t = 1 h and t = 25 h was 0 79, which is in good accordance 
with the value of 0 79 + 0 02 found by Zylber-Katz and coworkers in 12 healthy 
subjects [7] and with that of 0 73 ± 0 08 found by Hildebrandt cum suis in 6 
healthy nursing women [S] 
5 5 DISCUSSION 
In caffeine analysis, as in the analysis of so many other drugs, the 
older non-chromatographical techniques, like the inspecific and insensitive 
U V spectrofotometrical measurements and the laborious radio-immuno-assays, 
have been replaced by rapid, specific and sensitive chromatographical assays 
Many analytical procedures have been reported for the analysis of caffeine and 
related methylated xanthines and -uric acids in biological fluids using 
straight-phase [9-13] or reversed-phase [3, 14-22] high-performance liquid 
chromatography (HPLC) or cation-exchange HPLC [23] In all these methods, 
detection invariably is accomplished by monitoring the U V -absorbance of the 
eluent at either 250-260 nm or at 270-280 nm Two until up to sixteen xan­
thines and/or uric acids are separately eluted in one run [21], runtimes vary­
ing from 2 5 m m [3] until more than 45 min [20] 
Published GLC assays for caffeine and related compounds in biological 
fluids typically cover the analysis of one or two di- or trimethylated xan­
thines in plasma/serum or saliva [3, 24-33] Detection is accomplished by a 
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flame-ionization detector (FID) [24-29], a nitrogen-phosphorus detector (NPD) 
[30, 31] or by mass spectrometry (MS) [32, 33] GLC and HPLC xanthine assays 
rival in accuracy, in the higher concentration range (2 0 5 mg/t) the liquid 
chromatographic methods tend to be slightly more reproducible, which maybe is 
due to the more wide-spread use of automated injection facilities in LC, 
whereas in the lower concentration range the GLC methods yield superior 
results because of the higher sensitivity of especially FID and NPD compared 
to U V.-absorbance detection The GLC runtimes rarely exceed 10 minutes. 
Unfortunately, the GLC caffeine assay having the shortest runtime (2 
m m ) is afflicted with a non-linear shape of the regression line and with 
accordingly adverse reproducability characteristics [3]. Another, early pub-
lished method employs an external rather than an internal standard, hampering 
reproducability as well [24] 
Mass spectrometry as a detection technique for caffeine is less sensi-
tive than either FID or NPD This drawback can be partially compensated for by 
using a capillary GLC column in combination with splitless injection [32]. The 
GLC-MS method reported by Merriman et al. [33] however does not employ a cap-
illary column and indeed is less sensitive than the former mentioned method 
[32] In addition, its specificity is insufficient, it probably co-determines 
caffeine and an endogenous compound, resulting in perceptible overestlmations 
of caffeine amounts at concentrations lower than 1 jiM (.- 0.2 mg/l) [33] 
The GLC-FID method for caffeine analysis developed by Gurtoo and 
Phillips [25] is characterized by broad peak shapes and at least one unidenti-
fied interference The peaks of caffeine and its ISTD in the method of Perrier 
and Lear [26] elute on the tailing slope of a giant solvent/endogenous peak, a 
condition that doesn't foster the accuracy and reproducability of the analyti-
cal results The method published by Cohen et al [27] suffers from an endoge-
nous bump present in the chromatograms, whose late elution forces the runtime 
to be as along as 12 mm. Gurtoo and Phillips [25] and Brazier and co-workers 
[30] do not specify analytical reliability data of their assays. 
The GLC method reported here and the assays of Johnson et al. [28], 
Bradbrook et al. [29], Least et al [31] and Floberg et al [32] have in com-
mon well-resolved chromatograms with peaks ascending from baseline and 
descending back to it, no interferences from endogenous or exogenous com-
pounds, a linear regression line over a wide concentration range, and excel-
lent specificity, sensitivity and reliability characteristics. In addition, 
the reported method has an extremely short runtime (3 3 min), only the Bonati 
GLC method [3] is faster (2 0 min), but, as stated before, in other respects 
has adverse characteristics 
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Because of the sensitivity of the assay, the starting volume of plasma 
or saliva, defined as 1.0 mi under 'Procedure', may easily be reduced to 100 
yí or even less if the samples originate from neonates or small laboratory 
animals. Except to plasma, saliva or coffee the method may be applied to tea, 
cola-flavored soft-drinks and cocoa, but not to human urine. 
Like in the assays developed by Johnson [28], Least [31] and Floberg 
[33] and.their respective co-workers, in the method presented here the struc-
tural analogy between the ISTD and the xanthine compound to be analyzed is 
very close and certainly contributing to the beneficial characteristics of 
these assays. 
In our laboratory the present assay has been used to determine the CAF 
concentrations in coffee and tea drank by six healthy volunteers and subse-
quently to elucidate the absorption and disposition kinetics of CAF in these 
subjects. Detailed data are reported elsewhere in this dissertation. 
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Chapter 6 
SIMULTANEOUS ANALYSIS OF CAFFEINE AND THE THREE 
DIMETHYLXANTHINES IN BODY FLUIDS AND XANTHINE 
BEVERAGES USING HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY AND UV DETECTION 
Harald W A Teeuwen, Eric L Eibers2, and Jacques M Van Ros s um 
Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Mathematics, University of Nijmegen, Ρ 0 Box 9101, 6500 HB Nijmegen, 
The Netherlands 
6 1 INTRODUCTION 
Caffeine (1,3,7-trimethylxanthine), theophylline (1,3-dimethylxanthine), 
and theobromine (3,7-dimethylxanthine) are closely related alkaloids (see fig­
ure 1) that occur m plants with wide geographical distribution and are part 
of man*s dietary habit from time immemorial 
Coffee, the most important source of caffeine in the American and Euro­
pean diet is extracted from the fruit of Coffea arabica and related species 
At least half the uorld consumes tea, prepared from the leaves of Thea sinen­
sis and containing caffeine, small amounts of theobromine and traces of theo­
phylline Cocoa and chocolat, from the seeds of Theobroma cacao, contain theo­
bromine and some caffeine Cola-flavored drinks contain 100 - 150 mg/l 
caffeine, partly so because the nuts of Cola acuminata are processed in these 
drinks, and partly because of the addition of caffeine as such m their pro­
duction 
1
 Present address Stichting Bedrij fs laboratorium voor Grond- en Gewasonder-
zoek, Afdeling Bijzonder Onderzoek, Mariendaal β, 6861 WN Oosterbeek 
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Caffeine, theophylline and theobromine share m common a variety of 
pharmacological actions [1] They stimulate cardiac muscle, relax smooth mus­
cle (notably bronchial muscle), act on the kidney to produce diuresis, and 
they stimulate the central nervous system (CUS). The latter action is the 
basis for the popularity and the mass-consumption of the xanthme-contaimng 
beverages 
" Γ 
ι 
снз 
theobromine 
Ν Γ 
Η 
paraxanthine 
FIGURE 1. Structural formulas of caffeine and the three dimethylxanthines. 
In adults, the methylxanthmes are mainly metabolized in the liver, 
undergoing successive N-demethylation and oxidation steps, giving rise to xan­
thines and uric acids containing less than 3 methyl groups [2]. Also the 
5-membered xanthine ring may be metabolically cleaved to yield substituted 
uracils [3]. A detailed scheme of caffeine metabolism is included m this dis­
sertation (Chapter 13, figure 1) 
After an oral or intravenous dose of caffeine, the dimethylxanthines are 
detectable m m human plasma. However, the concentrations of paraxanthine 
(1,7-dimethylxanthine, see also figure 1) outweigh those of theobromine and 
theophylline, indicating the 3-demethylation pathway to be the most important 
initial step in caffeine metabolism [4,5] 
theophylline 
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In the course of a study of the pharmacokinetics of caffeine and the 
rate and extent of its biotransformation into paraxanthme, не have developed 
a reversed-phase HPLC method suited to monitor caffeine and paraxanthme m 
the range of concentrations that occur m human biological fluids after admin­
istration of a caffeine dose m the order of magnitude of 100 mg. It probably 
is also applicable to the analysis of theobromine and theophylline in biologi­
cal fluids, however, the Accuracy of the presently proposed method was not 
investigated for theobromine and theophylline analysis. The method may also be 
applied to xanthine beverages. 
To demonstrate its appropriateness, it was applied to determine caffeine 
levels m tea drank by a volunteer subject, and to those of caffeine and 
paraxanthme m samples of body fluids produced by this volunteer. 
TABLE I. COMPOUND ABBREVATIONS EMPLOYED 
CAP = caffeine (1,3,7-trimethylxanthine) 
PX = paraxanthme (1,7-dimethylxanthine) 
TP = theophylline (1,3-dimethylxanthine) 
ТВ = theobromine (3,7-dimethylxanthine) 
ISTD = internal standard (antipyrme) 
6 2 MATERIALS A N D METHODS 
Chromatography A Hewlett Packard high performance liquid Chromato­
graph (model 1081B) equipped with a variable-volume injector was used. The 
stainless steel column (15 cm χ 4 6 mm ID) was packed in our laboratory with 
S 
Li-Chrosorb RP-8, particle size 5 um (Merck, Darmstadt, F.R G.). The oven 
temperature was chosen 40° and the Injection volume 15 ul. The mobile phase, 
consisting of 5 mM acetic acid (pH = 3 5 ) / methanol / acetonitrile / tetrahy-
drofuran (90 4 4 2, v/v) was delivered at a flow of 1 0 mi/min, the 
resulting pressure drop being 150 Bars The eluate was monitored at 254 nm 
UV. The detector signal was displayed on a flow chart recorder (Kipp & Zonen 
model BD-8, Wormer. The Netherlands) and was as well transferred to a Hewlett 
Packard 3353 Lab Auto System for the purpose of electronic peak integration. 
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Reagents САГ and TP were purchased both as the monohydrate from 'De 
Onderlinge Pharmaceutische Groothandel', Utrecht, The Netherlands TB was 
obtained from Jansen Chimica, Beerse, Belgium, and PX from Fluka, Buchs, 
Switzerland The internal standard (ISTD) antipynne, and trivial solvents and 
chemicals, all of analytical grade, were obtained from Merck, Darmstadt, West-
Germany Doubly distilled water was used for the preparation of the HPLC 
mobile phase and a phosphate buffer solution 
Standards and solutions Stock solutions of CAT and PX in ethanol (1 00 
mg/mí) were diluted to produce working solutions of 100, 10 and 1 0 iig/ml The 
solutions do not show any signs of decomposition up to at least one month 
after preparation if stored at 4' An ISTD stock solution in ethanol (1 mg/ml) 
was diluted to produce a working solution of 50 yg/m£ The ISTD solutions were 
stable for at least 6 months after preparation when stored at 4° 
A 0 S M phosphate buffer solution was made up by dissolving the appro-
priate amount of disodium hydrogen phosphate in aqus bidest followed by 
adjustment of the pH to 7 9 by addition of a few drops of concentrated 
hydrochloric acid 
Procedure Xanthine beverages were diluted a factor 100 (coffee) or 40 
(tea) in case of CAP analysis, but were not diluted in case of dimethylxan-
thme analysis A 100 μΐ aliquot of the ISTD working solution was pipetted 
into a 10 ml extraction tube and evaporated to dryness at 45° under a gentle 
stream of dry nitrogen A 1 0 ml plasma, saliva or (whether or not diluted) 
beverage sample, 1 ml of phosphate buffer and 6 ml of dichloromethane was suc­
cessively added to the tube which was then closed with a poly-tetra fuoro-
ethylene (PTFE) srew-cap and shaken mechanically in a horizontal position for 
10 minutes, followed by centrifugation (1000 g, 10 min) The aqueous and pro­
tein layers were removed by suction, the organic layer was transferred to a 
clean tube and evaporated to dryness at 40° under nitrogen The residue was 
taken up in 100 y£ of the HPLC mobile phase An aliquot of 15 μΐ was injected 
onto the column and run under the conditions described under 'Apparatus' 
Calibration was accomplished by using the procedure on a series of 11 
prepared water or blank plasma standards which were spiked with mounting, 
known amounts of CAP and PX (0 - 10 pg/mH for both compounds) Water standards 
were prepared in case of saliva and beverage analysis 
Calibration curves for CAP and PX were prepared by plotting the peak 
area ratio of CAP to ISTD and of PX to ISTD against the spiked concentration 
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of CAF and PX, respectively The least-squares regression line of these 11 
calibration points was calculated by a handcalculator program The concentra-
tions of CAF and PX in unknown samples were calculated according to this 
regression line 
Pharmacokinetic pilot study A healthy female non-smoking volunteer (age 
24 years, weight 68 kg), free of medication at the time of the study partici-
pated in the following experiment After a 60 hours abstinence period from 
coffee, tea, cola, chocolate and caffeine-containing medications and after an 
overnight fast she produced a blank sample of blood and saliva Then she drank 
400 ml of freshly prepared tea The mid-point of ingestion of the 400 ml 
aliquot was taken as zero-time Blood-samples (8 ml) were taken at t = 9 - 18 
- 29 - 37 - 47 and 56 m m and at t = 1 1 - 1 4 - 1 6 - 1 9 - 2 6 - 3 6 - 4 9 -
7 8 and 15 6 h At t = 1 0 h, the volunteer was requested to brush her teeth 
and rinse her mouth thoroughly Samples of saliva ( 1 0 - 2 0 ml) were pro-
duced att = 1 3 - 1 8 - 2 5 - 3 7 - 4 8 - 5 9 - 6 6 - 8 0 a n d l 5 7 h Ten 
aliquots of 25 \il each were taken from the tea just before ingestion and 
diluted to 1 0 mi with aqua dest for the purpose of CAF analysis Ten other 
tea-samples (1 0 ml) were not diluted and analysed for their dimethylxanthine 
concentration Blood and saliva samples were centnfuged for 10 m m at 1000 g 
to produce blood plasma and clear salivary supernatant Biological and bever-
age samples were stored at -20° pending analysis, which was performed within 7 
days after termination of the experiment 
6 3 RESULTS 
Chromatography Figure 2 shows representative chromatograms of a 
variety of commonly processed kinds of samples 
The peaks of the xanthines and the ISTD are well-resolved, except for 
the PX and TP peaks which overlap to some extent This overlap may be elimi-
nated by the use of a 25 cm-column or by an increase of the volume ratio of 
the aqueous phase and the organic modifier in the mobile HPLC-phase to 92i / 
7i vol % instead of 90 / 10 vol % We let the run time advantage associated 
with the latter mobile phase composition preponderate before complete peak 
separation offered by the former one, as the peak overlap did not interfere 
seriously with good analysis (see 'Discussion') 
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FIGURE 2 Chromatograms of (a) a column resolution test mixture, consisting of 
a 1 ml water sample spiked with roughly equal amounts (by weight) of CAF, each 
of the 3 dimethylxanthmes and ISTD, (b) an undiluted tea sample, (c) a plasma 
sample and (d) a saliva sample taken from the pilot subject almost simultane­
ously at about t = 1 35 h after ingestion of 60 4 mg of CAF as tea, (c') a 
plasma and (d') a saliva sample both taken from the subject just before tea 
consumption Peaks 1 = ТВ, 2 = PX, 3 = TP, 4 = CAF, 5 = ISTD 
Chromatograms of plasma and saliva showed a similar appearance, as those 
of coffee and tea Retention times are 2 7 m m for ТВ, 3 4 min for PX, 3 В min 
for TP, 5 1 min for CAF and 9 3 m m for the ISTD As there are no endogenous 
peaks eluting after the ISTD, the chromatographical runtime is 11 minutes The 
'blank' chromatograms (figure 1 c'/d') show the peak of the endogenous 
(desmethyl) uric acid at about 2 min, and a small unidentified lump at 5 75 
m m The latter was invariably present in the body fluids of the pharmacoki­
netic subjects, although hardly detectable in the case of many of them It 
interfered markedly with a precise CAF-peak area integration at CAF-
concentrations < 0 2 pg/mt At these low levels, the CAF to ISTD peak height 
ratio was used to determine the exact CAF concentration The CAF peak height 
was not affected by the lump at any concentration above the detection limit 
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TABLE II. TOTAL RECOVERY AND ACCURACY OF THE ASSAY 
CV = coefficient of variation, R = total recovery, η = number of samples 
Matrix Compound Spiked Measured CV R η 
cone. cone. 
mgll mgll Ζ X 
Plasma 
Vater 
CAF 
PX 
ISTD 
CAF 
PX 
ISTD 
0.100 
1 00 
10.0 
0.100 
1.00 
10.0 
5.0 
0.100 
1.00 
10.0 
0.100 
1.00 
10.0 
5.0 
0.104" 
1.04 
9.9 
0.099 
o.sa 
10.1 
-
0.101 
1.04 
9 75 
0.097 
0.97 
10.0 
-
10.5 
2.5 
1.5 
9.6 
2.7 
1.6 
-
8.9 
3.1 
1.9 
11.0 
4.2 
2.0 
-
102.1 
95.6 
96 1 
104.6 
97.4 
94.9 
100 9 
96.9 
96.1 
94.3 
106.0 
98.7 
96.0 
101.0 
10 
10 
10 
10 
10 
10 
60 
10 
10 
10 
10 
10 
10 
60 
At this concentration the peak height ratio of CAF to ISTD was used rather 
than the area ratio. 
Total recoveries and accuracy. The total recoveries of CAF, PX and the 
ISTD are listed in the 'R'-column of Table II The total recovery of these 
compounds has a value between 95 and 106 X in the concentration range investi­
gated. 
Calibration curves are linear up to concentrations of at least 9 yg/m£ 
of CAF and the three dimethylxanthines in plasma and saliva. Correlation coef­
ficients mostly exceeded 0.999 and the y-mtercepts were not significantly 
different from zero for any of the xanthines. The precision of the assay pro­
cedure is more than satisfactory, measured CAF and PX concentrations deviating 
no more than 4% from the spiked concentrations (see Table II) The CAF and PX 
concentrations which are determinable with a coefficient of variation (CV; 
Table II) less than 10% nicely covers the the range of CAF and PX plasma and 
saliva levels occurring in man after consumption of a dose of CAF as small as 
60 mg (see figure 3). 
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FIGURE 3 Concentration vs time profiles of caffeine (·) m plasma and (o) m 
saliva, and of its mam metabolite paraxanthme again (k) in plasma and (L) m 
saliva, obtained from a healthy female volunteer after drinking a 400 ml vol­
ume of freshly brewed tea containing 60 4 mg of caffeine 
Pharmacokinetic pilot study Analysis of the diluted and undiluted tea 
samples revealed the following amounts of xanthines to be present in the 400 
ml-volume of tea drunk by our volunteer subject 60 W ± 1 1 mg of CAF, 2 05 ± 
0 04 mg of ТВ, and 0 08 ± 0 01 mg of TP So, contrary to popular belief this 
brew of tea, as well as brews of other brands of tea we analyzed, hardly con­
tained any TP No PX at all was found (see also figure 2b) 
The CAF and PX concentrations in the plasma and saliva of the volunteer 
subject are depicted as a function of time in figure 3 The CAF peak plasma 
concentration is reached after approximately 45 mm, indicating rapid CAF 
absorption m the GI tract After the peak time the CAF plasma and saliva con­
centration profiles decrease in parallel with a biological half-life of 3 8 
hours The saliva to total plasma CAF concentration ratio averages 0 72 in 
this subject 
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caffeine 604 mg 
administered as 400 ml of tea 
subject 4 
The CAF plasma concentration-time curve was fitted to a biexponential 
equation; from the fitted parameters the following pharmacokinetic quantities 
were calculated: MRT = 5.14 h, and, assuming complete systemic availability 
(6,7], CL = 6.83 t/h, V d s s = 35.1 t. 
These values agree with the values found for the other pharmacokinetic 
subject (GS, see previous chapter) and with earlier published kinetic data for 
CAF (see references in the previous chapter). 
The PX plasma and saliva concentration profiles are highest at t = 4 h. 
These curves have a typical convex 'gamma' shape, indicating that the dominant 
characteristic times 'τ' in the disposition (transport) functions of the par­
ent compound (CAF) and the metabolic daughter (PX) are similar. The plasma 
curves of CAF and PX intersect at t = 10| h. The PX concentration ratio in 
saliva to total plasma is 0.60. Hence it appears that PX cumulates in saliva 
to a lesser extent than CAF does, which indeed was to be anticipated on the 
basis of its stronger plasma protein binding compared to CAF [9]. 
6.4 DISCUSSION AND CONCLUSIONS 
The reported assay procedures for the analysis of CAF and PX in biologi­
cal fluids and xanthine beverages is rapid, sensitive and selective. It is 
composed of a single dichloromethane extraction of the sample followed by 
evaporation of the extraction solvent and reversed-phase high performance liq­
uid chromatography of the concentrated residue. Its limit of analysis, defined 
as the threshold concentration value at which CV = 10 %) is 0.1 yg/ml for both 
CAF and PX departing from a 1 mt sample volume. 
The assay procedure may very well be valid for analysis of ТВ and TP in 
biological fluids and beverages. The recovery and accuracy data for the latter 
compounds were not established, but are likely comparable to those of CAF and 
PX (Table I). If analysis of both PX and TP is desired, measures should be 
taken to eliminate the overlap existing between the PX and TP peaks (fig. 1). 
Suggestions for such measures have been proposed in the section 'Results-
chromatography'. If either PX or TP is to be analyzed, and if this compound is 
present in excess of the other (in our case concentrations of PX outweigh 
those of TP), then such measures are superfluous since in these circumstances 
the minor peak does not interfere with the major one (e.g., see figure Ic/d). 
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Though the chemical structure of the internal standard antipyrine hardly 
bears any resemblance to that of the xanthines, the reproducability character­
istics of the described method are evidently good. A synthetical xanthine 
widely employed as an ISTD in literature on caffeine assay: U-hydroxyethyl 
theophylline, was abandoned as its peak and the PX-peak appeared to overlap in 
the chromatograms of the present method. 
Taking the rapidness, sensitivity, accuracy and applicability features 
together, the present method compares with the assays published by Wahllander 
et al. [10], Schulz et al. [11], Tse and Szeto [12] and Muir et al. [13]. Sev­
eral assay methods for the analysis of CAF and the dimethylxanthines have been 
published in which the peaks of PX and TP overlap heavily (e.g. [14]), are 
stated to coincide, or in which there is made no mention of PX [15-18] in 
spite of the presence of a CAF-peak. In the latter case the apparently missing 
PX-peak again must be suspected to hide under the peak designed 'TP', so there 
is every reason to be sceptical of the 'theophylline'-levels reported! 
A final remark concerns the relative abundances of CAF and the 
dimethylxanthines in the coffee and the tea ingested by the volunteers partak­
ing in the pharmacokinetic experiments described in the section of this dis­
sertation dedicated to the clinical pharmacokinetics of caffeine. 
The coffee we brewed in the course of the above experiments (brand: 
Douwe Egberts Zilvermerk, Douwe Egberts, Joure, The Netherlands) as analyzed 
by our method was found to contain CAF and ТВ in a ratio of approximately 1000 
to 1. No TP was found. 
The tea we served to our pilot subject and to the other subjects (brand: 
Pickwick Chinese melange, Douwe Egberts) contained CAF, ТВ and TP in a ratio 
of roughly 1000 to 20 to 1. No PX was found. 
In theory, dimethylxanthine competition with CAF for the hepatic micro­
somal enzyme systems could become manifest at total methylxanthine concentra­
tions high enough to render methylxanthine metabolism capacity-limited. As the 
total abundance of the dimethylxanthines in coffee and tea constituted no more 
than 0.1 and 2 % of the CAF abundance, respectively, the presence of this 
small amount of dimethylxanthines is unlikely to have contributed significant­
ly to any occurrence of capacity-limited CAF disposition kinetics in our 
experimental volunteers. 
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Chapter 7 
SELECTIVE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD FOR ESTIMATING QUININE LEVELS IN BIOLOGICAL 
FLUIDS 
Harald W A Teeuwen, Jacques M van Rossum, Robert A A Maes 
Department of Pharmacology, Faculties of Hecicme and of Natural Sciences and 
Mathematics, University of Nijmegen, Ρ 0 Box 9101, 6500 HB Nijmegen, and 
Netherlands Institute for Drugs and Doping Research (N I D D R ) , State 
University of Utrecht, Vondellaan 14, 3521 GE Utrecht, The Netherlands 
7 1 SUMMARY 
А пен reversed·phase high-performance liquid chromatografic method 
employing fluorescence detection for the rapid quantification of plasma and 
urine levels of quinine is described The method involves internal standard­
ization, an enzymatic hydrolysis of quinine glucuronide m urine samples and 
extraction of alkalmized serum or urine The organic extract is evaporated 
and the residue reconstituted m a small volume of the mobile phase 10 lit 
aliquots are injected onto the column The effluent is monitored using fluo­
rescence detection The minimum determinable concentration with в coefficient 
of variation of 10 % is 0 05 vg/mt for plasma samples and 0 1 vg/ml for uri­
nary samples 
Advantages of the present method are selective and reliable detection 
without interferences from endogenous plasma or urine compounds or detergents 
derived from the tube-cleaning machine, a very short chromatogram runtime (5 
minutes), the employment of relatively nontoxic extraction- and mobile phase 
solvents and isocratic delivery of the mobile phase, suiting the method to be 
run on any ffPLC equipment The method is convenient for the routine analysis 
of large quantities of samples and is facile adaptable to the monitoring of в 
number of other compounds, e g quinidme 
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7 2 INTRODUCTION 
Quinine (Q), (figure 1-1), a member of the cinchoa alkaloid family, has 
been widely used for the treatment of falciparum malaria Though largely 
replaced by synthetic antimalarial drugs, including mecapnne and choroquine, 
Q is still the only consistently effective drug for severe chloroquine-
resistent falciparum malaria [1] Besides, Q is used as a bitter principal in 
the flavoring of carbonated soft drinks 
Q is metabolized in man by oxidation of the quinoline and quinuclidine 
moieties, resulting in metabolites with a phenolic and nonphenolic character, 
respectively [2] Q metabolism parallels the metabolism of its isomer quim-
dine, but the relative quantities in which the various metabolites are formed 
in man differ significantly for the antimalarial and the antiarrhythmic agent, 
as well as the amount of drug excreted unchanged in the urine [2, 3] 
Few definite knowledge is available of the relative amounts in which the 
various Q metabolites are formed in man However, some important Q metabo-
lites, whose structural formulas are shown in figure 1, appear to be Q-N-oxide 
(II), 3-OH-Q (III) [2, 4], 6 ' -OH-cmchonine (O-desmethyl Q) (IV) [4] and the 
keto-enol tautomer pair 2,-quininone (V) - 2*-OH-quinine [2, 4) 
A limited number of Q assay procedures has been reported in modern lit-
erature, e g [4-9] In contrast quimdine, which is still in widespread ther-
apeutic use, has been the object of numerous assay procedures, e g [6-21], 
many of which can be applied unmodifledly, or are easily adapted, to Q assay 
The Q and quinidine assay procedures include plasma protein precipitation com-
bined with fluorescence [11], where the background fluorescence may be deter-
mined by selectively quenching cinchona alkaloid fluorescence with chloride 
ions [12], single extraction-fluorescence [5, 13] and double extraction-
fluorescence [14] These fluorescence methods all suffer from fluorescent con-
tributions from either metabolites or unknown constituents of the plasma, 
often leading to spurious estimates of Q concentrations In clinical analysis 
co-determination of the metabolites can be essential because the metabolites 
may have pharmacological activity too In determining pharmacokinetics however 
it is a prerequisite to measure merely Q 
Thin-layer chromatographic (TLC) methods [10, 15, 16) can be made very 
specific but are tedious and time-consuming and hence unconvenient for the 
routine processing of large numbers of samples 
The most recently published methods utilize high-performance liquid 
chromatography (HPLC), offering rapidity, specificity, and sensitivity These 
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Η,Ο 
quinine (1) 
Η,ΟΟ. 
Η,Ο 
quinine N-oxlde(D) 
3-OH-quinineail) 
H3CO. 
6-ОН-сіпсПопіпе(Ш 
methaqualone (Ш) 
(internal std ) 
FIGURE 1 Structural formulas of quinine (I), its metabolites quinine N-oxide 
(II), 3-hydroxy-quinine (III), 6'-hydroxy-qumme (O-desmetbyl-quinme) (IV), 
2'-qummone (V), and the internal standard methaqualone (VI) 
methods indicate the use of a normal-phase column with alkaline extraction and 
either UV detection [9] or post-column acidification and fluorescence detec­
tion [5] Another possibility is the use of a reversed-phase column with 
direct injection of plasma [17] or urine [18], injection of a supernatant 
obtained after plasma protein precipitation and centrifugation [19], or injec­
tion of an aliquot of residue reconstituted m the mobile phase after alkaline 
extraction and evaporization to dryness [8, 20, 21] Both U V and fluores­
cence detection may be employed 
The vast majority of the HPLC methods referred to are applicable to 
either only urine, only plasma/serum or only suspensions of pharmaceutical 
preparations (capsules or tablets) Some of them utilize a multiple solvent 
delivery system to achieve gradient elution or a post-column mixing chamber to 
acidify the eluent The selective and straightforward HPLC procedure described 
here is suitable to all kinds of biological samples and is characterized by 
isocratic solvent delivery The method is aimed for rapid routine analysis of 
large amounts of samples 
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7 3 MATERIALS A N D METHODS 
Apparatus A Hewlett Packard HP 1081B high-performance liquid Chromato­
graph equipped with a variable-volume injector was used The stainless-steel 
column had a length of 15 cm and an internal diameter of 4 6 mm» and was 
packed with LiChrosorb RP-8, particle size 5 Jim (Merck, Darmstadt, FRG), in 
our laboratory The oven temperature was 40° and the injection volume was )0 
]il Q and the internal standard were measured with a fluorescence spectrometer 
(Perkin-Elmer Model 3000), the excitation wavelength was 320 nm (slit 15 nm) 
and the emission wavelength was 355 nm (slit 20 nm) The mobile phase, con­
sisting of 85 mM acetic acid buffer pH = 4 1 and tetrahydrofuran (THF) (60 40) 
was delivered isocratically at a rate of 1 0 m£/min, the resulting column head 
pressure being 220 bars The mobile phase constituents were seperately fil­
tered, the acetic acid buffer through a 0 45 ym filter and THF through a 1 0 
ym filter (Millipore), then mixed and degassed thoroughly in a Model 220 Boni­
fier (Bransonic) at room temperature Peak areas were determined with the aid 
of a Hewlett-Packard 3353 Lab Auto System 
Reagents Q was used as the diquinine sulfate dihydrate 
(Q ·Η250,·2Η 0) The internal standard (ISTD) metaqualone was supplied by 'De 
Onderlinge Pharmaceutische Groothandel', Utrecht, The Netherlands 
ß-Glucuromdase was obtained from Sigma Chemicals, St Louis, M 0 , USA 
Diethyl ether, acetic acid, sodium acetate, sodium dihydrogen phosphate, dis-
odium hydrogen phosphate, sodium hydroxide, ethanol and tetrahydrofuran were 
all of analytical grade (Merck, Darmstadt, G F R ), diethyl ether was dis-
tilled shortly before use Buffers were made up in distilled water 
Standard solutions A stock solution of Q in ethanol at a concentration 
of Ig/t (as free base stable for at least two months at 4') was diluted to 
prepare standard solutions of Q at 100, 10 and 1 mg/t in ethanol Internal 
standard solutions were prepared in ethanol at a concentration of 1 g/l for 
the internal standardization of plasma samples and at a concentration of 10 
g/l for the internal standardization of urine samples A S M sodium hydroxide 
standard solution was prepared in distilled water 
Procedure Until! analysis, plasma and urine were stored at -20° in the 
dark Analysis was carried out avoiding direct irradiation by sunlight (see 
'Photo-desintegration of Q') In an extraction tube with PTFE screw-cap, 100 
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μί of ISTD standard solution (1 g/fc for plasma samples, 10 g/î for urine sam-
ples) were pipetted and evaporated to dryness under a gentle stream of dry 
nitrogen at 50' Aliquots of 1 0 ml of plasma or urine, 100 νί of sodium 
hydroxide standard solution and 7 mi of ether-dichloromethane (2 1) were suc­
cessively pipetted into the extraction tube The tube was closed with a screw-
cap and shaken mechanically for 10 minutes, followed by centrifugation at 800 
g for 12 minutes The organic layer was transferred to another tube and evapo­
rated to dryness under a gentle stream of air at 40° The residue was recon­
stituted in 0 1 ml of the mobile phase (1 0 mi for urine) An aliquot of 10 ut 
of this solution was injected into the high-performance liquid Chromatograph 
Calibration was accomplished by using the procedure on ten prepared 1 mî 
plasma or urine standards to which known amounts of Q (0 - 10 yg for plasma, 0 
- 100 pg for urine standards) had been added Before analyzing subjects' sam-
ples, the standard samples were analyzed and the peak areas of the Q and the 
ISTD peaks were measured For each standard sample the Q peak area was divided 
by the ISTD peak area to obtain the ratio A calibration curve was prepared by 
plotting the peak area ratio against the Q concentration A basic programme 
calculated the regression line of the calibration curve The subjects' sam-
ples were analyzed and the peak area ratios were determined The Q concentra-
tion in each sample was calculated according to the regression line 
Analysis of Q glucuromde in urine Every aliquot of urine from a vol-
unteer having taken Q orally (see 'Pharmacokinetic pilot study') was divided 
into two portions In one portion free Q was determined as described under 
'Procedure' In the other portion the total amount of free Q and Q glucuromde 
was determined in the following way 
To an extraction tube containing an amount of internal standard (250 pfc 
of a solution of 1 g/£, evaporated to dryness) were added 250 \ιί of urine and 
250 μί of 0 2 M phosphate buffer (pH = 6 8) containing 500 units of 
8-glucuronidase The extraction tube was closed and the contents were incubat­
ed for 4 hours at 37° in a heating block After chilling to room temperature, 
the sample was processed further as described under 'Procedure' and measured 
as described under 'Apparatus' A calibration curve was prepared by spiking 
ten 250 μί standards of blank urine with known amounts of free Q since Q glu­
curomde was not available to us 
Photo-desmtegration of Quinine A solution of 20 mg/l Q in mobile phase 
solvent was spread over four Erlenmeyer flasks Three of these flasks were 
exposed to light The first flask was exposed to standard laboratory lighting 
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(fluorescent lights Philips TL 40Vi/34 'de Luxe' at a distance of 0 40 m) The 
second flask was exposed to daylight without direct irradiation by the sun and 
the third flask was exposed to direct sunlight The fourth flask served as a 
reference and was stored in the dark All flasks were closed tightly to pre-
vent evaporation of the solvent 
At various times a 1 mi aliquot of each flask was transferred to a vial 
and 10 vi of this was injected onto the column Q peak areas of the three 
light-exposed solutions were divided by the corresponding peak area of the 
dark-stored solution The peak area ratio was plotted against the time of 
exposure for each of the three light-exposed solutions Photo-desintegration 
half-lifes t, . of Q and the ISTD in the three light-exposed solution* 
were determined 
Pharmacokinetic pilot study A healthy male volunteer (23 years old, 
weight 77 kg) refrained from drinking Q-containing beverages for one week 
After production of a blood sample and a urine sample the volunteer ingested 
107 7 mg Q in a gelatine capsule after a sober breakfast at 9 50 a m (t = 0) 
S mí blood samples were taken a t t = 0 3 - 0 6 - 0 9 - 1 2 - 2 1 - 3 0 - 4 2 -
5 1 - 6 1 - 7 1 - 11 7 - 24 7 - 31 3 hours During this period ten urine sam-
ples were collected after spontaneous voiding 
7 4 RESULTS 
Chromatography Figure 2 represents chroroatograms of plasma and urine 
samples produced by the pilot volunteer before and after Q intake The 'blank' 
chromatograms (a2 and b2) reveal that endogenous plasma and urine constituents 
do not interfere with the peaks of Q and the ISTD Urine chromatogram Ы shows 
a peak of an unidentified Q metabolite (probably being 3-OH-Q, see 'Discus­
sion') which in low concentrations also was observed in the volunteers' plas­
ma, but not until several hours after dosage Retention times are 1 9 m m for 
the unidentified metabolite, 2 4 m m for Q and 4 0 m m for the ISTD 
Procedure For plasma Q concentrations from 0 to at least 10 yg/mt, 
there is a linear relationship between the peak area ratio of Q to internal 
standard (Y) and the plasma Q concentration (X) as given by the equation 
Y = 0 878 X - 0 0094 (r = 0 999, η = 10) 
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FIGURE 2 Chromatograms of (al) a plasma extract of a healthy male volunteer 
1 20 h after intake per os of 107 7 mg quinine base, (a2) an extract of blank 
plasma, (Ы) an extract of a urine aliquot (195 at), voided 2 23 h after qui­
nine adainistratíon, (Ы) an extract of blank urine, (c) a 20 mg/I solution of 
quinine in HPLC mobile phase, exposed to direct sunlight during 6 h, (d) the 
latter solution, exposed to direct sunlight for 24 h Peaks: 1 = unidentified 
Q metabolite(s), 2 = quinine, 3 = internal standard (methaqualone), 4 = photo-
degradation product of quinine. 
For urine concentrations from 0.0 to at least 100 vg/mt, a linear relationship 
between the peak area ratio of Q to internal standard (Y) and the urinary Q 
concentration (X) is given by. 
Y = 0 0724 X - 0 0176 (r = 0 999, η = 10). 
Using blank human plasma and urine, the overall recoveries of Q and the 
ISTD always were in excess of 90%, the ecact values are indicated in Table I. 
Within-day assay reproducabillty and accuracy as a function of plasma and 
urine Q concentrations are given in Table II The limit of analysis (LA), 
defined as the concentration giving rise to a coefficient of variation (CV) of 
£ 10 % (n = 10), is approximately 0 05 yg/ml for plasma and 0.1 yg/mî for 
urine, as Table II shows. 
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The LA values can be lowered further by increasing the injection volume 
or by decreasing the volume of the mobile phase in which the residue is recon­
stituted after evaporation to dryness At concentration levels exceeding ten 
times the LA the CV is less than 3 X The limit of detection (LD), defined as 
the injected quantity giving rise to a signal that is twice the noise level 
(S/N = 2 ) , is 50 pg Q The range of determinable concentrations nicely covers 
the drug levels occurring after intake of a relatively small amount of Q (± 
100 mg) by a volunteer subject, as the pharmacokinetic pilot study revealed 
Photo-desmtegration of Quinine Figure 2c and d represent chromatograms 
of Q having been exposed to direct sunlight during 6 hours and 24 (4x6) hours, 
respectively A degradation peak (peak 4) is observed having a retention time 
of 2 7 minutes The same degradation peak was observed in case of exposure to 
shaded daylight and laboratory lighting Desintegration of Q was found to 
obey first-order kinetics to a reasonable approximation whether exposed to 
sunlight, shaded daylight or laboratory lighting, and consequently in each of 
these cases a photo-desintegration half-life (t, , ) could be calculated 
(Table III) The values of this half-life naturally depend on the quality of 
the particular lightsources to which the Q solutions are exposed, and probably 
on the nature of the solvent as well The values shown in Table III therefore 
should be viewed merely as an indication of the order of magnitude of the rate 
of the degradation process 
Irradiation by direct sunlight should thus be strictly avoided while 
processing Q samples Dark-brown glassware offers sufficient protection 
against daylight if direct solar irradiation is excluded, while no special 
precautions are necessary if samples are exposed only to internal laboratory 
light sources of the kind we investigated 
Pharmacokinetic pilot study A computer fit to a sum of three exponen­
tials of the volunteers plasma Q concentration versus time is plotted in fig­
ure 3 (top) Two peak plasma levels were found 0 92 Ug/mi at 2 1 h and 0 73 
Ug/mt at 6 1 h The curve fitting program was provided with a second dose 
statement in order to obtain a satisfactory fit of the dual-peaked curve, the 
ratio of the two Q doses and time of administration of the 2 dose were opti­
mized iteratively The area under the plasma curve (AUG) was calculated as 
11 2 mg h/l The absorption constant к was determined as 0 73 h , the elimi­
nation half-life t, as 8 73 h, and the mean residence time (MRT) as 11 6 h 
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TABLE I ANALYTICAL RECOVERY OF QUININE AND ITS INTERNAL STANDARD AT VARIOUS 
CONCENTRATIONS IN PLASHA AND URINE 
plasma total recovery from blood plasma, R = total recovery from 
urine, η - number of analyses 
Compound 
Quinine 
ISTD 
Concentration 
Vg/ml 
0 5 
5 0 
100 
1000 
plasma 
Ζ 
94 + 2 
93 ± 1 
99 + 2 
97 ± 3 
R 
urine 
Ζ 
92 + 3 
93 ± 2 
97 ± 2 
97 + 3 
η 
10 
10 
10 
10 
TABLE II VITRIN-DAy ACCURACY OF THE PROPOSED ASSAY AT VARIOUS CONCENTRATIONS 
OF QUININE IH PLASHA AND URINE 
CV = coefficient of variation, η = number of analyses 
Matrix 
Plasma 
Urine 
Spiked 
cone 
Vg/ml 
0 050 
0 20 
0 50 
2 00 
0 100 
1 00 
5 00 
20 00 
Measured 
cone 
Vg/ml 
0 055 
0 20 
0 51 
2 05 
0 098 
0 98 
5 02 
20 10 
0 
0 
0 
1 
0 
0 
4 
19 
Range 
Vg/ml 
041 
18 
49 
98 
086 
95 
81 
26 
- 0 061 
- 0 23 
- 0 54 
- 2 15 
- 0 117 
- 1 02 
- 5 18 
- 20 60 
CV 
10 1 
5 3 
2 8 
2 7 
9 8 
2 8 
2 6 
2 6 
10 
10 
10 
10 
10 
10 
10 
10 
TABLE III PHCrrO-DESINTEGRXTION HALF-LIFES OF DISSOLVED QUININE EXPOSED TO 
VARIOUS SOURCES OF IRRADIATION 
Source of 
irradiation 
i,photo 
Daylight 
(bright sun) 
8+2 hours 
Daylight 
(shaded) 
3 0+05 days 
TL tube (at 
40 cm distance) 
60+9 days 
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Plasma concentration (mg/1, log scale) • 
Ю т 
0 6 : 
0 4 -
0 2 -
0 1 -
0 0 6 
004-Η 
0 0 2 -
0 0 1 
Quinine 107.7 mg po 
Subject H.T. 
τ -
5 
ι 
20 
ι 
30 
—t 
35 0  10 15 
Cumulative renal excretion (mg) 
25 
30 35 
Time (h) 
FIGURE 3 (Top) Quinine plasma concentration versus time profile m a healthy 
male volunteer after ingestion of a gelatine capsule containing 107 7 mg of 
quinine base (Bottom) Cumulative renal excretion of (a) unchanged quinine, 
and (b) the sum of unchanged and conjugated quinine (the latter expressed as 
mg of free quinine base) as a function of time in the volunteer subject 
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Q was excreted as the glucuronide conjugate to a minor but significant 
extent in this subject. The cumulative renal excretion of Q in 31 hours 
amounted to 18.42 mg (figure 3, bottom, curve a), whereas after incubation of 
the urine with 0-glucuronidase 23.80 mg of free Q base was recovered (figure 
3, bottom, curve b). The 5.38 mg increment (5.0 % of the ingested dose) 
reperesents the amount of Q excreted as the conjugate. The MRT of Q as calcu­
lated from the renal excretion data (figure 3, bottom, curve a) is 11.3 h, a 
value virtually identical to the one calculated from the plasma data. 
As the second peak was reached about 2 hours after the subject's lunch, 
the intake of food may have stimulated renewed absorption of so far unabsorbed 
Q. Alternatively, because Q metabolism apparently includes conjugation, the 
dual plasma peak pattern could be the result of enterohepatic recirculation of 
Q. Again, the subject's lunch could have been the trigger of biliary secretion 
of Q-glucuronide, setting the recirculation going. It was not possible on the 
basis of the given observations to assign truth to one of both hypotheses. 
7.5 DISCUSSION 
The method presented here for the analysis of Q in biological fluids has 
been used to determine the pharmacokinetics of Q after oral and intravenous 
administration in 7 volunteers. Apart from its beneficial selectivity and sen­
sitivity characteristics, the method is quite suitable in toxicological 
respect. It utilizes ether and dichloromethane as extraction solvents instead 
of the widely employed solvent toluene, which is far more toxic and should not 
be handeled in a routine fashion. THF is used as a modifier of the mobile 
phase replacing the cheaper but highly toxic acetonitrile. By this choice of 
organic solvents time-consuming safety precautions or special expensive adap­
tions of the chromatographic equipment are rendered superfluous. In fact these 
toxicological considerations have led us to develop a new Q assay method, 
because the ventilation characteristics of the operating room of our HPLC 
equipment did not allow us to use toluene or acetonitrile. 
An important contribution to the selectivity of the method, the separa­
tion of Q metabolites, deserves a brief word. The polarity of the N-oxide 
group probably results in a poor co-extraction of Q-N-oxide (figure l-II) into 
the apolar extraction phase and, in so far as extracted, in an excellent sepa­
ration from Q on the column. Phenolic metabolites, including 2'-ΟΆ-Q, S'-OH-Q, 
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6'-OH-cinchonine (IV) and the vast majority of the minor polyhydroxylated 
metabolites bear a unity negative electric charge at pH-values i 10 and are 
consequently left behind in the aqueous layer (pH Ì 12) during extraction [2, 
20] 2l-quininone (V) has altered fluorescence properties compared to Q [21] 
and probably occurs in small quantities in subjects' plasmas compared to Q 
Besides, it rapidly enolizes to 2'-OH-Q under the extraction conditions and 
consequently is retained in thp aqueous layer as an anionic species The non-
phenolic hydroxylated metabolites 2-0H-Q and 3-OH-Q (figure l-III) are co-
extracted to a reasonable extent and have fluorescence properties identical to 
Q [2], 3-OH-Q is formed in appreciable amounts [2, 4] Therefore it is most 
likely 3-OH-Q that gives rise to the pronounced peak in the urine chro-
matograms of the volunteer subject (figure 2b , peak 1) Maybe the minor 
metabolites 2-OH-Q and the N-oxide contribute to some extent to this peak At 
later times of blood-sampling (έ 4 h after dosage) the same peak is observed 
in plasma chromatograms too 
In contrast to the 9-0H hydroxy group of quinidine [3], this group in 
case of Q appears to be a site of glucuronide conjugation The urine of our 
pilot pharmacokinetic subject was found to contain 29% more free Q after its 
treatment with В-glucuronidase than without such a treatment In accordance 
with this observation are the findings of Salvador! and co-workers [4], who 
reported an elevation of the urinary Q recovery of about 20% after a prelimi­
nary enzymatic hydrolysis of the urine voidings of their pilot subject 
Four hours was found to be the optimal incubation time of urine samples 
with U-glucuronidase Longer incubation times, e g during an overnight peri­
od, resulted in considerable loss of Q This loss might be due to bacterial 
conversion 
Dual plasma peaks have been observed after oral administration of quini­
dine to human volunteers [22, 23], their occurrence too was attributed to 
enterohepatic recirculation 
Slight adjustments of the fluorescence excitation and emission wave­
lengths and maybe of the volume ratio of THF/acetate buffer in the mobile 
phase render the present assay procedure suitable for the monitoring of e g 
papaverine, propanolol, promethazine, bendrofluazide, quinethazone and quini­
dine Injection into the HPLC under the conditions described under 'AppaiaLus' 
showed that all these compounds were fluorescence-detected and gave rise to 
good peak shapes and short retention times 
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SECTION III 
EXPERIMENTAL CLINICAL PHARMACOKINETICS 
OF NICOTINE, CAFFEINE, AND QUININE 
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Chapter 8 
NICOTINE INTAKE BY SMOKERS OF FILTER CIGARETTES. 
PART I: CONVENTIONAL FILTER CIGARETTES. 
Plasma concentration profiles of nicotine and its main metabolite cotinine 
vere measured over 24 hrs on tvo separate occasions in a group of 25 habitual 
smokers, uniformly distributed over 4 current cigarette brands (coded Fl to 
F4) equipped with conventional (non-ventilated) filter tips. On one of these 
occasions the smokers vere administered a known reference dose of cold-labeled 
cotinine by mouth. 
Pharmacokinetical information calculated from the circadian plasma profiles 
of nicotine and cotinine derived from smoking and from the single-dose profile 
of the labeled cotinine vas combined и ith smoking machine data on the relative 
retention of mainstream smoke nicotine in the cigarette filters in order to 
estimate the smokers' nicotine intake at mouth-level and at the level of the 
systemic blood. 
The nicotine intake rate at mouth-level amounted to 1.33 ± 0.25 mg/h, cor­
responding to a nicotine dose of 1.5S ± 0.48 mg, 1.05 ± 0.16 mg, 1.51 f 0.42 
mg, and 1.67 ± 0.48 mg of nicotine delivered per cigarette to the smokers' 
mouths for the smokers of brands Fl to F4, respectively (mean ± SD). 
The bioavailability or fractional uptake of nicotine in the respiratory 
tract as calculated from the cotinine plasma data amounts to 88 ± 13 Z· 
It vas concluded that for the 4 medium nicotine yield brands studied in 
this report, the smoking machine standard procedure yields a fairly good indi­
cation of the nicotine Intake of human smokers. 
Harald W.A. Teeuwen1, M.Sc, Martin Hissink1, M.Eng., Ronald Bosman2, 
M.Sc, Ronald J.W. Aalders1, M.Eng., and Jacques M. van Rossum1, Ph.D. 
^Department of Pharmacology, Faculties of Hedicine and of Natural Sciences and 
Hathematics, University of Nijmegen, P.O. Box 9101, 6500 BB Nijmegen, and 
^Department of Analytical Chemistry, Division of Technology for Society, 
Netherlands Organization for Applied Scientific Research (T.N.O.), P.O. Box 
342, 7300 AB Apeldoorn, The Netherlands. 
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The amount of nicotine absorbed from the smoke of a cigarette may be deter­
mined by comparing the area under the plasma nicotine vs time curve (AUC) 
during and following cigarette smoking to the AUC observed after intravenous 
administration of a reference dose of nicotine If cigarette smoking and infu­
sion of (stable isotope-labeled) nicotine are performed simultaneously, the 
rate at which εη experimental subject self-administers nicotine by smoking 
cannot be expected to be representative of smoking in everyday life as it is 
affected (slowed) by the intravenous nicotine input 
So, nicotine intake by smoking and by intravenous administration must be 
1 2 
performed on time-separated occasions ' , but now short-term intra-individual 
fluctuations in nicotine disposition kinetics might interfere with a clear 
evaluation of the dose of nicotine absorbed from the smoke 
3 4 4 
Renal nicotine clearance strongly depends upon urinary pH ' and flow , 
suggesting variability of the latter quantities (e g , as a result of food and 
drink intake) as a mechanism of short-term fluctuations of renal nicotine dis­
position rate 
Metabolic nicotine clearance approximates hepatic blood flow and therefore 
is influenced by factors affecting this flow, like physical exercise, posture, 
ingestion of a high protein meal, or the cardiovascular effects of nicotine 
itself, the susceptibility to which may vary from one time to another within a 
single individual 
Of course, age and previous exposure to nicotine are examples of factors 
affecting nicotine clearance as well, but these factors are likely to induce 
relatively long-term changes of total nicotine clearance within a given indi­
vidual 
Attempts to minimize intra-individual differences in nicotine disposition 
rate by standardizing one or more of the short-term factors mentioned, e g , 
2 
by hospitalizing the subjects (meals, posture, physical exercise) or by oral 
administration of ammonium chloride (urinary pH) , may be conceived However, 
30-32 
as (renal) nicotine disposition rate influences its intake rate , Feyer-
1 2 
abend et al and Benowitz et al may have standardized nicotine intake of 
their subjects as well, loosing relevance of their conclusions for nicotine 
intake in natural smoking circumstances 
In addition, nicotine disposition kinetics is very fast Monitoring rapid 
increases and decreases of its plasma profile after ι ν injection or infu­
sion, or after smoking cigarettes requires multiple samples and a strenuous 
sampling scheme, and therefore poses a major interference with a natural smok-
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ing behaviour. Furthermore, it is ethically unacceptable to administer the 
toxic tobacco alkaloid routinely to large numbers of subjects. 
In contrast, the kinetics of the major nicotine metabolite cotinine is 
β 9 20 
rather slow ' ' . Blood sampling may be done at ease, and measured plasma 
concentrations are less dependent on the exact times of sampling. Metabolic 
conversion of nicotine into cotinine is linear for nicotine input rates up to 
at least 30 mg/day , and subsequent elimination of cotinine is independant of 
7 β 
plasma concentrations up to at least 400 Pg/i ' . Cotinine therefore is more 
26 
suitable as a marker of nicotine intake in smokers than nicotine itself 
Cotinine displays extremely weak, if any, pharmacological or toxic effects, 
9 10 
and psychological activity ' Therefore its administration to volunteer 
smokers is free of danger, and its effect on their smoking desire is minimal. 
Taking advantage of the rapid and complete absorption of cotinine from the 
g 
human GI tract , we determined cotinine clearance in steady smokers by oral 
administration of a dose of dideuterated cotinine, smokers meanwhile smoking 
in their usual manner. Kinetical evaluation of circadian (24 hr) profiles of 
unlabeled cotinine (derived from nicotine) and of cold-labeled cotinine after 
ingestion of a known dose enabled us to determine the amount of cotinine gen­
erated from the smoke-absorbed nicotine. By investigating the retention char­
acteristics of nicotine in the filters of the brands studied, we also were 
able to obtain information concerning the amount of nicotine delivered to the 
mouths of our subjects in the act of smoking, and to obtain a reasonable esti­
mate of the nicotine bioavailability f . 
1« 
The results of this newly designed experiment for 25 smokers are reported. 
8.1 MATERIALS A N D M E T H O D S 
Subjects. Subjects were recruited from the local university student pop­
ulation. Selection criteria included faith to a single brand, inhalation of 
the smoke, and a more or less regular consumption pattern, that is, a consump­
tion rate varying only moderately between days, amounting to 20 cigarettes a 
day on the average, and a regular within-day spread of cigarettes smoked. Reg­
ularity of consumption was investigated during a week preliminary to the 
experiment by having the subjects put a streak for each cigarette smoked on a 
paper strip with a time table on it. Subjects were kept unaware of the precise 
purpose of their recordings. 
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TABLE I. SUBJECT CHARACTERISTICS 
Brand/ Sex Age BU tied Cig/day 
subj.nr. yrs kg 
Fl 
I 
2 
3 
4 
5 
6 
MEAN 
± SD 
m 
m 
m 
f 
f 
f 
24 
40 
26 
24 
30 
20 
27 
7 
74 
65 
68 
61 
52 
56 
63 
В 
-
-
-
-
SOC 
-
19.8 
19.9 
23.1 
22.3 
20.1 
22.5 
21.3 
1.5 
Brand/ Sex Age Ш Med Cig/day 
subj.nr. yrs kg 
F3 
14 
15 
16 
17 
18 
19 
л 
я 
в 
ƒ 
f 
f 
29 
Z~ 
26 
23 
24 
20 
24 
3 
80 
92 
75 
66 
53 
64 
72 
14 
-
-
-
soc 
-
-
18.3 
20.tr 
19.9 
21.3 
28.5 
24.7 
20.3 
1.2 
F2 F4 
7 
8 
9 
10 
11 
12 
13 
MEAN 
± SD 
f 
f 
f 
f 
f 
f 
f 
21 
30 
21 
21 
25 
23 
28 
24 
4 
47 
57 
61 
65 
60 
60 
60 
59 
6 
SOC 
-
-
soc 
-
-
soc 
20.4 
19.0 
20.3 
26.0 
18.1 
25.3 
21.6 
21.5 
3.0 
20 
21 
22 
23 
24 
25 
f 
f 
f 
f 
f 
f 
23 
26 
24 
23 
22 
28 
24 
2 
65 
48 
64 
56 
57 
62 
59 
6 
-
-
soc 
-
-
-
24.0 
23.1 
21.3 
19.9 
24.1 
22.3 
22.5 
1.6 
OVERALL MEAN: ACE: 25 yrs, WEICHT: 63 kg, CIC. CONS.: 21.4 cig/day. 
OVERALL SD : 4 10 2.1 
BW = body weight, Med = medication, Cig/day = mean number of cigarettes smoked 
per day in the experimental period, SOC = steroid oral contraceptives. 
The selected subjects were 6 males and 19 females, all apparently 
healthy, between 20 and 40 yrs of age Cmean ± SD = 25 ± 4), and having a body 
weight between 47 and 92 kg Cmean ± SD = 63 ± 10). They all gave their written 
informed consent. All had normal history, baseline hemoglobin and hematocrit. 
None had any clinical evidence of hepatic, renal, or hematologic disease. The 
subjects were habitual smokers, who had been smoking their brand for at least 
6 months, and engaged in no other nicotine-related practices Ccigars, pipes, 
snuff, chewing tobacco, gum). Their daily cigarette consumption during the 
experiment was 21.4 ±2.1 cigarettes. 
130 
TABLE II. CHARACTERISTICS OF THE CIGARETTE BRANDS 
Filter Overwrap Cigarette R . 
length length length 
Brand 
Fl 
F2 
F3 
F4 
Таг* 
«8 
16 
16 
16 
13 
Φ
 Stated by 
* * < nie 
Nicotine* 
Bg 
1.2 
1.1 
1.1 
1.0 
the ¡¡at 
= relative 
lufac 
filt 
of 
Bg 
17.5 
16.2 
15.0 
12.0 
turen 
er ret 
22 26 84 31.9 ± 2.5 
18 22 80 35.1 ± 2.1 
21 25 84 34.1 ± 2.5 
21 25 84 31.7 ± 2.4 
ог
14
'
15
. 
subjects' brands. Listed values are mean ± SD for duplicate groups of 10 
cigarettes, васЫпе-SBoked at 6 different combinations of puff volume and puff 
duration. 
Eight female smokers took oral contraceptives. No other medications had 
been received for several weeks by any of the subjects. They all consumed xan­
thine beverages on a regular basis. Alcohol was consumed in a moderate way (± 
10 g/day). Subject characteristics are summarized in Table I. Characteristics 
of the four cigarette brands smoked are similar (Table II). 
Experimental design and sampling. In an experimental period of 16 con­
secutive days, subjects kept a record of time and number of cigarettes smoked 
by putting streaks on a time strip. In addition, they pooled the butts saved 
at each of the 16 days in 55 ml screw-capped containers made of transparant 
brown polystyrene. At day 4 and day 11 (Tuesdays) subjects attended the labo­
ratory. At about 9.00 a.m. at day 11 (not at day 4) the subjects swallowed a 
gelatine capsule containing a precisely known amount (± 0.1 rag/kg) of 
4' ,4' -dideutero cotinine (cotinine-DZ) with 200 mt of water. In all other 
respects the experimental protocols at days 4 and 11 were identical. 
In the course of these two days, 13 blood samples were taken at 35 min 
intervals between 9.00 a.m. and 17.00 p.m., allowing a lunch break between 
12.30 and 14.00 p.m.. Two further samples were obtained at times between 21.30 
and 24.00 p.m., and between 9.00 and 9.30 a.m. next morning. In the morning of 
days 4, 5, 11, and 12, subjects were not allowed to smoke until the first 
blood sample was obtained (at ± 9.00 a.m.). Otherwise, no constraints with 
respect to consumption of cigarettes, meals, alcoholic drinks, and xanthine 
beverages were imposed on the subjects in order to preserve maximum resem-
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Ыапсе to their everyday way of smoking For this same reason, subjects bought 
their own cigarettes during the experimental period (after termination of the 
period they received a payment for their participation), and no attempt was 
made to standardize subjects' urinary flow and pH Subjects were asked not to 
behave extraordinarily in any respect in the experimental period 
Blood was centrifuged (1000 g, 10 m m ) and the plasma was stored at 
-20' Samples could be stored for at least 6 months without detectable loss of 
nicotine, cotinine, and cotinine-D2 Butts of cigarette filters were dark-
stored in the polystyrene containers at room temperature Butts having the 
tobacco-end of the filter occluded by some residual unburnt tobacco could be 
stored up to 1 month, nicotine loss in the filter remaining smaller than 
11a 
10% As general practice, all butts saved by a subject were analyzed for 
butt length and nicotine content at the day following the subject's experimen­
tal period, butt age then ranging from 1 to 17 days Nicotine content was mea­
sured in 10 selected butts returned by the subject at each day in the experi­
mental period Criteria for butt selection were a representative average butt 
length, the absence of lipstick stains as a potential source of compounds 
interfering with analysis, and the presence of a tuft of unburnt tobacco 
occluding the filter Residual tobacco and ashes were removed just prior to 
. 11a 
analysis 
Nicotine retention in machine-smoked cigarettes Cigarettes of the 
brands smoked by our subjects were conditioned to standard conditions of 
(inter alia) temperature and relative air humidity (ISO 3402, atmosphere A) , 
and subsequently machine-smoked with one puff per minute to a butt length 
14 
equal to the length of the filter + 8 mm (ISO 3308) In partial contraven­
tion to the standard, puff volume was chosen either 35, 45 or 60 m£, and puff 
duration either 1 or 2 sec At each of the six possible combinations of puff 
volume and duration, duplicate groups of 10 cigarettes of each of the 4 brands 
were smoked The particulate matter in the mainstream smoke was trapped on a 
glass fibre filter (a so-called 'Cambridge' filter) The amounts of nicotine 
in the cigarette filter (F) and on the glass fibre filter (D) were determined 
by GC-NPD The relative retention of nicotine in the cigarette filter was 
determined as 
R ,r = F/(F + D) (I) 
nie 
Drug determinations Smokers' plasma samples (1 ml) were extracted in 
duplicate on ethyl silica solid phase extraction columns Extracts were ana-
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lyzed by GC-NPD to determine nicotine and (total) cotinine. Linearity, speci­
ficity and sensitivity of the method have been demonstrated for nicotine and 
cotinine concentrations ranging fron 1 - 6 0 ng/mt and from 5 - 400 ng/ml, 
respectively . Extracts of plasmas produced at days of cotinine-D2 adminis­
tration were also analyzed by GC-MS/SIM in order to determine the molar 
fractions of cotinine (at m/z = 98) and cotinine-D2 (at m/z = 100). 
The nicotine amounts retained in cigarette filters and on glass fibre 
filters were determined by preparing suspensions of the (crushed) filters in 
methanol and by analyzing filtered suspension aliquots using a GC-NPD method 
derived from the method used for plasma analysis. 
Kinetic calculations. Plasma concentration versus time profiles of 
cotinine-D2 after oral administration were fitted to a sum of three exponen­
tials: 
2 -t/t -t/T 
C(t) = I A i (e
 1
 - e
 0 ) (II) 
From the concentration coefficients (A.., A ) and the time constants (τ , т.), 
the total area under the plasma concentration versus time curve (AUC) and the 
total area under the time'concentration vs. time curve (TAUC) were calculated 
as: 
2 2 2 2 
AUC = ΣΛ.τ, - ( I A . ) t and: TAUC = Ι Α . τ . ' - (ΣΑ,)τ » ( I I I a/b) 
i i i ι ι о 1 1 1 i l o 
Mean residence time (MRT), total clearance (CL), distribution volume 
(V. ), terminal half-life (t,), extraction ratio (E), number of recircula­
tions (N ), and mean transit time (MTT) of cotinine-D2 were calculated as: 
MRT = TAUC/AUC - t
o
, CL = Dose«h
a
 / AUC, V d s s » CL'MRT, t, = T2«ln2, 
E = CL / CO., N = (1-E)/E, MTT = MRT / N (IV a/b/c/d/e/f/g) 
Systemic availability (h ) of orally administered cotinine-D2 was assumed to 
be unity. The cardiac output CO. was taken 6 t/min = 360 t/hr. 
The average nicotine dose D delivered per cigarette to the mouth of a 
smoker at day 4 or at day 11 of the experimental period was calculated as: 
D = F (1-R . ) / R . (V) 
nie nie ' 
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where F is the average amount of nicotine found in ten selected butts of the 
respective subject at the particular day, and R is the relative retention 
of nicotine in filters of the smokers' brand If η is the number of cigarettes 
smoked at the day in question, the mean circadian nicotine delivery rate to 
the smoker's mouth is calculated according to 
D = n«D / (t 1 5 - t ^ (VI) 
where the time interval (t.,. - t ) between the 1 and the 15 venipuncture 
closely approximates 24 hrs 
Plasma concentration-time data ({C (t), t }, with ι = 1,2, 15) of 
nicotine and unlabeled cotinine were fitted with the aid of the curve fitting 
FORTRAN programme 'FARMFIT' developed at the Department of Pharmacology in 
Nijmegen Both nicotine and cotinine were assumed to have a biexponential 
transport functions in all subjects The rapid pulmonary nicotine input in 
smoking was simulated by considering each cigarette smoked as an intravenously 
injected dose of nicotine, the slower formation rate of cotinine from nicotine 
was simulated by the introduction of an exponential absorption-like phase 
• 24 
Subsequently, FARMFIT computed circadian areas (AUC ) under the fitted 
24 
nicotine and cotinine curves Pseudo steady-state concentrations (C ) of 
24 
nicotine and cotinine were obtained by division of the respective AUC by the 
24 hr time interval [ΐ.,ί..], representing one oscillation period of a steady 
smoker's circadian nicotine and cotinine plasma concentration profiles 
С 2 4
П
І С =
 A U c 2 4
nic / ( t15 - V a n d c 2 4cot = A U c 2 \ o t / <'l5 * V ( V I 1 а / Ь ) 
In the characteristic period of a steady smoker's nicotine intake, sys­
temic input rate and output rate for nicotine and cotinine are balanced The 
nicotine input (absorption) rate equals its input rate at mouth-level (D) 
times its systemic availability f. The cotinine input (formation) rate is 
obtained by multiplication of the nicotine absorption rate by the conversion 
factor fM The disposition rates of both substances equal their respective 
clearances times their pseudo steady-state concentrations The plasma mass 
balance formulas thus read as follows 
for nicotine Ώ·ί
τ
 = CL «С 2 4 (Vili a) 
L m e m e 
for cotinine D«fT«fu = CL 'С
2 4
 „«f (VIII Ь) 
L M cot cot согг 
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The factor f in eqn VIII b equals 0 921 if the nicotine input rate D and 
24 
the average circadian cotinme concentration С are expressed on a (m or 
μ) gram basis, rather than on a mole basis, to correct for the different 
molecular weights of nicotine (162 2) and cotmine (176 2) Rearranging eqns 
VIII a/b to collocate all measured quantities in the right equation terms, and 
(hence) all unknowns in the left ones, we obtain 
CL . / fT = D / C
2 4
 , (IX a) 
nie L nie 
fT«fM = CL «C
2 4
 . / D (IX b) 
L M cot cot 
Although the nicotine systemic availability f and the conversion factor 
fM cannot be solved from eqns IX a/b, the context of the known quantities in 
these equations confines the theoretical range of values of f. and f (from 0 
to 1) to a small interval close to unity, as will be shown in the next sec­
tions A fairly accurate estimate of the systemic nicotine intake in our smok­
ing subjects is therefore possible In particular, after heaving rationalized 
that fM should approximate 0 75 in the subjects (see 'Discussion'), eqns 
VIII b and VI were combined to compute the amount of nicotine per cigarette 
delivered systemically as 
D«fT = (t.. - t,)«CL «C
2 4
 «f /(η·0 75) (X) 
L 15 1 cot cot corr 
8 2 RESULTS 
Machinal smoking of brands Fl to F4 revealed a highly linear relation­
ship (r > 0 96) between the amount of nicotine deposited in the cigarette fil­
ter and the amount passing through it in the mainstream smoke in the ranges of 
puff volume and puff duration applied In these ranges, relative retention of 
nicotine in the cigarette filter is virtually independent of puff volume and 
duration and may be regarded in good approximation as a constant for each 
brand These constants are included in Table II (right column) About one 
third of nicotine in the unfiltered smoke offered to the tobacco/filter inter­
face is retained by the filter for all four brands studied The complementary 
two thirds pass through it and are delivered to the smoker's mouth A similar 
relative retention (37%) was observed by Hopkins et al for another filter 
brand 
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plasma concentration ( n g / m l ) 
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5 0 0 
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subject MS 
brand F 4 
day 4 
subject MS 
brand F 4 
day 11 
τ 1— 
3 6 9 
clock time (h) 
FIGURE 1 Circadian nicotine (o), cot mine {·) and cotmme-DZ (x) plasma con­
centration profiles m subject nr 24 at day 4 (upper panel) and day 11 (lower 
panel) of the experimental period, which were the two days of all subjects' 
laboratory attendance Each bottom arrow denotes the (time of) booking of a 
single cigarette by this subject 
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TABLE III. PHARMACOKINPTIC PARAMETERS OF C0TININE(-D2) IN OUR SUBJECTS 
HAT HRT CL „ V. t, E N NTT 
cot dss f re 
Лг Лг l/hr 1 Лг ο/σο аіп 
MEAN 0.99 14.1 3.56 Í9.8 IJ .7 9.9 103 8.3 
± SD 0.44 2.5 0.65 11.0 1.8 1.8 20 1.8 
Kinetic parameters were calculated from the plasma profile following oral 
administration of ± 0.1 tng/kg of dideuterated cotinine in a gelatine capsule. 
The nicotine dose D reaching the mouths of our subjects per cigarette 
smoked therefore is about twice the average filter nicotine content of 
subject-smoked cigarettes. At the days of laboratory attendance it averages 
1.45 ± 0.28 mg for all subjects, and is similar (1.5 - 1.7 mg) for brands Fl, 
F3, and F4 (see Table IV left-hand column, and figure 2). The nicotine yield 
of F2 is lower than that of the other brands (but not significantly so) and is 
even slightly lower than its standard smoking machine yield (Table II, figure 
2). Nicotine delivery per cigarette (D) and per hour (D) are similar (Table 
IV, two left-most columns) because subjects of all subjects smoked about one 
cigarette per hour (= 24/day; see Table I). 
In figure 1 circadian nicotine and cotinine plasma concentration pro-
files of a representative subject are shown for the two days of the subject's 
laboratory attendance: day 4 (upper panel) and day 11 (lower panel). The nico-
tine and cotinine curves during these days are rather congruent, and as a con-
sequence, pseudo steady state concentrations of these compounds are quite sim-
ilar at days 4 and 11. Concentrations of nicotine and cotinine are lowest in 
the morning and start rising when smoking is initiated. After about 5 
cigarettes, in this subjects as in all subjects a nicotine plateau level is 
attained. Cotinine concentrations keep rising until late in the afternoon or 
evening. During the night, both curves return to approximately their pre-
smoking morning values and thereby close the circadian cycle. 
In the lower panel the concentration profile of orally administered 
cotinine-D2 is displayed. Cotinine is absorbed rapidly from the CI tract, mean 
absorption time amounting to 1 hr (Table III). Its volume of distribution 
indicates a slight extent of tissue cumulation. Cotinine disposition is rather 
slow as indicated by its mean residence time of 14 hrs, its terminal half-life 
of 12 hrs, and its low total clearance of 3i t/hr. The extraction ratio 
reveals 1% of cotinine molecules to be eliminated during each body transit of 
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6.3 min. On the average, a cotinine molecule may complete some 100 circula­
tions before being disposed of. 
These pharmacokinetic parameters largely confirm those reported by De 
β 9 20 
Schepper et al. , Benowitz et al. , and Kyerematen et al. In particular, 
the values of total cotinine clearance encountered in the present study are 
less than those observed in intravenous studies conducted by De Schepper et 
al. (3.66 ± 0.57 1/hr)8 and Benowitz et al. (4.33 ± 0.79 l/hr)9, implicating 
complete systemic availability of cotinine after ingestion as a gelatine cap­
sule by our subjects. Pharmacokinetic parameters of cotinine did not differ 
between men and women, nor between the subject populations of the 4 brands. 
In Table IV, measured and computed parameters of nicotine and cotinine are 
listed for all subjects at both days of laboratory attendance. Parameters have 
been averaged for the smokers' population of each brand, as well as for all 
24 
subjects. Nicotine and cotinine pseudo steady-state concentrations (C ) are 
intra-individually very reproducible, but assume a wide range of values 
between subjects. Cotinine levels are more than tenfold higher than nicotine 
levels; the reverse is true for the clearances of these compounds. 
Assuming the nicotine availability f to be close to unity, the quotient 
CL . ¡t may be regarded as a slight overestimation of the nicotine clearance 
CL . , which thus is seen to amount to 50 - 60 t/hr and to approximate the 
hepatic blood flow. 
Footnotes ad Table IV 
Brand mean ± std. deviation, overall mean ± standard deviation. 
For each subject, the upper row of figures refers to the 1 day, and the 
lower row to the ¿^ day of laboratory attendance (days 4 and 11 of the 
experimental period, respectively). 
D mean nicotine input at mouth-level per cigarette 
D mean nicotine input at mouth-level per hour 
c24 mean circadian nicotine plasma concentration 
mean circadian cotinine plasma concentration 
nie 
cot 
CL . lfT total nicotine clearance divided by its bioavailability 
nie L· 
CL total cotinine plasma clearance 
cot r 
.J* EL mean circadian cotinine elimination rate = CL 
cot cot cot 
/r*/„ nicotine availability · fraction converted into cotinine 
D'fj mean systemic (blood-level) nicotine input per cigarette, fr 
is calculated from the fraction product fr'f„ for ƒ„ = 0.75 
L π η 
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TABLE IV. NICOTINE INPUT Я MOOTS- AND КГ BLOOD-LB/EL, CIRCADIAN 
PLASMA LEVELS AND CLEARANCES OF NICOTINE AND COTININE, ELIMINATION 
RATE OF COTININE, AND SYSTEMIC AVAILABILITY OF NICOTINE TIMES ITS 
FRACTIONAL CONVERSION INTO COTININE IN TSE SUBJECTS (see footnotes) 
Brand 
Subj. 
Fl 
1 
г 
3 
t 
s 
6 
MEAN* 
± SD* 
F2 
7 
8 
9 
10 
11 
12 
13 
MEAN* 
± SD* 
D 
nglcig 
1.02 
0.92 
2.03 
2.10 
1.17 
1.34 
1.68 
1.88 
2.53 
1.75 
1.24 
1.32 
1.58 
0.48 
1.15 
1.13 
1.13 
0.83 
0.81 
0.94 
1.09 
0.97 
0.99 
0.91 
1.11 
1.26 
0.94 
1.38 
1.05 
0.12 
b 
nglhr 
0.88 
0.85 
1.60 
1.67 
1.10 
1.21 
1.54 
1.65 
2.14 
1.80 
1.13 
1.11 
1.39 
0.41 
0.96 
1.05 
0.85 
0.73 
0.68 
0.72 
1.06 
0.92 
0.80 
0.85 
1.39 
1.55 
1.15 
1.36 
1.01 
0.27 
тс 
vg/t 
23.1 
25.5 
34.5 
33.1 
33.1 
33.5 
17.7 
18.6 
46.0 
43.2 
15.0 
17.2 
28.4 
10.9 
18.8 
18.7 
17.1 
17.7 
9.9 
11.1 
15.7 
14.9 
17.4 
20.4 
36.1 
41.9 
20.1 
25.9 
20.4 
9.0 
CL . ¡f, 
тс' L 
t/hr 
38.1 
33.5 
46.4 
50.5 
32.9 
36.1 
87.3 
88.5 
46.7 
41.6 
75.6 
64.4 
53.5 
21.2 
51.2 
56.4 
49.7 
41.2 
68.7 
64.9 
67.5 
61.7 
45.9 
41.6 
38.5 
37.0 
57.2 
52.5 
52.4 
10.8 
c
24
 , 
cot 
Vg/t 
226 
207 
301 
278 
271 
311 
364 
318 
304 
307 
266 
254 
284 
42 
181 
204 
269 
249 
126 
146 
137 
134 
246 
241 
298 
289 
275 
334 
224 
70 
CL _ 
cot 
t/hr 
-
3.00 
-
3.94 
-
3.04 
-
3.39 
-
3.82 
-
2.93 
3.35 
0.44 
-
4.57 
-
2.66 
-
3.22 
-
4.03 
-
2.83 
-
3.49 
-
3.14 
3.42 
0.68 
EL ^ 
cot 
ttg/hr 
0.68 
0.62 
1.19 
1.10 
0.82 
0.95 
1.23 
1.08 
1.16 
1.17 
0.78 
0.74 
0.97 
0.22 
0.83 
0.93 
0.72 
0.66 
0.41 
0.47 
0.55 
0.54 
0.70 
0.68 
1.04 
1.01 
0.86 
1.05 
0.75 
0.22 
fLfM 
0.71 
0.67 
0.68 
0.60 
0.69 
0.72 
0.74 
0.60 
0.50 
0.60 
0.63 
0.62 
0.65 
0.06 
0.79 
0.82 
0.78 
0.84 
0.55 
0.60 
0.48 
0.54 
0.80 
0.74 
0.69 
0.60 
0.69 
0.71 
0.69 
0.12 
»h 
ag/cig 
0.9^ 
o.a/ 
1.84 
1.69 
1.08 
1.28 
1.66 
1.51 
1.68 
1.40 
1.05 
1.10 
1.34 
0.34 
1.22 
1.22 
1.16 
0.91 
0.60 
0.73 
0.70 
0.70 
1.06 
0.89 
1.01 
1.00 
0.86 
1.33 
0.96 
0.20 
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TABLE IV (cont'd). NICOTINE INPUT AT MOUTH- AND AT BLOOD-LEVEL, 
CIRCADIAN PLASMA LEVELS AND CLEARANCES OF NICOTINE AND COTININE, 
ELIMINATION RATE OF COTININE, AND SYSTEMIC AVAILABILITY OF NICOTINE 
TINES ITS FRACTIONAL CONVERSION INTO COTININE IN THE SUBJECTS (see notes) 
Brand 
Subj. 
F3 
14 
15 
16 
17 
18 
19 
MEAN* 
± SD~ 
F^-
ZO 
21 
22 
23 
24 
25 
MEAN* 
± SD* 
D 
mglcig 
1.66 
1.57 
1.37 
1.41 
1.03 
0.94 
1.33 
1.13 
2.32 
2.12 
1.60 
1.67 
1.51 
0.42 
1.41 
1.62 
1.47 
1.82 
2.41 
2.38 
0.97 
1.11 
2.12 
1.89 
1.40 
1.38 
1.67 
0.48 
MEAN** 1.45 
± SD** 0.38 
D 
mg/hr 
1.09 
1.12 
1.14 
1.14 
0.79 
0.79 
1.11 
1.19 
2.31 
2.20 
1.23 
1.43 
1.30 
0.5O 
1.44 
1.63 
1.59 
1.66 
2.67 
2.32 
0.96 
0.91 
1.93 
1.64 
1.44 
1.29 
1.62 
0.52 
1.32 
0.46 
c
24
 . 
nie 
vgl ι 
12.6 
12.8 
17.8 
19.2 
13.4 
15.5 
20.7 
22.1 
32.6 
26.9 
24.6 
24.4 
20.2 
6.4 
28.9 
27.5 
19.6 
21.5 
32.0 
28.5 
23.3 
21.1 
17.6 
17.8 
21.0 
19.8 
23.2 
4.9 
22.9 
8.3 
Cl
nicl{L 
l/hr 
86.5 
87.5 
64.0 
59.4 
59.0 
51.0 
53.6 
53.8 
70.9 
81.8 
50.0 
58.6 
64.7 
13.9 
49.8 
59.3 
81.1 
77.2 
83.3 
81.5 
41.2 
43.1 
109.7 
92.1 
68.6 
65.2 
71.0 
21.0 
60.0 
17.8 
cot 
Vg/l 
230 
225 
253 
247 
194 
174 
195 
192 
396 
314 
224 
224 
239 
62 
384 
417 
339 
321 
306 
306 
373 
349 
243 
229 
170 
166 
299 
86 
260 
70 
CL ^ 
cot 
l/hr 
-
3.94 
-
3.16 
-
3.32 
-
3.96 
-
4.23 
-
4.50 
3.85 
0.52 
-
2.80 
-
3.52 
-
4.39 
-
2.35 
-
4.25 
-
4.61 
3.65 
0.92 
3.56 
0.65 
EL ^ 
cot 
mg/hr 
0.91 
0.89 
0.80 
0.78 
0.64 
0.58 
0.77 
0.76 
1.68 
1.33 
1.01 
1.01 
0.93 
0.31 
1.08 
1.17 
1.19 
1.13 
1.34 
1.34 
0.88 
0.82 
1.03 
0.97 
0.78 
0.77 
1.04 
0.21 
0.91 
0.25 
fLfM 
0.77 
0.73 
0.65 
0.63 
0.75 
0.67 
0.64 
0.59 
0.67 
0.56 
0.75 
0.65 
0.67 
0.05 
0.69 
0.66 
0.69 
0.63 
0.46 
0.53 
0.84 
0.83 
0.49 
0.55 
0.50 
0.55 
0.62 
0.13 
0.66 
0.10 
D
'
fL 
ig/de 
1.70 
1.53 
1.18 
1.18 
1.02 
0.85 
1.13 
0.88 
1.55 
1.18 
1.61 
1.45 
1.27 
0.28 
1.29 
1.42 
1.35 
1.52 
1.50 
1.68 
1.09 
1.22 
1.39 
1.38 
0.93 
1.00 
1.31 
0.22 
1.27 
0.20 
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Systemic availabilitity of inhaled nicotine (f.) and its extent of conver-
sion into cotinine (f
u
) must both be high, since nicotine delivery rate (Ь) 
π 
and cotinine disposition rate (EL ) diverge less than a factor two (Table 
IV). The fraction product fj'iu calculated from these mass transfer rates 
averages 0 66 ± 0.10 in our subjects, and is similar for the populations smok­
ing the 4 brands However, it was noticed that the sequences of magnitude of 
fj'fw and the dose of nicotine delivered per cigarette at mouth-level run 
antiparallel for the 4 brands, suggesting (a smoking technique aimed at) high­
er nicotine availability in subjects with decreasing mouth-level delivery of 
their brand. 
The value of the product fT*fu draws the lower line for the value of both L π 
fractions at 0.66 on the average. On the basis of few literature information 
(see: 'Discussion'), we estimated f. and ί„ to average 0.88 and 0.75, respec-
L· π 
tively, in our subjects. Systemic nicotine delivery per cigarette (D'fr) was 
calculated for a value of f. calculated on basis of f
u
 = 0.75, and is included 
in Table IV. Mouth-level and systemic nicotine delivery for the smokers of all 
brands have been visualized in figure 2. 
8.3 DISCUSSION 
The approximate proportionality between the amount of nicotine (and 
'tar') retained by a cigarette filter and the amount passing through has been 
17 IB 19 
recognized previously ' ' . In agreement with this previous work, the rela­
tive retention of nicotine in the cigarette filter was found to depend on 
smoking parameters, and in particular with the quotient of puff volume and 
puff duration, which is the smoke flow through the filter during a puff. Rela­
tive nicotine retention decreased slightly with increasing smoke flow, sug­
gesting interference of short smoke filter transit times with aerosol deposi­
tion in the filter In the range of smoke flows applied (17.5 - 60 mî/sec), 
relative nicotine retention in the filters of the 4 brands studied was of suf-
ficient Constance to be useful as a tool for calculation of mouth-level nico-
tine exposure of our subjects. 
Puff volume and puff duration in machine smoking were chosen so as to 
cover the range of values frequently employed by smokers, according to smoking 
12 13 16 35-39 topography studies > > > Available data indicate that these and other 
smoking topography parameters are subject to considerable variability from 
puff to puff, cigarette to cigarette, and from one smoker to another 
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FIGURE Ζ Nicotine deliveries of the four cigarette brands studied D = nico-
tme yield by standard smok mg-mach me procedure D and O'f. = nicotine 
intake at mouth-level and at blood-level (systemic level), respectively, of 
the subject populations of the four cigarette brands Numbers given are mg of 
nicotine per cigarette Mean values and standard deviations have been indicat­
ed numerically and graphically 
Brand nicotine deliveries to our subjects did not differ significantly from 
each other, nor from the nicotine yields as determined by the standard machine 
smoking test of each brand, the result of which is mentioned on the packet 
(except for F4 delivery at mouth- and at blood-level of this brand were sig­
nificantly higher than its machinal delivery (P < 0 02 by two-tailed t-test) 
lid,12,13,35-39
 T . ... ., t .. , ... . ^ 
In view of these fluctuations we averaged relative nicotine 
retentions over the various circumstances of puff volume and puff duration at 
which each brand was machine-smoked, and used the resultant overall retention 
for computation of mouth-level deliveries 'in vivo' 
U2 
Reliability of this approach was further enhanced by analyzing nicotine 
in filters of subject-smoked cigarettes taking 10 butts per day and per sub­
ject, the random check thus amounted to nearly half the whole amount of butts! 
11a 
Furthermore, nicotine loss was investigated as a function of time and 
storage mode, the best storage mode and an acceptable storage time were 
employed We query the suitability of the storage procedures reported by 
Forbes et al (butt freezing) and by Hopkins et al. (removal of residual 
tobacco before storage) In our hands both procedures yielded inferior 
results 
The validity of the present approach is supported by the amounts of 
nicotine found in filters of subject-smoked cigarettes, which were nearly all 
in the range obtained when machinally smoking the corresponding brand under 
the conditions specified In addition, the retention data derived by machine-
smoking of the 4 brands are consistent with the information obtained by plasma 
concentration measurements of nicotine and cotinine, combination of these 'in 
vitro' and 'in vivo' data, respectively, did not result in abnormally high or 
low nicotine clearances, fraction products ί
τ
·ί„ £ 1, or other clear-cut arti-
L Π 
facts, not even at one of the 50 experimental days for which 'in vitro' and 
'In vivo' data were combined' 
Previous studies have shown that time and number of cigarettes smoked 
can be self-monitored reliably by smokers, the main condition required being 
21 22 
that no attempts are made to change their smoking behaviour ' Our subjects 
were encouraged to smoke In their usual way, and were left in their natural 
environment, except of course at the days of laboratory attendance. Paper 
strips for recording smoking times were given dimensions that suited them to 
be stored in the cigarette packets, in order to let 'smoking accounts' inter­
fere minimally with smoking behaviour. Some subjects who counted streaks them­
selves at the end of each day were amazed that they smoked 'so much'. Smoking 
rates and mouth-level nicotine delivery of these subjects did not decrease m 
the course of the experimental period, nor did those of the other subjects. 
For each subject, we investigated whether the following quantities 
exhibited significant differences at each of the days of laboratory atten­
dance, and at the 14 days of non-attendance butt length, number of cigarettes 
smoked, amount of nicotine retained in the filters, and the product of the 
latter two quantities In all cases, differences were far from significant. 
However, minimal and maximum amount of filter nicotine as daily analyzed in 
(and averaged for) 10 filters, invariably diverged by a factor li - 2 for all 
subjects for days of non-attendance. Intra-mdividual smoking technique 
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appears to fluctuate not only from puff to puff and from cigarette to 
cigarette, but also rather long-term, from day to day Possible differences in 
filter nicotine content for days of laboratory attendance on the one hand and 
for those of non-attendance on the other could be camouflaged by the (greater) 
differences existing between days of non-attendance as a result of other-than-
expenmental factors affecting smoking behaviour For what it is worth, we 
conclude that the smoking behaviour of our subjects was not, or at least not 
markedly, affected by the experimental protocol 
Total nicotine clearance averaged f «{бО 0 ± 17 В) î/hr in our subjects 
(Table IV), whose urinary pH remained uncontrolled in the experiments For 
high systemic availability of inhaled nicotine (f =• 1), this finding conpares 
L· 
well to those observed after ι ν nicotine administration in subjects with 
3 
alkaline urine (pH > 7) by Rosenberg et al (58 0 ± 5 3 £/hr in б men after a 
single injection, 46 7 ± 3 0 t/hr in 5 men for repetitive injections), in sub-
3 
jects with acidified urine (pH < 5) by Rosenberg et al (78 5 ± 10 1 t/hr, 5 
men, single inj , 61 6 + 5 8 t/hr, 5 men, repetitive inj ), by Benowitz et 
al S (77 5 ± 17 6 t/hr, 5 men), and by Feyerabend et al 1 (54 9 + 8 8 t/hr, 5 
men), or in subjects with uncontrolled, physiological urinary pH by Benowitz 
et al 2 (1 23 ± 0 30 t/hr/kg in 13 men, 0 94 ± 0 28 t/hr/kg in 9 women) 
Scarce literature reports estimate nicotine availability in habitually 
23 24 inhaling cigarette smokers to assume a value 0 75 - 1 00 , > 0 90 , and 0 82 
25 
- 0 92 Taking f = 0 88 in the average subject equates mean total nicotine 
clearance to an acceptable 52 8 t/hr, at the same time equating mean f
u
 to the 
plausible value of 0 75 A high fractional conversion of nicotine to cotinine 
was expected beforehand on the basis of the relative small abundance of the 
other primary nicotine metabolites (cis and trans) nicotine-l'-N-oxide, nor-
nicotine, and the isomethylnicotinium ion, in smokers' body fluids Cori et 
26 27 
al and Cohen & Roe have speculated f.. to approximate 0 70 , which value 
for our subjects appears rather conservative regarding the close proximity of 
the lower deadline for fM obtained in the present study (= 0 66) 
Returning to the nicotine clearance, then, 52 8 t/hr is in the lower 
range of literature values However, literature data on nicotine clearance 
1 2 3 1 2 3 5 
were obtained in experiments with men ' ' performed during daytime ' As 
women (n=19) outnumber men (n=6, Table I) m this study and eliminate nicotine 
at a significantly slower rate than men , and as nicotine recirculation by 
reabsorption from the urine bladder may manifest itself especially during 
nighttime when bladder emtying is less frequent than during daytime, a low 
clearance value in our subjects may be explained Nicotine reabsorption from 
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the bladder was indicated by the nicotine concentrations in the presmoking 
9 00 a m plasma samples With few exceptions, these concentrations usually 
exceeded predictions on the basis of previous day plateau concentrations com-
bined with a conservative estimate of nicotine elimination half-life of 2 hrs. 
The discrepancy could not be attributed to extraneous nicotine introduced into 
the sample during storage or analysis since sources of contamination were 
under control A sex différence m the quotient CL /fT was not observed 
n
 nie L 
in our subjects, presumably because of the smallness of our male subject popu-
lation, and because random values of f. may camouflage significant differences 
m nicotine clearance 
Within-subject variability of nicotine clearance (divided by f ) a', the 
two days of laboratory attendance, separated by 6 days, ranged from 0 4 to 
2 
20 6 %, largely confirming figures of Benowitz et al. (0 3 - 6.4 %, 3 days 
interspacing) Between-subject variability of nicotine clearance («f ) was 
as great as threefold Inter-individual differences in nicotine disposition 
2 16 2fi 
rate of this magnitude are encountered commonly ' ' , even in studies where 
renal nicotine clearance (urinary pH) was standardized Consequently we agree 
with Benowitz et al that the accuracy of estimates of a smoker's nicotine 
intake from the area under his/her circadian plasma nicotine concentration 
curve is greatly improved if the smoker's individual nicotine clearance is 
known from measurement on a separate occasion (e g., the previous or subse-
quent day). 
Our approach of nicotine intake estimation involving circadian AUC mea-
surement of nicotine and cotinine was similar to the strategy of Benowitz et 
2 29 30 34 
al ' ' ' In contrast to these experiments, our subjects were not hospi-
talized and hence it was practically unfeasible to obtain more than one blood 
sample in the evening/night from them Using the trapezoidal rule for AUC cal-
2 32 
culation ' would in case of our data result in a substantial overestimation 
of (especially nicotine) AUC in the nocturnal phase of the experiment (see 
fig 1). Therefore we computed AUC by fitting procedures using biexponentials. 
Pseudo steady-state concentrations of nicotine and cotinine are intra-
individually very similar at the two days of laboratory attendance, presumably 
resulting from smokers' strive to attain a nicotine level within in relatively 
narrow range ('index of indulgence'), in which nicotine dynamics are dppreci-
33 
ated best Similarity of the cotinine levels then follows from the propor-
tionality between nicotine concentration and cotinine formation rate , and 
from within-subject constancy of cotinine disposition kinetics Inter-
individually, plasma concentrations differ widely as a result of differences 
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in nicotine intake and disposition rate, extent of conversion to cotinine, and 
cotinine disposition rate. The time course of the profiles show a nicotine 
plateau reached by noon and a cotinine plateau reached in the late afternoon/ 
evening, designating the letter phase of day as most suitable for obtaining a 
characteristic indication of a smoker's nicotine and cotinine exposure if the 
number of samples is restricted to just one, as is practice in epidemiological 
investigations. Our findings thus support the design of the Gori and Lynch 
study 
The amount of nicotine delivered systemically per cigarette to the smok­
ers on the average comes to 1.34 ± 0.34 , 0.96 ± 0.20 , 1.27 ± 0.28 , and 1.31 
± 0.22 for brands Fl to F4, respectively (Table IV). These amounts differ by 
+12, -13, +15, and +31 % from the nicotine labels printed on the packets 
(Table II). In view of the great differences that may exist between the stan­
dard machine-smoking procedure and individual human smoking patterns, it is 
remarkable to observe the relative proximity of the intake figures predicted 
by the smoking machine and observed for the small subject populations of each 
of the 4 (medium nicotine-yield) brands. 
The results of a similarly designed experiment for subjects smoking 
cigarette brands equipped with ventilated filters will be presented in β 
forthcoming report. 
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Chapter 9 
NICOTINE INTAKE BY SMOKERS OF FILTER CIGARETTES. 
PART I I . VENTILATED FILTER CIGARETTES 
Plasma concentration profiles of nicotine and its mam metabolite cotinine 
were measured over 24 hrs on tuo separate occasions m a group of 10 habitual 
smokers, distributed over two current ventilated cigarette brands coded VI and 
VZ. On one of these occasions the snokers were administered a peroral refer-
ence dose of cold-labeled cotinine. 
Pharmacokmetical information calculated from the circadian plasma profiles 
of nicotine and cotinine derived from smoking and from the single-dose profile 
of the labeled cotinine was combined with smoking machine data on the relative 
retention of mainstream smoke nicotine in the cigarette filters in order to 
estimate the smokers' nicotine intake at mouth-level and at the level of the 
systemic blood. 
The nicotine intake rate at mouth-level amounted to 1.68 ± 0.60 mg/hr for 
the 6 subjects smoking brand VI and to 0.63 ± 0.25 mg/hr for the 4 subjects 
smoking brand V2 These input rates correspond to a per cigarette nicotine 
intake at mouth-level of 1.67 ± 0.46 mg, and 0.73 ± 0.25 mg of nicotine for 
the smokers of VI and V2, respectively (mean ± SD) . 
The bioavailability or fractional uptake of nicotine in the respiratory 
tract as calculated from the cotinine plasma data amounts to 91 ± 13 Ï. 
It was deduced that the two ultra-low cigarette brands studied m this 
report yielded substantially more nicotine to our habitual smokers of these 
brands than the imprint on the packet predicts. 
Harald W A. Teeuwen1, M Sc, Martin Hissink1, M.Eng., Ronald Bosman2, 
M.Sc, Ronald J.W. Aalders1, M Eng., and Jacques M. van Rossum1, Ph.D. 
1Department of Pharmacology, Faculties of Medicine and of Naturai Sciences and 
Hathematics, University of Nijmegen, P.O. Box 9101, 6500 ИВ Nijmegen, and 
2Department of Analytical Chemistry, Division of Technology for Society, 
Netherlands Organization for Applied Scientific Research (T.N.O.), P.O. Box 
342, 7300 AH Apeldoorn, The Netherlands. 
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In a previous article, we reported the nicotine intake of habitual smokers 
of medium nicotine yield cigarettes equipped with conventional (i e , non-
la 
ventilated) filters These intake figures approximated the machine-
determined nicotine labels on the cigarette packet rather well On the basis 
of compensatory smoking behaviour, which is well-documented in litera-
ture ' , it is expected that for both high and (ultra) low nicotine yield 
cigarettes machinal and human intake figures would deviate more from each 
other 
Using the same approach of combining 'in vitro' data relative nicotine 
retention in cigarette filters, and 'm vivo' data circadian plasma concen-
trations of nicotine, its main metabolite cotinine and the plasma concentra-
tion profile of an orally administered cold isotope-labeled cotinine analogue 
(4' ,4' -dideutero cotinine, cotinine-D2), we subsequently investigated the 
nicotine intake in 10 habitual smokers of two currently marketed brands of 
ventilated filter cigarettes 
la 
Philosophy and design of the experiment have been outlined previously 
The intake figures were compared to the machinal nicotine yield of the brands 
and to the intakes of 25 smokers of conventional cigarette brands reported 
before 
9 1 MATERIALS AND METHODS 
Subjects Subjects were recruited from the local university student pop-
ulation Selection criteria included faith to a single brand, inhalation of 
the smoke, and a more or less regular consumption pattern, that is, a consump-
tion rate varying only moderately between days, amounting to Ì 20 cigarettes a 
day on the average, and a regular within-day spread of cigarettes smoked Reg-
ularity of consumption was investigated during a week preliminary to the 
experiment by having the subjects put a streak for each cigarette smoked on a 
paper strip with a time table on it Subjects were not informed of the purpose 
of their recordings 
The selected subjects were 2 males and 8 females, all apparently 
healthy, between 19 and 44 yrs of age (mean ± SD = 29 ± 9), and having a body 
weight between 51 and 76 kg (mean ± SD = 63 ± 9) They all gave their written 
informed consent All had normal history, baseline hemoglobin and hematocrit 
None had any clinical evidence of hepatic, renal, or hematologic disease The 
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TABLE I. SUBJECT CHARACTERISTICS 
Brand/ Sex Age BU Hed Cig/day 
subj.nr yrs kg 
VI 
26 
27 
28 
29 
30 
31 
HEAN 
± SD 
π 
f 
f 
f 
f 
f 
21 
35 
3B 
36 
27 
44 
34 
8 
76 
57 
63 
55 
64 
51 
61 
9 
-
-
-
soc 
Lo 
-
26 3 
21.4 
23.9 
24 0 
30.0 
17.3 
23.8 
4.3 
Brand/ Sex Age BU Hed Cig/day 
subj nr. yrs kg 
V2 
32 
33 
34 
35 
m 
f 
f 
f 
19 
20 
26 
26 
70 
70 
52 
66 
-
soc 
soc 
. 
21.0 
20.3 
19.5 
17.5 
23 
4 
65 
9 
19.6 
1.5 
OVERALL ПЕАН: AGE- 29 yrs, WEIGHT: 63 kg, CIO. CONS.. 22.1 cig/day. 
OVERALL SD : 9 9 4 0 
Bill = body weight, Hed = medication, Cig/day = mean number of cigarettes smoked 
per day m the experimental period. Lo 
glycate), SOC = steroid oral contraceptives. 
user of Lomusol and Loaedal (cromo-
TABLE II CHARACTERISTICS OF THE CIGARETTE BRANDS 
Brand Tar0 Nicotine^ C<ß Filter Wrapper Cig. VR ^ VR & 
nom min 
length length length 
mm mm mm Ζ Ζ 
27 32 84 81 ± 1 6 + 1 
25 32 84 64 ± 1 3 ± 1 
Stated by the manufacturer m accordance with ISO 3308 and ISO 340Γ' . 
00 
VR and VR . nominal and minimal ventilation rate (this chapter). 
nom mm
 r 
VI 
V2 
mg 
1.0 
1.0 
mg 
0 2 
0.1 
mg 
1.3 
4 6 
subjects were habitual smokers, who had been smoking their brand for at least 
6 months Their daily cigarette consumption during the experiment was 22.1 + 
4 0 cigarettes 
Three female smokers used steroid oral contraceptives, and another 
female subject took cromoglycate All subjects consumed xanthine beverages on 
a regular basis Alcohol was consumed moderately (± 10 g/day). Subject char-
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acteristics are summarized in Table I Data on the two ventilated cigarette 
brands are listed in Table II 
Experimental design and sampling Venipuncture schedule, administration 
of cotinine-D2, collection, storage, and selection of subjects' cigarette 
butts, and plasma and butt analysis for nicotine and related compounds were 
performed identically to a previous study ' ' ' 
Nicotine retention in machine-smoked cigarettes Overwraps of cigarettes 
of both brands were treated with a mixture of polyvinyl acetate resin and 
starch-paste in order to block ventilation holes to a variable degree Another 
aliquot of cigarettes remained untreated to preserve the nominal (maximum) 
ventilation rate After drying of the lime, cigarettes were placed one at a 
time in a specially designed holder While drawing in air at the mouth end of 
the filter at a flow rate of 17 5 mt/s, the air flow v' entering the tobacco 
rod of the cigarette was measured (m£/s) Thus, the ventilation rate (VR) of 
each individual cigarette was computed as 
VR = {(17 5 - v') / (17 5)) · 100% 
Untreated cigarettes of both brands showed nominal ventilation rate, 
VR (Table II), and constituted one ventilation class Treated cigarettes 
nom " 
were selected to constitute three further ventilation classes, having ventila­
tion rates of about 2/3»VR , 1/3'VR , and VR , respectively The VR 
nom nom min min 
class consisted of cigarettes whose perforations had all been blocked by the 
lime treatment Due to filter paper porosity, their ventilation rate actually 
did not equal zero, but rather ranged from 2 to 7 X (Table II) Each class 
encompassed 140 cigarettes (a total of 560 cigarettes per brand) Absolute 
standard deviations of V of the cigarettes in each class were about 1 0 % 
Cigarettes of each ventilation class and brand were conditioned for 48 
hrs to standard conditions of temperature and relative air humidity (ISO 3402, 
2 
atmosphere A) , and subsequently machine-smoked with one puff per minute to a 
3 
butt length equal to the length of the overwrap -I- 3 mm (ISO 3306) , using a 
Filtrona SM 302 smoking machine equipped with β smoking channels In partial 
contravention to the conditions stipulated in ISO 3306, puff volume was chosen 
either 35, 45, 60, or 75 ml, and puff duration either 1 or 2 sec At seven of 
the eight possible combinations of puff volume and duration (45 ml/2 sec was 
arbitralily omitted), duplicate groups of 10 cigarettes of each ventilation 
class and brand were smoked The particulate matter in the mainstream smoke 
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was trapped on a glass fibre filter (a so-called 'Cambridge' filter). The 
amounts of nicotine in the cigarette filter (F) and on the glass fibre filter 
(D) were determined by GC-NPD. For both brands, plots of D versus F were con-
structed and linear least squares regression parameters were calculated. In 
addition, correlation coefficients and 95% confidence prediction limits of D 
for given F were computed. 
The average amount of nicotine delivered per cigarette to the mouth of 
smoking subjects at a particular day in the experimental period (comprising 16 
days) was estimated by substituting the average nicotine content (F) of 10 
selected representative butts (smoked by the subject at the particular day) 
into the regression line of the appropriate brand. 
Drug determinations. Smokers' plasma samples were analyzed for nico-
tine, cotinine, and, whenever appropriate, for cotinine-D2 according to spe-
cific and sensitive methods described elsewhere ' . Nicotine amounts retained 
in cigarette filters or trapped on glass fibre filters were determined by 
preparing suspensions of the filters in methanol and by analyzing filtered 
suspension aliquots using an assay derived from the method used for plasma 
, . Id 
analysis 
Kinetic calculations. Pharmacokinetic and input rate calculations were 
la 
done as described in the previous chapter 
9.2 RESULTS 
A grossly linear relationship was observed between the amount of nico-
tine retained in the cigarette filter and the amount passing through it in the 
mainstream smoke during machine smoking of brands VI and V2 (figure 1). How-
la 
ever, in contrast to conventional cigarettes , the relative retention of 
nicotine in the ventilated filters of VI and V2 was not a constant within nar-
row boundaries, but rather appeared to depend on puff volume, puff duration 
and ventilation rate. These fluctuations of the relative retention resulted in 
the ribbon-like appearance of the data points shown in figure 1. Correlation 
coefficients of regression lines were substantially lower than those calculat-
ed for conventional cigarettes, resulting in rather large prediction limits of 
D computed according to the regression lines for given F. 
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nicotine in mainstream smoke (D, mg) 
2 25 τ 
- ι η 
025 0 5 0 075 100 125 150 175 2 0 0 225 
nicotine in cigarette (liter (F, mg) 
nicotine in mainstream smoke(D, mg) 
1 125 
1 0 0 0 -
0Θ75 
0 7 5 0 
0 625 
0 5 0 0 
0 375 
0 250 
0 125 
0 5 0 0 7 5 100 125 150 175 2 0 0 2 2 5 
nicotine in cigarette filter ( F , m g ) 
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Averaged over all machine-smoking parameters employed, R amounted to 
52% for brand VI and to 68% for brand V2, both values being higher than the 
la 31-35% encountered for the conventional brands F1-F4 studied previously 
From figure 1 it may be discerned that for high puff volumes and low 
ventilation rates the amount of nicotine in the mainstream smoke can mount up 
to as much as 10 times the nominal value of the label on the cigarette packet 
of VI and V2 (Table II). The nicotine dose D delivered at mouth-level to the 
volunteer smokers at days of laboratory attendance averages 1.67 ± 0.46 rog/cig 
for the subjects smoking VI and to 0.73 ± 0 25 mg/cig for those smoking V2 
(Table IV) These amounts differ significantly from the nominal machine yields 
of these brands (VI Ρ < 0 0005, V2 Ρ < 0.01) and from each other (P < 0.01), 
strongly suggesting a smoking technique characterized by a less-than-nominal 
ventilation rate, larger puff volumes, and/or higher puff frequencies to have 
been employed by our human smokers as compared to the parameters used in the 
standard machine-smoking procedure Mouth-level nicotine yield of brand VI is 
statistically indistinguishable from those of the 4 conventional filter brands 
la (Fl to F4) studied previously , whereas V2 per cigarette yields less nicotine 
than Fl (Ρ < 0.01), F2 (NS), F3 (Ρ < 0.05) and F4 (Ρ < 0.01) at mouth-level. 
Nicotine delivery per cigarette (D) and per hour (D) for most smokers are sim­
ilar (Table IV) as most of them smoked about a cigarette each hour when calcu­
lated over a circadian period (= 24 cig/day). 
In figure 2 circadian nicotine and cotinine plasma concentration vs. 
time profiles of a subject smoking brand V2 are shown for the two days of lab­
oratory attendance day 4 (upper panel) and day 11 (lower panel). In the lower 
panel the profile of cotinine-D2 is shown as well. 
FIGURE 1. Relationship between the amount of nicotine present in the main­
stream smoke (D) and the amount retained m the cigarette filter (F) In 
machine smoking of brands VI and V2. Smoking parameters puff volume / pu f f 
duration О = 35 ml/2 s, о = 35 ml/1 s, Q = 45 ml/l s, Δ = 60 ml/Ί s, V = 
60 ml/2 s, а = 75 ml/1 s, C3 = 75 ml/1 s. Open symbols = nominal ventilation 
rate (VR ) , symbols blackened less than half 2/3*VR , symbols black-
nom пои' 
ened more than half. 1/3'VR , totally blackened symbols: minimal ventila-
nom 
tion rate (VR ) Regression lines. VI. D = 1 0789 'F - 0.1778, η = 56, r 
mm 
= О 816 VI. D = 0.5433'F - О 0956, η = 56, r = 0.873. 95% Confidence pre­
diction intervals of D for given F have been indicated. 
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FIGURE Z. Circadian nicotine (o), cotinine ('), and cotinine-DZ (1) plasma 
concentration profiles in subject nr. 3Z at day 4 (upper panel) and at day 11 
(lower panel) of the experimental period, which were the two days of all sub­
jects' laboratory attendance. Arrows denote the (time of) smoking of a single 
cigarette by this subject. (Cf. fig. 1, chapter 8). 
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TABLE III PHARÍIACOKINSTIC PARAMETERS OF C0TININE(-D2) IN THE SUBJECTS 
HEAH 
± SD 
MAT 
hr 
o ai 
0 30 
HUT 
Ar 
IS 2 
2 4 
CLcot 
l/hr 
3 56 
0 43 
VäSs 
I 
S3 9 
10 2 
4 
hr 
12 4 
1 8 
E 
ο/σο 
9 9 
1 2 
Ν 
re 
101 
13 
OTT 
mm 
9 0 
1 7 
Kinetic parameters were calculated from the plasma profile following oral 
administration of ± 0 1 mg/kg of dideuterated cotmine in a gelatine capsule 
Pharmacokinetic parameters of cotinine as calculated form the plasma 
profiles following oral administration of cotinine-D2 in a gelatine capsule 
(Table III) agreed with those observed for the smokers of conventional filter 
cigarettes and those observed by Benowitz et al , De Schepper et al , and 
g 
Kyerematen et al Combining the present data with those of the conventional 
la filter cigarette study , we found none of the kinetic cotinine parameters to 
be significantly different between the smokers' populations of the six brands 
(VI, V2, F1-F4), between sexes, or between female subjects taking steroid oral 
contraceptives (representing about 40% of the women smokers both studies) and 
those not taking SOC 
24 Circadian plasma levels (C ) of nicotine and cotinine average 28 4 and 
326 ng/ml for smokers of VI, and 10 4 and 139 ng/mî for those of V2, respec-
tively (Table IV) The levels of the smokers of VI are slightly higher, those 
of the V2-smokers substantially lower than those observed in smokers of the 
conventional cigarettes F1-F4 The differences are entirely attributable to 
proportional differences in nicotine intake rate at mouth-level, since sys-
temic availability of smoke-inhaled nicotine (f.), nicotine total clearance 
(CL . ), fractional conversion of systemic nicotine into cotinine (ί„), and 
nie π 
cotinine total clearance (CL ) appear to be similar for the smokers1 popula­
tions of all brands (Table IV, cf Table IV in chapter 8) However, note that 
the fraction product t *f of the lowest-delivery brand V2 (= 0 71) is higher 
than observed for any other brand, confirming our earlier suggestion of (a 
smoking technique aimed at) higher nicotine availability in smokers of low 
nicotine brands 
Scarce literature information indicates smoke-inhaled nicotine avail-
11 12 13 
ability (fT) to approximate unity ' * and the fractional conversion of 
14 15 
systemic nicotine into cotinine (f^ ,) to be around 0 7 ' Like in the con­fi 
ventional filter cigarette study, in this study f., was taken 0 75 as a mean 
value for our subjects Fractional uptake of nicotine based on the product 
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f.'f^ . (Table IV) for f.. = 0 75 can be shown to average fT = 0 88 ± 0 15 in L π π L 
smokers of VI and f = 0 95 ± 0 12 in smokers of V2 Individual values of f 
L L 
were used to compute the nicotine dose D*fT delivered systemically (absorbed 
into the pulmonary blood) These values have been included in Table IV (right-
hand column) and are also visualized in figure 3 for the smokers1 populations 
of VI and V2 
9 3 DISCUSSION 
/ 
In case of ventilated filters, linear velocity and flow rate of the 
smoke during a puff are not merely a function of puff volume, puff duration, 
and cigarette diameter, but rather are influenced by vent air and hence by 
ventilation rate, as indeed was experimentally observed by us and by oth-
4 5 
ers ' The higher the ventilation rate, the more air is drawn in during a 
puff, reducing flow and linear velocity of the smoke As a result, deposition 
of particulate matter in unburnt tobacco and cigarette filter will be promot­
ed In the present study, cigarettes of VI and V2 were machine-smoked with 
ventilation rates varying from 3-6% to 64-81% (Table II), effectuating sub­
stantial elevations of aerosol transit time in the filters This phenomenon 
Footnotes ad Table IV 
Brand mean ± standard deviation, overall mean ± standard deviation 
For each subject, СЛе upper row of figures refers to the 1 day, and the 
lower row to the 2 day of laboratory attendance (day 4 and day 11 of the 
experimental period, respectively) 
Ό mean nicotine input at mouth-level per cigarette 
D mean nicotine input at mouth-level per hour 
4 
nie 
2  
С mean arcadian nicotine plasma concentrât ion 
24 
С mean arcadian cotmme plasma concentration 
cot 
CL ¡fr total nicotine clearance divided by its bioavailability 
nie L 
CL . total cotmme plasma clearance 
cot 
EL mean arcadian cotmme elimination rate = CL ^ % СГ 
cot cot cot 
fT'f„ nicotine availability · fraction converted into cotmme 
L η 
D'f. mean systemic (blood-level) nicotine input per cigarette, f 
L· L· 
is calculated from the fraction product /.·/„ for f„=075 
L π fi 
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TABLE IV. NICOTINE INPUT AT MOUTH- AND AT BLOOD-LEVEL, CIRC ADI AN 
PLASHA LEVELS AND CLEARANCES OF NICOTINE AND COTININE, ELIMINATION 
RATE OF COTININE, AND STSTEMIC AVAILABILITY OF NICOTINE TIMES ITS 
FRACTIONAL CONVERSION INTO COTININE IN THE SUBJECTS (see footnotes) 
Brand 
Subj. 
VI 
26 
27 
28 
29 
30 
31 
MEAN* 
± SD* 
V2 
32 
33 
34 
35 
MEAN* 
± SD 
D 
mg/cig 
2.22 
2.65 
1.33 
1.18 
1.51 
1.70 
1.15 
1.19 
1.91 
1.83 
1.87 
1.53 
1.67 
0.46 
0.72 
0.86 
1.05 
1.06 
0.55 
0.49 
0.56 
0.54 
0.73 
0.25 
MEAN 
± SD 
b 
mg/hr 
2.31 
2.10 
1.27 
1.28 
1.81 
1.89 
1.13 
1.03 
2.44 
2.60 
1.10 
1.22 
1.68 
0.60 
0.83 
0.95 
0.75 
0.85 
0.41 
0.39 
0.42 
0.43 
0.63 
0.25 
c
24
 . 
nie Vg/l 
48.5 
46.2 
25.8 
26.1 
25.9 
26.4 
15.0 
14.6 
32.8 
36.1 
16.8 
16.7 
28.4 
10.9 
14.1 
14.0 
9.5 
11.0 
11.0 
9.3 
6.8 
7.3 
10.4 
2.9 
CL . lfT me' L 
l/hr 
47.6 
45.6 
49.2 
49.0 
69.9 
71.6 
75.3 
70.6 
74.3 
72.1 
65.2 
73.2 
63.3 
12.4 
56.7 
67.9 
79.4 
76.9 
37.2 
42.1 
62.0 
59.1 
60.2 
15.8 
62.2 
13.1 
cot 
Ui/t 
351 
338 
384 
416 
333 
326 
233 
205 
416 
423 
247 
238 
326 
81 
200 
202 
159 
189 
77 
77 
107 
103 
139 
58 
CL ^ 
cot 
l/hr 
-
4.15 
-
2.75 
-
3.79 
-
4.11 
-
3.39 
-
3.45 
3.61 
0.53 
-
3.91 
-
3.32 
-
3.52 
-
3.24 
3.50 
0.30 
3.56 
0.65 
EL _ 
cot 
mg/hr 
1.46 
1.40 
1.06 
1.14 
1.26 
1.24 
0.96 
0.84 
1.41 
1.43 
0.85 
0.82 
1.16 
0.26 
0.78 
0.79 
0.53 
0.63 
0.27 
0.27 
0.35 
0.33 
0.49 
0.24 
fLfM 
0.58 
0.61 
0.78 
0.82 
0.64 
0.60 
0.78 
0.75 
0.53 
0.51 
0.71 
0.62 
0.66 
0.11 
0.87 
0.77 
0.65 
0.68 
0.60 
0.64 
0.76 
0.71 
0.71 
0.09 
0.68 
0.10 
D
'
fL 
iiigl с ig 
1.7¿ 
2.17* 
1.35 
1.29 
1.30 
1.36 
1.20 
1.20 
1.31 
1.23 
1.79 
1.26 
1.43 
0.27 
0.83 
0.88 
0.91 
0.97 
0.44 
0.42 
0.56 
0.52 
0.69 
0.24 
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brand 
D* 
\** 
VI 
0 2 
1Ç7 
0 4 6 
V2 
01 
073 
025 
Df , * * * 143 
027 
0Ç9 
0 24 
FIGURE 3 Nicotine deliveries of the two ventilated cigarette brands studied 
D = nicotine yield by standard mach me-smok mg procedure D and D,f. = 
nicotine intake at mouth-level and at blood-level, respectively, by the sub-
ject populations of the two brands Numbers given are mg of nicotine per 
cigarette Mean values and standard deviations have been indicated numerically 
and graphically (cf fig Z, chapter 8) 
Average nicotine deliveries to the subjects, both at mouth-level and at 
blood-levelj significantly differred from the machine-derived deliveries, both 
for brand VI (P < 0 0005) and for brand V2 (P < 0 01) Average subject nico-
tine deliveries of VI and VZ as well differred from each other (P < 0 01) 
may very well explain in part the high average relative nicotine retention in 
the filters of VI and V2, compared to the filters of the conventional brands 
The nicotine amounts retained in the filters of VI and V2 when machine-
smoked under the conditions specified (see figure 1) cover the amounts 
retained in the filters of cigarettes smoked by our subjects, with the excep-
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tion of subject 26 Filters of the butts saved by this subject contained more 
nicotine than any of the machine-smoked cigarette filters Subject 26 probably 
did not employ larger puff volumes than 75 ml (the highest machinal puff vol-
ume employed in this study), but rather may have puffed more frequently than 
once a minute (the machine-smoking frequency) 
In spite of the large prediction interval of D for given F (figure 1), 
application of the smoking machine-derived regression line to predict human 
intake at mouth-level appears to work out well, producing no clear-cut arti-
facts in total nicotine clearance and the fraction product fj'fu The values 
of these latter quantities compare well to those obtained in the conventional 
la filter cigarette study Actual computing errors probably are smaller than 
indicated by the prediction limits, presumably because structural positive and 
negative deviations from the regression lines as observed to result from rigid 
machme-smoking patterns are due to cancel in fluctuating intra-individual 
smoking technique The existence of such fluctuations is evident from individ-
ual highly variable CO yields of single within-day cigarettes to our sub-
jects , and at longer term from the variability of mean daily nicotine con-
tent of subject-smoked butts For all subjects, highest and lowest mean 
nicotine content, as averaged over 10 butts analyzed per day, diverged by a 
factor li-2 over the 16 days of the experimental period, as also was observed 
for smokers of conventional filter-tipped cigarettes in part I of this study 
Filter nicotine content, number of cigarettes smoked, the product of nico-
tine content and number of smoked cigarettes, and butt length did not differ 
between each of the two days of subjects' laboratory attendance on the one 
hand, and the 14 days of free movement on the other Once more, we conclude 
that the experimental setting used in this study does not notably affect con-
la 
sumption rate and smoking technique of our subjects 
la 
Comparing the conventional cigarette brands studied (F1-F4) to the venti-
lated brands studied presently with regard to mean mouth-level nicotine yield 
(D), it is recalled from the section 'Results' that brands VI and F4 rank at 
the top of the list, whereas V2 definitely is the brand poorest in nicotine 
delivery (compare "D " in figure 3 of the present chapter to figure 2 in 
la 
chapter 8 ) 
It is instructive also to compare the total amount of nicotine distilled by 
the smokers of the 6 brands from the tobacco of their cigarettes in the act of 
smoking (i e , the amount retained in the filter F, augmented by the amount 
passing through it and reaching the smoker's mouth D) These amounts, aver-
aged over the smokers' population of each brand, read as follows F + D = 2 32 
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(Fl), 1 56 mg (F2), 2 29 mg (F3), and 2 45 mg (F4), 3 38 mg (VI), and 2 25 mg 
(V2) Неге VI heads the list with distance, V2 now being indistinguishable 
from Fl, F3, and F4 
An explanation for the high value of (F + D) for brand VI could be that the 
tobacco variety or blend utilized in VI production might be particularly rich 
in nicotine, which would be in accordance with the significant inverse corre­
lation found by Benouitz et al between nicotine concentrations in tobacco of 
15 brands and the amount of nicotine delivered in machine-smoking of these 
brands under standard conditions This hypothesis is supported by the ratio 
of total nicotine to carbon monoxide (CO) delivery ({F + D) / DT , see chap-
ter 10, figure 2), which is higher for VI than for any other of the investi­
gated brands 
The (F + D)-value of brand V2 does not give occasion to suspect a nicotine-
rich tobacco blend to be used in its manufacturing The conspicuously low 
mouth-level nicotine delivery D of this brand seems entirely attributable to 
the high efficiency of the filters of V2 with respect to nicotine retention 
This high efficiency may be due in part to the occurrence of ventilation (see 
the beginning of this section) Cross-sections of the proximal ends of 
V2-cigarettes as smoked by our volunteers indeed showed tar staining patterns 
characteristic of a substantial (though certainly not nominal) ventilation 
rate 
In literature, reductions in nicotine exposure have been reported to occur 
in smokers after short-term experimental switching from relatively high tar/ 
nicotine brands to ultra low yield ventilated brands ' , or to cigarettes 
20 provided with ventilated cigarette holders , after spontaneous switching to 
19 
ventilatcd-fliter cigarettes in smoking cessation programs , and in habitual 
smokers of ventilated-fliter cigarettes as compared to habitual smokers of 
21 higher nicotine yield brands Extent of reduction varied from slight (< 
5 20 18 
10%) ' to substantial (56*») , but in all studies was less than the extent 
that would be expected on the basis of machine-determined nicotine yields of 
the brands switched from and to Thus, like our subjects, literature subjects 
compensated for reduced concentrations of smoke constituents in the mainstream 
smoke of their cigarettes 
25 
Reduced availability of nicotine is generally viewed as the motivation to 
compensate, although one report states tar compensation to govern smoking 
23 behaviour over and above nicotine compensation The array of compensatory 
actions through which human smokers manage to extract more nicotine from their 
cigarettes than the smoking machine does, may be constituted of (a combination 
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of one or more of) the following factors: development of a smoking technique 
characterized by more frequent and/or more voluminous puffs, or by deeper 
inhalation and/or longer breathholding (lung exposure) times, by smoking a 
greater length of tobacco rod, by the (unconscious or intentional) blockade of 
the ventilatory mechanism by smokers' lips and/or fingers , or merely by 
increase of cigarette consumption rate. 
In a recent study, Zacny et al. pointed out that the increased number and 
volume of puffs taken from ventilated cigarettes may as well be due to changes 
in the physical characteristics of these cigarettes (resistance to draw), and 
24 
not to smokers actively compensating for reduced smoke constituent yields 
Whatever its main determinant, we realized that puff volumes appear to be 
24-27 greater for smokers of ventilated cigarettes than for those of conven-
28-36 
tional cigarettes , and added 75 mt as a puff volume in machine smoking of 
brands VI and V2 compared to 60 mt as the largest puff volume in machine smok-
la ing of the conventional brands F1-F4 
Our subjects smoking VI and V2 extracted considerably more nicotine from 
their cigarettes than the smoking machine does in the standardized procedure. 
This obviously demonstrates that humans may smoke in a way that is different 
from the machine standard. Our subjects tended to compensate for the low nico-
tine yield produced under standard conditions by one or more of the possibili-
ties to do so. 
The present experimental protocol, involving two days of laboratory atten-
dance and analysis of 30 plasma samples for nicotine and cotlnlne (and 
cotinine-D2 in 15 of them), and of 16 daily portions of butts for cigarette 
length and nicotine content, for obvious reasons does not lend itself to be 
employed in large-scale surveyal studies. Adaptations to suite it for studies 
at large scale go without saying, and will be applied in future research. 
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Chapter 10 
CARBON MONOXIDE INTAKE BY SMOKERS OF CONVENTIONAL 
AND VENTILATED FILTER CIGARETTES 
A pending public health issue is whether the newly marketed ultra-low tari 
nicotine I carbon monoxide yield ventilated filter cigarettes are less hazardous 
than others and whether smokers who cannot quit smoking should be advised to 
switch to these ultra-low cigarettes We studied carbon monoxide exposure m 
habitual smokers of conventional and ventilated filter cigarettes In order to 
resolve the issue with respect to this toxic constituent of tobacco smoke. 
Carbon monoxide (CO) is an odorless, colorless, asphyxiant, gaseous com­
pound commonly resulting from incomplete combustion of organic matter. It is 
present in the mainstream smoke of cigarettes in a volume percentage of 1 -4, 
44 depending on substance factors, ventilation, and smoking technique . Upon 
inhalation of the smoke, CO Is distributed throughout the lungs and Into the 
alveoli Here the alveolar air CO (CO . ) is absorbed into the pulmonary blood 
and combines with hemoglobin to form carboxyhemoglobm (COHbJ Very quickly a 
CO I СОНЬ equilibrium is reached, which is the basis for the direct corre­
lation found between the two forms of CO. 
1 2 In two earlier studies ' , we investigated the nicotine yield to smokers of 
(4 brands of) conventional cigarettes and (2 brands of) ventilated filter 
cigarettes In these studies, we also determined the CO yield to smokers, by 
analyzing CO In their expired alveolar air post and pre smoking single 
cigarettes The CO yields of the two classes and the various brands of 
cigarettes will now be reported, compared with each other, and related to the 
nicotine yields 
Harald W A Teeuwen, M Sc , Ronald J W. Aalders, M Eng , 
Jacques M van Rossum, Ph D. 
Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Mathematics, University of Nijmegen, Ρ 0 Box 9101, 6500 ИВ Nijmegen, 
The Netherlands 
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The harmful effects of CO in humans appear to be related to two character-
istics of CO First, CO has an extremely strong affinity for the oxygen trans-
porting agent in the blood, hemoglobin Inspired CO interferes with oxygen 
transport in two ways It competes with oxygen for hemoglobin binding sites 
In addition, combination of part of the hemoglobin with CO makes the rest of 
the hemoglobin in the capillary circulation cling to its oxygen with abnormal 
23 tenacity, causing impaired oxygen release to organs and tissues The 
impaired oxygen transport ultimateley produces a relative oxygen 'starvation' 
in the heart, coronary vessels, and other tissues 
The second destructive characteristic of CO pertains to its effect on the 
blood vessel walls The CO serves to increase the permeability cf the vessel 
wall, resulting in fluid buildup and reduced resistance to cholesterol 
deposits 
Indeed, elevated CO levels have been associated with increased risks to 
21 health, including increased risk of ischemic heart disease , decreased exer-
37 
eise tolerance, especially in those with angina pectoris , decreased cardiac 
37 
contractability in persons with coronary heart disease (CHD) , impairment of 
38 
survival rate in patients with acute myocardial infarction , and atheroscle-
39 
rosis In fact, individuals with COHb concentrations greater than 5% have a 
20 times greater risk of developing atherosclerosis than individuals with con-
centrations less than 3% ' Carbon monoxide, possibly aided by nicotine, 
has been found to be related to the incidence of CHD, and CHD sudden death, 
the most significant cause of mortality in persons who smoke In addition, CO 
has been cited as one of the prime contributors to respiratory diseases such 
as chronic obstructive pulmonary disease (COPD), and has been associated with 
fetal damage 
While representing a health hazard to all of us, CO is a particularly 
important risk factor for smokers, whose role in the pathogenesis of the 
above-mentioned smoking-related diseases long has been underestimated, atten-
tion being focussed on nicotine and tar Even now that product law makes it 
mandatory upon cigarette manufacturers to mention the brand's standard smoking 
machine yield of nicotine and tar on the packet in many countries, the stan-
dard CO yield remains unmentloned in most of these countries, including The 
Netherlands 
We investigated and compared the CO yields of two classes of filter 
cigarettes conventional and ventilated filter cigarettes 
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10.1 MATERIALS AND METHODS 
Subjects. The subjects were 35 apparently healthy volunteers (8 males, 
27 females), habitually smoking 22.1 ±2.1 cigarettes of one brand per day. 
Subject's characteristics, and their distribution among the two classes and 
1 2 
six brands of filter cigarettes have been given earlier ' . 
The characteristics of their cigarette brands have been summarized in 
Table I. Written informed consent to participate in the experiments was 
obtained from all subjects. 
TABLE I. CHARACTERISTICS OF THE CIGARETTE BRANDS SMOKED BY THE SUBJECTS 
Brand Tar9 Nicotine9 CCp Filter Wrapper Cig. S . ** VH W VR . ** 
П1С ПОЯ ЯЗ.П 
length length length mean 
Bg ng ng mm вв вш Ζ Ζ Ζ 
Fl 16 1.2 17.5 22 26 84 32 NA NA 
F2 16 1.1 16.2 18 22 80 35 NA NA 
F3 16 1.1 15.0 21 25 84 34 NA NA 
F4 13 1.0 12.0 21 25 84 32 NA NA 
VI 1 0.2 1.3 27 32 84 52 81 6 
V2 1 0.1 4.6 25 32 84 68 64 3 
0 
Stated by the manufacturer according to ISO 3308, ISO 3402, and ISO 8454. 
00 
R = mean relative filter retention of nicotine during mach ine-smok ing 
тс
 β 
under specified conditions (ref. 1, 2), VR and VR . = nominal (maximum) 
r
 l i s t
 n o B O J n 
and minimal ventilation rate, resp. (ref. 1, 2), NA - not applicable. 
Experimental design and sampling. The experimental protocol has been 
described before with respect to butt collection and venipuncture schedule . 
Subjects attended the laboratory at two consecutive Tuesdays from 9.00 a.m. to 
17.00 p.m., during 15 minutes in the evening of these days (between 21.30 and 
24.00 p.m.) and during 15 minutes (9.00 - 9.30 a.m.) in the morning of the 
subsequent Wednesdays. Subjects were instructed not to smoke at both Tuesdays 
and both Wednesdays until the first sample of breath had been produced. Other­
wise they were allowed to smoke ad libitum. Twenty paired samples of expired 
air were obtained 1 min before and 4 min after the smoking of 10 single 
cigarettes, including the first-of-the-day cigarettes at the 4 days mentioned 
and 6 cigarettes smoked at = 11.20 a.m., 14.30 p.m. and 17.00 p.m. at both 
Tuesdays. In the course of the latter days, unpaired samples of expired air 
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(not related to the smoking of any particular cigarette) also were obtained, 
at 10 10 a m , and 12 30 ρ m , 15 45 ρ ra , and 21 30 ρ m 
The time interval elapsing between the last puff and the production of 
the post-smoking breath sample was chosen A min as pilot experiments gave evi­
dence of a biexponential decay of CO in alveolar air after cigarette smoking, 
the first (rapid) phase being extinguished 4 min after smoking at the most 
Expired air samples were produced according to a breath holding tech-
3 
nique described by Jones et al Its principle involves use of the alveoli as 
aerotonometers until CO gas pressures of pulmonary blood and alveoli approach 
equilibrium After maximum inspiration from residual volume, subjects held 
their breath for 20 sec and then exhaled partially into a l i polyvinyl anes­
thesia bag Exhalation was interrupted for a moment to switch bags, and an 
end-expiratory (alveolar) breath sample of 1-2 E was collected in a second 2 1 
anesthesia bag that previously had been emptied by wringing, and which was 
equipped with a valve which the subjects closed after complete exhalation The 
dead space of the valve caused an insignificant error (< 1%) Expired air was 
analyzed for its CO concentration a few minutes after production Expired 
alveolar air CO boosts as a result of cigarette smoking were calculated as the 
difference between corrected СО-concentrations (see eqn II) in paired breath 
samples obtained post and pre cigarette smoking 
ЛСО , = CO . ^ - CO . (I) 
alv alv.post alv.pre 
expressed in parts per million (ppm) 
Blood hemoglobin concentration (Hb) was taken the average of 6 measure­
ments 50 μί aliquots of the first six blood samples taken in succession from 
each volunteer for the purpose of nicotine and cotinine plasma analysis was 
used for {Hb} measurements 
Analytical methods Samples of expired alveolar air samples were drawn 
through tuo consecutive glass cylinders (150 χ 25 mm ID) filled with granules 
of dry calcium chloride (Merck, Darmstadt, F R G ) and soda lime (Grace, 
Espernon, France) in order to absorb water vapour and carbon dioxide (CO.), 
respectively The remaining gas mixture was led through a portable CO analyzer 
containing a nondispersive infrared cell ('CO-monitor', Telegan Ltd , Kenley, 
U K ) with a linear response in the range of 0 - 2000 ppm of CO 
Before operation, the combined CO monitor and connected filters were 
iteratively calibrated using air containing 103 ppm CO (B 0 С , London, U K ) 
and ambient air freed of CO by a hopcalite filter (The Mine Safety Appliances 
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Co , Pittsburgh, U S A ) until the monitor displayed both 0 and 103 pptn cor­
rectly CO reading values were corrected for the volume contraction resulting 
from water and CO. removal from expired air samples and the concomittant CO 
enrichment of the remaining gas sample according to 
CO
alv,corr _ COalv,read { 1 " fvol,C02 " fvol,H20} ( I I ) 
For the purpose of correction, end-expiratory air produced by the Jones' tech­
nique was assumed to contain a fractional volume f . „„» = 0 OSO of carbon 
3 3 
dioxide and to be saturated with water vapour (partial saturation pressure 
of water vapour 37° 62 mBar) The fractional volume of water vapour in the 
air samples was calculated according to 
f
 1 „ = 62/(barometric pressure in mBar) (III) 
and varied from 0 060 to 0 064 in the course of the measurements. Barometric 
pressure was measured with a Casella London 4456 barometer (Casella, London, 
UK) A single 10 I expired air sample containing 51 ppm of CO was analyzed 10 
times with 1 hr interspacings during a working day, the observed coefficient 
of variation (CV) was 2 % 
Blood hemoglobin concentration (Hb) was measured spectrofotometrically 
4 
as azidemethemoglobin by absorption measurements at 565 and S80 nm using a 
S 
Hemocue photometer (AB Leo, Helslngeborg, Sweden) calibrated at 128 g/1 with 
the aid of a standard absorption cuvet Using six venous blood samples sepa­
rately obtained from the same individual within 3 hrs, the CV was 3 5 1 
Calculation of CO intake To determine the CO intake of our smokers, we 
made use of the empirical relationship between CO.. (ppm) and the percentage 
of Hb binding sites occupied by CO (%C0Hb) as determined simultaneously in 
expired air and blood of 162 smokers and 25 nonsmokers by Wald et al 
C 0
a l v = 5 09 %С0НЬ + 2 34 (n=187, r=0 97) (IV) 
For our purpose, it is more convenient to replace the percentage of 
occupied Kb binding sites (%С0НЬ) with a fraction of sites (fСОНЬ) occupied by 
CO (%C0Hb = 1 = fCOHb = 0 01) 
CO , = 509 fCOHb + 2 34 (V) 
alv 
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If CO . and fCOHb change as a result of net CO absorption (e.g., dur­
ing cigarette smoking) or disposition, the magnitude of the change of these 
quantities is related as: 
ΔfСОНЬ = ДСО , / 509 (VI) 
alv 
ΔfСОНЬ is the number of Moles of CO that have been absorbed (ÄfCOHb > 
0) or eliminated (AfCOHb < 0) per mole of circulatory (monomelic) Hb. The 
total amount of Hb (moles) present in the blood can be computed by multiplica-
tion of the Hb concentration (Hb) (moles) by the total blood volume VB (t). 
Subsequently, multiplication of AfCOHb by this total amount of circulatory Hb 
results in the net change of the amount of CO (moles) in the blood: 
ДСО
с
. = ДСО
а 1 (Hb) в / 509 (VII) 
If the CO boost ACQ is a result of cigarette smoking, and if the 
smoker's total blood volume is related to body weight (BW) as: 
V B / BW - 0.08 t/kg
6,8
 (VIII) 
the CO yield of this cigarette (in moles) to the smoker may be calculated as: 
D. = ІСО (Hb) 0.08 BW / 509 (IX a) 
or, if the CO yield is expressed in mg, (Hb) in g/fc, and allocating all 
scalers. 
DL CO ( m s ) = 2 · 7 3 · 1 0 " 4 A C Oalv { H b ) B W i I X Ь ) 
Statistical evaluation. Variance analysis was performed using F-test (two 
populations) or Bartlett's test (multiple populations). Differences in two 
population averages were attributed (non-)significance on the basis of the 
unpaired Student's t-test, while Tukey's test (q-test) was used for the simul­
taneous evaluation of differences in multiple population averages. Both t-test 
and Tukey's test were applied two-tailed. Significance of differences in aver­
age age of smokers' populations of the six brands were investigated using the 
rank sum test of Kruskall & Wallis (H-test). 
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10.2 RESULTS 
Figure 1 shows a representative circadian alveolar air concentration 
profile. The profile bears a natural resemblance to profiles of nicotine, 
1 2 
observed in this study ' . Trough levels of CO (and nicotine) were present in 
the morning before the first cigarette was smoked. Upon smoking, the CO level 
gradually increased throughout the day as a function of smoking rate and 
-pattern, each cigarette producing a distinct boost in alveolar CO. A plateau 
level was reached by the afternoon and evening. Termination of smoking was 
followed by a gradual decline of expired air CO in all subjects. Nocturnal CO 
half-lifes of 4 - 6 hrs were in accordance with the findings of Peterson and 
22 Stewart . 
alveolar air CO cone (ppm) 
100 
Θ0 
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40-
20 
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clock time (h) 
FIGURE 1. Circadian alveolar air carbon aonoxide concentration profile in a 
representative smoking volunteer (subj. 18). Cigarettes smoked by the volun­
teer are indicated at the figure bottom. Triangles denote cigarettes smoked at 
times unrelated to CO measurement, whereas arrows denote cigarettes for which 
alveolar air CO was measured just before and after smoking. Each smoked 
cigarette produces a dinstinct alveolar air CO boost. 
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subject M Kr 
brand F3 
day 4 
f·* «4 »»»»4«» • 
TABLE II MEAN EXPIRED ALVEOLAR AIR CO BOOSTS AND BLOOD KEHOGLOBIN 
CONCENTRATIOHS OF THE SUBJECTS 
"Oalv 
Brand/ 
Subj.nr. 
Fl 
1 
2 
3 
4 
5 
6 
MEAN 
± SD 
F2 
7 
a 
9 
10 
11 
12 
13 
MEAN 
i SD 
= CO 
№ ) 
g/t 
161 
149 
167 
140 
141 
139 
150 
12 
131 
149 
148 
143 
164 
133 
130 
142 
12 
alv¡post 
^ші 
ppm 
1.8 
6.2 
4 4 
12.5 
9.3 
8.9 
7.2 
3 8 
7.0 
10.8 
4 5 
4 8 
10 9 
7 6 
8 1 
7.7 
2 6 
CO , fn= 
alv,pre 
Brand/ 
Subj.nr 
F3 
14 
15 
16 
17 
18 
19 
F4 
20 
21 
22 
23 
24 
25 
-
10), {1 
№) 
sit 
148 
164 
162 
152 
158 
147 
155 
7 
152 
145 
148 
152 
151 
156 
-
151 
4 
lb) = blood 
ЬСО , 
alv 
ppm 
2.4 
1.7 
9.8 
9.2 
8.7 
9.2 
6.8 
3.7 
3.6 
3.2 
10.1 
9 8 
5.1 
3 1 
-
5 a 
3.3 
hemoglobin 
Brand/ 
Subj.nr. 
VI 
V2 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
-
-
-
cone. 
{Hb} 
g/1 
159 
145 
144 
141 
141 
154 
147 
7 
157 
140 
153 
146 
-
-
-
149 
8 
(n=6) 
ЬСО , 
alv 
ppm 
4.3 
10.3 
5.3 
5.7 
12.2 
6.4 
7.4 
3.1 
9.2 
4.5 
8.3 
4.9 
-
-
-
6.7 
2.4 
OVERALL MEAN ± SD- ÍHb) = 149 ± 9 g/1, àCOa] = 7 0 ± 3.0 ppm. 
Table II lists individual blood hemoglobin concentrations and expired 
air CO boosts related to the smoking of a single cigarette as averaged over 10 
cigarettes for each subject Hemoglobin was normal in all subjects, although 
some female subjects (nrs. 11,18,25) exhibited rather large values, suggesting 
7 8 
elevation due to the very habit of smoking * Average CO boosts varied widely 
between subjects, ranging from 1.7 to 12 5 ppm Within subject CO boosts again 
were rather variable, indicating large fluctuations in smoking technique (in 
particular duration of inhalation, see 'Discussion') from one cigarette to the 
next Intra- and inter-individual variability of CO boosts is proportionally 
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TABLE III. CARBON KONOXIDE YIELDS OF CONVENTIONAL AND VENTILATED FILTER 
CIGARETTE BRANDS TO THE SUBJECTS 
Brand/ 
Subj.nr. 
DL,CO 
HEAH ± SD* 
"g le ig. 
Brandi 
SubJ.nr. 
L,CO 
MEAN ± SD* 
Bg/cig. 
Brand/ 
Subj.nr. 
DL,CO 
ПЕАН ± SD' 
ag/cig. 
Fl 
F2 
7 
В 
9 
10 
11 
12 
13 
W 
;D 
11.7 
25.0 
11.1 
12.1 
29.2 
16.5 
17.2 
17.5 
7.0 
5.2 
25.0 
5.7 
6.6 
24.1 
8.5 
8.7 
MEAN 
t S  
OVERALL MEAN ± SD : D 
F3 
F4 
20 
21 
22 
23 
24 
25 
9.7 
6.1 
26.0 
22.8 
12.0 
8.2 
14.1 
8.2 
5.1 
5.9 
10.0 
7.0 
9.4 
6.3 
VI 
1 
2 
3 
4 
5 
6 
MEAN 
± SD 
5.9 
16.4 
13.7 
29.1 
18.6 
18.9 
17.1 
7.6 
5.5 
12.7 
8.4 
20.9 
10.4 
8.5 
14 
15 
16 
17 
18 
19 
7.8 
7.0 
32.5 
25.2 
19.8 
23.5 
19.3 
10.1 
4.2 
5.3 
23.5 
24.1 
9.8 
11.0 
26 
27 
28 
29 
30 
31 
14.1 
23.2 
13.1 
12.1 
30.1 
13.7 
17.7 
7.3 
8.5 
22.8 
9.2 
5.1 
17.8 
9.4 
V2 
32 
33 
34 
35 
27.5 
12.0 
18.1 
13.4 
22.4 
8.3 
10.0 
9.6 
17.8 
7.0 
L,CO 17.6 ± 8.7 Bg oí CO per cigarette. 
intra-individual mean ± SD (n=10); inter-individual mean ± SD. 
reflected in the ratio of mean and standard deviation of single cigarettes' CO 
yields to subjects, as shown in Table III. 
In contrast to the fluctuations of (inter-)individual CO boosts and 
yields, brand CO yields, as averaged over the smokers of each brand, were rel-
atively constant and ranged from 14 to 19 mg of CO per cigarette of the vari-
ous brands, including the ventilated ones (Table III, figure 2). Subjects 
smoking the four conventional brands were delivered quantities of CO which 
compared reasonably with the machinal CO yield (figure 2). 
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brand 
D 
F1 
175 
F2 
163 
F3 
150 
F4 
120 
V1 
13 
V2 
4 6 
171 
+ 
76 
175 
+ 
70 
193 
+ 
1Ó1 
141 
+ 
€2 
177 
+ 
73 
178 
+ 
70 
FIGURE 2 Carbon monoxide deliveries of the cigarette brands studied D - CO 
yield in the standard machine smoking procedure, D = CO intake (at systemic 
level) by the subject populations of each cigarette brand Numbers are mg of 
CO per cigarette Mean values and standard deviations have been indicated 
numerically and graphically 
CO-deliveries of the conventional filter brands to their smokers did 
not differ significantly from the machinal yields, m contrast to those of the 
ventilated filter brands which did differ Ρ < 0 0001 for brand VI, Ρ < 0 02 
for brand V2 
CO-deljverics of the 6 brands were not significantly different from 
each other 
In contrast, smokers of the ventilated brands VI and V2 derived more 
than 13 times, respectively nearly 4 times as much CO from their cigarettes 
than does the smoking machine in the standard procedure Differences between 
human intake and machinal yield of CO were strongly significant (P < 0 0001 
for brand VI, Ρ < 0 02 for brand V2) 
Statistical analysis revealed no significant differences in mean age, 
weight, Hb concentration, CO boost, and CO intake between the subject popula­
tions of the six cigarette brands studied 
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10 3 DISCUSSION 
Analysis of CO in alveolar air It has long been recognized that blood 
carboxyhemoglobin and expired air CO levels are directly correlated ' 
3 11 
Although the relationship between COHb and CO , essentially is nonlinear ' , 
this non-linearity becomes manifest only at a relatively high СО-saturation of 
Hb If %C0Hb S 20% (s CO . Í 100 ppm), that is in the low range of 
hemoglobin saturation, correlation coefficients up to 0 98 were found by Wald 
et al , Jarvis et al ' , Cohen et al , and Ringold et al Slopes of 
13 14 
the regression equations relating CO . to COHb given by these authors ' 
vary substantially, from 3 3 to 6 3 ppm / %C0Hb (cf eqn IV) The intermedi-
ate value of 5 09 obtained by Wald et al appeared to correlate excellently 
3 
with the slope of the scattergram constructed by Jones et al (who themselves 
unfortunately did not perform regression analysis on their data), and was used 
in this study 
The firm relationship between CO . and COHb, and the development of 
relatively inexpensive, easy to operate, and fully portable instruments for 
assessing atmospheric CO levels, based on nondispersive infrared absorption by 
CO or on catalytic conversion of CO to CO (in which case the conversion rate 
is proportional to the electrochemical current produced) have rendered expired 
air CO analysis an attractive means of non-mvasively, yet in vivo, determin-
ing the CO-yield of tobacco products to human smokers Its non-invasive char-
acter was particularly convenient in this study, since it allowed us to tune 
the venipuncture schedule entirely to the pseudo steady-state kinetics of 
nicotine and cotinine, and to preserve the full volume of the blood samples 
obtained for analysis of these compounds only The breathhold technique was 
easy to perform for all subjects CO in expired air samples was analyzed con-
veniently (digital reading) and rapidly (li - 2 min per sample) with our appa-
ratus Control of the filter materials for residual absorption capacity of 
water vapour and CO was facile (visually) to perform Refreshment of the fil-
ter materials was necessary every 5 operation days Resetting of the monitors 
zero level occurred whenever the instrument had not been in use for 1-5 hours 
Recalibration of both the zero and the 103 ppm level was done when the instru-
ment had been out of operation for one or more days 
Experimental Design In developing the experimental design focussed on 
the determination of the absolute CO uptake of smokers, two approaches were 
conceivable The first approach was followed for nicotine and its metabolite 
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cotinine ' , and departs from the balance of intake and elimination rates of 
smoke-inhaled substances during one characteristic period of a smoker's сігса-
dian living (and smoking) rhythm, this period being 24 hrs naturally Elimina­
tion rate of CO at any moment equals its blood concentration times its clear­
ance If CO clearance were approximately constant and known, the total amount 
of CO eliminated during 24 hrs could be calculated as clearance times 24 hrs-
averaged blood concentration However, CO is cleared exclusively alveolarly 
and hence its clearance depends on ventilation rate and is known to vary 
21 22 
greatly as a function of physical exercise ' Standardizing the ventilation 
rate by imposing physical inactivity upon the experimental subjects is imagin­
able, but still leaves us with the problem of not knowing the exact value of 
CO clearance Moreover, we felt that 24 hrs of dictated inactivity would be 
too big an infringement of subjects' personal lives 
We therefore turned to the second approach, involving measurement of 
alveolar air CO boosts following smoking single cigarettes This strategy is 
afflicted uith the (minor) disadvantage that there is no way of measuring a 
subject's amount of extravascular hemoglobin (in spleen, skin, bone marrow, 
etc ), and intracellular myoglobin (of red muscles), which substances together 
bind 30-40% of absorbed CO when the distribution of CO in the body has reached 
, ,. 43 complete equilibrium 
The proportion of CO combined with myoglobin (Mb) in man is estimated 
to be only about 5» of that combined with Hb of the circulating erythrocytes, 
41 
even when equilibrium has been reached The small amount of CO which com­
bines with Mb is believed to be related in part to its lesser quantity in the 
42 body and in part to its lower affinity for CO as compared with Hb 
As to the extravacular Hb, CO diffusion to, and reaction with, the Hb 
of stagnant red cells in spleen, skin and bone marrow is estimated to be slow, 
43 
distribution times being in the order of magnitude of an hour Considering 
that this time is large compared to the mean input time of CO from a single 
cigarette (± 5 min), just after smoking termination the absorbed amount of CO 
in good approximation is still almost completely bound to circulatory Hb Thus 
the use of eqn VII is validated 
The shortness of mean CO input time during single cigarette smoking 
renders measurement of CO boost insensitive to subjects' exposure to CO from 
environmental sources and also from endogenous physiologic processes The 
intensity of exposure to CO from these sources tends to vary, if variable at 
all, at much longer term than cigarette smoking time 
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Influence of sex on the magnitude of the СО-boosts. CO boosts for 
smokers of regular filter cigarettes in this study on the average were compa­
rable in magnitude to those observed by Frederiksen and Martin , Rüssel et 
25 45 
al. , and Ashton et al. ; they were slightly larger than those found by Hen-
17 18 
ningfield et al. , and Ossip-Klein et al. , and smaller than those measured 
19 20 
by Stepney , and Gori et al. for smokers of medium nicotine and tar yield 
cigarette brands. CO boosts for smokers of ventilated filter cigarettes in 
this study on the average were comparable with those observed by Zacny et 
24 
al. for habitual smokers of unventilated cigarettes, who in the experiment 
smoked ultra low yield cigarettes whose filter vents had been blocked deliber-
ately to an extent of either 50 or 100%. 
A negative though nonsignificant correlation existed between blood Hb 
concentration and alveolar CO boost in our subjects (r = -0.216). The correla-
tion between body weight and CO boost was both negative and significant (r = 
-0.389, Ρ < 0.05), whereas the product of body weight and Hb concentration 
correlated even more significantly with CO boost (r = -0.392, Ρ < 0.01). 
Any physiological/anatomical textbook makes mention of a sex difference 
with respect to blood hemoglobin concentration, in that this concentration is 
higher in men than in women. We indeed observed such a difference (Hen: {Hb) = 
158.4 ± 6.8 g/t, n=8. Women: {Hb) = 146.0 ±8.1 g/t, n=27, Ρ < 0.001) (mean ± 
SD) in our subject group. Since mean body weight of our male smokers (BW = 
75.0 ± 8.4 kg) was greater than that of our female smokers (BW = 56.9 ± 11.8 
kg, Ρ < 0.0005), it was inferred that our male subjects also had a greater 
blood volume, and hence a greater total amount of circulatory hemoglobin than 
our female subjects. Since there was no sex difference in CO intake, it might 
be expected that smoking a cigarette might give rise to a higher increment of 
hemoglobin CO-saturation and thus to a greater boost of alveolar CO in women 
than in men. This supposition was true. We observed in men a CO boost of 4.98 
± 3.18 ppm; in women boosts averaged 7.56 ± 2.80 ppm, Ρ < 0.05 (mean ± SD). 
The inverse relation between hemoglobin level and carboxyhemoglobin 
(and alveolar CO), and the resulting sex difference in A%C0Hb (and ACO . ) 
given equal CO intake have been observed only once before to our knowledge, by 
25 
Russell et al. . These authors remarked that this finding might have especial 
implications for anemic women smoking in pregnancy. 
Because of the spreading of male and female smokers over the various 
cigarette brands studied, and because of the relatively small brand popula­
tions, the observed sex differences in weight, hemoglobin concentration and 
alveolar air CO boost were not significantly carried over into the brand popu­
lations. 
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Relationship between intake of nicotine and CO by the smokers 
Insignificant correlations were found between subjects' mean intake of CO on 
the one hand, and that of nicotine (either at mouth-level D, or at systemic 
level D*fT> r = 0 10, η = 35) on the other, both intake figures individually 
averaged over the 2 days of laboratory attendance This low correlation sug­
gests a loose relationship between the (inter)individual intake of the two 
compounds Maybe a stronger correlation exists between the nicotine and the 
CO yield of individual cigarettes smoked by one person, but even at the intra-
individual level a large extent of independence of nicotine and CO must be 
anticipated 
CO naturally is found in the gaseous phase of the smoke, whereas nico­
tine almost exclusively is associated with aerosolized particles The mecha­
nism of absorption of gaseous and aerosolized compounds in inhaled tobacco 
smoke differs fundamentally In the next reasoning inhalation depth is sup­
posed to be sufficient for smoke constituents to reach the deeps airways 
Aerosols are rapidly deposited in the respiratory tract, they are 
trapped in the mucous layer or in the fluid film covering bronchi, bronchioli 
and alveoli, respectively, the first time they come into collision with it 
26 27 
The mean deposition time is estimated to be in the order of a second ' The 
extent of aerosol deposition, and, concomittant, extent of nicotine absorption 
therefore is independent of lung expsosure time (breathholding time) after the 
first second or so 
Absorption of CO from the alveoli into the pulmonary blood is governed 
by diffusion laws Rate and extent of CO absorption therefore depend on the CO 
concentrations in the inhaled smoke and in the pulmonary blood, and on the 
time interval available for diffusive exchange These three quantities are all 
subject to considerable fluctuation from one cigarette to the next Duration 
of inhalation and breathholding is especially important, since exhalation 
abruptly removes the CO and thereby terminates its abborption process Lung 
exposure time under natural smoking conditions endures only for a small frac­
tion of the time that is required for completion of the CO absorption process 
The latter time is equal to the time to reach CO blood-air equilibrium, and 
3 
hence to the time of breathholding of the method adopted from Jones et al 
20 sec Thus, m contrast to nicotine absorption, absorption of CO is depen­
dent on lung exposure duration in the range of lung exposure durations normal­
ly employed by smokers 
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Summarizing, physical separation of CO and nicotine in tobacco smoke 
and the resultant difference in dependence of absorption of either compound 
upon puff duration is likely to be the major factor underlying the observed 
poor correlation of nicotine and CO intake between individuals. The hypothe­
sized dependence of CO intake on lung exposure time, and the independence of 
nicotine intake on it, have recently been experimentally verified by Zacny et 
2B 
al. . These authors also showed that inhalation depth is less critical than 
lung exposure time for the extent of CO absorption. Other factors held con' 
stent, 20 % of vital capacity is sufficient an inhalation depth to allow for 
rapid CO (and nicotine) absorption. Any surplus inhalation depth above 20X 
does not give rise to a corresponding increment of rapidness and extent of 
28 
absorption of both CO and nicotine 
Other authors also observed the ability of smokers to take in nicotine 
29 30 
and CO in an independent way ' . The question raised by Ashton et al. in the 
title of their article: 'Should intake of carbon monoxide be used as a guide 
29 
of intake of other smoke constituents?' should be answered 'no!' for all 
'other' smoke constituents which are abundant in the aerosol phase of tobacco 
smoke. 
Fluctuation of СО-yield within and between smokers, and between 
brands. Variability in CO yield between and within subjects smoking the same 
brand are large (Table II) and reveal proportional inter-individual and intra-
individual differences in smoking technique and other factors. Apparently, 
smokers do not have a fixed technique, but rather smoke each cigarette in a 
different way, this way being affected by momentary circumstances of a social, 
psychological or pharmacological nature. At longer term, variability in smok­
ing behaviour persists, as was shown by the highest/lowest ratio = \i - 2 in 
mean daily butt nicotine content in the 16 day experimental period (see figure 
2 in chapter 3). 
Because of the relatively small СО-saturation of Hb in the morning (see 
figure 1), diffusion of CO to the pulmonary blood is facilitated in this phase 
of the circadian smoking rhythm. Indeed, the morning cigarettes tended to 
boost COHb and CO . to a greater extent than did the other cigarettes (though 
just not significantly so), accounting for some of the observed variability. 
In addition to technique and time of smoking, the substance smoked 
might exert great influence on CO intake of smokers. The potential CO deliv­
ery varies according to size and shape of the cigarette, the presence and type 
of the filter, and paper porosity, to moisture content, cut, packing density, 
31,32,33 
and variety of the tobacco .In view of these multiple factors, that 
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hardly can be expected to be alike for the six brands studied, it is highly 
surprising to observe the similar level of CO yields of all six brands, 
including the two ventilated brands This similarity may be explained by the 
observation of Herning et al , that 'how a cigarette is smoked' determines 
intake and levels of cigarette smoke compounds, or, stated differently, that 
so-called 'topographical' factors (smoking technique) are more important than 
substance factors in the determnation of CO-intake A certain degree of coin­
cidence cannot be excluded either in 'explaining' the observed similarity in 
CO yield 
In addition, the CO yield of the ventilated brands can only then be 
similar to that of the regular brands, if the smokers of the ventilated brands 
exhibit a smoking technique directed at compensation for the ventilation-
induced low nicotine delivery of their brands Compensation may be achieved by 
(a combination of) blocking the vent holes by fingers and/or lips, or by smok­
ing more intensely, that is by taking larger puffs (facilitated by the low 
resistance to draw of ventilated cigarettes), more puffs, leaving a shorter 
24 35 
butt, and by inhaling the smoke more deeply and longer ' than is usually 
done by smokers of regular filter-tipped or plain cigarettes 
Literature comparison of CO-delivenes of conventional and ventilated 
filter cigarettes In literature, reductions of smokers' exposure to CO have 
been reported after short-term experimental switching from medium nicotine 
brands uith conventional filters to ultra-low ventilated-filter 
51 52 49 
cigarettes ' ' or to cigarettes provided with ventilated cigarette hold­
ers , after long-term experimental switching to ultra-low cigarettes ' , 
and in habitual smokers of ultra-low cigarettes compared to habitual smokers 
57 56 
of conventional filter cigarettes ' The extent of these reductions in all 
studies was less than the extent that would be predicted comparing machine CO 
yields of the cigarettes involved, indicating compensatory smoking behaviour 
like in the present study 
Reduction of CO-intake, if observed at all, has been reported to to be 
less than reduction of nicotine intake in smokers switching from high or medi-
45-51 
urn nicotine/tar yield brands to brands (ultra) low in nicotine and tar 
No reduction in CO exposure (i e , complete co-compensation of CO 
intake) as well has been reported after short-term experimental switching from 
medium nicotine brands with conventional filters to ultra-low ventilated-
5Θ 
filter cigarettes by Robinson et al on the basis on non-invasive and inva-
48 
sive measurements, to cigarettes provided with ventilated cigarette hold-
186 
ers , after long-term experimental ' and natural switching to ultra-low 
cigarettes, and in habitual smokers of ultra-low cigarettes compared to habit­
ual smokers of conventional filter cigarettes 
Precise comparison of the results of literature studies to those of the 
present study regarding the issue whether or not differences in CO exposure 
between smokers of conventional filter cigarettes high or medium in nicotine/ 
tar, and smokers of ventilated cigarettes ultra-low in nicotine/tar are sig­
nificant, is confounded by many factors 
As to the brand switching studies, it is not known if results of short-
term experimental switching studies are valid at long term There is only one 
report that deals with th^s question and suggests extrapolation of short-term 
results to the long term makes sense in case of switching from high- or medium 
yield to Jew-yield cigarettes The authors of this report raise ал interest­
ing point in discriminating between experimental and 'natural' (spontaneous) 
switching, m that 'natural' switchers tend to compensate completely for nico­
tine, whereas experimental switchers compensate only partially As an explana­
tion, these authors argue that "the low-yield smokers in natural switching 
studies are self-selected, whereas in experimental studies all smokers are 
required to switch It is possible that, under natural conditions, switching 
to lower yield cigarettes is maintained only by those who compensate fully and 
that those who fail to do so revert to a higher yielding brand " 
Comparison to either switch- and non-switch literature studies is fur­
ther confounded by changes in smoking rate, variability in time passed between 
the last cigarette and sampling of blood or alveolar air, variability in 
breathing technique and breathholding time in sampling expired air, and the 
ocurrence of subject feedback on his/her personal CO-levels 
While exercising some prudence in view of the small smokers' popula­
tions of the brands involved, data obtained in the present study suggest that 
smokers of ventilated filter cigarettes do not take up less CO than smokers of 
conventional filter cigarettes 
187 
10 4 CONCLUSIONS 
The CO intake of 35 smokers spread over 4 brands of conventional and 2 
brands of ventilated filter cigarettes was studied in conditions of natural 
steady state smoking behavior The CO yield of all six brands to their smokers 
was similar and amounted 14 - 20 mg of CO per cigarette For the sake of 
reduction of CO intake» there probably is no reason to advise people who are 
unable (yet) to quit smoking to switch to ventilated cigarettes 
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Chapter 11 
INTRAVENOUS SINGLE DOSE PHARMACOKINETICS OF 
CAFFEINE. A SYSTEMS DYNAMICS APPROACH 
Harald W.A. Teeuwen1, Paul J. de Schepper1, T. Budya Tjandramaga', 
and Jacques M. van Rossum' 
^Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Mathematics, University of Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, 
The Netherlands, and 
IDepartment of Pharmacology, Catholic University of Leuven (K.U.L.), Campus 
Gasthuisberg, В-ЭО00 Leuven, Belgium. 
11.1 SUMMARY 
The disposition kinetics of caffeine was investigated in 6 healthy vol­
unteers after intravenous infusion of a 200 mg (2.8 - 3.2 mg¡kg) dose. Plasma 
samples were collected over 30 hours and analyzed for caffeine using reversed-
phase HPLC combined with UV detection. Pharmacokinetic analysis was performed 
by non-compartmental dynamic systems pharmacokinetics. 
Intravenous caffeine was characterized by a mean (± SD) residence time 
of 6.5 ± 2.0 h, a total clearance of 7.1 ± 3.6 l/h, and a volume of distribu-
tion of 42 i 8 I. Mean residence time ranged from 3.7 to 9.5 h, and total 
clearance from 4.9 to 14.3 t/h, indicating considerable inter-subject vari-
ability in caffeine disposition. Upper and lower extremes of caffeine disposi-
tion rate were encountered in a heavy smoker and in a female subject taking 
steroid oral contraceptives, respectively. 
The extraction ratio of systemic caffeine molecules averaged 2 Ζ per 
transit in our volunteers, with a mean body transit time of 7 min. The mean 
number of transits per caffeine molecule came to 56. 
Key words: Caffeine, intravenous infusion, systems dynamics pharmacokinetics. 
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Caffeine (1,3,7 trimethylxanthine) on a molar basis probably is the 
second most widely consumed drug on earth, after alcohol It is found In 
plants and shrubs of various families and genera edigenous to all continents. 
Many of these plants are cultivated nowadays. Man ingests caffeine most fre­
quently as hot aqueous beverages constituted of these plants, like coffee, 
tea, mate, etc Furthermore caffeine is manufactured into soft drinks (e.g., 
cola), coffee liqueurs, certain foodstuffs, pick-me-ups, and as an adjuvant in 
many non-prescriptive medications, mainly analgesics. Caffeine has been used 
succesfully as a therapeutic in the treatment of apnea in neonates [1-5]. 
Notwithstanding its mass consumption, certain aspects of caffeine phar­
macokinetics are rarely dealt with in literature, such as the kinetics of gas­
trointestinal absorption of caffeine, those of caffeine biotransformation into 
its most important primary dimethylxanthine metabolite paraxanthine, and the 
kinetics of the latter metabolite Caffeine absorption is generally believed 
to be 'rapid' and 'complete', although until now only one study was specifi­
cally designed to investigate caffeine absorption kinetics [6]. Lelo et al. 
[7,8) were the first and until now the only investigators to report plasma 
paraxanthine kinetics after oral administration, and the fractional conversion 
of caffeine into paraxanthine. 
We designed a sequence of studies as to determine the kinetics of caf­
feine and paraxanthine after intravenous and oral administration, the rate and 
extent of caffeine metabolism into paraxanthine, and paraxanthine kinetics. As 
the first part of the program, the kinetics of caffeine after intravenous 
infusion in six healthy young volunteers are presently reported 
Π 2 MATERIALS A N D METHODS 
Subjects Six healthy Caucasian volunteers (3 males and 3 females), 
participated in the experiments after their written informed consent was 
obtained according to institutional policy. Their mean age (± SD) and weight 
was 23 ± 1 years and 67 ± 4 kg, respectively The subjects were assessed as 
being 'healthy' on the basis of a normal health history and standard physio­
logic tests All of Lhem were habitual consumers of coffee and/or tea They 
were free of medication, except subject 6 who took oral contraceptives. All 
volunteers were nonsmokers and modest social drinkers of alcoholics, except 
subject 2 who consumed beer and cigarettes in substantial amounts. Subject 
characteristics are summarized in Table I 
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The subjects were instructed to abstain from coffee, tea, chocolat, 
cacao, caffeine-containing soft drinks and medications, and alcohol for a 60 h 
period prior to the experiment, and during its course The intravenous dose 
was administered at approximately 10 00 a m on the day of the kinetic trial 
Subjects were alloued a light breakfast in the morning of this day Otherwise 
they had free access to allowed foods and drinks 
Intravenous administration and sample collection The caffeine infusion 
solution was prepared by diluting 6 mt of injectable caffeine preparation 
(Caffeine and Sodium Benzoate injection fluid, 50 mg of caffeine/ml, lot nr 
84I24-F3404, Cooperative Pharmacists' Society 'De Onderlinge Pharmaceutische 
Groothandel', Utrecht, The Netherlands) with isotonic sodium chloride solution 
to produce 45 mi of infusion solution A 30 ml aliquot was then administered 
via a heparin lock placed in a forearm vein at a constant rate of 1 mi/min 
using a Braun PerfusorVI infusion pump (Braun AG, MeIsungen, FRG) The 
remainder of the solution was stored for analysis 
Blood samples (5 mt) were withdrawn via a heparin lock in a vein of the 
contralateral arm at time zero (blank) and at approximately the following 
times after the start of the infusion 5, 10, 15, 20, 25, 30 (at infusion 
stop), 45, and 60 mm, and at approximately li, li, 24, 5, 7¿, 14, 21 and 31 
h Prior to the removal of each blood sample, 2 ml of blood was withdrawn 
through the heparin lock and discarded The blood sample then was collected in 
a heparimzed syringe (Monovette, 5 mt, Sarstedt) The last 4 samples were 
obtained by individual venipunctures 
After sampling, plasma was separated by centnfugation (1000 g for 10 
m m ) Plasma samples were stored at -20a pending analysis, which as a rule was 
performed within 1 month No caffeine decomposition was detectable over 6 
months in plasma samples stored as indicated 
Caffeine analysis in plasma and infusion fluids Samples (1 mt) of plas-
ma or of infusion fluids (after dilution by a factor 1000) of each subject 
were spiked with the internal standard (ISTD) 7-3-hydroxyethyltheophylline, 
and extracted with dichloromethane in a single step at pH = 12 The evaporiza-
tion residue was reconstituted in the mobile phase consisting ot water, 
methanol, acetomtrile, and THF (v/v/v/v = 85 6 6 3) and 200 yt/1 of glacial 
acetic acid The mobile phase was delivered at 40' and at a rate of 1 mt/min 
to a 150 χ 4 4 mm I D column home-packed with octadecy Is liane (Chormosorb 
RP-18 , particle size 5 μιη, Merck, Darmstadt, FRG) Effluent was monitored at 
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254 nm UV Retention times were 4 0 and 3 2 m m for CAF and the ISTD Coeffi­
cients of variation (CV) amounted to 3%, 4% and SX at plasma caffeine concen­
trations of 5 0, 1 0 and 0 1 mg/1 The assay is a minor modification of a 
method described elsewhere [9] 
Pharmacokinetic Analysis The plasma concentration vs time data 
(C (t), t) during the 30 m m (Τ) ι ν infusion were fitted to a sum of expo­
nentials according to 
m -t/τ 
C i v(t) = Ï (Ai ti/T)«(l-e 1) 
and af ter the infusion to 
m -Τ/τ - ( t -T)/ t 
С ( t ) = Ι (Α. τ /Τ)·(1-β V e 
IV i l l 
Parameter estimates were obtained by use of the non-linear curve fitting pro­
gram 'FARMFIT' [34] A relative error equal to the coefficient of variation 
(CV) of the analytical procedure (see 'Caffeine analysis') was attributed to 
each data point (weight factor W = 1/{CV*C (t )}2) Given a set of parame­
ters, the 'FARMFIT' program iteratively minimizes the weighted sums of squared 
deviations (WSS) 
WSS = Ζ W (C . (t.) - C, , (t )} 2 
ι j iv.obs j iv.calc j 
where η is the number of data points, and С . (t ) and С . (t ) are the 
r
 ' iv.obs j iv,cale j 
intravenous plasma concentrations observed respectively calculated according 
to the fit parameters at the j time of sampling 'FARMFIT' provides the min­
imal value of WSS finally obtained 
Data points with concentrations less than 0 075 mg/i (CV > 10%) were 
excluded from the fit procedure since their accuracy was considered insuffi­
cient to be compatible with correct data analysis 
The number of exponential functions was chosen on the basis of two cri­
teria, the first being the Akaike Information Criterion (AIC) [10,11] 
AIC = n«ln(WSS) + 2p 
where ρ is the number of parameters to be estimated The number of exponential 
functions yielding the lowest AIC value was considered the best representation 
of experimental data for each subject 
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The second criterion to decide on the number of exponentials was a sta­
tistical comparison of the fits by the F ratio test [12,13]· 
Vp.n-q = (WSSp/WSSq " 1)(П-Я)/(Ч-Р) Ρ < Я 
where WSS and WSS are the weighted sums of squared deviations obtained by 
fittjng equations with ρ and q parameters (p ^ q), respectively, to the number 
of η data points This test indicates if WSS is reduced (i e , if the goodness 
of fit has improved) significantly (P < 0 05) by the addition of one exponen­
tial to the fitting equation 
From the concentration coefficients (A ) and the time constants (τ ), 
total areas under the plasma concentration vs time curve (AUG), under the 
time*concentration versus time curve (TAUC), and under the squared 
time'concentration vs time curve (T'AUC) were computed according to statisti­
cal moment theory [14] 
AUC = I A "t., TAUC = Σ Α ·Τ *, and T'AUC = 2 Σ Α -τ, 1 
, i i' , ι ι ' i l l 
The total body transport function (or disposition function) ψ(ΐ) was 
calculated as [15]. 
m "«/τ. 
*(t) = 1/AUC Σ Α.·β 1 
i i 
Mean residence time (MRT), variance of residence times (VRT), terminal 
ife (t,), total clearance (CL), and apparent 
(V ) of caffeine were respectively computed as [15] 
half-l . volume of distribution 
MRT = TAUC/AUC, VRT = T'AUC/AUC - (TAUC/AUC)a, 
t. = 0 693 τ , CL = Dose/AUC, and V. = MRT'CL t 2 ass 
where τ. is the time constant of the terminal declining phase of the concen­
tration profile Assuming cardiac output ( C O ) in our healthy subjects to 
average 360 l/h, the extraction ratio (E), the average nurober of recircula­
tions (N ) and the mean transit tine (MTT) can be calculated as [15]: 
E = CL / C O (·100%), N
r c
 = (1-E)/E = 1/E, and MTT = MRT / N 
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11.3 RESULTS 
Akaikes Information Criterion (AIC) and the F ratio test with a signif­
icance level of 0.05 yielded the same decisions regarding the number of expo­
nentials used for fitting the data points. The data of subject 1 were fitted 
to a monoexponential function, those of the other subjects to a biexponential 
function. Subjects' fitted plasma profiles and curve fitting data are shown in 
figure 1 and Table I, respectively. The plasma concentration profile over the 
first 3 experimental hours of subject 6 is repeated in figure 2, together with 
her caffeine total body transport function Ψ(ί) both over 3 and 30 hrs. 4>(t) 
is proportional to the plasma concentration profile after an i.v. injection of 
caffeine in this subject and represents the frequency distribution of body 
residence times of caffeine [15]. 
Pharmacokinetic parameters of caffeine in our 6 volunteers have been 
listed in Table II. Plasma half-lifes and mean body residence time (MRT) aver­
age about 4i and 6i h, respectively. Variance of residence times equals 
approximately MRT-square, which may be expected in case of essentially monoex­
ponential kinetics. Caffeine is a low-clearance drug (CL = 7 l/h) and dis­
tributes throughout the total body water (V = 42 ± 8 i Ξ 0.63 ± 0.13 t/kg). 
During each circulatory transit through the body, 1.4 - 4.0 X of systemic caf­
feine molecules was withdrawn from the circulation in our 6 volunteers, mainly 
by hepatic biotransformation (average: E = 2 ± 1 % ) . The mean time of a single 
transit through the body (MTT) amounts to about 7 min. The average number of 
body transits (N ) is more than 50, some of the molecules already being elim­
inated already during the first transit while others may complete several hun­
dreds of recirculations. 
Values of caffeine kinetic parameters in subjects 2 and 6 represent 
upper and lower extremes, respectively, of disposition rate. 
FIGURE 1. (Top) Caffeine plasma concentration profiles during and after a 30 
min intravenous infusion in 6 volunteers. For the sake of surveyability, 
individual profiles have been interspaced by 5 h. Profiles of consecutively 
numbered subjects have been presented from the left (subject 1) to the right 
(subject 6). (Bottom) Caffeine transport function it(t) for subject 6 depict­
ed both over 3 and 30 h (solid lines), and the plasma concentration profile 
over the first 3 h in this subject (dashed line). Note the tuo ordinate 
scales and the dual abscissas. 
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concentration (mg/1) 
caffeine 200 mg 
iv infusion over 30 mm 
in 6 healthy volunteers 
frequency ( I / h ) 
0 2 
plasnna concentration (mg / l ) 
0 1 
0 0 5 
0 0 1 -
0 0 0 5 - 0 5 
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TABLE I. SUBJECT CHARACTERISTICS, AND CURVE FITTING DATA OF CAFFEINE 
FOLLOWING I.V. INFUSION OF 200 ПС OVER 30 MIN IN 6 HEALTHY SUBJECTS 
Subj 
1 
2 
3 
4 
5 
6 
MEAN 
± SD 
Sex 
m 
m 
m 
f 
f 
f 
Age 
yrs 
23 
22 
24 
24 
22 
24 
23 
1 
BW 
kg 
68 
63 
72 
68 
60 
68 
67 
4 
Med/ 
Ind. 
A 
ΑΑ,Τ 
A 
-
-
SOC 
-
-
Α
ι 
mg/l 
-
2.59 
9.39 
8.05 
310 
4.17 
-
. 
A2 
mg 11 
5.81 
2.83 
4.00 
5.65 
5.19 
4.00 
4.58 
1.17 
τ
ι 
min 
-
49.4 
4.61 
7.78 
0.13 
24.4 
-
-
'2 
h 
5.70 
4.18 
7.89 
6.34 
6.28 
9.90 
6.72 
1.97 
AUC 
mg'h/l 
33.1 
13.9 
32.3 
36.9 
33.3 
41.2 
31.8 
9.4 
TAUC 
mg'h'/t 
188.4 
51.2 
249.1 
227.4 
204.6 
392.1 
218.8 
109.8 
т
г
т 
mg-h', 
2147 
416 
3931 
2881 
2569 
7749 
3282 
2472 
BU = body weight, fíed/Ind. = medication and drugs of indulgence: A = modest 
consumption of alcohol (± 10 gfday), AA = excessive consumption of alcohol (± 
100 g¡day) j Τ = tobacco consumption (25 cigarettes/day), SOC = steroid oral 
contraceptives. 
TABLE II. PHARMACOKINETIC PARAMETERS OF CAFFEINE CALCULATED FROH TRE PLASNA 
CONCENTRATION VS. TINE PROFILE DURING AND FOLLOWING INTRAVENOUS INFUSION 
Subj 
1 
2 
3 
4 
5 
6 
MEAN 
± SD 
'i 
h 
3.95 
2.90 
5.47 
4.40 
4.35 
6.86 
4.65 
1.36 
t . = plasma elimii 
For cal 
subjects. 
culation 
MET 
h 
5.70 
3.69 
7.72 
6.16 
6.15 
9.51 
6.48 
1.97 
nation 
of E, 
VRT 
h1 
32.5 
16.4 
62.2 
40.1 
39.4 
97.5 
48.0 
28.4 
half-life •• 
МП, and Ν 
CL 
l/h 
6.05 
14.35 
6.20 
5.42 
6.01 
4.85 
7.15 
3.57 
= 0.693'\z. 
, cardiac 
ГС 
VdsS 
ι 
34.4 
52.6 
47.8 
33.4 
37.0 
46.1 
41.9 
8.0 
output 
E 
% 
1.7 
4.0 
1.7 
1.5 
1.7 
1.4 
2.0 
1.0 
OTT 
min 
5.7 
8.8 
8.0 
5.6 
6.2 
7.7 
7.0 
1.3 
was taken 360 
Ν 
ГС 
59 
24 
57 
65 
59 
73 
56 
17 
í/h it 
200 
Il 4 DISCUSSION 
Occurrence of both monoexponential and biexponental decline of caffeine 
plasma profiles in different volunteers after a 30 min ι ν infusion of caf­
feine have been observed previously by Blanchard and Sawers [6] A bird's-eye 
visual insoection of the plots in figure 1 reveals that they all are essen­
tially monoexponential one exponential outweighs the other with respect to 
contribution to the sequential statistical moments (> 95% < 5%, except for 
st 
the 1 statistical moment (AUG) of subject 2) 
Slight nonlinearities seem to exist in the p^ots of subjects 3 and 6, 
who are the slowest eliminators of caffeine witness their relatively long 
plasma half-lifes of elimination (Table II) Caffeine disposition in these 
subjects might be rate-limited by metabolic enzyme capacity, as was observed 
previously by Tang-Liu and colleagues [21] However, because of the inaccuracy 
of the plasma concentration of the last data points (< 0 075 mg/t rejected 
for kinetic analysis) that are responsible for the major part of the apparent 
nonlineanty, and regarding the apparent weakness of the nonlinear phenomenon 
anyuay, convexity was ignored and data were treated as being linear 
While the kinetic parameters of caffeine obtained in this study (Table 
II) are in good accordance with data for healthy and lean subjects reported 
earlier [6,7,16-21], three aspects require further comment 
In Table 11 the rapid disposition parameters of caffeine in subject 2 
are conspicuous Subject 2 was the only smoker among the subjects and consumed 
a daily average of 25 plain French cigarettes (Gauloises) with inhalation As 
in nonsmokers about 95% of a caffeine dose is cleared via one of three 
demethylation pathways [8], and as demethylation is mediated by a polycyclic 
aromatic hydrocarbon (PAH)-inducible isozyme of microsomal cytochrome(s) P-450 
[22], induction of P-450 activity in subject 2 by PAHs present in cigarette 
smoke may account at least partially for the rapid elimination of caffeine m 
this subject Accelerated disposition of caffeine and related compounds, the 
dimethylxanthines, in smokers compared to nonsmokers has been observed before 
[9b,23-26] 
In addition, the apparent volume of distribution of caffeine was higher 
in subject 2 than in any of the other subjects, both on a liter and on a 
liter/kg basis (Table II) If not coincidental, the high distribution volume 
is probably connected with the drinking habit, rather than with the smoking 
habit of subject 2 As caffeine distributes over total body water, its appar-
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ent volume of distribution may well be affected by state of hydration and 
hence by fluid intake An estimated 5 £ of fluid was taken in by subject 2 
regularly throughout the day, enabling this subject to maintain a high level 
of hydration 
In this context it is interesting to note that Trang et al [16] 
observed a strong positive correlation between total (i e , almost exclusively 
hepatic) caffeine clearance and urine flow rate Thus the rapid elimination 
clearance of caffeine in subject 2 may also in part be explained by his high 
fluid input and output rates 
Another factor that might elevate (and hence might contribute to inter-
individual variability of) caffeine elimination rate is induction of metabolic 
enzymes by high exposure to dietary caffeine Kalow [27] reported the habitual 
intake of caffeine not to alter the urinary metabolite pattern of caffeine in 
man, suggesting all enzymes involved m caffeine metabolism either be activat-
ed to an equal extent, or not at all Mitoma et al [28] demonstrated caffeine 
to induce mixed-function oxidase activity toward certain substrates in ani-
mals The same might apply to other constituents of coffee 
In contrast to subject 2, caffeine elimination in subject 6 appeared to 
be retarded At the time of the experiments, subject 6 was taking steroid oral 
contraceptives (SOC), and had been doing so for over 1 year Several investi-
gators established a relationship between the use of SOC and a decelerated 
pace of caffeine metabolism [29-31] The latter phenomenon also was observed 
in pregnant women [32,33] As both pregnant women and women on oral contracep-
tives have a greater estrogen and progesterone load than women not taking SOC 
and men, decrease in caffeine clearance may be related to the increased estro-
gen and/or progesterone load in (especially in the later stages of) pregnancy 
and while taking SOC It is not known whether the estrogen or the progesterone 
component in SOC gives rise to deceleration of caffeine elimination It was 
speculated that SOC suppresses the mixed-function oxidase system involved in 
the metabolism of caffeine [30] The exact mechanism of suppression has 
remained obscure as yet 
The presently reported results of individual caffeine kinetics after 
intravenous administration will be applied to the problem of determining abso-
lute caffeine bioavailability after administration as freshly brewed coffee 
and tea These data will be reported in a forthcoming paper 
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12 1 SUMMARY 
Six healthy young volunteers were administered caffeine as 400 at of 
coffee or tea, or as a 30 ml intravenous infusion on separate occasions m 
randomized order Following each treatment, plasma samples were collected over 
a 32 h period (or over 15 h after drinking tea) and analyzed for unchanged 
caffeine 
The caffeine transport function ty(t) was calculated for each subject 
from the intravenous data as described previously [la] Absorption rate versus 
time profiles for each subject and each oral treatment were computed by numer­
ical deconvolution of ^(t) and the plasma caffeine concentrât ion vs time data 
obtained after oral administration Statistical moment analysis of the 
absorption rate profiles yielded systemic availability and characteristic 
absorption times 
Systemic availability of caffeine averaged 0 99 m coffee and 0 95 m 
tea Its mean and median absorption times were 26 and 20 mm from coffee, and 
23 and 19 mm from tea, respectively Differences of rate and extent of caf-
feine absorption kinetics from either beverage were not significant 
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Individual volumes of distribution for caffeine fluctuated only slight­
ly between treatments, whereas caffeine disposition kinetics exhibited sub­
stantial individual variability m the various treatments. As averaged over 
the 6 volunteers, means of caffeine body residence times increased m the 
order tea treatment ·* coffee treatment •* ι v. infusion treatment, while means 
of total caffeine clearance increased m the reverse order. Mean body resi­
dence time and mean total clearance of caffeine m the latter (i.v ) treatment 
significantly differred from the corresponding quantities m the former (tea) 
treatment. 
The mean administered caffeine dose was greatest in the coffee treat­
ment, somewhat less in the i.v. infusion treatment, and was significantly 
greater m the two former treatments than m the tea treatment 
Means of urine flow rate during the first 10 h after dosage were sig­
nificantly greater m the coffee and tea treatments than in the i.v. infusion 
treatment, presumably because of the i I volume of the administered beverages. 
It was concluded that caffeine total clearance and mean body residence 
time depend both on dose and on urine flow The effect of mtra-mdividual 
variability of caffeine clearance on calculation of systemic availability is 
discussed. 
Key words' Caffeine, systemic availability, mean and median absorption 
times, numerical deconvolution, individual variability of clearance, depen­
dence on dose and urine flow. 
In spite of its world-wide mass consumption, little is known of the 
rate and extent of CAF absorption after oral administration. Ever since Axel-
rod and Reichenthal [2] in 1953, one hour after oral CAF administration to 
three volunteers, reported plasma CAF levels that 'closely approximated those 
following the intravenous administration', it was generally believed that CAF 
was absorbed rapidly and completely from the GI tract. Blanchard and Sawers 
recently confirmed this belief in the only study specifically designed to 
determine CAF bioavailability after oral administration having been reported 
so far [3]. 
However, the latter authors characterized absorption rate unsatisfacto­
rily, by plasma peak concentrations and times of peak occurrence. Peak concen­
trations reflect dose and volume of distribution, rather than rate or extent 
of absorption, whereas peak times are a complex function of absorption, dis-
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tribution and elimination rates and again provide little information on the 
course of the absorption process 
In addition, the aqueous CAF solution employed in the Blanchard and 
Sawers study might differ from the xanthine beverages coffee and tea with 
respect to rate and/or extent of CAF absorption Inasfar as the latter quanti-
ties are affected by factors of a physicochemical nature (e g , fluid tempera-
ture, possible complexing agents present in coffee or tea, etcetera) 
In the present study, CAF absorption rate vs time was calculated in 6 
volunteers after drinking coffee and tea A point-area numerical deconvolution 
technique [4] was used, and proved to be a valid and convenient tool In the 
characterization of absorption processes 
In the course of the experiments, large intra-lndividual changes of CAF 
disposition kinetics were encountered The cause of these differences and 
their influence on the outcome of bioavailability evaluations will be dis-
cussed 
12 2 MATERIALS AND METHODS 
Subjects Six healthy Caucasian volunteers (3 males and 3 females), 
participated In the experiments after their written informed consent was 
obtained according to institutional policy Their mean age (± SD) and weight 
were 23 ± 1 years and 67 ± 4 kg, respectively Subjects were assessed as being 
'healthy' on the basis of a normal health history and standard physiologic 
tests All of them were habitual consumers of coffee and/or tea Subjects were 
free of medication, except subject 6 who took oral contraceptives Volunteers 
were nonsmokers and modest social drinkers, except subject 2 who consumed 
alcohol and cigarettes in substantial amounts Subject characteristics are 
summarized in Table I 
Experimental design The six volunteers were administered coffee, tea, 
or intravenous CAF in a randomized complete block design (each subject under-
going the three treatments in a unique sequence) with intervals of 2 weeks 
Subjects were instructed to abstain from coffee, tea, chocolat, cacao, soft 
drinks and medications containing CAF, and alcohol for a 60 h period prior to 
experiments, and during their course Doses were administered at approximately 
9 00 a m on days of kinetic trials 
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Intravenous administration of CAF The reader is referred to a previ­
ous report [la] for the mode of intravenous CAF administration and the scheme 
of blood sample collection It is remarked here that subjects were allowed a 
light breakfast in the morning of the ι ν dose Subjects kept record of time 
and volume of each urine voiding 
Oral administration of CAF The subjects were fasted trom the previous 
evening until 2$ h after ingestion of the oral dose Again, they kept record 
of time and volume of urine voidmgs 
Coffee preparation and administration A 45 g aliquot of coffee powder 
(Douwe Egberts Silver Brand, Douwe Egberts, Joure, The Netherlands) and 1 t of 
tap water was used to prepare 1 £ of coffee by means of a Philips model HD 
5339/A coffeemachine, which after its defection was replaced with a Douwe 
Egberts model Techmvorm Type 71 machine A 200 mi-volume of coffee was poured 
into a cup and allowed to cool down to 65° At this temperature, five 10-μΐ 
samples of coffee were taken from the cup for dose analysis No milk or sugar 
were added The subject then emptied the cup in 5-10 draughts, taking a 
draught once or twice a minute (time of first draught t=0) Time and mass of 
each draught were recorded by the subject with the aid of a stopwatch and a 
digital balance The temperature of the last draught typically was 54" (range 
52° - 56°) 
At t = 15 min, the subject consumed a second 200 ml cup of coffee fol­
lowing the same draught regimen Again, five 10-μ£ samples were taken for dose 
analysis The coffee cup and the subject's oral cavity were then rinsed with 
two additional 50 mil portions of water to ensure intake of the entire dose 
Blood samples (8 mil) were collected in heparinized s>ringes (10 mi, 
Monovette, Sarstedt) before t=0 (blank), at t=10 m m (between the two cups of 
coffee), at approximately t = 20, 28, 36, 42, 50, and 60 m m , and at t = Ij, 
lii 2, 4, 7, 14, 23 and 32 h Blood samples were immediately centrifuged (10 
m m , 1000 g) Coffee samples (10 pH) were diluted to 1 ml with distilled 
water Blood and diluted coffee samples were stored at -20° pending analysis, 
which as a rule was performed within one month No detectable loss of CAF due 
to decomposition was found up to at least 6 months of storage at -20° 
Tea preparation and administration One liter of tap water was decar­
bonated by 5 m m boiling Two tea-bags (Pickwick Chinese Melange, Douwe 
Egberts, Joure, The Netherlands) together containing 8 g of tealeaves were 
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submerged in the hot water immediately following boiling After 5 min the bags 
were pulled up and down in the tea for a few s and were removed Drinking tem­
perature and draught regimen for tea were similar to those for coffee Because 
tea contains relatively less CAF than coffee when both beverages are brewed as 
indicated, the volume of the tea samples taken from subjects' cups for dose 
analysis comprised a 25 yi volume, and blood sampling was pursued for no more 
than 15 h Blood samples were taken as indicated before t=0 (blank), at ~ t = 
10, 18, 25, 32, 39, 46, 53 and 60 rain, and at = 1J, li, 2, 3, 5, 7 and 15 h 
Caffeine analysis in plasma and beverages Plasma samples (1 mt) were 
analyzed for unchanged CAF as described previously [la,b] Samples of bever­
ages diluted to 1 ml by a factor 40 in case of tea and 100 in case of coffee 
were spiked with the internal standard (ISTD) and extracted with 
dichloromethane in a single step at pH = 7 9 The evaporization residue was 
reconstituted in the mobile phase consisting of water, methanol, acetonitnle, 
and THF (v/v/v/v = 90 4 4 2) and 200 yi/l of glacial acetic acid The mobile 
phase was delivered at 40° and at a rate of 1 mi/rain to a 150 χ 4 4 mm I D 
column home-packed with ODS (Chromosorb RP-18 , Merck, Darmstadt, FRG) Efflu­
ent was monitored at 254 run UV Retention times were 2 7, 3 4, 3 8, 5 1, and 
9 3 min for theobromine, paraxanthine, theophylline, CAF, and antipyrine 
(ISTD), respectively Coefficients of variation amounted to 3%, 4% and 81 at 
plasma CAF (and paraxanthine) concentrations of 5 0, 1 0 and 0 1 mg/1 This 
assay is described in more detail elsewhere [lb] 
Pharmacokinetic analysis, intravenous data The plasma CAF concentra­
tion after ι ν administration of CAF was fitted to a sum of exponentials The 
CAF transport function ψ(ί) for each of the subjects was then calculated as 
m "t/T, 
•(t) = 1/AUC Σ A e 
[5], where AUC is the area under the plasma concentration vs time curve. Cal­
culation of pharmacokinetic parameters of CAF after 1 ν dosing is described 
in reference [la] 
Pharmacokinetic analysis, oral data After peroral dosage of a drug 
solution as a series of delayed draughts, the resulting drug plasma concentra­
tion vs time profile of the drug is a convolution of the dosage function 
D(t), the absorption function Η (t) and the body transport function ψίί) 
according to 
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С (t) = 1/CL · D(t) - H
a
(t) - *(t) 
where CL is the total clearance and '*' denotes the convolution operator The 
plasma data (C (t), t) were interpolated by a quasi-Hermite cubic spline [6] 
by means of the IMSL routine IQHSCU [7] The time increment used for interpo­
lation was 0 001 h Deconvolution of the cubic splined oral plasma profile and 
the body transport function ψ(0 according to the numerical deconvolution 
method described by Vaughan and Dennis [4] yielded the convoluted dosage and 
absorption functions D(t) * H (t) Statistical moment analysis [8] of D(t) * 
H (t) resulted in the oral dose (D) times the systemic bioavailability (h ), 
and the summation of the mean dosage time (MDT) and the mean absorption time 
(MAT) 
u 
D · h = J D(t) *· H (t) dt, and 
о 
u u 
MDT + MAT = I t · D(t) л H (t) dt / J D(t) * H (t) dt 
a a 
о о 
where the upper Integrand 'u' represents the end-time of absorption and the 
the cutting-off point of oral data included m bioavailability computation (u 
= 1-2 h, see figure 2, and 'Discussion') The mean dosage time is calculable 
as the mass-weighted average time of the draughts 
MDT = Σ t M / £ M, 
ι J J J 
where t and M are timp and mass of the j draught The MAT may be deter­
mined by subtraction of the MDT from (MDT + MAT) The median absorption time 
(MedAT), at which half the available dose has been absorbed, is given implic­
itly as 
MDT+MedAT 
J D(t) ν H (t) dt = i · h · D 
о 
Oral (С (t), t) data were also fitted to a biexponential equation 
-t/T -t/T 
С (t) = A (e - e ), τ > τ 
or о 
Data points with concentrations less than 0 075 mg/l (CV > 10%) were 
not included in the curve fitting procedure, as their accuracy was considered 
insufficient to be compatible with correct data analysis The area under the 
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plasma concentration vs. time curve (AUC) and under the timepconcentration vs. 
time curve (TAUC) were calculated according to statistical moment theory [8] 
as: 
AUC = Α(τ - t ), and: TAUC = Α(τ 2 - τ 2 ) 
о о 
The mean residence time (MRT) of CAF was estimated from the drug plasma 
concentration profile following absorption from the GI tract as: MRT = 
TAUC/AUC - τ = т Total clearance (CL) and apparent volume of distribution 
(V. ) of CAF were estimated as CL = D'h /AUC, and- V. = t^CL, where h was dss a dss ' a 
taken unity. 
For each subject and each treatment, cumulative voided urine volume was 
plotted vs. time. The volume voided at t = 10 h was determined by linear 
interpolation in this plot, and was divided by 10 to yield the mean urine flow 
rate (UFR..) over the first 10 h following CAF dosing. 
Statistical analysis. Mean values are reported with their standard devia­
tions (SD) All tests were applied two-tailed. Mean caffeine doses in coffee 
and in tea were compared to the i.v. CAF dose by application of a version of 
t-test treating the latter dose as an external (deviationless) reference val­
ue The difference of mean CAF dose administered as coffee and as tea was 
tested for significance by two-tailed t-test assuming dissimilar SDs and hence 
including calculation of an 'effective' number of degrees of freedom. Differ­
ences of mean systemic availability of CAF in coffee and tea were compared by 
t-test for pairwise observations. 
Differences between means of triple sets of observations in the same 
voluntrers (e g. , of MRT, t., CL, V. , UFR,., and of h as calculated by 1) 6
 i dss 10' a ' 
numerical deconvolution, 2) plain AUC ratio, and 3) AUC ratio corrected for 
individual changes of CAF clearance) were evaluated by univariate analysis of 
variance combined with Duncan's multiple range test. Ρ = 0.05 was taken the 
minimum level of significance. 
FIGURE 1 (next page). Caffeine plasma concentration vs. time profiles fol­
lowing consumption of two cups of coffee (top) or tea (bottoai) m 6 healthy 
subjects. Administered doses of caffeine are listed m Tables I and II. ... 
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concentration (mg/l) 
plasma concentration (mg/l) 
N ag J L carreme 
ІГ 7"¿ admin as 400 ml of tea 
. A \ . ' 4· to 6 volunteers 
FIGURE 1 (cont'd) For the sake of surveyability, individual profiles have 
been interspaced by 5 h Profiles of consecutively numbered subjects are pre-
sented from subject 1 (left) to subject 6 (right) 
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12.3 RESULTS 
Subjective and side effects. Abstination periods prior to each experi-
ment steadily effectuated head-ache and lethargy in subject 1. These abstina-
tion effects readily disappeared after experimental CAF administration. No 
adverse side effects resulting from CAF administration were experienced. 
Intravenous administration of CAF. Pharmacokinetic parameters of CAF 
as calculated from the plasma concentration profile during and following i.V. 
infusion of CAF over 30 min have been reported and discussed previously (la). 
A selection of important parameters is included in Table I for convenience of 
comparison with the corresponding parameters obtained after peroral dosage of 
CAF. 
Oral administration of CAF. Plasma concentration profiles in the 6 
volunteers after drinking 400 ml of coffee and of tea are depicted in figures 
1 a and b, respectively. Profiles are typically 'nose-shaped', with conspicu-
ously short half-lifes for subject 2 (smoker) in each case. CAF doses adminis-
tered as coffee and as tea, and pharmacokinetic parameters of CAF after admin-
istration of these beverages have been tabulated in Table II (coffee) and in 
Table III (tea) for each subject. 
The amount of CAF in the second cup of coffee/tea always equalled that 
in the first cup, indicating that CAF on a 15 min scale is stable in the hot 
aqueous environment of the freshly brewed beverages. The CAF dose administered 
to subjects 1, 4, and 5 as coffee brewed with the Philips machine was smaller 
than that administered to subjects 2, 3, and 6 with the aid of the Douwe 
Egberts machine, presumably because the latter machine sprinkled the hot water 
directly onto the coffee powder, whereas in the former machine the hot water 
was collected in a basin and from there, while cooling down, was gradually 
allowed to soak through the powder. 
The i.V. CAF dose and the average dose administered as coffee both dif-
ferred significantly from the average dose in tea (P < 0.001 in each case), 
but not from each other (P < 0.1) (Tables II and III). The mean dosage time 
(MDT) was shorter for tea than for coffee (P < 0.02). As MDT was under volun-
teer control, the difference problably reflects a better tolerance of tea than 
of coffee by subjects' empty stomaches. 
Median and mean CAF absorption times came to 20 and 26 min for coffee 
and to 19 and 23 min for tea. Systemic availability amounted to 0.99 ± 0.04 
for CAF from coffee and to 0.95 ± 0.06 for CAF from tea. Individual CAF 
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TABLE I SUBJECT CHARACTERISTICS, AND PHARMACOKINETIC PARAMETERS OF CAFFEINE 
FOLLOWING I V INFUSION OF 200 MG OVER 30 MIN IN 6 HEALTHY VOLUNTEERS 
Subj 
1 
*» 
3 
·* 
5 
6 
MEAN 
± SD 
Sex 
m 
m 
m 
f 
f 
f 
Age 
yrs 
23 
22 
24 
24 
22 
24 
23 
1 
BW 
kg 
68 
63 
72 
68 
60 
68 
67 
4 
Med/ 
Ind 
A 
ΑΑ,Τ 
A 
-
-
SOC 
-
-
TAUC 
mg'h'/t 
188.4 
51.2 
249 1 
227.4 
204.6 
392.1 
218.8 
109.8 
AUC 
mg'h/t 
33.1 
13.9 
32 3 
36 9 
33.3 
41 Ζ 
31.8 
9.4 
MRT 
h 
5 70 
3.67 
7 72 
6.16 
6 15 
9 51 
6 48 
1 97 
* 
X2 
h 
5.70 
4.18 
7 89 
6.34 
6 28 
9 90 
6.72 
1 97 
'i 
h 
3.95 
2.90 
5.47 
4.40 
4.35 
6.86 
4 65 
1 36 
CL 
г/л 
6 05 
14.35 
6 20 
5.42 
6.01 
4 85 
7.15 
3.57 
VdSS 
l 
34.4 
52.6 
47.8 
33 4 
37.0 
46.i 
41.9 
8 0 
υΐ
«ιο 
at/h 
135 
180 
59 
128 
92 
37 
105 
53 
BU = body weight, Med/Ind = medication and drugs of indulgence· A = modest 
consumption of alcohol (± 10 g/day), AA = excessive consumption of alcohol (± 
100 gl day), Τ = consumption of tobacco (25 cig. /day), SOC = steroid oral con­
traceptives. 
τ„ and t, denote the natural time constant and the half-life of CAF elimina­
tion, respectively t,=0 693'τ For subject 1, whose ф(і) is monoexponen-
tial, ИНТ equals τ . 
absorption rate vs time profiles are shown in figure 2 In many of the pro­
files the dual cup administration schedule can be recognized 
Mean body residence times (MRT) and CAF plasma elimination half-lifes 
(t,) as averaged over the 6 volunteers decreased between treatments in the 
order ι ν infusion •* coffee •* tea, whereas CAF total clearance (CL) 
decreased in the reverse order Differences of means were not significant 
between intravenous and coffee treatments, except for t, which was shorter (P 
< 0 05) m the latter treatment Parameters again did not differ significantly 
between coffee and tea treatments However, between intravenous and tea 
treatments, means of MRT, t,, and CL all three were substantially different (P 
< 0 01) The apparent volume of distribution (V, ) of CAF for each subject 
was approximately constant between treatments 
Individual variability of CAF clearance and body residence time were 
most prominent in subjects 3 and 6 These two subjects in the intravenous 
treatment showed the slowest CAF disposition kinetics (greatest MRTs and 
rather low total plasma clearances), which in the two oral treatments was 
notably accelerated by up to 50% (subject 3) and up to 90% (subject 6) 
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TABLE II PHARMACOKINETIC PARAMETERS OF CAFFEINE FOLLOWING 
ORAL ADMINISTRATION AS COFFEE TO ó HEALTHY VOLUNTEERS 
Subj 
1 
2 
3 
4 
5 
6 
MEAN 
± SD 
/ 
As 
of 
Dose 
ag 
173 
327 
307 
232 
192 
287 
253 
63 
NS 
the 
CAF 
МВТ 
nun 
10.1 
11.3 
9.5 
12.5 
10.2 
8.8 
10.4 
1.3 
NA 
HAT 
min 
22 6 
20 6 
20.2 
25.9 
20.8 
34.0 
25.9 
5.4 
NA 
declining part 
equals 
MedAT 
mm 
18.5 
20.8 
20.2 
23 4 
16 0 
23.3 
20.3 
2.8 
NA 
h 
a 
Ζ 
103 
100 
97 
95 
102 
94 
99 
4 
NA 
AUC 
mg-h/l 
28.7 
23.9 
33.5 
36 3 
31.7 
41.5 
27.1 
7.4 
ND 
• of the plasma CAF 
MRT 
h 
5.47 
4.08 
5.05 
5 51 
6.29 
6.68 
5.51 
0.92 
NS 
'i 
h 
3.79 
2.83 
3.50 
3.82 
4.36 
4.63 
3.82 
0.64 
P<0.05 
CL 
l/h 
6.03 
13.67 
9.17 
6 41 
6.08 
6.92 
8.05 
2.99 
NS 
Vdss 
l 
33.0 
55.8 
46 3 
35.3 
38.2 
46.3 
42.5 
8.5 
NS 
profiles was monoexponent ia! 
the elimination time constant τ ΜΙΠ· = τ2 
-v 0.693 
υ
™ιο 
mt/h 
167 
208 
75 
130 
152 
75 
135 
53 
P<0.01 
, MRT 
Norma]lied to a 200 mg dose of CAF 
а 
Statistical analysis of means of kinetic parameters between coffee and 
infusion treatments. NS = not significant (P > 0.05), NA = not applicable, 
ND = not done In cases of significance, the type I error probability (P) 
has been indicated 
12 4 DISCUSSION 
Caffeine bioavailability and correction of its evaluation for changing disposi­
tion kinetics 
This report confirms the findings of Blanchard and Sawers [3] and the 
prior general belief, that CAF is absorbed rapidly and virtually completely 
from the human gastrointestinal tract No differences between coffee and tea 
with respect to either rate and extent of CAF absorption, putting a stop to 
speculations with respect to such differences based on limited or ambiguous 
data [19,20] As Blanchard and Sawers, arriving at about the same results, 
administered a 200 mi CAF solution made up in distilled water and in one go, 
it is inferred that CAF absorption probably is affected neither by beverage 
temperature, nor by chemicals present in coffee or tea, nor by the volume 
administered or by the rate of its self-administration. 
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ADMINISTRATION AS TEA TO 6 HEALTHY VOLUNTEERS 
TABLE III. PHARMACOKINETIC PARAMETERS OF CAFFEINE FOLLOUING 
Subj 
1 
2 
3 
4 
5 
6 
MEAN 
± SD 
Dose 
ag 
53.5 
80 1 
55.0 
60.6 
75.1 
80.1 
67.4 
12.5 
МВТ 
min 
9 00 
6.96 
7.26 
7.92 
9.78 
7.50 
8 04 
1 08 
f? P<0.0001 NA 
МАГ 
am 
21.8 
18.5 
20.2 
27.5 
24.3 
24.2 
22.8 
3.2 
NA 
MedAT 
min 
16.0 
15.8 
19.4 
25.1 
20.8 
19.5 
19 4 
3.4 
NA 
Л
* 
Ζ 
91 
87 
97 
101 
101 
94 
95 
6 
NA 
AUC 
ag'h/t 
7.75 
4.71 
6.12 
9.20 
10.74 
9 49 
24.3 
it* 
6 9 
ND 
MRT 
h 
5.18 
2.97 
5.09 
4.86 
5.32 
5.08 
4.75 
0.89 
P<0.01 
ч 
h 
3.59 
2.06 
3.53 
3 37 
3.69 
3.52 
3.29 
0.61 
P<0.01 
CL 
Uh 
6.90 
17.02 
8.99 
6.57 
6 99 
8.44 
9.15 
3.97 
Ρ<ΰ.01 
VäSS 
t 
35.7 
50.5 
45.7 
31.9 
37.2 
42.8 
40.6 
6.9 
NS 
υ
™ιο 
ml/h 
142 
199 
75 
151 
101 
65 
122 
51 
Ρ<0.05 
f№ Ρ<0.001 Ρ<0 02 NS NS NS ND NS NS NS NS NS 
As the declining part of the plasma CAF profiles is monoexponent jal, MRT of 
CAF equals the elimination time constant τ,: MRT = τ = t, / О 693 
Normalized to a 200 mg dose of CAF 
' Statistical analysis of means of kinetic parameters between tea and 
00 
infusion treatments, and between tea and coffee treatments. For the 
meaning of NS, NA, ND, and P, see the bottom of Table II. 
In the literature [9-14] a 2\- to 7-fold inter-individual variability 
of CAF disposition kinetics was observed for healthy volunteers In the 
present study and that of Blanchard and Sawers [3] in addition a li- to 2-fold 
W-ztAjn-subject variability of CAF disposition kinetics was established in some 
volunteering individuals 
As both the AUC ratio and the numerical dpconvolution method of esti­
mating bioavailability assume invariability of individual kinetics of drug 
distribution and disposition between experiments, estimations of availability 
will be falsely elevated or reduced If changes of disposition kinetics yet 
occur. Systemic availability of CAF in the present study as calculated by 
plain AUC ratio method is listed in the center columns of Table IV. Spurious 
results are obvious for subjects 3 and 6. 
Such spurious results may be avoided by undertaking corrective actions. 
If the apparent distribution volume remains approximately constant for each 
volunteer, as is the case in the present study, the AUC ratio method may be 
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FIGURE 2 Profiles of gastrointestinal absorption rate {D(t) + Я (t)} vs time 
of caffeine in 6 healthy volunteers following consumption of coffee (solid 
line) and tea (dashed line) on separate occasions 
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FIGURE 2 (cont'd) For each subject, absorption rate profiles were calculated 
by numerical deconvolution of the total body transport function ty(t) with the 
first part (until t = u, at the arrow) of the plasma caffeine ... 
220 
absorption rate (mg/h) 
6 0 0 -
5 0 0 -
4 0 0 -
3 0 0 -
2 0 0 -
1 0 0 -
и 
— ι ι—« coffee 
— ι к-н feo 
/1 
/ 
/ ^ 
/ *  
ƒ .· 
ι ι 
Г 
ν_ 
- 4 
1 1 
D ( t ) * H a ( t ) 
in subject 6 
^Ч .. 
ι ι I 
0 5 10 15 2 0 
t ime (h) 
FIGURE 2 (cont'd) concentration vs time profile following coffee or tea 
consumption Dual time intervals of D(t) (i e , of consumption of two cups of 
coffee or tea) have been indicated m the upper left corner for each subject. 
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corrected for individual variance of disposition kinetics by multiplication by 
the ratio of the terminal plasma elimination time constants after intravenous 
and peroral dosage τ /τ [3,15,16] r
 iv po l 
Again under the assumption of constant distribution volume, evaluations 
of bioavailability using numerical deconvolution may be corrected for changing 
individual disposition kinetics by the very same procedure, or alternatively, 
by using oral data cut off at times absorption has stopped, rather than whole 
oral data. The latter approach was used presently and Is valid only for combi­
nations of drug and formulation having a mean absorption time that is small 
compared to the mean body residence time (MAT « MRT) 
As the approach of estimating systemic availability by numerical decon­
volution with incomplete oral data is entirely new to our knowledge, no cri­
teria as yet have been developed with respect to the choice of the cutting-off 
point, ι e , the last (cone , time) data point after non-intravenous drug 
administration involved In the evaluation of systemic availability Through­
out this study, the cutting-off point was chosen the oral data point right-
nearest to the time at which absorption rate for the last time deviated posi­
tively from zero by 5% of the maximum absorption rate In practice this 
criterion proved satisfactory and led to cutting-off times of 1-2 h The exact 
times of cutting off have been indicated for each subject and oral treatment 
in figure 2 
As is revealed by comparison of left and right colums for coffee and 
tea in Table IV, if corrected for individual variability of disposition rate 
the AUC ratio method and numerical deconvolution are equivalent with respect 
to evaluation of the extent of systemic availability of CAF in coffee and in 
tea However, the numerical deconvolution approach in a unique way is able to 
describe the time course of absorption rate (see figure 2), where traditional 
compartmental approach with its assumption of a monoexponentia! time course of 
absorption rate obviously would fail 
Causes underlying individual variability of caffeine disposition kinetics 
Factors that give rise to differences between experiments of CAF elimi­
nation rate within a given individual must be discriminated into two cate­
gories random factors and experiment-related factors Factors which are 
responsible for differences of elimination kinetics between individuals may 
also vary within any given individual These randomly fluctuating factors 
include transient states of disease, phase of menstrual cycle, changing 
dietary influences, and fluctuating exposure to drugs and environmental chemi­
cals amongst others Because of their very randomness, these influences are 
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TABLE IV. SYSTEMIC Я/AILABILITY OF CAFFEINE IH COFFEE AND IN TEA AS CALCU­
LATED BY NUMERICAL DECONVOLUTION (h ) , PLAIN ШС RATIO (F), AND BY AUG RATIO 
CORRECTED FOR INDIVIDUAL CHANGES OF CAFFEINE ELIMINATION KINETICS (F ') 
Subj 
J 
г 
3 
<¡ 
5 
6 
MEAN 
t SD 
f 
"о 
Ζ 
103.1 
100.3 
97.3 
95.3 
101.6 
94.i 
98.7 
3.5 
Il— » s . 
1 
coffee 
F 
г 
100.2 
104.9 
67.6 
84.6 
99.0 
70.1 
87.7 
16.1 
— \\-P<o 
NS 
F' 
Ζ 
104.1 
107.6 
105.7 
97.3 
98.8 
103.8 
102.9 
4.0 
•«-Il 
I 
h
a 
Ζ 
91.4 
86.7 
97.0 
101.4 
100.8 
94.4 
95.3 
5.7 
\\-P<o. 
1 
tea 
F 
Ζ 
87.6 
84.3 
68.9 
82.5 
86.0 
57.5 
77.8 
12.0 
• 02_\\_JX0 
NU 
F1 
Ζ 
96.4 
118.8 
106.9 
107.7 
101.6 
112.1 
107.3 
7.8 
•oiM 
I 
? Statistical analysis of means of h , F, and F*. NS = not significant. In 
cases of significance, the type I error probability (P) has been indicated. 
not likely to induce statistically significant differences of kinetic parame­
ters between experiments. 
Differences of the latter kind are mostly related to experimental 
methodology. Four experiment-related factors can be discerned in the present 
study design: 
1) route of administration (i.v. and p.o.), 
2) possible co-administration of pharmacodynamlcally or -klnetically relevant 
compounds (except CAF) present in coffee and/or tea, 
3) dose of CAF administered in the various treatments, and 
4) volume of uater co-administered with CAF (500 mt p.o., 30 mt i.V.). 
Comments on these four possible causes will now pass under separate review. 
Ad 1. As CAF after peroral administration to man is completely 
absorbed and undergoes a negligible first-pass effect, it is unlikely that it 
will display kinetics different from those after intravenous administration. 
Indeed no such differences were observed by Blanchard and Savers (3]. 
223 
Ad 2 Compounds other than CAF present m coffee or tea might exert 
influence on CAF disposition rate, о g , by competition for metabolizing 
enzymes The class of dimethylxanthine compounds may be excluded, since analy­
sis of coffee and tea of the presently used brands revealed that the total 
amount of theobromine and theophylline constituted about 0 1% and 2 1% of the 
amount of CAF in coffee and tea, respectively, expressed on a molar base [lb] 
Furthermore, competitive inhibition of САГ metabolism by other coffpe or tea 
constituents would be expected to result in prolonged body residence time and 
diminished clearance of CAF after drinking these beverages as compared to ι ν 
infusion of pure CAF, whereas the results indicate the reverse 
Ad 3 Dose dependence of CAF disposition kinetics was observed after 
oral administration of 7} mg/kg as a powder by Tang-Liu et al [12], but not 
after administration ρ о of various doses up to 10 mg/kg as a solution by 
Bonati et al [17] Assumption of dose dependence of CAF disposition kinetics 
may explain the relative shortness of MRT and t,, and the concomitant great­
ness of CL, after administration of the smallest CAF dose as tea However, it 
does not explain why MRT and t, are shorter, and CL is greater, after CAF 
administration as coffee compared to the infusion of CAF, while the doses 
involved in coffee drinking tended (P < 0 1) to be higher than those intra­
venously administered The assumption of dose dependence of CAF disposition 
furthermore seems to be incompatible with the apparent log-linear decline of 
CAF plasma concentration vs time profiles observed throughout this study, 
whereas convpx-descendending profiles would be anticipated in case of dose 
dependence 
Ad 4 Oral doses of CAF in this study were administered with a 500 mí 
aqueous volume (including two 50 ml portions of water to rinse subjects' oral 
cavities) Intravenous doses were administered as 30 mí infusions 
The substantial water load co-administered with coffee and tea is the 
most probable cause of the significantly greater urine flow rate observed dur-
ing 10 h after administration of either beverage than after i ν infusion of 
CAF (cf IJFR 1 0 in Tables I-III) 
Trang et al [18] in elderly men observed a highly significant positive 
correlation between urine flow rate and total clearance of CAF As renal 
clearance of CAF contributes negligibly (< 5л) to total clearance both at low 
and at high urinary flow rates [18], the above correlation apparently exists 
between metabol ic CAF clearance and urine flow rate As an explanation of 
their findings, the authors [18] suggested that the primary dimethylxanthine 
metabolites of CAF might reach sufficiently high concentration levels to com-
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petitively retard CAF demethylation, and that increased renal excretion of 
these dimethylxanthine metabolites at higher urine flow rates could result m 
a reduction of the competition, thereby increasing metabolic (and total) 
clearance of CAF 
In the present study, diuresis induced by administration of i 1 of 
water with oral CAF doses, probably reinforced by the diuretic properties of 
CAF iself, via the mechanism described may have elevated dimethylxanthine 
excretion during at least 10 h following ingestion, a time interval covering 
the peak time of CAF and that of its main metabolite paraxanthine By the 
time UFR returned to baseline, the total xanthine plasma concentration may 
already have been below the level at which nonlinear kinetics are clearly man­
ifest The absence of convex-declining concentration profiles after adminis­
tration of coffee and tea is thus accounted for, as well as the relative 
rapidness of CAF elimination kinetics after coffee drinking compared to ι ν 
administration of CAF, in spite of a higher mean CAF dose in the former treat­
ment 
In the light of the above hypothesis it was to be anticipated that 
metabolic elimination rate of CAF in subjects 3 and 6, being slowest in the 
ι ν treatment, would increase most with elevation of urine flow rate in the 
oral treatments, since saturation of demethylation-mediating enzymes and hence 
the occurrence of capacity-limited mcthylxanthme metabolism should be most 
prominent in these slow metabolizers Importantly, in the Blanchard and Sawers 
study [3], the two subjects showing the greatest change of CAF elimination 
rate between experiments, also cleared CAF more rapidly after an oral dose 
administered as a 200 ml solution than after virtually the same dose as a 30 
ml ι ν infusion As in the present study, the latter authors and Bonati et 
al [17] after oral doses of dissolved CAF did not observe convexity of CAF 
plasma profiles, whereas Tang-Liu et al [12] did after oral doses of anhy­
drous pulverized CAF to their volunteers 
In summary, available evidence points toward CAF disposition kinetics, 
which are dose-dependent at the levels at which consumers of coffee and tea 
normally take in CAF, a dose-dependence that may be masked by the concomitant 
intake of substantial volumes of water The contrary conclusion drawn by Bon-
ati et al [17] is arrived at on the basis of limited data and may be disputed 
on the basis of CAF plasma elimination half-lifes increasing with dose as pre­
sented by these very authors in Table I of the challenged article [17] 
225 
A C K N O W L E D G E M E N T S 
The authors wish to acknowledge the excellent cooperation of the sub­
jects and the financial support provided by Douwe Egberts Royal Coffee, Tea, & 
Tobacco Factories 
12 5 REFERENCES 
1 Teeuwen HWA (1988) Clinical pharmacokinetics of nicotine, CAF and quinine 
A systems dynamics approach (a) 'Intravenous single dose pharmacokinetics 
of caffeine A sys>tems dynamics approach' (chapter 11), (b) 'Simultaneous 
HPLC analysis of caffeine and the three dimethylxanthines in body fluids 
and xanthine beverages using high-performance liquid chromatography and UV 
detection' (chapter 6) Ph D Thesis, University of Nijmegen, Nijmegen, 
The Netherlands 
2 Axelrod J, Reichenthal J (1953) The fate of CAF in man and a method for 
its estimation m biological material J Pharmacol Exp Ther 107 519-23 
3 Blanchard J, Sawers SJA (1983) The absolute bioavailability of CAT in man 
Eur J Clin Pharmacol 24 93-98 
4 Vaughan P, Dennis M (1978) Mathematical basis of point-area deconvolution 
method for determining in vivo input functions J Pharm Sci 67 663-665 
5 Van Rossum JM, Burgers J, Van Lingen G, De Bie J (1983) Pharmacokinetics, 
a dynamic systems approach TIPS 41 27-30 
6 Akima H (1970) A new method of interpolation and smooth curve fitting 
based on local procedures JACM 17 589-602 
7 IMSL Library, Edition 9, Volume 2, Chapter I (1982) Interpolation, approx­
imation, smoothing - Subroutine IQHSCU IMSL, Houston, USA 
8 Yamaoka K, Nakagawa T, Uno Τ (197B) Statistical moments in pharmacokinet­
ics J Pharmacokm Biopharm 6 547-58 
9 Levy M, Zylber-Katz E (1983) Caffeine metabolism and coffee-attributed 
sleep disturbances Clin Pharmacol Ther 33 770-5 
10 Abernethy DR, Todd EL, Schwartz JB (1985) Caffeine disposition in obesity 
Br J clin Pharmac 20 61-2 
11 Parsons WD, Neims AH (1978) Effect of smoking on CAF clearance Clin Phar­
macol Ther 24 40-5 
226 
12. Tang-Liu D D-S, Williams RL, Riegelman S (1983) Disposition of CAF and its 
metabolites in man. J Pharmacol Exp Ther 224: 180-5 
13. Blanchard J, Sawers SJA (1983) Comparative pharmacokinetics of CAF in 
young and elderly men. J Pharmacokin Biopharm 11: 109-25 
1A. Wang T, Kleber G, Stellaard F, Paumgartner G (1985) Caffeine elimination: 
a test of liver function. Klin Wochenschr 63: 1124-8 
15. Koup JR, Gibaldi M (l'JSO) Some comments on the evaluation of bioavailabil­
ity data. Drug Intell Clin Pharm 14: 327-30 
16. Chiou WL, Lui CY, Lam G (1981) Plasma area method in relative bioavail­
ability evaluation of drugs with changing biological half-lifes. J Pharm 
Sci 70: 109-12 
17. Bonati M, Latini R, Gaietti F, Young F, Tognoni G, Garattini S (1982) Caf­
feine disposition after oral doses. Clin Pharm Ther 32: 98-105 
18. Trang JM, Blanchard J, Conrad KA, Harrison GG (1985) Relationship between 
total body clearance of CAF and urine flow rate in elderly men. Biopharm 
Drug Dispos 6: 52-6 
19. Marks V, Kelly JF (1973) Absorption of CAF from tea, coffee, and coca 
cola. Lancet i:827 
20. Czok G, Schmidt B, Lang К (1969) Vergleichende tierexperimentelle Unter­
suchungen mit Kaffee und Tee. Zeitschr Ernahrungsw 9: 103-8 
227 
228 
Chapter 13 
CLINICAL PHARMACOKINETICS OF PARAXANTHINE, THE MAIN 
CAFFEINE METABOLITE IN MAN 
Harald W.A. Teeuwen1, Paul J. de Schepper', T. Budya Tjandramaga1, 
and Jacques M. van Ross um1 
^Department of Pharmacology, Faculties of Medicine and of natural Sciences and 
Mathematics, University of Nijmegen, P.O. Box 9101, 6500 ИВ Nijmegen, 
The Netherlands, and 
'Department of Pharmacology, Catholic University of Leuven (K.U.L.), Campus 
Gasthuisberg, B-3000 Leuven, Belgium. 
13.1 ABSTRACT 
Pharmacokinetics of paraxanthine, the main phase-I metabolite of caf­
feine in man, were investigated in healthy subjects after oral and i.v. admin­
istration of both caffeine and paraxanthine. Intravenous infusion of caffeine 
uas performed first in all volunteers. I.v. infusion of paraxanthine, and oral 
administration of both caffeine and paraxanthine were then performed in ran­
domized order. Pharmacokinetic analysis was performed using a non-
compartmental dynamic systems approach. 
Kinetics of caffeine and paraxanthine were rather similar in all volun­
teers. After i.v. administration, volume of distribution (52 ± 5 I) and total 
clearance (11.8 ± 2.2 l/h) of paraxanthine were slightly higher than those of 
caffeine (45 ±9 1, and 8.9 ± 4.8 t/h resp.), whereas paraxanthine mean resi­
dence time (4.5 ± 1.0 h) and elimination time constant (4.6 ± 0.8 h) after 
i.v. administration were somewhat smaller than the corresponding caffeine val­
ues (5.7 ± 2.0 h, and 5.9 ± 1.9 h, respectively). 
Like caffeine, paraxanthine was rapidly and virtually completely 
absorbed after ingestion as an aqueous solution: averaged over the 3 volun­
teers, mean absorption time was 22 ± 1 min, and bioavailability came to 0.94 ± 
0.10 . For caffeine these quantities amounted to 23 ± 6 min and 1.03 ± 0.13 . 
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The fraction of caffeine converted into paraxanthme averaged 0 77 t 
0 07 after ι ν infusion and 0 84 ± 0 09 following ingestion of caffeine The 
difference was attributed to competitive capacity-limited demethylation caf­
feine and paraxanthme, combined with elevated urinary excretion of paraxan­
thme after oral administration of caffeine due to the higher load of water 
co-admmistcred with oral caffeine The water load also seemed to affect elim­
ination half-lifes of both xanthines 
After caffeine dosage, similarity of caffeine and paraxanthme half-
lifes effectuated typical convex paraxanthme plasma profiles which could be 
described excellently by gamma distributions of residence times 
Key words Paraxanthme, caffeine, systems dynamics pharmacokinetics, per­
oral and intravenous dosing, individual variance of elimination rate, conver­
sion fraction, gamma distribution of metabolite residence times 
Caffeine (CAF) in healthy adults is almost exclusively disposed of by 
biotransformation Only about 0 5 - 5* of an oral or ι ν dose of CAF is 
excreted unchanged via the urine [2] CAF metabolism is very complex, compris­
ing many diverging and converging pathways, mediated by at least 4 distinct 
enzymes or enzyme systems, leading to a number of at least 17 metabolites 
known to date (figure 1) The metabolic route between CAF and theophylline in 
adults is reversible [3,4], the enzyme mediating the acetylation pathway is 
polymorphic [5], and at least some of the routes are capacity-limited at sub­
strate concentrations lower than 10 mg/t [lb,6,7] 
Four types of metabolic degradations of CAF and its 3 metabolites abun­
dant in plasma theophylline (13X), theobromine (37X), and paraxanthme (PX, 
17X) are knoun to occur 1) N-demethylation at positions 1, 3 and 7 to yield 
di- and monomethylxanthines, and possibly hypoxanthine, and 2) oxidation at 
C-8 to yield dimethylated uric acids are mediated by mixed-function oxidases 
containing cytochrome(s) P-450 of human liver microsomes Demethylation reac­
tions are catalyzed mainly by the polycyclic aromatic hydrocarbon 
(PAH)-inducible fraction of cytochrome(s) P-450, also known as Ρ -450 or 
P-44B, whereas C-8 oxidation is catalyzed predominantly by the non-PAH-
inducible fraction of P-450 enzymes [8] 
C-8 oxidation of monomethylxanthines is mediated by the enzyme xanthine 
oxidase, which is involved as well in the metabolism of endogenous purines 
which are structurally related to methylxanthines Particularly 1-methyl xan­
thine seems to be a good substrate for xanthine oxidase [9,10] 
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AA3MU (AAMU) 
» A F 3 M U ( A F M U ) 
- Р А З MU (17DAU) 
FA 13 DMU (137 TAU) 
\ — • F A I MU (37DAU) 
FIGURE 1. Pathways of caffeine (137X) metabolism in adult man. 
™^^ pathway of major importance, • pathway of minor importance, 
• unestablished pathway, • in vitro pathway, "
 K reversible pathway. 
Ρ-44β: N-demethylation pathway mediated mainly by microsomal mixed-funtion 
monooxygenases containing the PAH-inducible cytochrome P448 (P -450). P-450.· 
C-8 oxidation pathway mediated in part by cytochrome P-448, and in part by 
other, non-PAR-inducible forms of cytochrome P-450. 
XO: C-8 oxidation pathway mediated by the soluble enzyme xanthine oxidase. 
AT: N-acetylation mediated by the polymorphic enzyme N-acetyl transferase. 
X = xanthine, U = uric acid. 1,3,7: positions of methyl groups. 137X = caf­
feine, 17X = paraxanthine, 13X = theophylline, 37X = theobromine. 
ААЗНи = 5-acetylamino-6-amino-3-methyl uracil 
AF3HU = 5-acetylamino-6-formylamino-3-methyl uracil 
AF13DHU = 5-(N-formylmethylamino)-6-amino-l,3-dimethyl uracil 
AFinU = 5-(H-formylmethylamino)-6-amino-l-methyl uracil 
AF3HU = 5-(N-formylmethylamino)-6-amino-3-methyl uracil 
[?] - unstable, possibly ring-opened intermediate arising after 
7-demethylatlon of 17X, which in fast acetylators is rapidly acetylated, but 
in slow acetylators tends to ree Jose to form IX. 
This figure has been composed after consultation of re/. [2-10, 19-26, 49-59]. 
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In addition to these metabolic routes, 3) cleavage of the 5-membered 
ring betueen C-8 and N-9 may take place to yield a non-acetylated uracil 
derivative (the mediating enzyme is unknown), or 4) between C-8 and N-7 to 
yield an acetylated uracil derivative The latter reaction is mediated by the 
polymorphic enzyme N-acetyl transferase and occurs only for CAF and PX (figure 
1) [5] 
Ratios of renally excreted amounts of selected CAF metabolites may 
serve as an indicator of relative activity of the various hepatic enzymes 
Thus the ratio of urinary recoveries of 1U to IX provides a measure of xan-
thine oxidase activity, whereas the ratio of (AF3MU + AA3MU) to (1U + IX) is a 
marker of N-acetyl transferase activity, and hence of individual acetylator 
status (neglecting any contibution via 13X to IX and 1U) The 17U to 17X ratio 
is an index of 8-oxidation activity by cytochrome(s) P-450 Finally, the ratio 
of urinary recoveries of (AF3MU + IX + 1U) to 17U is an index of PX demethyla-
tion activity vs oxidation activity (figure 1) 
CAF terminal half-life under conditions standardized with respect to 
CAF dose and urine flow reflects the activity of microsomal cytochrome 
P-448-mediated demethylation activity, which is reinforced by previous expo-
sure to inducers (PAHs, cigarette smoke, rifampine) [11-15] and reduced by 
liver disease or intake of steroid oral contraceptivob [16-18] 
The multiplicity of enzymes involved in CAF degradation (which one 
could hope to monitor), the ubiquitous use of CAF, its cheapness, safety, and 
desirable kinetic features including rapid and complete gastrointestinal 
absorption, negligible first-pass and renal elimination, low plasma protein 
binding (20-25 %), and distribution throughout total body water, render CAF a 
close-to-ideal test substance of liver function Indeed, it has been proposed 
as such by man> authors [19-25] 
Paraxanthine (PX or 17X) is a central intermediate in CAF biotransfor-
mation It is the major primary mono-demethylated metabolite of CAF, whose 
plasma concentration in most human subjects eventually exceeds that of CAF 
after a single dose of the latter compound It shares with CAF all (four) 
types of metabolic degradation, and for that might serve itself as a test com-
pound of liver function As such, it would allow more rapid diagnosis than 
CAF, as CAF conversion to PX is by-passed Thus the mean conversion time (= 
mean body residence time of CAF, amounting to 4 - 8 h in healthy volunteers 
and longer in patients with liver disease) is saved 
Pharmacokmetical data on PX are scarce Arnaud and Welsch recovered 
approximately 60* of orally administered PX as unchanged drug and methylated 
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xanthines and uric acids in the urine of 5 volunteers [26] Lelo and co­
workers [27] studied plasma kinetics of CAF and its three primary metabolites 
after oral administration of each compound and under the assumption of com­
plete s>stemic availability concluded that kinetics of CAF and PX were very 
similar in nature In a consecutive study [28] these authors demonstrated that 
the fractional conversion of oral CAF to PX was about 80% 
In the present study Ρλ kinetics following intravenous administration, 
and its rate and absolute extent of absorption from the GI tract are reported, 
and compared to the corresponding figures of CAF in the same volunteers 
13 2 MATERIALS A N D M E T H O D S 
Subjects Three male healthy volunteers participated in the experi­
ments, after hritten informed consent was obtained according to institutional 
policy Volunteers were 22, 23, and 24 years old and their body weights were 
62, 73, and 74 kg All subjects were free of medication Subjects 1 and 3 con­
sumed alcohol at a modest level and did not smoke, while subject 2 was a 
steady smoker and an excessive drinker All volunteers were habitual consumers 
of both coffee and tea Subject characteristics are included in Table I 60 
Hours before the start of an experiment and during its course, subjects 
refrained from consuming alcohol, coffee, tea, cola, chocolat, and analgesics 
containing CAF as an adjuvant Subjects had free access to cigarettes, drinks 
free of alcohol and CAF 
Study design and protocol The intravenous infusion of CAF was part of 
a randomized cross-over sequence of kinetic trials designed to assess absolute 
bioavailability of CAF given as coffee and as tea in 6 volunteers About 6 
months later, three of these volunteers participated in a 3x3 balanced incom­
plete block design of treatments (latin square), receiving 200 mg of CAF and 
PX as oral solutions, and 100 mg of PX as an ι ν infusion over 25 min on sep­
arate occasions with 2 week intervals In the morning of days of ι ν dosage, 
they were allowed a light breakfast, whereas they were fasted from the previ­
ous evening until at least Zi h after oral dosing In each of the latin square 
treatments and after ι ν infusion of CAF, subjects kept record of time and 
volume of each urine voiding 
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Intravenous administration and sample collection Details of prepara­
tion and administration of the CAF infusion solution and blood sampling scheme 
have been reported before [la] Curve fitting data and pharmacokinetic parame­
ters of ι ν CAF have been repeated and averaged for the present 3 volunteers 
in Tables I and II for ease of comparison 
PX was purchased from Fluka (Buchs, Switzerland) and was purified from 
> 98% to > 99 9% by recrystallization in doubly distilled water For prepara­
tion of the PX infusion solution, 150 mg of thus purified PX was dissolved in 
75 ml of isotonic sodium chloride solution, the solution was rendered free of 
pyrogens and sterilized by filtration A 50 ml volume was administered via a 
heparin lock placed in a forearm vein at a constant rate of 2 ml/min using a 
β 
Braun Perfusor VI infusion pump (Braun AG, Melsungen, FRG) The remaining 25 
mi-volume was stored for dose control 
Blood samples (5 mi) were withdrawn via a heparin lock in a vein of the 
contralateral arm at time zero (blank) and at approximately the following 
times after the start of the infusion 5, 10, 15, 20, 25 (at infusion stop), 
30, 35, 45 and 60 mm, and at t = li, li, 2 0, 3 0, 6 3, 11, 23 and 27 h Pri­
or to the removal of each blood sample, 2 mi of blood was withdrawn through 
the heparin lock and discarded The blood sample then was collected in a hep-
® 
annized syringe (Monovette , 5 mí, Sarstedt) The last 4 samples were 
obtained by individual venipunctures 
After sampling, plasma was separated by centrifugation (1000 g for 10 
m m ) Plasma samples were stored at -20° pending analysis, which as a rule was 
performed within 2 weeks No decomposition of CAF and PX was detectable over 6 
months in plasma samples stored as indicated 
Oral administration and sample collection A quantity of 250 mg of CAF 
(as caffeine monohydrate, Cooperative Pharmacists' Society 'De Onderlinge 
Pharmaceutische Groothandel', Utrecht, The Netherlands) or of PX (Fluka, 
Buchs, Switzerland) was dissolved in 125 mi of mineral water of ambient tem-
perature \olunteers were administered 100 mi at one go (t = 0), the remaining 
25 mi volume was stored for dose control The drinking glas and the subject's 
oral cavity were consecutively rinsed with 2 additional 100 mi-portions of 
distilled water to ensure intake of the entire dose Blood samples were col-
lected by repeated venipunctures before t = 0 (blank), and at t = 10, 20, 30, 
40, 50, 60, and 70 mm, and at t = li, 2, 2i, Зі, Si, β, 12, 24, and 32 h 
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Caffeine and paraxanthine analysis in plasma and injection fluids Plas-
ma samples (1 mi) and samples of administered fluids diluted a factor 1000 to 
1 mi were spiked with the internal standard (ISTD) ß-hydroxyethyl theophylline 
and extracted with dichloromethane in a single step at pH = 7 9 The evapor-
ization residue bas reconstituted in the mobile phase consisting of water, 
methanol, acetomtnle, and THF (v/v/v/v = 90 it 't 2) and 200 μί/Ι of glacial 
acetic acid The mobile phase was delivered at 40e and a rate of 1 m£/irin to a 
S 
150 χ 4 4 mm ID column home-packed with octadecylsilane (Chromosorb RP-18 , 
particle size 5 ym, Merck, Darmstadt, FRG) Effluent was monitored at 254 nm 
UV Retention times were 3 4, 3 8 and 4 5 min for PX, the ISTD, and CAF, 
respectively Coefficients of variation (CV) were similar for CAF and PX and 
amounted to 3%, 4% and 8% at plasma concentrations of 5 0, 1 0 and 0 1 mg/t 
The assay is a minor modification of a method described elsewhere [1c] 
Pharmacokinetic Analysis For each subject and each experiment, cumu­
lative voided urine volume was plotted versus time The volume voided at t = 
10 h was determined by linear interpolation in this plot, and was divided by 
10 to yield the average urine flow rate (UFR ) over the first 10 h following 
dosage 
Intravenous data. The plasma concentration vs time data (C (t), t) of 
CAF and PX during the time (T) of ι ν infusion of the respective compounds 
were fitted to a sum of exponentials according to. 
m -t/τ 
C l v(t) = Σ (A1 τι/Τ)·(1-β
 1 ) 
and following the infusion to : 
-ΤΛ -(t-T)/T 
С ( t ) = Σ (Α τ /T)«(l-e V e 
IV [ i l 
Parameter estimates were obtained by use of the non-linear curve fit­
ting program 'FARMFIT' [29] Each data point was attributed a weight factor· 
W = 1/{CVC (t ))*, where CV is the coefficient of variation (CV) of the 
analytical procedure (see above) Given a particular fit equation, 'FARMFIT' 
iteratively minimized the woighted sums of squared deviations (VSS) 
WSS = Σ W «AC 2(t ) 
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where η is the number of data points, and AC 2(t ) is the squared deviation 
of the measured concentration from the concentration calculated according to 
the fit equation at the j time of sampling Data points with concentrations 
less than 0 075 mg/i (CV > 10%) were excluded from the fit procedure since 
their accuracy was considered insufficient to be compatible with correct data 
analysis 
Tlie number of exponential functions was chosen on the basis of two cri­
teria, tho first being the Akaike Information Criterion (AIC) [30,31] 
AIC = n«ln(WSS) + 2p 
where ρ is the number of parameters to be estimated The number of exponential 
functions yielding the lowest AIC value was considered the best representation 
of experimental data for each subject 
The second criterion to decide on the number of exponentials was a sta­
tistical comparison of the fits by the F ratio test [32,33] 
Fq-p,n-q = WSSp/^q " 1 ) { ( П" Ч ) / ( Ч" Р ) ) ' P * Ч 
where WSS and WSS are the weighted sums of squared deviations obtained by 
fitting equations with ρ and q parameters (p < q), respectively, to the number 
of η data points This test indicates if WSS is reduced (i e , if the goodness 
of fit has improved) significantly (P < 0 OS) by the addition of one exponen­
tial to the fitting equation 
From the concentration coefficients CA ) and the time constants (t ), 
ι ι 
areas under the plasma concentration vs time curve (AUC), the time'conc vs 
time curve (TAUC) and the time2*conc vs time curve (T2AUC) were computed to 
infinite time according to statistical moment theory [34] 
AUC = Σ Α ·τ , TAUC = Ι Α ·τ I, and T2AUC = 2 Ι Α ·τ.3 
I l l 1 1 1 ' i l i 
The total body transport function (or disposition function) i/i(t) was 
calculated as 
<Kt) = 1/AUC I A »e 
ι i 
Mean residence time (MRT), terminal half-life (t,), total clearance (CL), and 
apparent volume of distribution (V, ) were respectively computed as 
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MRT = TAUC/AUC, t, = 0 693 τ 2, CL = D/AUC, and V = MRT'CL 
where τ is the time constant of the terminal declining phase of the concen­
tration profile Assuming cardiac output C O in our healthy subjects to aver­
age 360 i/h, the extraction ratio (E), the average number of recirculations 
(N ) and the mean transit time (MTT) can be calculated as [35,36] 
E = CL/C 0 , N = (1-E)/E = 1/E, and MTT = MRT/N 
Oral data After rapid swallowing of the CAF and PX solutions, the 
plasma concentration vs time profile of either drug is a convolution of the 
absorption function H (t) and the total body transport function Φ(ΐ) according 
to 
С (t) = D/CL · Η ft) » iMt) 
or a 
where D is the oral dose, CL is the total clearance, and '*' denotes the con­
volution operator Plasma data (C (t), t) after peroral administration of CAF 
po 
and PX were interpolated by a quasi-Hermite cubic spline [37] by means of the 
I4SI, routine IQHSCU (36] The time increment for interpolation was 0 001 h 
The absorption function H (t) was obtained for each subject and both ingested 
xanthines by deconvolution of his splined oral data and the appropriate body 
transport function 4>(t) according to the numerical deconvolution method 
described b> Vaughan and Dennis [39] Statistical moment analysis (34] of 
H (t) yielded systemic availability (h ) and mean absorption time (MAT) 
υ u u 
h = ] H (t) dt, and MAT = S f H (t) dt / I H (t) dt 
a a a a 
о о о 
fchere the upper integrand 'u' denotes the time of the oral data point right-
nearest to the to the time at which the absorption rate for the last time 
deviated positively from zero by 5% of the maximal absorption rate (u * li h, 
see figure 3) After determination of h , the median absorption time (HedAT), 
at which half the available dose is absorbed, could be calculated numerically 
according to the implicit expression 
MedAT 
J H (t) dt = i h 
Oral (С (t), t) data were also fitted directly to a biexponential 
equation 
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- t / t - t / t 
С (t) = A (e - e ), τ > τ 
or о 
The area under the plasma concentration vs time curve (AUG) and under the 
time'concentration vs time curve (TALC) were calculated as |34] 
AlC = A (t - τ ), and TAUC = Α (τ* - τ I) 
о о 
Mean residence times (MRT) of CAF and P>. were estimated from the plasma con­
centration profiles foliohing oral dosage as the elimination time constant τ 
HetaboJic formation of paraxanthme from caffeine PX plasma concentra­
tion vs time profiles after either oral or ι ν administration of CAF were 
fitted to a power function of time 
к -t/τ 
CT(t) = A (t/x) e 
where к > 0 to impose the origin as a left boundary upon the function The 
area under the plasma concentration vs time curve (AUG) and under the 
tjme*conc vs time curve (TAUC) were calculated as [34,40] 
AUG = Α τ Γ(κ+1), and TAUC = A t2 Γ(κ+2) 
- χ -t 
where Γ(χ+1) = / t « e dt, x > - l 
0 
denotes the mathematical gamma function (see e g , Churchill [41]) The quo­
tient TALC/AIC as usual yields the sum of the mean times of all processes con-
tribating to dispersion of the respective concentration profile [36] In the 
present caset TAUC/AUC is mainly made up of three mean times, with negligible 
contribution from some others These three mean times are, in reverse order 
the mean residence time of the metabolite PX (MRT), that of its parent com­
pound CAF (MRT ), and the mean input time (MIT) of CAF The MIT equals the 
mean absorption time (MAT) in case of oral CAF dosage at one go (in case of 
deldyed oral dosage MIT = MAT + MDT (mean dosage time), see ref lb) In case 
of intravenous dosage, MIT equals the mean infusion time (iT) Consequently, 
the mean residence time of PX may be computed as 
MRT = TAUC/AUC - MRT - MIT 
Ρ 
The conversion fraction f of CAF into PX was determined as 
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fM = {(ALOCL ) / (D'O 928)} · (MRT /MRT) 
where CL is the total PX clearance observed after ι ν administration of PX 
to each subject, D is the oral or intravenous dose of CAF administered to each 
subject (200 mg, assumed to be completely available after oral dosage), and 
0 928 is a factor correcting for the different molecular weights of CAF (MW = 
194) and PX (MVÍ = 180) The ratio of the PX mean body residence times after 
infusion of this compound as such (MRT ) and after dosing of CAF (MRT) is 
employed to correct f for individual changes of PX elimination rate between 
the two experiments mentioned 
plasma concentration (mg/1) 
I I I I I 
О 5 10 15 20 25 
time (h) 
FICURb 2 Plasma concentration vs time curves of paraxanthme m a healthy 
volunteer (o) after instantaneously swallowing an aqueous solution of the 
drug, and (·) during and following a 25 mm intiavcnous infusion 
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TABLE I SUBJECT CHMACTERISTICS, AND CURVE FITTING PARAHETERS OF CAFFEINE 
AND ΡΑΚΛλΛΝΤΗΙΝΕ FOLLOWING INTRAVENOUS INFUSION IN 3 HEALTHY SUBJECTS 
Subj 
CAFFEINE 1 
2 
3 
MEAN 
± SD 
Ρ AR AX ANT'E 1 
2 
3 
flEAN 
± SD 
Sex 
m 
m 
m 
-
-
Age 
yrs 
23 
22 
24 
23 
1 
24 
23 
25 
25 
1 
BU 
kg 
68 
63 
72 
68 
5 
* 
73 
62* 
ri-
74 
70 
7 
»ed/ 
Ind 
A 
ΑΑ,Τ 
A 
-
-
A 
ΑΑ,Τ 
A 
-
. 
AI 
mg/I 
-
2 59 
9 39 
-
-
-
1 81 
-
-
-
A2 
nglt 
5 
2 
4 
4 
1 
1 
3 
2 
2 
0 
81 
83 
00 
21 
50 
73 
37 
03 
38 
87 
τ
ι 
min 
-
49 4 
4 61 
-
-
-
6 68 
-
-
-
1 
l2 
Λ 
5 
4 
7 
S 
1 
5 
3 
4 
4 
0 
70 
18 
89 
92 
87 
33 
67 
76 
59 
85 
AUC 
mg'h/l 
33 1 
13 9 
32 3 
26 4 
10 9 
9 20 
7 00 
9 69 
8 63 
1 43 
TAUC 
mg'h'/l 
188 4 
51 2 
249 1 
162 9 
101 4 
49 05 
24 33 
46 11 
39 83 
13 50 
ffl = body weight, fled/Ind = medication and drugs of indulgence A = modest 
consumption of alcohol (± 10 g f day), excessive consumption of alcohol (± 100 
glday), Τ = tobacco consumption (± 25 cigarettes I day) 
I ν dosing of PX was performed 5-7 months after ι ν dosing of CAF During 
this period, subjects' body weights changed by 1-5 kg 
13 3 RESULTS 
Intravenous administration of paraxanthine Like in case of fitting CAF 
data [la], Akaike's Information Criterion and the F ratio test (applying a 
minimal level of significance of Ρ < 0 05) again yielded the same decisions 
regarding the number of exponentials used for fitting the PX data points Data 
points of subjects 1 and 3 were fitted to a monoexponential equation (e g , 
see figure 2, lower curve), whereas those of subject 2 were fitted to a biex-
ponential function Subjects' curve fitting data and pharmacokinetic parame­
ters of PX have been tabulated in Tables I and II, resp , In which the corre­
sponding quantities of CAF in these subjects [la] have been repeated for ease 
of comparison 
Plasma elimination half-lifes and mean body residence times (MRT) of PX 
averaged about 3 and 4£ h, respectively The variance of residence times (VRT) 
well approximates MRT1 in subject 2, emphasizing the basically monoexponential 
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TABLE II. PHARHACOKINETIC PARAMETERS OF CAFFEINE AND PARAXANTHINE AS CAL-
CULATED FROH THE PLASMA CONCENTRATION PROFILES FOLLOWING I.V. INFUSION 
PX 
CAF 
•mbj 
1 
2 
3 
HEAtt 
t SD 
1 
2 
3 
HEAN 
± SD 
'i 
h 
3.70 
2.S4 
3.30 
3.18 
0 59 
3.95 
2.90 
5.47 
4.11 
1.29 
MRT 
h 
5.33 
3.48 
4.76 
4.52 
0.95 
5.70 
3.69 
7.72 
5.69 
2.03 
VRT 
h' 
28.4 
13.4 
22.7 
21.5 
7.6 
32.5 
16.4 
62.2 
37.0 
23.3 
CL 
l /A 
10.9 
14.3 
10.3 
11.8 
2.2 
6.05 
14.35 
6.20 
8.86 
4.75 
V
dss 
í 
58.0 
49.7 
49.2 
52.3 
4.9 
34.4 
52.6 
47.8 
45.0 
9.4 
E 
Ζ 
3.0 
4.0 
2.9 
3.3 
0.6 
1.7 
4.0 
1.7 
2.5 
1.3 
im 
mia 
9.7 
8.3 
8.2 
8.7 
0.8 
5.7 
8.8 
8.0 
7.5 
1.6 
N 
ГС 
32 
24 
34 
' 30 
5 
59 
24 
57 
47 
19 
VF
*io 
ml Ih 
130 
193 
131 
151 
36 
135 
180 
59 
125 
61 
For calculation of E, MTT, and N , cardiac output CO. uas taken 360 t/h 
tj = plasma elimination half-life - 0.693 τ„ 
kinetics of PX in this subject in terms of statistical moments. PX distributes 
throughout total body water and is cleared from plasma at a rate of nearly 12 
t/h. During each systemic transit of PX, on the average 3 - 4% of circulating 
PX molecules were extracted from our volunteers' system, either by biotrans­
formation or by excretion. The mean time to complete one circulatory transit 
through the body (MTT) came to nearly 9 min. The mean number of transits per 
PX molecule amounted to 30, some PX molecules managing to complete only a few 
transits, others recirculating up to more than hundred times. 
Kinetic parameters of CAF and PX were rather similar. Means of total 
clearance and apparent volume of distribution were some 30% and 15% higher for 
PX than for CAF, while MRT and t, for PX were 25 - 30% lower for PX than for 
CAF (Table II). Student's t-test did not reveal significant differences 
between CAF and PX with respect to any of the listed parameters. 
Oral administration of caffeine and paraxanthine. The plasma level of 
PX as a function of time in subject 3 after oral administration of an aqueous 
solution of PX is displayed in figure 2 (upper curve); similar profiles of CAF 
after dosage of aqueous CAF solutions have been displayed in figure 4 for all 
volunteers. 
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FIGURE 3 Profiles of gastrointestinal absorption rate {D · H (t)) vs time of 
paraxanthine (dashed line) and of caffeine (solid line) m 3 healthy 
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absorption rate ( m g /h) 
40O 
3 0 0 
2 0 0 
100 
t ime (h) 
hlGURE 3 (cont'd) volunteers following instantaneous ingestion of aqueous 
solutions containing ZOO mg of either compound For each subject and each com­
pound, absorption rate profiles were calculated by numerical deconvolution of 
the appropriate total body transport function ^(t) with the first part (until 
t = иt at the arrow) of the plasma concentration vs time profile following 
oral administrât ion of the solution 
Absorption and disposition parameters of perorally administered PX and 
CAI are given in Table III Both compounds are rapidly and virtually complete-
ly absorbed, median absorption times coming to 18-20 min, mean times to 22-23 
m m , and absolute availability to 94 ± 10 % for PX and to 103 ± 13 i for CAT 
as averaged over our volunteers Absorption rate profiles of PX and CAF in 
each volunteer have been depicted in figure 3 Profiles of PX tend to be 
smoother than those of CAF 
Plasma half-lifes of PX elimination were similar after oral and ι ν 
administration for subjects 1 and 3 (see figure 2), but not for subject 2, who 
disposed of PX considerably faster after ingestion than after i ν infusion 
All subjects disposed of oral CAF more rapidly than of ι ν CAF (also compare 
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TABLE III ABSORPTION PARA1ÌETERS AND MEAN RESIDENCE TIMES Of CAFFEINE 
AND PARAXANTHINE, AND SUBJECTS' URINE FLOU RATES FOLLOW INC ORAL 
ADMINISTRATION OF SOLUTIONS CONTAINING 200 MG OF EITHER COMPOUND 
PARAXANTHINE 
Subj hg 
X 
1 105 1 
2 89 9 
3 86 3 
MEAN 93 8 
t SD 10 0 
МАГ 
mm 
21 5 
23 2 
21 2 
22 0 
1 1 
McdAT 
nun 
15 9 
18 0 
15 5 
16 5 
1 3 
MRT''' 
h 
5 43 
2 71 
4 75 
4 30 
1 42 
υ
™ιο 
ml/h 
140 
213 
135 
163 
44 
CAFFEINE 
b
a 
I 
89 2 
106 5 
114 3 
103 4 
12 a 
HAT 
min 
16 1 
29 0 
23 5 
22 9 
6 5 
McdAT 
mm 
12 0 
23 5 
19 9 
18 5 
5 9 
1> 
MRT 
h 
5 05 
2 95 
6 43 
4 81 
1 75 
UFR10 
ml/h 
151 
202 
79 
144 
62 
MRT here equals the single elimmation time constant τ 
TABLE IV CURVE FITTING DATA AND PHARMACOKINETIC PARAMETERS OF PARAXANTHINE 
AS CALCULATED FROM THE PLASMA CONCENTRATION PROFILES DURING AND FOLLOWING 
INTRAVENOUS (IV) AND PERORAL (PO) ADMINISTRATION OF 200 MG OF CAFFEINE 
I V 
Ρ 0 
Subj 
1 
2 
3 
MEAN 
± SD 
1 
2 
3 
MEAN 
± SD 
'. is an 
A 
mg/i 
г 
3 
2 
2 
0 
2 
3 
2 
2 
0 
57 
04 
07 
56 
49 
66 
11 
49 
75 
32 
apparent 
I 
1 
0 
1 
1 
0 
1 
1 
1 
1 
0 
с. 
с 
16 
95 
00 
04 
и 
07 
13 
05 
08 
04 
τ 
A 
5 
4 
6 
5 
1 
4 
2 
6 
4 
1 
56 
02 
59 
39 
29 
98 
95 
02 
65 
56 
limmation time 
TAUC 
mg-h1/! 
150 
93 
179 
152 
51 
140 
61 
188 
130 
64 
0 
4 
7 
8 
5 
4 
2 
6 
1 
3 
ι constant 
AUC 
mg'h/l 
IS 4 
11 9 
13 6 
13 7 
1 7 
13 7 
9 7 
IS 3 
12 9 
2 9 
, result. 
MRT 
h 
6 
3 
5 
5 
1 
4 
2 
5 
4 
1 
ing 
07 
91 
22 
07 
09 
98 
85 
51 
45 
41 
from 
fM 
0 794 
0 818 
0 691 
0 768 
0 068 
0 855 
0 915 
0 736 
0 835 
0 091 
simulta\ 
ous PX elimination and its continued formation from CAP 
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plasma concentration (mg/l) 
τ 1 1 1 1 1 1 
Ο 5 10 15 20 25 30 
time (h) 
plasma concentration (mg/l) 
1 1 1 1 1 1 
О 5 Ю 15 20 25 30 
time (h) 
plasma concentration (mg/l) 
time(h) 245 
plasma concentration ( m g / l ) 
5 caffeine 2 0 0 mg 
administered as a Ю О т і solution 
subject ι 
plasma concentration (mg/I) 
5 η 
1 : 
0 5 
0 1 : 
0O5 ; 
0 0 1 : 
0 0 0 5 : 
i caffeine 200 mg 
^ administered as a 100 ml solution 
X subject 2 
Г\\ 
\ \ 
1 1 1 • r 1 
20 25 
time(h) 
plasma concentration (mg/1) 
5 caffeine 2 0 0 mg 
administered as a lOO ml solution 
subjects 
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the mean residence times of PX and of CAF as administered via both routes, 
Tables II and III) 
Metabolic formation of paraxanthine from caffeine Plasma concentration 
profiles of CAF after oral and ι ν administration, and of PX originating 
from CAF through metabolism, are shown in figure 4 The metabolite curves 
assume a typical convex time course and all intersect the curves of their par­
ent compound, be It at widely varying times The convex PX profiles could not 
be fitted properly to sums of up to 4 exponentials, but were described excel­
lently by the mere 3 parameters of a gamma distribution of residence times 
('gamma function') 
Gamma function curve fitting data and kinetic parameters after adminis­
tration of the metabolic parent CAF have been listed in Table IV Values of 
the time power 'к' were close to unity in all instances The time constant 'τ' 
in all but one case assumed an intermediate value between the elimination time 
constants of CAF and of PX administered via the route in question Estimated 
molar fractions of 0 77 and 0 84 of intravenous and peroral CAF doses, respec­
tively, were converted into PX 
13 4 DISCUSSION 
This is the first study describing kinetics of PX after intravenous 
administration to man Kinetics of PX and CAF after ι V infusion to the same 
3 volunteers in the present study were found to be similar in nature, a simi­
larity that was also recognized by Lelo and colleagues [27] after oral dosage 
to the double number of volunteers The similarity is the result of similari­
ties of chemical structure and physicochemical properties (affecting binding 
to proteins and tissue) and of metabolic degradation via the same metabolic 
routes by the same enzyme(s) of cytochrome P-450 (figure 1), for which both 
FIGURE 4 (previous two pages) Plasma concentration ys time profiles of (L·) 
caffeine and of (o) paraxanthine (p 245) during and following ι ν infu­
sion of caffeine over 30 mm, and (ρ Z46) after swallowing an aqueous solu­
tion containing the same dose of caffeine Caffeine profiles have been fit­
ted to a biexponential function, those of paraxanthine to a single 'gamma' 
function 
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xanthines probably have alike affinities. 
After ingestion as a solution, absorption kinetics of PX also resembled 
that of CAF. Rate and extent of CAF absorption data reported here are In 
agreement with more extensive data derived in a previous study on this subject 
[lb]. Mean systemic availability of PX after oral dosage was lower than that 
of CAF, but did not differ significantly from it or from unity. Our findings 
probably support the validity of thr assumption of complete availability of 
oral PX as it was made by Lelo et al. [27], though it must be bore in mind 
that the latter authors administered a gelatin capsule with PX rather than a 
solution. Although not discernable from figures on overall rate and extent of 
absorption, profiles of absorption rate vs. time for PX apparently were 
smoother than for CAF. The significance of this finding is unclear. 
PX plasma concentration vs. time functions after intake of CAF could 
well be fitted to a single gamma function. The gamma power function of time 
was originally derived by Wise [42-44] to assess the kinetics of bone-seeking 
elements, and which function was interpreted in terms of combined diffusive 
and convective motion of administered molecules ('random walks with drift'). 
An excellent paper on the application of gamma distributed residence times in 
pharmacokinetics has been published by Weiss [40]. 
For the first time to our knowledge, in the present study gamma func­
tions have been applied to metabolite kinetics. Van Rossum et al. have shown 
theoretically that the concentration of a primary metabolite (e.g., PX) may be 
seen as the output of a metabolic system in which the parent compound (e.g., 
CAF) concentration is the input [36]. Since the transport functions $(t) of 
both PX and CAF are largely monoexponential and have similar time constants, 
the PX concentration following a short (pulse-like) input of the parent com­
pound CAF should follow the profile of a gamma function with к s 1. 
In the experimental practice of the presently described work, slight 
deviations of к from unity are observed. These may be explained on the basis 
of slight differences between the elimination time constants τ of CAF and PX. 
Also, the mean input time of CAF by i.v. infusion or gastro-intestinal absorp­
tion may not be short (pulse-like) enough to be negligible compared to the 
mean residence times of CAF and PX, elevating dispersion of the PX profile, 
resulting in a value of к > 1. 
It is stressed here that the gamma function as a description of PX 
kinetics after CAF dosage as presented above was arrived at under the assump­
tion of linear pharmacokinetics. Thus, the convexity of the plasma PX concen­
tration profile is solely due to similarity of the elimination time constants 
of CAF and PX. The log-nonlinear course obviously should not in itself be mis-
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interpreted as an indication of capacity-limited metabolism of PX after its 
formation from CAF However, in slow metabolizprs capacity-limitedness of PX 
metabolism might certainly contribute to convexity 
Fits of PX profiles after CAF intake to gamma functions with κ-values 
left free were very useful in determining the statistical moments of these 
profiles In case of convex profiles, numerical methods like the widely used 
trapezoidal rule are apt to underestimate statistical moments, as Lelo et al. 
correctly recognized [28] These authors apparently were ignorant of the pos­
sibility of fitting gamma functions to the PX plasma concentration profiles 
obtained after a single dose of CAF, and escaped from underestimation of AUC 
by performing their study under steady-state conditions, administering multi­
ple doses of CAF to their subjects 
Combining statistical moments with systems dynamics pharmacokinetics 
also rendered possible calculation of PX mean body residence time (MRT) after 
its metabolic formation from CAF The calculated MRT was applied to correction 
of the conversion factor f of CAF into PX for changing individual disposition 
rate of the latter compound The need for such a correction was demonstrated 
by within-subject variability of values of PX body residence times between 
experiments in this study The correction of fM for changing drug MRT is ana-
loguous to the correction of bioavailability for changing drug elimination 
half-lifes or t's [45-47] In the present case, MRT was preferred to τ as a 
correction parameter because! in the convex PX gamma profiles reflects simul­
taneous elimination of PX and its formation from CAF 
To our initial surprise, conversion fractions of CAF into PX were sig­
nificantly higher (P < 0 05, pairwise two-tailed t-test) after oral intake of 
CAF than after its intravenous administration At first we were inclined to 
attribute the difference to first-pass metabolism of oral CAF However, the 
assumption of a notable first-pass effect of ingested CAF is neither supported 
by literature data, nor by a previous study of our own in which we established 
virtually complete systemic availability of CAF from coffee and from tea [lb]. 
Instead, in the latter study evidence was presented for a marked dependence of 
CAF total clearance on urine flow rate In a study specifically designed to 
investigate this dependence, Trang and co-workers [48] explained an observed 
strongly positive correlation between total clearance of CAF and urine flow 
rate by suggesting that the primary dimethylxanthine metabolites of CAF might 
reach sufficiently high concentration levels to competitively retard CAF 
demethylation, and that increased renal excretion of these dimethylxanthine 
metabolites at higher urine flow rates could result in a reduction of the com­
petition, thereby increasing metabolic (and total) clearance of CAF 
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Urine flow rate of our subjects after oral administration exceded that 
after ι ν infusion of CAF (P < 0 01, pairuiso 2-tailed t-test), presumably by 
intake of a uater load of 300 mi with the oral dose compared to only 30 mi as 
an ι ν infusion Diuresis according to the mechanism proposed by Trang et 
al |68j may have resulted in a relatively fast removal of dimethylxanthine 
melabolitPb aft« г or.i 1 ilosing compared to ι ν dosing of CAF, thereby in the 
form<u experiment reducing saturation of <ytochrome P-A50 enzymes mediating 
demethylation routes in general and the 3-demethylation pathway to PX in par­
ticular In this way intake of water with oral CAi could have stressed 
demethylative metabolism of CAF at the expense of other metabolic routes that 
may not be capacity-limited (figure 1) 
Also, increase of renal (and total) clearance of PX due to diuresis 
following swallohing of a substantial water load with the oral dose may have 
contributed to the shorter elimination half-life of PX after oral dosage com­
pared to ι ν dosing of PX as such to subject 2 
Studies on the pharmacokinetics of other metabolites of CAF are in 
progress 
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Chapter 14 
ORAL AND INTRAVENOUS SINGLE DOSE KINETICS OF QUININE 
IN HEALTHY MAN 
Harald W A Teeuwen1, Paul J de Schepper2, Τ Budya Tjandramaga1, 
and Jacques M van Rossum1 
1Department of Pharmacology, Faculties of Medicine and of Natural Sciences and 
Hathematics, University of Nijmegen, Ρ 0 Box 9101, 6500 HB Nijmegen, 
The Netherlands, and 
'Department of Pharmacology, Catholic University of Leuven (KUL), Campus 
Gasthuisberg, B-3000 Leuven, Belgium 
14 1 SUMMARY 
The disposition and absorption kinetics of quinine were Investigated m 
7 healthy volunteers after intravenous and oral administration Plasma and 
urine samples were collected over 45 hours and analyzed for unchanged quinine, 
and m case of urine samples, also for conjugated quinine, using reversed-
phase HPLC combined with fluorescence detection Pharmacokinetic analysis was 
done using a non-compartmental dynamic systems approach Absorption and dispo­
sition parameters were calculated from the plasma curves by numerical deconvo­
lution and statistical moments 
Intravenous administration was characterized by a mean residence time 
of 12 1 h, total clearance of 8 08 l/h, and an apparent volume of distribution 
of 96 4 I Renal clearance was 1 26 l/h, and 15 5 Ζ of the dose was excreted 
unchanged m the urine 
After oral administration, median and mean absorption times of quinine 
were 1 26 and 1 42 h, respectively Mean systemic availability (± SD) was 0 90 
± 0 18 as calculated by numerical deconvolution, and 0 87 ± 0 11 as estimated 
by area ratio In accordance with incomplete availability, mean total urinary 
recovery (13 4 %) was slightly less than that observed after ι ν admmlstra-
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tion, whiJe renal clvaroncc and mean residence time were similar Mean resi­
dence times and mean excretion times calculated from plasma and urine data, 
respectively, correlated well both after oral and ι ν administration. 
In tuo subjects, dual plasma concentration peaks »ere seen fol loving 
oral administration. Conjugated quinine nas found in the urine of these sub­
jects, but not m that of the others On the basis of the available data we 
could not disci immate with certainty whether the second plasma peaks were due 
to delayed absorption of quinine after food intake by the subjects, or to 
enterohepatic circulation of quinine 
Key words Quinine, systems dynamic:, pharmacokinetics, numerical deconvolu-
tion, mean/median/modal absorption time, systemic availability, enterohepatic 
recirculation 
Quinine (Q) is one of the oldest drugs in the pharmacopoeia. Untili the 
third decade of this century Q and to a lesser extent the related cinchona 
alkaloids, represented the sole chrmotherapeutic agents for the specific 
treatment of all four forms of malaria While synthetic antimalarials largely 
replaced Q, the emergence of chloroquine-resistant Plasmodial strains in 
Southeast Asia and South America in the early 1960s, and recently in East 
Africa, has necessitated its continued therapeutic use 
In the L К Q is widel) prescribed as a reliever of nocturnal leg 
cramps In a recent double blind, placebo-controlled study, Q failed to effec-
tiiate a significant reduction in the number or severity of cramps (Warburton 
et al 19a7) 
Q is a marked local irritant Vascular dam.ige after intravenous admin* 
istration is the basis for the occasional application of quinine and urea 
hydrochloride for scleiosing varicose \eins and hemorrhoids 
As an ocytocic, Q is daily administered to women during the last 3-4 
weeks of pregnancy With laymen, it enjoys some popularity as an abortifa-
cicnt Its effect on th<> uterus and the developing fetus, however, is highly 
unreliable 
Q is a common adulterant of illicit heroin according to Berlin et al 
(1975) 
Finally, Q ts used as a bitter principal in the flavoring of carbonated 
soft drinks like 'tonic' or 'bitter lemon', the former drink in the Nether­
lands containing 40 - 85 mg'i of the alkaloid and the latter less than 40 mg/t 
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as laid down in the Dutch Merchandise Legislation Because of its use in soft 
drinks, Q has gained the character of a non-prescriptive, mass-consumed luxury 
drug Consequently, determination of Its kinetics in healthy subjects has 
gained proportional relevance 
At the same time, detailed comparison of Q kinetics in individuals of 
different ages and ethnic groups, in health and in various degrees of malaria 
severity (convalescence, uncomplicated and cerebral malaria), is required to 
rationalize optimally tailored doses and dosage regimens of this toxic natural 
product in each subpopulation 
Q kinetics after ι ν administration in Caucasian subjects have not 
been reported previously Besides, intra-individual comparison of Q kinetics 
after oral and ι ν administration has not been reported until now Finally, 
the analytical method employed in this study is a Chromatographical one 
(HPLC), whereas the majority of earlier investigations of Q kinetics was car­
ried out using the so-called 'double extraction - fluorescence' assay (Cramer 
& Isaksson 1963), which is thought to quantitate Q metabolites as well to some 
extent 
14 2 MATERIALS AND METHODS 
Subjects Seven volunteers (4 males and 3 females), ranking in age from 
21-32 ^ears and in weight from 59-84 kg participated in the study Written 
informed consent was obtained according to institutional policy Volunteers 
included 2 regular consumers of Q-containing soft drinks, 3 moderate consumers 
of alcoholics, and one subject taking a bronchodilator Table I summarizes 
subject characteristics inter alia 60 Hours before the start of an experiment 
and during its course, subjects refrained from consuming alcohol and Q They 
had free access to drinks free of the latter substances, and to food, except 
m the first three hours after oral administration of Q 
Intravenous quinine administration and sample collection After collec­
tion of a blank blood sample, 150 mg of pyrogen-free Q base (as Q monohy-
drochlonde monohydrate) dissolved in 50 mi normal (0 9 %) saline was infused 
over 12 min The drug was dispensed with a plastic syringe and an indwelling 
β 
catheter in the antecubital vein of the left arm A Braun Perfusor VI pump 
was used to ensure a constant rate of infusion A second identical catheter 
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inserted in the antecubital vein of the opposite arm was used for repeated 
blood sampling after removal of the dead space It was remained patent with 
hepannized saline The subjects remained supine from the start of the infu­
sion until 30 minutes after its termination 
β 
Blood samples were collected in heparimzed syringes (5 ml, Monovette , 
Sarstedt) 3, 6 and 12 minutes after starting the infusion, and at 1, 2, 4, 6, 
8, 12, 16, 22, 30 minutes and at 1, 2, 5, 9, 22, 30 and 45 hours after its 
termination The infusion catheter was removed immediately at the end of the 
infusion, the sampling catheter was removed 1 h afterwards The remaining 
blood samples and the urine samples were taken by individual venipuncture 
During the experimental time, subjects kept a record of time and volume 
of each urine voiding A 100 ml aliquot of each voiding was stored after mea­
surement of the pH No attempts were made to control urinary pH 
After sampling, plasma was separated by centrifugation at 1000 g for 10 
m m Plasma and urine samples were stored at -20° pending analysis, which was 
completed within 5 weeks No decomposition of Q in spiked plasma or urine was 
observed over a 6 months period if stored at the temperature indicated 
Oral quinine administration and sample collection After collection of a 
blank blood sample, a single oral dose of 2 0 mg/kg Q base (as Q sulfate dihy-
drate) was given to each subject in a gelatine capsule at 9 00 a m The cap­
sule was ingested with 200 m£ of water to prevent sticking m the oesophagus 
Subjects were in the fasting state A light standard lunch was allowed 3 h 
after Q ingestion 
Blood samples were collected by individual venipuncture in hepannized 
syringes (10 ml. Monovette , Sarstedt) from an arm vein at 0 25, 0 5, 0 75, 1, 
1 5, 2, 3, 4, 5, 6, 7, 12, 24, 31 and 48 h after ingestion of Q Again, the 
subjects recorded time and volume of urine voidings 
Oral and intravenous administration of Q were performed in a randomized 
cross-over design within 1 month for each subject, with one exception Three 
months elapsed between experiments featuring subject 1, who had been adminis­
tered 1 5 mg/kg of Q base per os in an early phase of the program as the oral 
pilot subject Only in this pilot experiment, sample collection was terminated 
at 30 h rather than at 45 h 
Plasma and urine quinine analysis Q in plasma and urine was deter­
mined uith a selective and sensitive HPLC technique employing fluorescence 
detection as described elseuhere (Tepuwen 1988) A 15 cm χ 4 2 mm ID reversed-
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phase octadecyl (C18) column was used with 0 08 M acetate buffer (pH = 4 2) 
and THF (v/v = 60 40) as a mobile phase at a flow of 1 mt/min Retention times 
of nonphenolic Q metabolites, Q, and the internal standard methaqualone were 
1 9, 2 4 and 4 0 mm, respectively 
Coefficients of variation were about 3% for concentrations greater than 
0 2 mg/t Urine samples were analyzed both with and without a prelimininary 
hydrolysis of Q-conjugates by the enzymes ß-glucuromdase and arylsulphatase 
Pharmacokinetic Analysis 
Intravenous data The plasma concentration-time data (C, (t), t) during the 12 
min (Τ) i ν infusion were fitted to the sum of 2 exponentials according to 
2 -t/τ, 
C i v(t) = Σ (Ai ті/Т)'(1-е ) 
and after the infusion to 
2 -Τ/τ -(t-T)/t 
С ( t ) = Σ (A. т./Т)'(1-е V e 
IV 1 1 1 
From the concentration coefficients (A , A.) and the time constants (tj, t.), 
total area under the plasma concentration vs time curve (AUC) and under the 
time*concentrâtion versus time curve (TAUC) was computed according to statis-
tical moment theory (Yamaoka et al 1978) 
2 г 
AUC = Σ Α ·τ and TAUC = Σ Α ·τ 2 
1 1 1 1 1 1 
Furthermore, the AUC until the last collected urine sample (at t = Ζ » 45 h), 
denoted AUC_, was approximated as 
и 
-Z/T, 
AUCZ = AUC - A 2T 2«e 
where A. and τ represent concentration coefficient and time constant corre­
sponding to the terminal declining part of the plasma concentration versus 
time curve The total body transport function ψ(ΐ) was calculated as 
2 -t/*4 
•(t) = 1/AUC Σ A.«e 1 
i i 
Mean residence time (MRT), total clearance (CL), and distribution vol­
ume (V. ), and terminal half-life (t,) were computed as 
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MRT = mC/ALC, CL = Dose/ALC, V = MRT'CL, and t, = 0 693 τ 
Assuming cardiac output C O in our subjects to a\erage 360 i/h, the extrac­
tion ratio (E), the average number о 
sit time ОПТ) can be calculated as 
of recirculations (\ ) and the mean tran-
E = CL/C 0 , \ (1-E)/E = 1/E, and MTT = MRT/N' 
(Van Rossum et al 1983) Renal clearance (CL ) uas calculated from CL = 
Q (Z)/AUC., uhere Q (Z) is the amount of Q excreted in the urine over 45 h 
Г L r 
The cumulative renal excretion, Q (t), bas fitted to a sum of two 'l minus' 
exponentials 
2 "t/t. 
q
r
(t) = CL
r
·! kff{\ - β ') 
From the latter A and τ , the mean urinary excretion time (MET) of Q was cal­
culated in analogy to MRT 
Oral data The oral concentration curve is a convolution of the absorption 
function H (t) and the total body transport function φ(ΐ) according to 
C
o r
(t) = D/CL · H
a
(t) * *(t) 
where D is the oral dose and '*' denotes the convolution operator The absorp­
tion function H (t) was calculated by deconvolution of the oral plasma data 
(C(t), t) and the body transport function Ψ(ΐ) known for each subject from the 
intravenous experiment, according to the numerical deconvolution method 
described by Vaughan and Dennis (1976) Statistical moment analysis of the 
absorption function H (t) yielded the systemic bioavailability (h ) and the 
mean absorption time (MAT) 
«· 
h = AUH = I H (t) dt, and 
a a a 
о 
MAT = TAUH /AUH = J f H (t) dt / I H (t) dt 
a a a a 
о о 
Modal absorption time (ModAT), the time of maximum absorption rate, was esti­
mated as such from the H (t) profile, while median absorption time (MedAT), at 
which half the available dose is absorbed, was calculated as 
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MedAT 
1 H (t) dt = i h 
a a 
о 
For a rapidly absorbed drug like Q sulfate H (t) need not be calculated ad 
infinitum In practice, the upper integrand '^ ' may be replaced by the time at 
which the oral plasma curve attains its terminal phase of decline 
The oral (C (t), t) data were also fitted to a triexponontial equa-
2 -t/'i -t^o 
С (t) = I A (e - e ) 
or ι 1 
In fitting the double-peaked curves of subjects 1 and A, two doses were 
assumed, the quantity and the dosage time of the 2 dose were iteratively 
optimized Again AUG, ADC and TAUC were calculated, and from these 
MRT = TAl/C/AUC - MAT, and CL = Q (Z)/AUC, 
Г Г ù 
Cumulative renal excretion, Q (t), was fitted to a sum of three 'l minus' 
exponentials 
CL(t) = CL [ Ι Α ίτ ·(! - e Ъ - τ 'U-e 0)) ] 
Again, from the A and τ obtained in the latter fit, mean urinary excretion 
1 1 
time (MET) of Q uas c a l c u l a t e d in analogy t o MRT 
14 3 RESULTS 
Intravenous dosing The plasma concentration vs tinn> plot following 
intravenous infusion of 150 mg of Q in a representative subject, and the Q 
transport function ψ(ί) in this subject are shown in figure 1 (left) Follow­
ing an initial rapid decrease in the plasma Q concentration (τ. = 3 56 ± 0 69 
m m ) , the terminal declining part of the curve was characterized by mean (± 
SD) time constants of τ = 12 25 ± 1 82 h, corresponding to terminal elimina­
tion half-lifes of 8 49 ± 1 26 h The Q transport function (or unit impulse 
response function) if>(t) may be viewed as a frequency distribution of residence 
times and therefore is proportional to the plasma concentration profile after 
ι ν injection of Q (Van Rossum et al 1983) Time constants and corresponding 
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FIGURE 1. (Top) Plasma concentration profiles of quinine in subject 7 follow 
mg (left) i.v. infusion of 150 mg over 12 mm, (right) ingestion of a gela­
tine capsule containing qumme sulphate. (Bottom left) Total body transport 
function ф(і) of quinine m this subject (displayed on two time scales) ... 
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TABLE I SUBJECT CHARACTERISTICS, AND CURVE FIIflNG DATA OF QUININE 
FOLLOWING I V INFUSION OF 150 HG OVER 12 MIN IN 7 HUMAN SUBJECTS 
Subj 
1 
2 
3 
4 
5 
6 
7 
MEAN 
± SD 
Sex 
m 
m 
m 
m 
f 
f 
f 
Age 
yrs 
23 
24 
32 
28 
21 
23 
22 
25 
4 
ВЫ 
kg 
72 
84 
77 
67 
64 
5Í 
63 
69 
9 
Med/ 
Ind 
Q,A 
A 
A 
-
-
V 
Q 
Α
ι 
mg/1 
12 
3 
5 
2 
3 
8 
7 
6 
3 
73 
12 
36 
75 
12 
41 
32 
12 
66 
A2 
mg/г 
0 
71 
24 
39 
55 
86 
89 
18 
55 
29 
τ
ι 
mm 
2 
4 
3 
3 
3 
3 
4 
3 
0 
44 
13 
53 
63 
52 
09 
57 
56 
69 
Z2 
h 
12 
13 
10 
14 
9 
12 
13 
12 
1 
3 
2 
8 
2 
1 
3 
9 
3 
a 
AUC 
mg'h/l 
21 
16 
15 
22 
17 
23 
17 
19 
3 
5 
6 
3 
2 
0 
7 
0 
0 
3 
AUCZ 
mg'h/l 
20 
16 
15 
21 
16 
23 
16 
18 
3 
9 
1 
1 
2 
9 
1 
3 
5 
1 
TAUl 
mg'h: 
259 
218 
163 
315 
154 
289 
230 
233 
61 
ВЫ = body weight, Med/Ind = medication and drugs of indulgence V - user of 
® 
Ventolin (salbutemol), Q = regular drinker of soft drinks containing quinine, 
A ~ modest consumer of alcohol (± 10 g/day) 
TABI E II PHARMACOKINETIC PARAMETERS OF QUiNINE AS CALCULATED FROM THE PLASMA 
CONCENTRATION VS TIME PROFILE DURING AND FOLLOWING INTRAVENOUS INFUSION 
Sub j 
1 
2 
3 
4 
5 
6 
7 
MEAN 
± SD 
h 
8 5 
9 2 
7 5 
9 9 
6 3 
8 5 
9 6 
8 5 
1 3 
MRT 
h 
12 
13 
10 
14 
9 
12 
13 
12 
1 
0 
1 
5 
1 
0 
1 
4 
0 
8 
CL 
Uh 
6 
9 
9 
6 
8 
6 
8 
8 
1 
For calculation 
taken 360 11 h 
99 
05 
81 
76 
82 
33 
82 
08 
36 
of 
V. dss 
l 
84 
118 
103 
95 
79 
77 
119 
96 
18 
F 
Ζ 
1 
2 
2 
1 
2 
1 
2 
2 
0 
Ε, MTT, 
9 
5 
7 
9 
5 
8 
5 
3 
4 
MTT 
mm 
14 
20 
17 
16 
13 
13 
20 
16 
3 
and Ν , 
ГС 
N 
rc 
50 
39 
36 
52 
40 
56 
40 
45 
8 
the 
QT(2) 
mg 
30 2 
18 3 
17 7 
25 2 
16 9 
30 8 
23 4 
23 6 
5 4 
subjects 
CL 
Γ 
l/h 
1 
0 
;' 
44 
14 
17 
18 
00 
33 
44 
26 
18 
cardi 
MET 
h 
11 
12 
9 
14 
9 
11 
12 
11 
2 
\ac 
1 
8 
2 
6 
3 
4 
7 
6 
0 
ou, 
pH 
6 1 
5 9 
5 7 
6 0 
6 2 
5 7 
5 5 
5 9 
0 2 
tput С 
UFR 
ml/h 
89 
56 
50 
55 
26 
87 
60 
60 
22 
0 w 
t , = 1η2·\ - 0 693 τ , pH = mean urmary pH, UFR = mean urine flow rate 
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concentration coefficients for the individual subjects have been listed in 
Table I, together with the derived statistical moments AUG, (AUC_) and TAUC 
The pharmacokinetic parameters calculated from the fitted data are giv­
en in Table II The mean residence time was about 12 0 h Total clearance of Q 
averaged 8 09 ± 1 36 i/h and its mean apparent volume of distribution amounted 
to 96 5 ± 17 7 t (mean ± SD) During each circulation transit through the 
body, a fraction E = 2 3 ± 0 4 % o f Q molecules is extracted by biotransforma­
tion and excretion On the average a Q molecule is able to make N = 4 5 body 
transits before being eliminated one way or the other, transits lasting 16 1 ± 
2 9 m m (= MTT) on the average 
Following the infusion, 15 5 ± 3 9 % of the Q dose was recovered 
unchanged in subjects' urine over a period of 45 h The cumulative renal 
excretion curve of subject 3 is shown in figure 3 Renal clearance amounts to 
1 26 ± 0 18 l/h and is independent of plasma Q concentration in the range of 
concentrations attained during the experiments) as indicated by linearity of 
Q (Θ) versus AUG. plots in all subjects, where β are times of urine voiding 
Urinary recovery for none of the subjects was elevated discernably following 
hydrolytic enzym treatment of urines prior to analysis Mean urinary excretion 
times of Q in each subject correlated reasonably with mean residence times in 
plasma (ЧЕТ = 11 6 ± 2 0 h, mean ± SD) 
Oral dosing The plasma concentration-time profile following ingestion 
of Q sulfate in a gelatine capsule by subject 7, and the absorption rate ver­
sus time profile in this subject are shown in figure 1 (right) Q is rapidly 
absorbed, mean absorption times ranging from 1-2 h (mean ± SD 1 42 ± 0 34 h) 
Averaged median and modal absorption times are virtually equal (1 26 h) and 
slightly smaller than the MAT, indicating slight tailing of absorption Sys­
temic availability of Q averaged (± SD) 0 90 ± 0 18 (range 63 - 113 %) Indi­
vidual absorption times are listed in Table III 
Mean residence time, mean urinary excretion time, and renal clearance 
after oral administration were almost identical to the values observed after 
ι ν dosing (Table III) In accordance with incomplete bio-availability, total 
urinary excretion of unchanged Q was somewhat less after ingestion (13 4 ± 4 0 
% of dose, mean ± SD) than after ι ν dosing The cumulative renal excretion 
of Q in subject 3 after oral dosing is included in figure 3 In five of the 
subjects, urinary recovery of Q was not changed by more than 1% after enzymat­
ic hydrolysis of urine specimens However, 45 h-pooled urine of subjects 1 and 
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TABLE III. CURVE FITTING DATA AND PHARMACOKINETIC PARAMETERS OF QUININE 
AFTER ORAL ADMINISTRATION OF 2.0 МСЩС? OF QUININE IN A GELATINE CAPSULE 
Subj MAT MedAT HodAT h AUG AUC TAUG MRT Q (Ζ) CL MET pH UFR 
h h h Ζ mg'h/l mg'h'/l h mg l/h h ml/h 
l' 1.53 1.43 1.64 72 14.6 13.7 191 11.6 18.4 1.34 11.3 6.1 71 
2 1.54 1.46 1.49 113 16.8 15.3 270 14.0 18.С 1.18 13.7 6.1 70 
3 1.33 1.26 1.19 63 10.0 9.8 126 11.3 11.0 1.12 11.6 5.6 60 
4 0.97 0.72 0.82 84 19.7 18.9 293 13.9 20.5 1.09 14.5 6.4 94 
5 1.05 0.76 0.66 97 13.1 12.9 130 S.9 13.3 1.03 9.1 5.6 38 
6 1.99 1.75 1.76 96 15.9 15.3 227 12.3 21.7 1.42 12.1 5.6 81 
7 1.57 1.40 1.28 105 12.9 12.3 189 13.2 18.6 1.50 13.4 6.0 52 
MEAN 1.42 1.25 1.26 90 14.7 14.0 204 12.2 17.3 1.24 12.2 5.9 67 
± SD 0.35 0.38 0.41 18 3.1 2.8 64 1.8 3.8 0.18 1.8 0.3 19 
pH = mean urinary pH, UFR = mean urine flou rate 
Subject 1 was administered 1.5 mg/kg of oral quinine (oral pilot study). 
MAT, MedAT
>
 ModAT, and h for subjects l
w
 and 4 apply to the first absorp­
tion peak. The other parameters listed for these tuo subjects were not cor­
rected for secondary absorption; as estimation of the amount of drug 
involved in secondary absorption was considered inaccurate (because of lack 
of sufficient plasma concentration data in the time interval of secondary 
absorption), and because this amount vas small anyway (й 12 Ζ of the oral 
dose). 
4 showed 5.4 and 4.7 mg increments of Q content (5.0 and 3.5 % of dose) 
respectively, after hydrolysis of Q conjugates. 
In these same two subjects, a second plasma concentration peak was 
observed aproximately 6 h after oral dosing. The dual-peaked plasma concentra­
tion - and the absorption rate - versus time profiles for subject 1 is shown 
in figure 2. The amounts of Q giving rise to the second peak in plasma concen­
tration profiles, and hence in the absorption rate profiles of subjects 1 and 
4, came to 11.2 *. and 5.6 % of oral dose, respectively. 
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FIGURE 2 Time profiles of (top) plasma concentration and (bottom) gastro­
intestinal absorption rate of quinine m subject 1 after swallowing quinine 
sulphate m a capsule Note the dual peaks m both profiles, and the analogy 
of this figure to the right part of figure 1 
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cumulative renal excretion (mg) 
2 0 0 -ι 
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time (h) 
FIGURE 3 Cumulative renal quinine excretion by subject 3 as a function of 
time as observed after (o) a 12 mm I ν infusion of ISO mg, and (*) oral 
administration of 153 mg as a capsule The latter curve runs louer as a result 
of the small systemic availability of the oral quinine dose m this subject. 
14 4 DISCUSSION 
Few pharmacokinetic reports deal in a detailed way with Q kinetics 
after ι ν administration (Vhite et al 1982, White et al 1983a) or after 
oral administration (Berlin et al 1975, Wanuimolruk et al 1986) to healthy 
adults or patients convalescing after an attack of falciparum malaria While 
largely confirming the results of these earlier studies, new information with 
respect to bioavailability, disposition and excretion of Q is provided by the 
intra-individual comparison of Q pharmacokinetics after its administration by 
ι ν infusion and per os as the most kidely used preparation, the sulfate salt 
in α gelatin capsule, and by the employment of chromatographical analysis in 
this study, rather than a double extraction (Cramer and Isaksson 1963) or pro­
tein precipitation assay (Brodie et al 19A3), both of which are thought to 
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quantitate Q metabolites in various degrees (Trenholme et al 1976, Edstein et 
al 1983, White 1985) 
Distribution and disposition The only pharmacokinetic report of ι ν Q 
administration to healthy man is the publication by White et al (1983a) who 
gave 5 rag/kg of Q over a 5 ram infusion to 7 male Thai subjects In the 
present study in Caucasian subjects, a mean dose of 2 2 mg/kg was infused over 
12 min 
In both studies a biexponciitial decay of plasma Q was observed after 
termination of the infusion, characterized by time constants of 'distribution' 
and 'elimination' phases of a few minutes, and many hours, respectively Mean 
terminal half-life and apparent volume of distribution of Q observed in 
White's subjects both are somewhat larger than in the present subjects (11 1 
vs 8 5 h, and 1 8 vs 1 4 î/kg, resp ), whereas mean total clearances were 
essentially the same (115 vs 117 mt/h/kg) See Tables I and II Berlin et al 
(1975) observed increasing individual half-lifes and distribution volumes with 
increasing Q dose, clearance remaining constant Thus, discrepancies in the 
two former kinetic parameters in White's study (1983a) and the present one 
could reflect a dose dependence of Q kinetics However, calculation of distri-
bution volume and, hence, total clearance as performed by Berlin et al is 
highly questionable, and dose dependence of Q kinetics remains to be confirmed 
in other studies In particular, Q pharmacokinetics were similar after 10 and 
20 mg/kg initial doses to patients with cerebral malaria (White et al 1983b) 
Plasma Q levels in the latter study (10-15 mg/I) significantly exceded those 
produced by Berlin and colleagues (1975) in their volunteers (<10 mg/î) 
Sex, genetics influences, and differences in environmental factors such 
as diet, smoking, and habitual consumption of alcohol and xanthine beverages, 
might as well underly the observed differences in Q half-life and distribution 
volume of our subjects and those of White et al (1983a) Differences in 
kinetic parameters between patients convalescing from malaria (White et al 
1982) and the normal volunteers m this study in addition may result from 
malaria-induced changes of Q kinetics (e g , as a result from altered plasma 
protein binding of Q Silamut et al 1985) that may still be apparent in these 
patients to a certain extent 
Absorption and availability Q sulfate is the most frequently used oral 
Q preparation (White 1985) The present study has shown that in healthy sub-
jects oral Q, formulated as a powder in a gelatine capsule, becomes available 
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rather rapidly (ЧАТ = 1 4 h) and rather completely (averaged 0 90) Extent of 
availability is comparable to the study of Hall et al (1973), in which oral 
administration of Q sulfate in gelatine capsules produced plasma Q levels and 
amounts of excreted Q that were 10-20 % lower than corresponding figures 
obtained after ι ν infusion of Q Similar results were obtained by Uanwimol-
ruk and co-workers (1986) who (over-) estimated total clearance of oral Q sul­
fate as forai dosr)/AUC and obtained a mean figure of 10 0 i/h as compared to 
β 1 t/h in the present study Grccnblatt et al (1977), and Conrad et al 
(1977) found the availability of oral quimdme sulfate to be 0 81 (range 
0 61 - 1 08) and 0 87 (range 0 62 - 1 20), respectively Q and quimdine are 
stereoisomers (diastereomers), which on the basis of their almost identical 
physico-chemical properties (Notterman et al 1986) may be hypothesized to 
have similar absorption kinetics As the relatively low soluble Q sulfate was 
found to be 90% bioavailable, at least equally complete availability may be 
anticipated for equivalent formulations of more soluble Q salts like the di-
and monotndrochloride, and for aqueous solutions (or soft drinks) of Q Plain 
and sugar-coated tablets at these Q sails appear to be less well absorbed 
(Garnham et al 1976) 
Incompleteness of systemic availability of oral Q preparations may as 
well m part be due to first-pass metabolism of these drugs Computing hepatic 
Q clearance (CL ) as the difference of total and renal clearance of Q, and 
m 
estimating hepatic blood flow (V, ) as 90 t/h in our healthy subjects, the 
quotient CL /V. in case of linear first-pass kinetics represents the first-
pass extraction ratio, averaging 74 « in our subjects 
Data on the rapidness of GI absorption of Q are scarce Wanwimolruk et 
al (1986) recorded peak plasma levels of Q to occur 1 5 h after ingestion of 
the sulfate salts Ochs et al (1980) collected and summarized literature data 
on quimdine absorption after oral administration In ten different studies 
using quimdine sulfate tablets, and two additional ones concerned with a cap­
sule and an aqueous solution of this salt, peak plasma levels were perceived 
at 1 0 - 3 1 h (mostly li-2 h) after dosage Reported absorption half-lifes 
varied from 14 to 38 min 
While these data at first sight compare fairly well to the absorption 
times listed in Table III, it should be remarked that, firstly, time intervals 
elapsing between dosing and plasma peaks provide no insight into the course of 
the absorption process, and secondly, that the specification of first-order 
absorption half-lifes (t, ) or rate constants (k ) implicates the assumption 
of a (mono-) exponential decline of absorption rate with time 
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Considering the complex concerted action of fluctuating factors affect-
ing absorption rate, such as dissolution rate of solid drug formulations, rate 
of gastric emptying, intestinal peristaltics, pH-gradient, and drug dispersion 
to, and consequent simultaneous absorption from various intestinal sites at 
different rates, it is obvious that the assumption of first-order absorption 
kinetics in general is an oversimplification which can only serve as a crude 
first approximation of the absorption process. Limiting ourselves to Q and 
quinidine, our argumentation is supported by the frequently noticed bumpy 
appearance of plasma concentration-time profiles after oral dosing of these 
drugs (present study; Greenblatt et al. 1977; Salvador! et al. 1982; Sawyer et 
al. 1982). Moreover, absorption profiles derived from 'smooth' oral curves, as 
obtained for subjects 2,3, and 5-7 in the present study (for subject 7, see 
figure Ic/d), neither show evidence of exponential decline, though the pro-
files slightly tail as indicated by the somewhat larger MAT compared to MedAT 
(Table III). 
Calculation of the absorption rate profile by numerical deconvolution 
of the oral plasma curve and the drug's transport function is generally appli-
cable as it assumes only linearity of kinetics and time-invariability of drug 
distribution and disposition. Fickleness of absorption, the rule rather than 
the exception, thus is left in its own right. Only the ascending leg and the 
peak(s) of the oral plasma curve is needed for calculation of the absorption 
rate profile H (t). As soon as the oral curve comes up to its terminal declin-
ing part, absorption in general has stopped; the remainder of oral concentra-
tion data are irrelevant for H (t) computation. For drugs having a mean resi-
dence time that is great compared with the mean absorption time of a 
particular formulation of this drug (as in the present case: 12.2 h = MRT » 
MAT = 1.4 h), the time interval in which absorption takes place constitutes 
only a minor fraction of total time of bloodsampling. In this condition, early 
cutting off oral data at twice or thrice the MAT renders the calculated 
absorbed amount of drug highly independent of intra-individual variability in 
disposition kinetics. Such variability has been observed for caffeine (Teeuwen 
1987) and for many other drugs (Rowland 1980) and may seriously affect calcu-
lations of absorbed drug fractions using 'whole curves' as does Dost's widely 
used law of corresponding areas (AUG ratio method): h = AUG /AUG · 
D. /D As Q elinination kinetics in the present study were individually iv or ' ' 
invariable, the AUG ratio method should yield a similar estimate of systemic 
availability of Q after oral dosage. It did: h = 0.87 ± 0.11. 
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Absorption times of subject 6 were greater than in any of the other 
subjects, though the differences just failed to reach significance (for MAT 
and MedAT, Ρ = 0 1 as judged by Dixon's test) Subject 6 at the time of the 
experiments happened to be under clinical observation because of vague diges­
tive disturbances' recurring irregularly in fits persisting for some weeks 
These disturbances eventually were diagnosed as sprue As in this disease 
absorptive area is reduced by atrophy of intestinal villi, retardation of 
absorption in this subject is comprehensible Extent of absorption neverthe­
less was virtually complete in this subject 
Conditions that may impair GI absorption in complicated falciparum 
malaria include vomiting, jejunitis, and intestinal lesion associated with 
acute falciparum malaria (Olsson & Johnston 1969, Karne> & Tong 1972) As both 
rate and extent of Q absorption may be significantly reduced, in these condi­
tions Q infusion is the preferred choice of administration 
Renal excretion After ι ν administration of Q, 15 5 ± 3 9 1 of the 
dose was excreted unchanged in our subjects' urine, whereas, consistent with 
incomplete availability, after oral dosing only 13 4 ± 4 0 % was recovered 
Excreted fractions in the present study largely confirm the findings of other 
investigators, though being rather small Hall et al (1973) and hhite et al 
(1982) recovered 19 and 22 » Of intravenous Q m urine voided by convalescing 
malaria patients, while Hall et al (1973) and Brooks et al (1969) came 
across 15 and 17 X of oral Q sulfate (as tablets) in their convalescing 
patients' urine on the average 
As the period of urine collection in the present experiments must be 
considered long enough for excretion to be virtually complete (AUC./AUC S 
0 94), genetic and environmental factors or disease-altered kinetics as men­
tioned before could underly the differences in excreted fractions Alterna­
tively, the extraction-fluorescence assay employed by the cited authors may 
co-quantitate Q-metabol ites that are separated from Q in the HPLC assay 
employed m this study Significantly, when comparing their HPLC assay with 
extraction-fluorescence, Edstein et al (1963) observed 37% higher plasma 
'quinine' levels using the latter method 
Mean urinary pH and flow did not differ between oral and ι ν experi­
ments (cf Tables II and III) Renal clearance did not differ either and aver­
aged 1 26 1/h which is close to the value calculated by Notterman et al 
(1986) on the basis of HPLC anal>tical results (1 3 £/h) As Q in healthy 
individuals is bound to plasma proteins for some 90*» (Silamut et al 1985, 
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Notterman et al. 1986), renal clearance of unbound Q ranges from 10 to 15 l/h 
in our subjects, probably exceding glomerular filtration rate in each of them. 
It is concluded that tubular secretion contributes to renal Q clearance as 
established previously by Notterman et al. (1986). 
Systemic availability of oral Q as estimated from excreted percentages 
of Q after oral and i.V. administration mounts to 0.86 ± 0.11 and is compara-
ble to the availability estimates from plasma data either by numerical decon-
volution or by AUC ratio method. 
Multiple plasma peaks, food intake, and enterohepatic circulation. Mul-
tiple plasma concentration peaks like those observed in subjects 1 and 4 some 
6-8 h after oral administration of Q were also observed by Salvador! et al. 
(1982) in their one pilot subject, and by Sawyer (1982), Greenblatt (1977) and 
their respective co-workers in part of their subjects after oral administra-
tion of quinidine. Subjects in these studies and the present one were sober 
until 3-4 h after oral administration, and then were allowed to have lunch. 
Renewed absorption of drug left behind in the GI tract hence could result fron 
stimulation of intestinal motility after food intake. This interpretation of 
dual peak pattern implicates that true systemic availability of Q for subjects 
1 and 4 should be augmented by the amounts absorbed in second instance, yield-
ing h = 0.84 and h • 0.90 respectively (cf. Table III). Importantly, multi-
ple peaks have never been observed after intravenous administration of Q or 
quinidine to our knowledge. 
However, the coincidence of dual plasma peaks and urinary excretion of 
notable amounts of conjugated Q in the same two subjects suggests some kind of 
relationship between these phenomena. The link could be enterohepatic circula-
tion of Q in subjects 1 and 4, as suggested by Sawyer et al. (1982) to effect 
dual plasma peaks of quinidine in two of their subjects. Food intake again 
might play a triggering role, by increasing bile production and biliary secre-
tion of Q, whether or not in conjugated form. Unfortunately, Sawyer et al. 
(1982) and Greenblatt et al. (1977) did not perform urine analysis. Salvador! 
et al. (1982) did, and recovered 20" more Q in their subject's urine with a 
preliminary enzymatic hydrolysis than without one. This figure compares fairly 
well to the 29 and 23 X elevations of Q recovery in the 45 hours pooled urine 
of our subjects 1 and 4, respectively, due to enzymatic pretreatment. 
If dual peaks in these subjects result from enterohepatic circulation, 
then their absence after i.v. administration may implicate that first-pass 
metabolism by gut wall or liver is related to the enterohepatic cyclus. As 
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remarked earlier, about 71 % of absorbed Q may be extracted in during the 
first liver passage The amount of Q accumulated in the liver during the first 
pass may persist for some hours, and may then be biliary secreted in bulk 
after food intake by the subject, be re-absorbed, and give rise to a pro­
nounced secondary peak This intngueing matter requires future attention 
A C K N O W L E D G E M E N T S 
The authors wish to acknowledge the excellent cooperation of the sub­
jects, the valuable advice of Yuen Tan with regard to the enzymatic hydroly­
sis, and the skillful assistance of Mrs Helene Amadjais in the preparation of 
the experiments 
14 5 REFERENCES 
Berlin CM, Stackman JM, Vesell ES (1975) Quinme-induced alterations In drug 
disposition Clin Pharm Ther 18 670-9 
Brodie BB, Udenfriend S (1943) The estimation of quinine in human plasma with 
a note on the estimation of quinidine J Pharmacol Exp Ther 78 154-β 
Brooks ЧН, Malloy JP, Bartelloni PJ, Sheehy TV, Barry KG (1969) Quinine, 
pyrimethamine, and sulphorthodimethoxine clinical response, plasma lev­
els, and urinary excretion during the initial attack of naturally acquired 
falciparum malaria Clin Pharmacol Ther 10 85-91 
Conrad KA, Molk BL, Chidsey CA (1977) Pharmacokinetic studies of quinidine in 
patirnts with arrhythmias Circulation 55 1-7 
Cramer G, Isaksson В (1963) Quantitative determination of quinidine in plasma 
Scand J Clin Lab Invest 15 553-6 
Edstein M, Stace J, Shann F (1983) Quantification of quinine in human serum by 
high performance liquid chromatography J Chromat 278 445-51 
Garnham JC, Raymond K, Shotton F, Turner Ρ (1976) The bioavailability of qui­
nine J Trop Med Hyg 79 264-9 
Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke К, MacLaughlin DS, Smith TW, Koch-
Weser J (1977) J Pharmacol Exp Ther 202 365-78 
Hall AP, Czeruinski AW, Madonia EC, Evensen KL (1973) Human plasma and urine 
quinine levels following tablets, capsules, and intravenous infusion Clin 
Pharm Ther 14 580-5 
274 
Karney WW, Tong MJ (1972) Malabsorption in Plasmodium falciparum malaria. Am J 
Trop Med Hyg 21 1-5 
Notterman DA, Drayer DE, Metakis L, Reidenberg MM (1986) Stereoselective renal 
tubular secretion of quimdine and quinine Clin Pharmacol Ther 40 511-7 
Ochs HR, Greenblatt DJ, Woo E (1980) Clinical pharmacokinetics of quimdine. 
Clin Pharmacokin 5 150-168 
Olsson RA, Johston EH (1969) Histopathologic changes and small-bowel absorp­
tion in falciparum malaria Am J Trop Med Hyg 18. 355-9 
Rowland M (1980) Intra-individual variability in pharmacokinetics In Breimer 
DD (ed) Towards better safety of drugs and pharmaceutical products. 
Elsevier/North-Holland Biomedical Press, New York, pp 143-51 
Salvador! C, Fannotti R, Dauphin A, Mahuzier G (1982) Dosage de la quinine 
dans le plasma et l'urine par chromatographic en phase liquide Ann Biol 
clin 40 667-72 
Sawyer WT, Pulliam CC, Mattocks A, Foster J, Hadzija BW, Rosenthal HM (1982) 
Bioavailability of a commercial sustained-release quimdine tablet compared 
to oral quimdine solution. Biopharm Drug Disp 3 301-310 
Sllamut K, White NJ, Looareesuwan S, Warrell DA (1985) Binding of quinine to 
plasma proteins in falciparum malaria Am J Trop Med Hyg 34 661-6 
Teeuwen HWA (1988) Clinical pharmacokinetics of nicotine, caffeine and qui­
nine A systems dynamics approach Ph D Thesis, University of Nijmegen, 
Ni]megen, The Netherlands 
Trenholm GM, Williams RL, Rieckmann KH, Frischer H, Carson PE (1976) Quinine 
disposition during malaria and during induced fever. Clin Pharm Ther 19: 
459-67 
Van Rossum JM, Burgers J, Van Lingen G, De Bie J (1983) Pharmacokinetics, a 
dynamic systems approach. TIPS 41 27-30 
Vaughan P, Dennis M (1978) Mathematical basis of point-area deconvolution 
method for determining in vivo input functions J Pharm Sci 67. 663-665 
Wanwimolruk S, Sunbhanich M, Pongraarutai M, Patamasucon Ρ (1986) Effects of 
Cimetidine and ranitidine on the pharmacokinetics of quinine Br J clin 
Pharmac 22 346-50 
Warburton A, Royston JP, O'Neill CJA, Jee RD, Denham MJ, Dobbs SM, Dobbs RJ 
(1987) A quinine a day keeps the leg cramps away7 Br J clin Phaimac 23: 
459-65 
White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta Τ 
(1982) Quinine pharmacokinetics and toxicity in cerebral and uncomplicated 
falciparum malaria. Am J Med 73· 564-572 
275 
White NJ, Chanthavanich P, Krishna S, Bunch С, Silaœut К (1983а) Quinine dis­
position kinetics. Br J clin Phannae 16: 399-403 
White NJ, Looareesuuan S, Varrei DA, Warrell MJ, Chantavanich P, Bunnag D 
(1983b) Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 32: 1-5 
White NJ (1985) Clinical Pharmacokinetics of antimalarial drugs. Clin Pharma-
cokinet 10: 187-215 
Yamaoka K, Nakagawa T, Uno Τ (1978) Statistical moments in pharmacokinetics. J 
Pharaacokin Biopharm 6: 547-58 
276 
POSTFACE 
APPENDIX I. SYNTHESIS OF 4,,4'-DIDEUTERO COTININE 
The synthetic route to 4',4'-dideutero cotinine consisted of eight steps: 
Step 1 An amount of 184 ml (2.5 Moles) of SOCI was added drop by drop to 
123 g (1 Mole) of nicotinic acid. The mixture was reflux-boiled for 2.5 h. The 
excess of SOCI, uds evaporated The resulting light-yellow colored solid was 
dissolved in a mixture of 160 mt (2 Moles) of pyridine and 100 ml of CH CI . 
While stirring, a solution of 85 g (1 Mole) of pyrrolidone in 50 ml of CH.C1. 
was added in drops, followed by reflux-boiling (15 min) and stirring (19 h, 
ambient temperature) of the reaction mixture. Subsequently a 500 mt solution 
of NaHCO, (1.1 Moles) was added and the reaction product was extracted with 
CH CI The extract was dried over MgSO,. Then the CH.Cl. was distilled off to 
yield a black solid, which was recrystallized three times in ethyl acetate to 
produce light-yellow colored needles of N-nicotinoyl-2-pyrrolidinone (m.p. = 
102-103'). The yield was 56 g (29 X). 
Step 2. 39 g (205 mMoles) of N-nicotinoyl-2-pyrrolidinone and 31 g (205 
mMoles) of ethyl nicotinate were dissolved in 300 mt of dry THF. The solution 
was heated to 70' and added in drops to a suspension of 5.28 g (220 mMoles) of 
NaH in 100 ml of dry THF (75*). The reaction mixture was kept under an argon 
atmosphere for 60 h at 70' and then was cooled to 0* by addition of ice and 
pH-neutralized with concentrated HCl. Extraction with CH.Cl. and evaporation 
of this solvent after drying over MgSO, gave l,3-dinicotinoyl-2-pyrrolidone. 
Yield· 45 g (74 X). 
Step 3. 45 g (153 mMoles) of crude 1,3-dinlcotinoyl-pyrrolidone was dis-
solved in 200 rot of concentrated HCl (37 %). The solution was reflux-boiled 
until no more carbon dioxide evolved (approximately 2} h). The solution was 
cooled to 0' and rendered slightly alkaline by addition of an appropriate 
amount of K.CO, The reaction product was subsequently extracted with CHC1, 
and dried over MgSO . The CHC1 was evaporated to produce 10 g of a dark-brown 
oily residue, which was purified by bulb to bulb distillation (Kugel rohr) at 
160° and 4 Torr to yield 8.5 g (38 %) of the white solid myosmine as confirmed 
by the -NMR spectrum of the reaction product. 
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Step 4 The glassware used in this step uas dried in an oven at 110' and 
100 Torr 8 5 g (58 mMoles) of myosmine were dissolved in 50 mí of D O (99 75 
%), and 3 g of K.CO. (dried overnight at 150' and 100 Torr) was added The 
solution was stirred for 5 days at 85* Then the reaction product was 
CHC1 -extracted, dried, and concentrated The yield was 6 5 g of 
31,3*-dideutero-myosmine (76 *) 
Step 5 6 5 g (44 mMoles) of 3',3 '-dideutero-myosmine was dissolved in 500 
mi of an ethanol-water mixture (1 3, v/v) 3 34 g (88 mMolesO of NaBH was 
added and the suspension was stirred for 7 days at ambient temperature The 
reaction product was extracted with five 150 mfc-portions of CHC1«, dried over 
MgSO,, and the solvent was removed by distillation Yield 6 15 g (93 %) of 
3',3'-dideutero-nornicotine, a light-yellow colored oil 
Step 6 6 15 g (41 mMoles) oí 3',3'-dideutero-nornicotine and 6 8 g (68 
mMoles) of N(C1I CH ) was dissolved in 200 mi of diethyl ether A solution of 
4 47 g (41 mMoles) of C1C00CH CH. in another 100 mi of diethyl ether was slow-
ly added while stirring After 5 min the reaction mixture was filtrated and 
the filtrate concentrated by ether evaporation The residue consisted of 8 4 g 
(92 %) of (N-ethoxy-carbonyl)^' ,4 ' -dideutero-nornicotane 
Step 7 8 4 g (38 mMoles) of (N-ethoxy-carbonyO-S' ,3'-dideutero-
nornicotine was dissolved in 100 mi of dry THF and added drop by drop to a 
well-stirred solution of 3 g (80 mMoles) of LiAlH in another 200 mi of dry 
THF The reaction mixture was stirred for 50 h at ambient temperature There-
after it was cooled to 0°, and 5 mi of aqua dest , 3 mi of a 15 % NaOH-
solution, and another 5 mi of aqua dest , respectively, were added Subse-
quently the reaction mixture was filtrated, the filtrate was extracted With 
diethyl ether, washed with two 5 mi-portions of aqua dest , dried over MgSO, 
and concentrated The yield was 5 8 g of a light-yellowish oil, which was 
purified by bulb to bulb distillation (Kugel rohr) (84°, 0 5 Torr) to yield 
3 4 g (55 X) of a colorless oily liquid 3',3'-dideutero-mcotine 1 g of the 
latter compound was stored as such and hence was not subjected to the final 
step 
Step 8 To a well-stirred solution of 2 4 g (14 6 mMoles) of 
3' ,3' -dideutero-mcotine in 10 mi of acetic acid (80 %) a solution of 5 mi of 
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bromine in another 15 mí of acetic acid (80 %) was added m drops The reac-
tion mixture was diluted with a 75 mi aliquot of distilled water and heated to 
80' until the deuterated nicotine was dissolved Then it was cooled slowly to 
4° and stirred for 16 h The solid reaction product (3',3'-dideutero-mcotine 
perbromide) was suspended in 50 mi of 5 N HCl 11 g of zinc powder was added 
gradually in the course of 3 5 h The suspension was stirred for one more 
hour Then the pH of tho suspension was set to 8 - 9 with ammonia The reac-
tion product was extracted with four 150 m£-portions of CH CI and dried over 
MgSO, The CH CI was distilled off to yield 1 4 g (54 %) of the colorless 
oily-appearing 4',4'-dideutero-cotinme (cotinine-D2), which was stored in an 
inert argon atmosphere The overall reaction yield of the eight successive 
synthesis steps was approximately 1 % 
Purity checks The thus synthetized cotinine-D2 was found to be £ 99% chem-
ically pure by spectrometncal (UV, IR, and H-NMR) and Chromatograph i cal-
spectrometrical techniques (reversed-phase HPLC with UV-monitoring at 254 nm, 
GC-NSD, GC-MS) 
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APPENDIX II THE LAPLACE TRANSFORM 
Definition of the Laplace Transform and its Inverse 
The Laplace transform is defined in the following manner Let F(t) be a real 
function of a real variable t defined for t > 0 Then 
£{F(t)} = F(s) Ξ lim J F ( t ) e " S t d t , for 0 < ε < -
ε|0 ε 
is called the Laplace transform of F(t) s is a complex variable defined by s 
= ο + ιω, where σ and и are real variables and ι is the basic imaginary num­
ber, equal to /(-1) 
Note that the lower limit on the integral is t = ε > 0 This definition of 
the lower limit is sometimes useful in dealing with functions which are dis­
continuous at t = 0 The real variable t always denotes time 
If F(t) is defined and single-valued for t > 0 and F(a) is absolutely con­
vergent for some real number σ , that is, 
-0 t 
lim ƒ |F(t)|e 0 dt < -, for 0 < с < -
tiO о 
then F(t) is Laplace transformable for Re(s) = σ > о 
The Laplace transforms a problem from the real variable time domain into the 
complex variable s domain After a solution of the transformed problem has 
been obtained in terms of s, it is necessary to invert' this transform in 
order to obtain the time domain solution The transformation from the s domain 
into the t domain is called the inverse Laplace transform Let F(s) be the 
Laplace transform of a function F(t), t > 0 The contour integral 
c+i-
£ {F(s)) Ξ F(t) = 1/(2τ!ΐ) ƒ F(s)e ds 
c-i» 
where ι = /(-1) and с > σ is called the inverse Laplace transform of F(s) 
о 
The following properties of the Laplace transform and its inverse, and the 
table of Laplace transforms given in this appendix may help to circumvent the 
actual performance of contour integrations in many instances 
xln 
Some properties of the Laplace transform and its inverse 
The Laplace transform is linear That is, if F(s) and G(s) are the Laplace 
transforms of F(t) and G(t), respectively, then £{fF(t) + gG(t)} = fF(s) + 
gG(s), where f and g are arbitrary constants 
The inverse Laplace transform is linear That is, if F(t) and G(t) are the 
inverse Laplace transforms of F(s) and G(s), respectively, then £ {fF(s) 
+ gG(s)} = fF(t) + gG(t), where f and g are arbitrary constants. 
The Laplace transform of the derivative dF/dt of a function F(t) whose 
Laplace transform is F(s) is 
£{dF/dt) = sF(s) - lim F(t) 
tlO 
t 
The Laplace transform of the integral / F(t)dt of a function F(t) whose 
о 
Laplace transforra is F(s) is 
t 
£{ J F(T)dt} = F(s)/s 
о 
The initial value F(0) of the function F(t) whose Laplace transform is 
FCs) is 
F(0) = lim F(t) = lim sF(s) for t > 0 
t+0 s·*-
This relation is called the Initial Value Theorem 
The final value F(-) of the function F(t) whose Laplace transform is F(s) 
is 
F(-) = lira F(t) = lim sF(s) for t > 0 
t-»« s-'O 
if lim F(t) exists This relation is called the Final Value Theorem 
t-»-
The Laplace transform of a function F(t/a) (Time Scaling) i s 
£{F(t /a)) = aF(as) 
where F(s) = £{F( t ) } . 
x l m 
The inverse Laplace transform of a function F(s/a) (Frequency Scaling) is 
t^iFU/a)} = aF(at) 
where t'1(F(&)) = F(t). 
The Laplace transform of the function F ( t - T ) (Time Delay) where Τ > 0 and 
F ( t - T ) = û for t < T,
 l s 
£ { F ( t - T ) } =
 e "
a T
 F ( s ) 
where F ( s ) = £ { F ( t ) } . 
•at 
The Laplace transform of the function e F(t) (Complex Translation) is 
given by 
£{e"at F(t)) = F(s+a) 
where F(s) = £{F(t)} 
The Laplace transform of the product of two functions F(t) and G(t) is 
given by the complex convolution integral 
c+iui 
£{F(t)«G(t)} = 1/(2іті) / F(u)G(s-u)du 
c-iu 
where F(s) = fíFCt)}, G(s) = £{G(t)] 
The inverse Laplace transform of the product of two transforms F(s) and 
G(s) is given by the convolution integrals 
-1 t * 
£ {F(s)»G(s)) = J F(T)G(t-T)dT = J F(t-t)G(T)dT = F(t)>-G(t) 
о о 
where £"1{F(s)} = F(t), f"1{G(s)} = G(t). 
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Some Laplace Transform Pairs useful for Dynamical Systems Analysis in 
Pharmacokinetics 
Functions in time domain 
F(t) ( t > 0) 
1 
a 
6(t) 
«(t-T) 
-at 
e 
e" a t /(b-a)(c-a) 
+ e" b t /(c-b)(a-b) 
+ e" c t /(a-c)(b-c) 
l/(b-a) (ae" a t -be" b t ) 
l/(b-a) { ( z - a ) e " a t 
-bt, 
-(z-b)e D t } 
, ,,. . . -at -bt. l/(b-a) (e -e ) 
Laplace transforms 
F(s) (= f ( F ( t ) ) 
1/s 
a/s 
1 
-Ts 
e 
-1 (s+a) 
} 
) l/{(s+a)(s+b)(s+c)} 
} 
s/{(s+a)(s+b)} 
) (s+z)/{(s+a)(s+b)} 
} 
l/{(s+a)(s+b)) 
unity 
constant 
unit impulse at t=0 
delayed impulse 
exponential 
( z - a ) e " a t / ( b - a ) ( c - a ) 
+ ( z - b ) e " b t / ( c - b ) ( a - b ) 
+ ( z - c ) e " C t / ( a - c ) ( b - c ) 
s m (ut) 
-at . . e b i n ( u t ) 
cos (wt) 
e cos (uit) 
u ( t ) or 1 
u(t-T) 
u ( t ) - u(t-T) 
l/ab (1 - b e " a t / ( b - a ) 
+ a e " b t ) / ( b - a ) > 
l/ω 2 ( l - c o s ( u t ) ) 
l/ab {z- b ( z - a ) e " a t / ( b - a ) 
+ a ( z - b ) e " b t / ( b - a ) 
l/a ( l -
e
"
a t ) 
- { ( d a 2 - e a + f ) / ( c - a ) ( a - b ) } e " a t 
-{(db 2 -eb+f)/(b-c)(a-b)}e" b t 
- { ( d c 2 - e c + f ) / ( b - c ) ( c - a ) ) e " C t 
s + z / { ( s + a ) ( s + b ) ( s + c ) ) 
2 2 (D/(S +U ) 
w/{(s+a) 2 +u 2 } 
2 2 
s/(sN-u ) 
(s+a)/{(s+a)2+0)2) 
•Ts 
1/s 
l/s e 
1/s (l-e"Ts) 
) l/{s(s+a)(s+b) 
} 
l/{s(s2+U
2)) 
) (s+z)/{s(s+a)(s+b)) 
) 
l/{s(s+a)) 
) 
) (ds2+es+f)/{(s+a)(s+b)(s+c)) 
) 
sine wave 
damped sine wave 
cosine wave 
damped cosine wave 
unit step at t=0 
delayed step 
rectangular pulse 
xlv 
Functions in time domain 
F ( t ) ( t > 0) 
Laplace transforms 
F(s) (= ¿ ( F i t ) ) 
(continued) 
, , 2 . . -at
 t -at. 1/a (1-е -ate ) 
,, 2 , - a t , , . - a t , 
1/a {z-ze + a ( a - z ) t e ) 
e "
a t
 {c+(b-ca)t} 
1/a2 ( a t - l + e " a t ) 
d/ab 
-{(a 2 -ca+d)/(a(b-a) ) )e" a t 
+{(b 2 -cb+d)/(b(b-a)) )e" b t 
t 
t n 
t™" 1 /^-!)! 0!=1 
n-1 -at ..
 ч
, t e l /(n- l ) ! 
( t / a ) k e " t / a k = 0 , 1 , 2 , 3 , . . . 
( t / a ) k e " t ' ' a kE<-l,-> 
l/ísís+a)"1) 
(s+z)/(s(s+a)2) 
(cs+b)/(s+a)2 
l/isCs+a)2} 
) 
) (s2+cs+d)/{s(s+a)(! 
) 
i/s2 
nl/.n+1 
l/s" 
(s+a)"" 
k!/{ak(s+l/a)k+1) 
5+Ь) 
unit ramp 
polynomial 
n=l,2,3,... 
n=l,2,3,... 
'gamma function' 
r ( k + l ) / { a k ( s + l / a ) k + 1 ) 'gamma function' 
x lv i 
S U M M A R Y A N D CONCLUSIONS 
This dissertation deals with the human pharmacokinetics of three alkaloids 
of plant origin on the boundary of medical and luxury drugs, which are being 
produced in huge quantities in the developing countries, and being consumed 
worldwide but especially so in western society Despite the mass consumption 
and the immemorial utilitive history of nicotine, caffeine and quinine, there 
still exist considerable gaps of knowledge with respect to the pharmacokinet­
ics and -dynamics of these drugs The research work described in the present 
dissertation was aimed at bridging some of these gaps 
The investigations are based upon a systems dynamics approach of pharma­
cokinetics As this modern approach is not (yet) generally accepted in this 
field, SECTION I, Chapter 1 as well, presents an introduction into systems 
dynamics pharmacokinetics 
Firstly the characteristics of an isolated organ or tissue regarding the 
passage of a quantity of drug injected at the arterial site are described A 
well-stirred flow vessel appears to be a reasonably good model for a single 
organ/tissue The most important features of such a single organ are the mag­
nitude of the blood flow through it, as well as the mean, median and modal 
transit times of the injected molecules 
Subsequently, bearing in mind physiology and anatomy of the human body, the 
total body (or system) is composed of the various organs and tissues (the sub­
systems) in an imaginary construction process The most prominent feature of 
the system is the blood circulation, which feeds drug output back as input in 
a proportional way and transforms the body into a so-called positive feedback 
system The dynamics of the body systeem are governed by those of the subsys­
tems, and may conveniently be summarized into the total body transport func­
tion ψ(τ) Ψ(ΐ) in essence is the probability density distribution of drug 
molecule residence times in the body, and differs for each drug and individu­
al Even intra-individually, if>(t) is a function of numerous 
(patho-)physiological processes, such as cardiac output, disease, and age 
Mathematically the concentration vs time profile of a drug in plasma (the 
drug-output) is the convolution- integral of the body transport function ψ(ί) 
and the rate at which the drug molecules reach the circulation (the drug-
input) The latter in turn depends on dosage regimen, formulation, and route 
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of administration of the drug The affection of drug input rate by formulation 
and route of administration may be condensed in the application transport 
function 
Be two of the three functions input-, transport-, and output function, 
known, then the third unknown function can be computed from the former two by 
either convolution or deconvolution The body transport function ψ(ί) of a 
drug may be derived from the plasma concentration vs time profile (output) 
after an accurately known drug input ( e g , by intravenous injection or con­
stant intravenous infusion) in a subject or patient Once ψ(0 has been deter­
mined, the drug output concentration in this person for an intended input may 
be predicted by convolution and, if so desired, be adjusted by adjustment of 
the input Also, for any given output and iKt) the inputfunction can be calcu­
lated back by deconvolution This is an excellent technique to determine 
bioavailability of drugs reaching systemic circulation by absorption from an 
application site, and to elucidate rate and extent of conversion of a parent 
drug into a particular metabolite 
For a precise knowledge of empirical input- en outputdata accurate analyti­
cal methods are indispensable In SECTION II the assays employed in the 
presently reported investigations have been allocated Except for a single 
working-up technique all methods were newly developed, and have in common a 
liquid or gas-liquid chromatographical separation procedure 
In Chapter 2 a capillary gaschromatographical method combined with 
nitrogen-detection is proposed for the estimation of nicotine and its princi­
pal metabolite cotinine in biological fluids An important advantage in favour 
of this method is the simulaneous occurrence of sample preparation and chro­
matographical separation for nicotine and cotinine The assay moreover is very 
rapid, which predominantly is due to the potent single-step solid phase 
extraction sample work-up Although applicable to saliva and urine, this 
method was employed mainly to analyze nicotine and cotinine in blood plasma of 
smoking experimental volunteers 
The smoked-out cigarette filters collected by these volunteers were ana­
lyzed for nicotine using an assay described in Chapter 3 The filter prepara­
tion technique involving crushing and ultrasonic vibration was kindly passed 
on to us by the Department of Analytical Chemistry of the Netherlands Organi­
zation for Applied Scientific Research ( T N O ) 
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Chapter 4 deals with a bioassay, derived from the GC-NSD method in Chapter 
2, in which the nitrogen detector has been replaced by a mass spectrometer 
fcith the facility of 'selective ion monitoring' (GC-MS-SIM) This assay 
enabled us to detect cotinine and a cold-isotope labelled (di-deuterated) 
cotimne-analogue separately in smokers' plasmas The smokers were given per-
orally a small dose of the labelled cot inine (cotinine-D2) at one of the two 
days of laboratory attendance The administration was followed by complete 
absorption and served the purpose of determining total cotinine clearance in 
each smoking volunteer 
Chapter 5 describes a gaschromatographical technique which utilizes a 
short packed column and nitrogen detection to estimate caffeine levels in 
caffeine-containing drinks and in plasma en saliva of human volunteers The 
chromatographical separation (runtime 3 min) is the most rapid ever reported, 
with one exception This method was put into service in the preliminary inves­
tigations preceding the human kinetical caffeine trials, to gain insight in 
the dose of caffeine to be expected in a given volume of freshly brewed coffee 
and tea, and to analyze body fluids of kinetical pilot volunteers 
In the time of the above pilot experiments a liquid chromatographic method 
for the analysis of caffeine in beverages end body fluids Ьесаше available 
This method using UV-detection at 254 пш is reported in Chapter 6 and is also 
suited to co-monitor the 3 dimethylxanthine metabolites of caffeine Further­
more the liquid Chromatograph was equipped with an automated injection facili­
ty Because of these advantages, the HPLC method (actually a composition of 
closely related methods with extraction conditions, constitution of mobile 
phase, and choice of internal standard varying with the nature of the sample, 
the separative potency of the column, and the identity of the analyte(s)) came 
to replace the earlier developed GC method in the remainder of the caffeine 
studies 
Eventually Chapter 7 presents a HPLC-method combined with fluorescence 
detection, suited for the analysis of quinine concentrations in infusion solu­
tions, blood plasma and urine of experimental volunteers 
In the last section, SECTION III, the results of the clinical-
pharmacokinetical investigations of nicotine, caffeine, and quinine are 
described 
Chapter 8 deals with the methodology and the results of an investigation 
of the nicotine intake by smokers of conventional (i e , imventilated) filter-
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tipped cigarettes Habitual and inhaling smokers of 4 cigarette brands belong-
ing to the conventional class (coded Fl t/m F4) were recruted to constitute 
6-membered populations of each brand (with the exception of the smokers' popu-
lation of brand F4, which consisted of 7 volunteers). The smokers collected 
their butts during a 16-day period and in this period provided blood samples 
while attending the laboratory for two days separated by a one-week interval. 
Smoking machine studies revealed nicotine retention in the cigarette filters 
of the 4 brands studied to be about one third, this relative retention largely 
being independent of smoking technique This characteristic rendered the 
cigarette filter a valuable tool to estimate smokers' nicotine intake at 
mouth-level. Butts of human-smoked filter cigarettes were analyzed for (abso-
lute retention of) nicotine, whereas blood plasma in addition was analyzed for 
nicotine-derived cotinine and cotinine-D2 The latter compound was given oral-
ly in a gelatine capsule to the volunteers The results of filter and plasma 
analyses were combined to resolve the intake issue 
In general the intake of nicotine intra-individually varied only slightly 
between the 2 days of laboratory attendance Inter-individual fluctuations of 
nicotine intake per cigaret between the smokers of a single brand on the other 
hand were considerable and amounted to about a factor 2 for all brands The 
amount of nicotine taken in at mouth-level by the smokers of the respective 
brands as determined by filter analysis was (mean ± SD, mg of nicotine per 
cigarette)· 1 58 ± 0.48 mg for Fl, 1 05 ± 0 16 mg for F2, 1.51 ± 0.42 mg for 
F3, en 1 67 ± 0.48 mg in case of F4 The nicotine imprints as determined by 
machine smoking of cigarettes of these brands amounts to 1 2 mg for Fl, 1 1 mg 
for both F2 and F3, and 1 0 mg for F4 
The majority (a fraction f ) of the nicotine reaching the oral cavity of 
the volunteers was absorbed in the pulmonary circulation, and for the major 
part (a fraction f ) converted into the main metabolite cotinine. The product 
of the fractions fj en fM as averaged over the smokers of all 4 brands (± SD): 
f'f., = 0 66 ± 0.10 For a degree of conversion of fM = 0.75 the systemic 
(blood-level) intake of nicotine was computed, which amounted to (mean ± SD, 
mg of nicotine per cigarette). 1 34 ± 0 34 mg for the smokers of Fl, 0.96 ± 
0.20 mg for those of F2, 1.27 ± 0 28 mg for the smokers of F3, and 1 31 ± 0.22 
mg for those of F4. 
We conclude that the nicotine label as printed on the packet is a reason-
ably good indication of the mean intake of smokers of the studied brands. The 
large inter-individual variability of the intake is in favour of introducing 
nicotine packet imprints as classes (intervals) rather than as a single number 
as is custom nowadays 
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In Chapter 9 the results of an identically designed investigation of nico­
tine intake by habitual smokers of 2 ventilated cigarette brands, coded as VI 
(6 smokers) and V2 (4 smokers) are reported. The 'ventilatedness' of these 
brands refers to the presence of minute perforations in the cigarette filter, 
through which extraneous air may be introduced during a puff. In this way the 
tobacco smoke may Ъг diluted, resulting in relatively small nicotine (and tar) 
yields as determined by machine smoking of cigarettes of this class, as shown 
by the nicotine labels of brands VI (0 2 mg) en V2 (0.1 mg). Human smokers may 
smoke with a degree of ventilation less than maximum, and the relative nico­
tine retention in de filters of these cigarettes is a function of the degree 
of ventilation with which they are smoked. Therefore, the amount of nicotine 
reaching the oral cavity of the smoker for a measured absolute nicotine filter 
retention cannot be estimated as accurately as for conventional filter 
cigarettes In practice, the accuracy of the estimation of this amount 
appeared to be amply sufficient. 
The nicotine-intake per cigarette at mouth-level amounted to 1.67 ± 0 46 mg 
for the smokers of VI and to 0 73 ± 0 25 mg for those of V2 on the average (± 
SD) The product of the systemic availability f- of inhaled nicotine and its 
fractional conversion fw into cotinine was 0 68 ± 0 10 for the smokers of VI 
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en V2 For f
u
 = 0.75 the systemic nicotine-intake of the smokers was deter-
n 
mined and amounted to 1.43 1 0 27 mg for those of VI, and 0.69 ± 0 24 mg for 
those of V2 Both mouth-level and systemic intake of nicotine by the smokers 
of VI and V2 are significantly greater than the machinally determined packet 
imprint In fact, the systemic intake did not approach the packet imprint 
closer than a factor 5 to 6 for any of the volunteers Of all 6 conventional 
and ventilated brands studied, VI delivered the greatest amount, and V2 the 
smallest amount of nicotine to habitual smokers of each brand. 
The difference between the nicotine imprint on the packet and intake of 
nicotine by human smokers must be due to corresponding differences in smoking 
technique between the smoking machine and the human smokers. The observed dif­
ferences are too large to be accounted for by assuming that human smokers puff 
more frequently or with larger puff volumes than the smoking machine does. The 
latter assumption may very well be true, but it is also almost inevitable to 
co-assume that our volunteers have blocked the ventilation mechanism of their 
cigarettes wholely or in part with their fingers or lips. Despite the small 
number of smokers of VI en V2 involved in the study, the observed tendency is 
evident to such an extent that the value of the standardized machine smoking 
li 
procedure to predict the intake of nicotine (and probably of the other con­
stituents of the aerosol phase of cigarette smoke) in general must be consid­
ered as limited 
In Chapter 10 the intake of carbon monoxide (CO) by the former smokers of 
conventional and ventilated cigarettes is discussed The study design involved 
the analysis of CO in smokers' exhaled alveolar air just before and just after 
smoking single cigarettes The Increase of the СО-concentration due to smoking 
was converted to the m vivo СО-yield of the cigarette with the aid of addi­
tional data (body weight, blood hemoglobine concentration) 
Conventional and ventilated filter cigarettes were indistinguishable with 
respect to their CO-delivery to smokers, which varied from 14 to 20 mg of CO 
per cigarette as averaged over the smokers' populations of each of the 6 
brands Within the population of a single brand, average individual CO-intakes 
amounted to a factor 2i - 5 between highest and lowest exposure Even larger 
differences existed between the C0-yields of single cigarettes subsequently 
smoked by the same volunteer No relationship was found between the individual 
average intake of nicotine on the one hand and that of CO on the other by the 
volunteers We did find a significant and negative correlation between the 
estimated total amount of hemoglobine in the volunteers' bodies and the aver­
age increment of the alveolar air CO concentration after cigarette smoking 
Existence and sign of this correlation are intelligible regarding the linear 
relation between CO-concentrations m breath and in blood, where CO occurs 
almost totally as a СО-hemoglobin complex 
Because women dispose of fewer hemoglobin than men on the average, but (in 
this study) take in just as much as CO as their male fellow-smokers, women 
build up higher blood CO concentrations and hence in theory are more apt to 
experience the toxic effects of CO than men 
Chapter 11 deals with the pharmacokinetics of caffeine (CAF) following 
intravenous infusion of a 200 mg dose over 30 min in 6 young and healthy vol­
unteers, equally distributed over the sexes The transportfunction ψ(ί) of CAF 
was monoexponent ia! for one subject and biexponential for the 5 others, the 
terminal exponent outweighing the rapid initial exponent in terms of statisti­
cal moments The mean (± SD) time constant τ. of the terminal exponent was 6 7 
± 2.0 h (= t, = 4 7 ± 1 4 h) A conspicuously large time constant (τ. = 9 9 h) 
was observed in a female taking oral contraceptives, whereas a very short τ, 
(4 2 h) was found in a stiff smoker Owing to the dominance of the terminal 
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exponent the mean residence time (± SD) of CAF in the body (65 + 2 0 uur) 
approximates т., and the variance of body residence times (46 uur1) is about 
the square of the mean residence time 
Mean ± SD of the plasma clearance and the apparent volume of distribution 
of CAF in our volunteers was 7 2 + 3 6 1/h and 42 ± 8 I, respectively Volume 
of distribution of CAF approximately corresponds to total body water 
Each circulatory transit a fraction (the extraction ratio of CAF) of 2 0 ± 
1 0 % of circulating CAF molecules was eliminated The circulatory transit 
time, and the number of transits completed by a CAF molecule before being 
eliminated, amounted to 7 0 ± 1 3 m m and 56 ± 17, respectively, as averaged 
over molecules and subjects 
The same volunteers who were administered CAF by intravenous infusion were 
given coffee and tea on two other occasions, as described in Chapter 12 CAF 
present m both these beverages was absorbed virtually completely from the GI 
tract (for 99 ± 4% in case of coffee, and for 95 ± 6% in case of tea) Absorp­
tion was also rapid the median absorption time (at which half the available 
quantity is absorbed) was for CAF drunk as coffee 20 ± 3 mm, and for CAF as 
tea 19 ± 3 min Mean absorption time was slightly higher due to 'tailing' of 
the absorption process 26 ± 5 min for CAF as coffee, and 23 ± 3 m m for CAF 
as tea Differences between coffee and tea with regard to rate and extent of 
CAF absorption were small and not significant Absorption rate vs time pro­
files showed a fickle multi-peaked course for each of the volunteers 
Individual volumes of CAF distribution were rather constant between the 3 
experiments involving CAF administration as ι ν infusion, coffee, and tea, 
whereas total clearance (CL) and the time constant of elimination (τ .) dis-
el 
played substantial intra-individual fluctuations between experiments It was 
inferred that the elimination kinetics of CAF in our subjects very likely was 
dose dependent (non-linear) In the tea treatment, involving by far the small­
est CAF dose administered, CI and t
 1 were significantly greater and smaller, 
respectively, than in the coffee and intravenous CAF treatments 
Comparison of CL en τ
 1 in the two latter treatments yielded the conclusion 
that the disposition rate of CAF in our volunteers also depended strongly upon 
their urine flow, which after dosage of coffee (and of tea) was significantly 
higher than following the ι ν infusion (in part owing to the aqueous volume 
of the coffee/tea itself) This dependence on urine flow has its origins in 
the proposed dose dependence of CAF disposition rate As renal clearance of 
CAF itself is negligible in adults, the linking of CAF-disposition to urine 
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flow probably is established by way of the 3 dimethylxanthines, into which CAF 
is converted for ± 95% in phase I of its metabolism 
The dimethylxanthines compete with CAF for the one or multiple enzymes of 
cytochrome P-450, which effect demethylation of xanthines, and at the same 
time undergo renal clearance to an Important extent Increase of urinary flow 
accelerates renal elimination of the dimethylxanthines, reduces competition of 
CAF with these compounds for P-450, and thus results in a higher total clear­
ance and a shorter elimination time constant of CAF 
In Chapter 13 the kinetics of CAF are compared to those of its main 
metabolite paraxanthine (1,7-dimethyl xanthine, PX) in the 3 male volunteers 
having participated in the above CAF-expenments The total body transport 
function tKt) of PX was monoexponential in two volunteers and biexponential in 
the third, the terminal exponent outweighing the initial one in terms of sta­
tistical moments Pharmacokinetical parameters of CAF and PX differred only 
moderately The time constant of PX elimination τ 9 amounted to 4 6 ± 0 9 h on 
the average (± SD) (cf 5 9 ± 1 9 h for CAF) Plasma clearance and volume of 
distribution of PX assumed mean values (± SD) of 11 8 ± 2 2 l/h and 52 ± 5£ 
(cf 8 9 1 4 8 t/h, and 45 ± 9 I for CAF) 
After oral administration in aqueous solution PX was absorbed rapidly (mean 
absorption time 2 2 + 1 m m ) and virtually completely (for 94 ± 10 %, cf 23 ± 
7 mm, and 103 ± 13 % for CAF, respectively) 
The similarity of elimination time constants of parent CAF and metabolic 
daughter PX effects a typically convex plasma PX concentration profile after a 
single dose of CAF, which profile often cannot be described adequately by a 
sum of exponentials, but all so much the better by a so-called gamma function 
Of an intravenous dose of CAF 77 ± 7 % was converted into PX by the 3 vol­
unteers, whereas this percentage was 64 ± 9 % (mean ± SD) for an equal oral 
dose of CAF Since a 'first-pass' effect for CAF has never been reported in 
literature, the cause of the difference in fractional conversion of oral and 
ι ν doses of CAF to PX probably is due to the difference in urine flow of the 
volunteers The latter was importantly higher after after oral than after ι ν 
dosage of CAF, partly owing to the large water load co-administered with the 
oral CAF dose Probably the high urinary flow rate in the oral experiment 
effected a relatively rapid (renal) excretion of PX and other dimethylxan­
thines generated from CAF by demethylation Hence competition between CAF and 
the dimethylxanthines for the demethylating enzymes was reduced, speeding up 
CAF disposition rate along the demthylation route (see Ch 12), and stressing 
this metabolic route at the cost of other routes 
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Eventually in Chapter 14 quinine kinetics In 7 young and healthy subjects 
(4 males, 3 females) are discussed both after intravenous infusion and after 
oral administration of a gelatine capsule containing the quinine sulphate 
salt The body transport function ψ(ί) was biexponential in all volunteers 
The time constants of both exponents diverged widely and amounted to 3 6 ± 0 7 
min, and 12 3 ± 1 6 h (mean ± SD) In terms of st-tistical moments the termi­
nal exponent was dominant by far The mean body residence time of quinine 
(12 0 + 1 8 h) therefore closely approximated τ Total quinine clearance in 
the subjects amounted to 8 1 ± 1 4 l/h, and the distribution volume to 96 ± 18 
t 
Averaged over volunteers and molecules, quinine molecules took 1 6 + 3 min 
to complete one circulatory transit in the body, and completed a total of 45 ± 
8 transits before being eliminated from the circulation Per transit a frac­
tion (the extraction ratio) of 2 3 ± 0 4 % of quinine molecules was eliminat­
ed, a minority of which (about 16% on the average) was excreted unchanged in 
the urine Renal clearance of quinine amounted to about 1 3 ± 0 2 I/h, sug­
gesting tubular secretion of quinine, since the plasma-proteinbound quinine 
fraction is as great as 90% 
Following oral administration of quinine sulphate in a gelatine capsule 
quinine was absorbed to a high extent (90 + 18 %) from the GI tract The 
absorption rate vs time profile of oral quinine was regular and symmetrical 
as indicated by the close proximity of median, modal, and mean absorption time 
(1 25 ± 0 38 h, 1 26 ± 0 41 h, and 1 42 ± 0 35 h) Absorption was slowest in 
a volunteer who afterwards was shown to suffer from sprue 
In two volunteers considerable time after the first absorption peak a sec­
ond absorption phase was seen, in which an additional 11% en 6% of the oral 
quinine dose was absorbed Since this second phase occurred just after the 
subjects' lunch, food intake constitutes a possible explanation for the 
renewed occurrence of absorption However, the presence of small quantities of 
the glucuronide conjugate of quinine in urine voidings of exclusively these 
\ery same two volunteers would indicate enterohepatic recirculation of quinine 
as the phenomenon underlying the occurrence of dual absorption peaks In this 
case food intake again could be the triggering event which gets the recircula­
tion going 
Because urinary quinine glucuronide was found only after oral, but not 
after ι ν administration of quinine in the two volunteers mentioned, quinine 
conjugation might be related to the so-called 'first pass' On the basis of 
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the available data the question of the dual absorption peaks could not be def-
initely resolved. 
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DE KLINISCHE FARMACOKINETIEK VAN NICOTINE, CAFFEINE, 
EN KININE 
EEN SYSTEEMDYNAMISCHE AANPAK 
Samenvatting en Conclusies 
Dit proefschrift behandelt de humane farmacokinetiek van drie plantaardige 
alkaloïden op het grensvlak van genot- en geneesmiddel, die in enorme hoeveel-
heden in de ontwikkelingslanden worden geproduceerd en mondiaal, maar vooral 
in de Westerse samenleving, worden geconsumeerd Ondanks hun massale verbruik 
en niettegenstaande de eeuwenoude gebruikshistorie van deze drie stoffen, die 
ons terugvoert tot de dageraad van de mensheid, bestaan er nog altijd aanzien-
lijke hiaten in de wetenschappelijke kennis van farmacokinetiek en -dynamiek 
van deze stoffen Dit proefschrift poogt enkele van deze hiaten te dichten 
Het beschreven onderzoek is geschoeid op de leest van de systeemdynamiscbe 
benadering van de farmacokinetiek Daar deze moderne benadering op dit weten-
schapsgebied (nog) geen gemeengoed is, geeft SECTIE I, tevens Hoofdstuk 1, 
een inleiding in de materie 
Eerst passeren de eigenschappen van een geïsoleerd orgaan of weefsel met 
betrekking tot de doorstroomsnelheid van een aan de arteriole kant aangeboden 
hoeveelheid farmacon de revue Het blijkt dat een goed geroerd doorstroomvat 
een redelijk model is voor een enkel orgaan De belangrijkste kenmerken van 
het geïsoleerde orgaan zijn de bloedstroom er doorheen, alsmede de gemiddelde 
tijd die de farmaconmoleculen nodig hebben om het orgaan te passeren (transit-
tijd) 
Vervolgens wordt, rekening houdend met fysiologische en anatomische feite-
lijkheden, het totale menselijk lichaam (het systeem) in een denkbeeldig con-
structieproces opgebouwd uit de afzonderlijke organen en weefsels (de subsys-
temen) Het meest kenmerkende van het systeem is de bloedcirculatie, die 
iarmacon-output evenredig terugvoert als -input en van het lichaam een zgn 
positief feedback systeem maakt De dynamiek van het totale systeem wordt 
bepaald door die van de subsystemen, en kan worden samengevat in de totale 
lichaams transport functie iMt) Ψ(ί) is in wezen de waarschijnlijkheids-
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dichtheidsverdeling van verblijftijden van farmaconmoleculen in het lichaam, 
en is voor elke stof en elk individu anders, en is ook voor een gegeven per-
soon en stof een functie van tal van (patho-)fysiologische processen, zoals 
hartminutenvolume, ziekte, en ouderdom 
Mathematisch bezien is het concentratieprofiel van een farmacon in 
bloed(-plasma) (de farmacon-ou£;>ut) de convolutie-integraal van de lichaams-
transportfunctie 4>(t) en de snelheid waarmee dat farmacon de bloedbaan 
bereikt (de farmacon-jnput) Dit laatste hangt op zijn beurt weer af van dose-
ringsschema, formulering, en toedieningswcg van dat farmacon De invloed van 
formulering en toedicningsweg op de farmacon-mput kan worden uitgedrukt in 
een eipplicatie-transportfunctie 
Zijn van de drie functies input-, transport-, en output functie, er twee 
bekend, dan kan de derde uit deze twee worden berekend door rekentechnieken 
die bekend staan als convolutie en deconvolutie De lichaamstransportfunctie 
Ï(t) van een farmacon is te berekenen uit het concentratieprofiel (output) na 
een nauwkeurig bekende input (bv intraveneuze injectie of constant infuus van 
de stof) in een proefpersoon of patient Is ψ(ί) eenmaal bekend, dan kan voor 
deze persoon het concentratieprofiel bij een voorgenomen input worden voor­
speld en eventueel bijgesteld (convolutie) Ook kan bij gegeven output en ^(t) 
de inputfunctie worden teruggerekend door deconvolutie Dit is een uitmuntende 
techniek ter bepaling van de biologische beschikbaarheid van farmaca die via 
een absorptiefase de systemische circulatie bereiken, en ter bepaling van de 
snelheid en de mate waarmee een verbinding wordt omgezet in een bepaalde 
metaboliet 
Voor een nauwkeurige kennis van experimentele input- en outputgegevens zijn 
goede analysemethodieken een noodzaak In SECTIE II zijn de m het thans 
beschreven onderzoekswerk gebruikte analytische methoden verzameld Op een 
onderdeel na zijn de methoden alle speciaal voor dit onderzoek ontwikkeld, en 
hebben een vloeistof- of gaschromatografische scheidingsprocedure met elkaar 
gemeen 
In Hoofdstuk 2 wordt een capillair gaschromatografische methode met stik-
stofdetectie beschreven voor de bepaling van nicotine en diens voornaamste 
metaboliet cotinine in biologische vloeistoffen Een belangrijk voordeel van 
deze methode boven eerder ontwikkelde en gepubliceerde methoden is dat mon-
stervoorbewerking, scheiding en detectie van nicotine en cotinine simultaan 
plaatsvinden De methode is bovendien erg snel, hetgeen voor een belangrijk 
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deel te wijten is aan de enkel-staps, zeer krachtige voorbewerkingsmethode 
waarbij gebruik wordt gemaakt van een vaste-fase extractietechniek met weg-
werpkolommetjes Het deze methode werden nicotine en cotinine in het bloed-
plasma van proefpersoon-rokers geanalyseerd 
De berookte sigarettenfliters van deze proefpersonen werden op nicotine 
geanalyseerd met de analysemethode beschreven in Hoofdstuk 3, waarvan de 
voorbeuerkingswijze ons vriendelijk werü toegespeeld door de afdeling Ana-
lytische Chemie van T N O 
Hoofdstuk 4 behandelt een techniek, afgeleid van de GC-NSD methode in 
hoofdstuk 2, waarbij de stikstofdetector is vervangen door een massaspectrome-
ter met 'selective ion monitoring'-faciliteit (GC-MS-SIM) Deze techniek 
stelde ons in staat de nicotine-metaboliet cotinine en een koud isotoop-
gelabeld cotinine-analoog separaat te detecteren in het plasma van de 
proefpersoon-rokers De proefpersonen kregen een kleine dosis van het gela-
belde cotinine (4',4'-dideutero cotinine) peroraal toegediend op een van de 
twee dagen van hun aanwezigheid in het laboratorium Op deze wijze kon een 
basale farmacokinetische parameter van cotinine (totale plasmaklaring) tijdens 
het experiment bepaald worden met minimale beïnvloeding van het rookgedrag 
Hoofdstuk 5 beschrijft een gaschromatografische techniek die gebruikmaakt 
van een korte gestapelde kolom en stikstofdetectie om caffeìne te bepalen in 
caffeïne-houdende dranken en in plasma en speeksel van menselijke vrijwilli-
gers na toediening van caffeine De chromatografische scheiding is de op-een-
na snelste ooit gerapporteerd (runtime 3 min) Deze methode werd ingezet in de 
voorbereiding op de caffeine-studies, waarbij de te verwachten caffeine-dosis 
in koffie en in thee werd ingeschat, en in de farmacokinetische 'pilot'-expe-
rimenten 
Ten tijde van de bovengenoemde 'pilot'-experimenten kwam een vloeistofchro-
matografische methode voor caffeine gereed voor gebruik De HPLC methode met 
UV-detectie, beschreven in Hoofdstuk 6, had als voordelen boven de eerder 
ontwikkelde GC-methode dat naast caffeine zelf de drie dimethylxanthine 
metabolieten van caffeine mede konden worden geanalyseerd, en dat gebruik kon 
worden gemaakt van een automatische injectiefaciliteit De HPLC methode 
(eigenlijk een samenstel van nauw verwante methoden, waarbij extractiemilieu, 
samenstelling van de mobiele fase en keuze van interne standaard wisselden al 
naar gelang de aard van het monster, de kwaliteit van de HPLC-kolom en de te 
bepalen substraten) werd voor het vervolg van het caffeine-project gebruikt 
ter analyse van caffeine en de dimethylxanthines in koffie, thee, 
infusievloeistoffen, en lichaamsvloeistoffen 
lix 
Tenslotte wordt in hoofdstuk 7 een HPLC-methode met fluorescentie-detectie 
beschreven, geschikt voor het meten van de concentratie van kinine in 
infusievloeistoffen, bloedplasma en urine van proefpersonen gemeten werd. 
In SECTIE III worden de resultaten van het klinisch farmacokinetisch onder-
zoek aan nicotine, caffeine, en kinine uit de doeken gedaan. 
Hoofdstuk 8 beschrijft de methodologie en de resultaten van een onderzoek 
naar de nicotine-inname van rokers van conventionele (dus ongeventileerde) 
filtersigaretten Van 4 sigarettemerken (gecodeerd als Fl t/m F4) uit deze 
klasse werden vnjwilligerspanels samengesteld, elk bestaande uit 6 gewoon-
tegetrouwe inhalerende rokers van deze merken (het panel van merk F2 bestond 
als enige uit 7 rokers) De vrijwilligers verzamelden gedurende een 16-daagse 
periode hun sigarettepeukcn en waren in deze periode tevens 2 dagen te gast op 
het laboratorium, waar bloedmonsters werden afgenomen Door middel van 
rookmachine-studies aan de 4 onderzochte sigarettemerken kwam vast te staan 
dat ongeveer 1/3 deel van de aan het sigarettefilter aangeboden hoeveelheid 
nicotine in het filter wordt achtergehouden, ongeacht de rooktechniek Deze 
eigenschap maakt van het sigarettefilter een waardevol hulpmiddel ter schat-
ting van de hoeveelheid nicotine die de mondholte van de roker bereikt. De 
peuken van door proefpersonen gerookte sigaretten werden geanalyseerd op nico-
tine, het bloedplasma bovendien op cotinine en cotinine-D2 welke laatste stof 
de vrijwilligers oraal kregen toegediend De analyseresultaten van filters en 
plasma werden gecombineerd ter oplossing van het innamevraagstuk. 
In het algemeen varieerde de inname van nicotine bij elke vrijwilliger 
slechts weinig tussen de 2 experimentele dagen Tussen de vrijwilligers in 
elk van de panels bleken echter aanzienlijke verschillen van de nicotine-
inname per sigaret te bestaan, voor drie van de merken signaleerden we een 
factor 2 discrepantie tussen de zwaarste en de lichtste roker in het panel De 
nicotine-inname op mondniveau bedroeg voor de rokers van de roerken (gemiddelde 
± SD, mg nicotine per sigaret) 1 58 ± 0 48 mg voor Fl, 1.05 ± 0 16 mg voor 
F2, 1 51 ± 0 42 mg voor F3, en 1 67 ± 0 48 mg voor F4 De pakjes-vermelding 
van nicotine, zoals die door machinaal verroken word vastgesteld, bedraagt 1 2 
mg voor Fl, 1 1 mg voor F2 en F3, en 1 0 mg voor F4 
Van de hoeveelheid nicotine die de mondholte van onze rokers bereikte werd 
het merendeel (een fractie fT) in de bloedbaan opgenomen, en daarvan weer het 
il 
merendeel (een fractie f ) in de metaboliet cotinine omgezet Het product van 
de fracties f en fM bedroeg gemiddeld over de rokers van alle merken (± SD) 
lx 
О 66 ± О 10 Voor een omzettingsgraad f = 0 75 werd de systemnche inname van 
nicotine berekend Deze bedroeg per sigaret (gemiddelde ± SD) 1 34 ± 0 34 mg 
voor Fl, 0 96 ± 0 20 mg voor F2, 1 27 + 0 28 mg voor F3, en 1 31 ± 0 22 mg 
voor F4 
We concluderen dat het mcotine-getal op het pakje een redelijke indicatie 
is voor de inname van de gemiddelde roker van de onderzochte merken De grote 
inter-individuele variatie van de inname oleit echter voor de opgave van een 
nicotine-klasse of -interval in plaats van het tot dusverre gebruikelijke 
enkelvoudige getal 
In Hoofdstuk 9 passeren de resultaten van een onderzoek naar de nicotlne-
inname van rokers van 2 merken geventileerde filtersigaretten, gecodeerd als 
VI (6 rokers) en V2 (4 rokers) de revue Opzet en uitvoering van het onderzoek 
waren identiek aan die van het onderzoek aan conventionele filtersigaretten 
Het 'geventileerd' zijn van de filtersigaretten refereert aan de aanwezigheid 
van minuscule perforaties in het filter, waardoor tijdens een trek lucht 
aangezogen kan worden, waarmee de tabaksrook wordt verdund De verdunning van 
de rook leidt bij machinaal verroken van sigaretten uit deze klasse tot spec­
taculair lage nicotine (en teer) opbrengsten, zoals de nicotinecijfers op de 
pakjes van VI (0 2 mg) en V2 (0 1 mg) aantonen Bij menselijk roken kan de 
ventilatiegraad gereduceerd worden door blokkering van het ventilatiemecha-
nisme De relatieve retentie van nicotine in de filters van deze sigaretten is 
afhankelijk van de ventilatiegraad, waardoor bij gemeten absolute retentie de 
hoeveelheid nicotine die de mondholte van de roker bereikt, minder nauwkeurig 
kan worden berekend dan voor conventionele filtersigaretten het geval was In 
de praktijk blijkt de accuratesse van de schatting van deze hoeveelheid toch 
ruimschoots voldoende 
De nicotine-inname per sigaret op mond-mveau bedroeg gemiddeld (± SD) 1 67 
± 0 46 mg voor VI en 0 73 + 0 25 mg voor V2 Het product van de systemische 
beschikbaarheid f. van geïnhaleerd nicotine en de omzettingsgraad fM in coti-
mne was 0 68 ± 0 10 in de rokers van VI en V2 Voor fM = 0 75 werd de sys-
temiscbe nicotine-inname van deze rokers berekend 1 43 ± 0 27 mg voor rokers 
van VI, en 0 69 ± 0 24 rag voor die van V2 Deze cijfers zijn voor beide merken 
statistisch significant hoger dan het door de rookmachine bepaalde pakjesver-
melding De systemische inname benaderde de pakjesvermelding voor geen enkele 
van de vrijwilligers dichter dan een factor 5 a 6 Van alle zes onderzochte 
merken leverde VI per sigaret de grootste, en V2 de kleinste hoeveelheid nico-
tine aan de panel rokers 
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Het verschil tussen pakjesvermelding en menselijke inname van nicotine moet 
gezocht worden in corresponderende verschillen in rooktechniek tussen rookma­
chine en menselijke rokers De gevonden verschillen zijn te groot om alleen 
verklaard te uorden door aan te nemen dat de rokers in de panels hun sigaret­
ten met meer en grotere trekken verroken dan de rookmachine dat doet Dit kan 
zeer wel het geval zijn, maar daarnaast moet haast wel worden aangenomen dat 
deze rokers liet ventilatiemechanisme van hun sigaret gedeeltelijk dan wel 
geheel blokkeren met vingers en/of lippen Ondanks het kleine aantal rokers 
van VI en V2 in de studie is de gevonden trend zo duidelijk aanwezig, dat de 
voorspellende waarde van de gestandaardiseerde machinale rookprocedure voor de 
inname van nicotine (en waarschijnlijk ook de andere bestanddelen van sigaret-
terook) door rokers van geventileerde filtersigaretten in het algemeen gering 
moet worden geacht Een aanpassing van genoemde procedure voor geventileerde 
sigaretten is derhalve gewenst 
In Hoofdstuk 10 wordt de inname van koolmonoxide door de (zelfde) rokers 
van de conventionele en geventileerde sigaretten behandeld De opzet van de 
studie voorzag hier in het analyseren van koolmonoxide (CO) in de adem van de 
rokers juist voor en Juist na het roken van individuele sigaretten Het incre­
ment in de CO-concentratie werd m b ν additionele gegevens (lichaamsgewicht, 
hemoglobinegehalte in bloed) omgerekend naar de in vivo CO-opbrengst van die 
sigaret 
Conventionele en geventileerde filtersigaretten waren ononderscheidelijk met 
betrekking tot CO-dosis die aan de rokers werd geleverd, en die gemiddeld over 
de rookpanels uiteenliep van 14 - 20 rag CO per sigaret De verschillen tussen 
de rokers van hetzelfde merk waren groter dan voor nicotine, en beliepen een 
factor 2 ^ - 5 tussen de zwaarste en de lichtste roker in de diverse panels 
Ook de verschillen in CO-opbrengst van opeenvolgende sigaretten, gerookt door 
eenzelfde individu, waren aanzienlijk Tussen de hoogte van gemiddelde inname 
van nicotine enerzijds en CO anderzijds van onze vrijwilligers bestond geen 
verband Wel werd een significante en negatieve correlatie gevonden tussen de 
geschatte totale hoeveelheid hemoglobine in het lichaam van de roker en de 
grootte van de concentratiesprong van CO in adem voor en na het roken van een 
sigaret De correlatie is begrijpelijk gezien het lineaire verband tussen de 
CO-concentraties in adem en in bloed, waar CO geheel aan hemoglobine gebonden 
voorkomt Aangezien vrouwen gemiddeld over minder hemoglobine beschikken dan 
mannen, maar (althans in deze studie) evenveel CO binnenkrijgen door roken, 
bouwen zij hogere bloedconcentraties aan CO op dan mannen en zullen zij in 
theorie de toxische effecten eerder ondervinden 
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Hoofdstuk 11 behandelt de farmacokinetiek van caffeine (CAF) na intra­
veneuze infusie van een dosis van 200 mg over 30 min in 6 jonge gezonde vrij­
willigers, gelijkelijk verdeeld over beide geslachten De transportfunctie 
ψ(ΐ) van CAF was van monofexponentiële aard in geval van een proefpersoon en 
van biëxponentiele aard in de 5 anderen, waarbij in alle gevallen de terminale 
exponent in termen van statistische momenten zwaar domineerde De tijdscon-
stante τ van deze terminale exponent bedroeg gemiddeld (± SD) 6 7 ± 2 0 
term 
uur (s t, = 4 7 ± 1 4 uur) Een opvallend lange tijdsconstante (τ = 9 9 $ tenu 
uur) werd waargenomen in een gebruikster van orale anticonceptiva, een zeer 
korte tijdsconstante (τ = 4 2 uur) in een straffe roker Vanwege de domi-
term 
nantie van de terminale exponent benadert de gemiddelde verblijftijd (± SD) 
van CAF in het lichaam (6 5 ± 2 0 uur) de waarde van τ , en is de variantie 
term 
van de lichaamsverblijftijden (48 uur2) ongeveer het kwadraat van de gemid­
delde verblijftijd 
Het gemiddelde ± SD van de plasmaklaring en het schijnbare distnbutievolume 
van CAF bedroeg in onze proefpersonen ongeveer 7 2 ± 3 6 i/uur en 42 ± 8 i, 
respectievelijk De grootte van het verdelingsvolurae komt ongeveer overeen met 
het volume van het totale lichaamswater 
Per rondgang in de bloedbaan werd een fractie (de extractieratio) van 2 0 ± 
1 0 % van de CAF-moleculen geëlimineerd De tijd voor een rondgang in de cir-
culatie (transittijd) en het aantal rondgangen dat een CAF-molecuul kon maken 
alvorens te worden geëlimineerd bedroeg gemiddeld over moleculen en proefper-
sonen 7 0 ± 1 3 min, en 56 ± 17, respectievelijk 
Dezelfde vrijwilligers aan wie CAF per ι ν infuus was toegediend kregen bij 
twee andere gelegenheden koffie en thee te drinken, zoals beschreven in 
Hoofdstuk 12 CAF, toegediend in deze beide dranken, werd zo goed als 
volledig uit de maag-darm tractus opgenomen (99 ± 4% voor CAF in koffie, 95 ± 
6% voor CAF in thee) De opname geschiedde vrij snel de mediane opnametijd 
(waarop de helft van de aangeboden hoeveelheid is opgenomen) bedroeg voor CAF 
toegediend als koffie 20 ± 3 min, en voor CAF in thee 19 ± 3 min De gemid­
delde opnametijd lag iets hoger door 'slepen' van het absorptieproces 26 ± 5 
min voor CAF in koffie, 23 + 3 min voor die in thee De verschillen tussen 
koffie en thee betreffende mate en snelheid van CAF-opname waren klein en non­
significant De profielen van de opnamesnelheid uitgezet tegen de tijd kenden 
een grillig verloop voor alle proefpersonen 
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Het distributievolume van CAF bleef voor elk van de proefpersonen ongeveer 
gelijk gedurende de experimenten De totale klaring (CL) en de tijdsconstante 
van eliminatie (τ ) vertoonden daarentegen aanzienlijke intra-individuele 
term 
fluctuaties van experiment tot experiment Geconcludeerd werd dat de vervijde-
nngskinetiek van CAF in onze proefpersonen naar alle waarschijnlijkheid 
dosisafhankelijk (non-lineair) was CL en τ waren in de theeproef, waarin 
term 
verreweg de laagste CAF-dosis werd toegediend, significant hoger en lager, 
respectievelijk, dan in de koffieproef en na het ι ν infuus van CAF 
Vergelijking van CL en τ in beide laatsgenoemde experimenten leverde als 
conclusie dat de eliminatiesnelheid van CAF in onze proefpersonen tevens sterk 
afhangt van hun urineflow, die na toediening van koffie (en thee) significant 
hoger was dan na het infuus (mede door het eigen volume van de koffie/thee) 
Deze afhankelijkheid laat zich terugvoeren op de veronderstelde dosisafhanke-
lijkheid van de verwijdenngskinetiek van CAF Aangezien namelijk de renale 
klaring van CAF zelf zeer klein is, kont de koppeling tussen CAF-eliminatie en 
urineflow kaarschijnlijk tot stand via de 3 dimethylxanthines, waarin CAF voor 
± 95°i, uordt omgezet in de eerste fase van zijn metabolisme 
De dimethylxanthines plegen competitie met CAF om een of meer enzymen van 
cytochroom P-450, die de demcthylering van xanthines bewerkstelligen, en wor­
den tevens in aanzienlijke mate renaal geklaard Verhoging van de urineflow 
bespoedigt de renale eliminatie van de dimethylxanthines, verlicht de competi­
tie van CAF met deze stoffen om P-450, en leidt zo ook tot een snellere ver­
wijdering van CAF 
In Hoofdstuk 13 wordt de kmetiek van CAF vergeleken met die van zijn voor­
naamste metaboliet paraxanthine (1,7-dimethyl xanthine, PX) in de 3 mannelijke 
vrijwilligers die eerder in de CAF-experimcnten hadden geparticipeerd De 
lichaamstransportfunctie V(t) was monoexponentieel in twee van hen en biexpo­
nentieel m de resterende persoon, waarbij net als bij CAF de terminale expo­
nent domineerde De farmacokinetische parameters van CAF en PX verschilden 
weinig De tijdsconstante van eliminatie τ. bedroeg voor PX gemiddeld (± 
term 
SD) 4 6 ± 0 9 uur (voor CAF 5 9 ± 1 9 uur) De plasmaklaring en het verdel-
ingsvolume van PX namen gemiddelde (± SD) waarden aan van respectievelijk 11 8 
± 2 2 t/uur en 52 ± 5 l (CAF 8 9 1 4 8 t/uur, en 45 ± 9 1) 
Na orale toediening in oplossing werd PX snel (gemiddelde opnametijd 22 ± 1 
min) en nagenoeg volledig (94 ± 10 %) opgenomen (CAF 23 ± 7 min, en 103 ± 13 
%, respectievelijk) 
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De gelijkenis van de tijdsconstanten van eliminatie van CAF en PX is er de 
oorzaak van dat de plasmaconcentratie curve van PX na toediening van een 
enkele dosis van de moederverbinding CAF een typerend vonvex profiel vertoont, 
dat zich vaak niet aan een som van exponentiële functies laat fitten, maar des 
te beter aan een zgn. 'gamma-functie'. 
Van een intraveneuze dosis CAF werd 77 ± 7 % in PX omgezet door de 3 vrij-
willigers, terwijl dit percentage voor een even grote orale dosis 84 + 9 X 
bedroeg. Aangezien een 'first-pass' metabolisme voor CAF nog nimmer werd ge-
rapporteerd in de literatuur, moet de oorzaak van het verschil waarschijnlijk 
gezocht worden in de urineflow van de proefpersonen. Deze was mede als gevolg 
van het grote volume water waarmee de orale dosis CAF werd toegediend, belang-
rijk hoger na orale dan na intraveneuze toediening van CAF. Waarschijnlijk 
werd door een relatief snelle (renale) verwijdering van de door de-methylering 
uit CAF gevormde dimethylxanthines (waaronder PX) dit metabole pad (de-
methylering van CAF) na orale toediening van CAF meer benadrukt ten koste van 
andere metabole routes, dan na i.v. toediening van CAF het geval was. 
In Hoofdstuk 14 tenslotte komt de kinetiek van kinine aan bod, zowel na een 
intraveneus infuus als na orale toediening van een gelatine capsule met het 
sulfaatzout van de stof aan 7 jonge gezonde proefpersonen (4 mannen, 3 
vrouwen). De lichaamstransportfunctie ψ(ΐ) was biëxponentieel in alle vrij-
willigers. De tijdsconstanten van de 2 exponenten lagen ver uiteen en bedroe-
gen gemiddeld (± SD) 3.6 ± 0.7 min, en 12.3 ± 1.8 uur. In termen van statis-
tische momenten was de terminale fase veruit dominant. De gemiddelde verblijf-
tijd van kinine in het lichaam (12.0 ± 1.8 uur) was dan ook bij goede benader-
ing gelijk aan τ . De totale kinineklaring in de proefpersonen bedroeg 8.1 
± 1.4 ï/uur, het distributievolume 96 ± 18 Í. 
Gemiddeld over proefpersonen en moleculen deden de kininemoleculen 16 ± 3 
min over een circulatoire transit door het lichaam, en completeerden zij 45 ± 
8 transits alvorens te worden verwijderd uit de bloedcirculatie. Per transit 
werd een fractie (de extractie ratio) van 2.3 ± 0.4 % van de kininemoleculen 
geëlimineerd, waarvan een minderheid (ongeveer 1/6 deel) door uitscheiding in 
onveranderde vorm in de urine. De renale klaring van kinine bedroeg ongeveer 
1.3 ± 0.2 l/uur. Deze waarde duidt op tubulaire secretie van kinine, aangezien 
de aan plasma-eiwitten gebonden fractie van kinine ongeveer 90 * bedraagt. 
Na orale toediening van kininesulfaat per gelatine capsule werd kinine in 
hoge mate (90 ± 18 %) in de bloedbaan geabsorbeerd. Het absorptieprofiel van 
de stof was regelmatig en symmetrisch in de vrijwilligers, hetgeen kan worden 
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opgemaakt uit het bijna samenvallen van mediane, modale, en gemiddelde absorp-
tietijd (respectievelijk 1 25 ± 0 38 uur, 1 26 ± 0 UI uur, en 1 42 ± 0 35 
uur) De traagste absorptie werd waargenomen in een vrijwilligster, van wie 
later werd vastgesteld dat zij leed aan coeliacie 
In twee vrijwilligers deed zich geruime tijd na de eerste absorptiepiek nog 
een tweede absorptiefase voor, waarbij nog eens 11% en 6% van de toegediende 
hoeveelheid werd opgenomen Daar deze tweede fase zich vlak na de lunch 
voordeed, is de inname van voedsel een mogelijke verklaring voor het hernieuwd 
optreden van absorptie De vondst van kleine hoeveelheden glucuromde-
conjugaat van kinine in de urine van uitsluitend deze zelfde twee vrijwilli-
gers zou ook kunnen wijzen op een hepato-enterale kringloop van kinine als 
verklaring voor de dubbele absorptiepiek, waarbij wederom de lunch het 
'startschot' zou kunnen zijn dat de kringloop m gang zet Daar in de urine 
van genoemde twee proefpersonen wel na orale, maar niet na intraveneuze toe-
diening kinme-glucuronide werd aangetroffen, is het mogelijk dat glucuronide-
nng van kinine gerelateerd is aan de 'first pass' Op grond van de beschik-
bare gegevens was het niet mogelijk een nadere uitspraak over de oorzaak van 
het het fenomeen van de dubbele absorptiepieken te doen 
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D A N K W O O R D 
De in dit proefschrift beschreven studies werden uitgevoerd op het Instituut 
Farmacologie in de onderzoeksgroep Farmacologische Systeemdynamica onder lei­
ding van Prof. Dr. Van Rossum, die in een door roij als bijzonder stimulerend 
ervaren wetenschappelijk klimaat mij de vrije hand liet in de opzet en de 
uitvoer van een grote verscheidenheid aan farmacokinetische experimenten. 
Een terugblik op de tijdsspanne van ternauwernood 3 jaar waarin dit proef­
schrift werd voltooid leert mij dat ik in deze tijd een beroep op de medewer­
king van zeer veel mensen gedaan heb. Een blijk van waardering voor hun aller 
bijdrage is hier op zijn plaats, daar het proefschrift zonder hun hulp het 
daglicht niet zou hebben gezien. 
Voor de vriendschappelijke sfeer en de morele steun, bij de gratie van welke 
het onderzoek voor dit proefschrift kon gedijen, zeg ik dank aan alle medewer­
kers van het Instituut Farmacologie, speciaal aan diegenen die werkzaam waren 
en/of zijn op de begane-grondse etage, en aan vele medewerkers in tal van 'on­
dersteunende diensten' in kliniek en prekliniek. Diegenen in de eerstgenoemde 
groep die de afgelopen jaren hun rookwaar op de gang buiten het laboratorium 
hebben genoten en zo hebben bijgedragen tot een nicotine-vrije atmosfeer bin­
nen het lab, verdienen een welgemeend extra dankwoord. Bij de gratie van de 
lage vluchtigheid van caffeine was het niet nodig ош consumptie van koffie en 
thee naar buiten het lab te verbannen (!) 
Speciaal gaat mijn diepe erkentelijkheid uit naar: 
• de medewerkers van de afdeling Klinische Farmacologie van de Katholieke 
Universiteit (K.U.L.) te Leuven, in het bijzonder Prof. Dr. P.J. de Schep­
per, Dr. T.B. Tjandramaga, mevr. Dr. A.M. van Hecken en mevr. Drs. I.M. de 
Lcpeleire voor hun enthousiaste en vakkundige uitvoering van alle infusen, 
• de medewerkers van de Hoofdgroep Maatschappelijke Technologie T.N.O. te 
Delft, vooral naar Ing. M. Hissink, Drs. R. Bosman en Mevr. W.A. de Jong-
Kleberg, voor hun al evenzeer enthousiaste en kundige uitvoering van het 
machinaal verroken van de door ons onderzochte merken filtersigaretten, en 
voor het uitdragen van hun uitgebreide expertise op het gebied van de 
analyse van berookte sigarettenfliters, 
• Prof. Dr. B. Zwanenburg en Dr. J. Lemmens van de afdeling Organische 
Chemie, Faculteit der Wiskunde en Natuurwetenschappen, voor de vakkundige 
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Synthese van het gelabelde cotinine, en Dhr, L Thijs van diezelfde afde-
ling, voor zijn kritische kanttekeningen bij de beschrijving van de syn-
theseroute (appendix I), 
mevr C o m e n Vcrwey-Van Wissen, dhr Yuen Tan en de talloze hulpvaardige 
artsen, to-assistenten en verplegers (m/v) die op dagen van proefnemingen 
bij nacht en ontij de EHBO-post bemanden, voor de afname van de in totaal 
ongeveer 1600 (') bloedmonsters, 
dhr Drs J Bakker van de afdeling Klinische Farmacie voor de snelle en 
vakkundige bereiding van de paraxanthine-oplossingen ter intraveneuze 
infusie, 
de studenten die een deel van hun doctoraalprogramma met veel toewijding 
hebben besteed aan een van de onderzoeken Drs Hans de Bie, Drs Annet 
Theunisse, Drs Monique Heek, Ruud Haverkamp (alias 'Dr Kleinood'), Rene 
Velthuis, en Margriet Hendriks Een aparte vermelding verdienen Rene 
Velthuis en Rob van Gammeren voor hun bijdrage als 'invallers' bij de 
analyse van sigarettepeuken, 
de OLAN-stagiairs Ronald Aalders, Ene Eibers, Lcnhardt van Teeffelen en 
Carolien Lemmen, voor hun hulp bij de analyse van gigantische aantallen 
plasma's, urine's en sigarettepeuken tijdens hun stage op 'Systeemdynami-
ca', 
Ronald Aalders voor de voortzetting van dat werk als gediplomeerd analist, 
in het bijzonder gedurende de 'stressy' periode in het voorjaar van 1987, 
die hem en mij ongetwijfeld nog lang zal heugen, 
de heren Jan Jansen en Yuen Tan, voor hun ontelbare technische ingrepen 
aan defecte of mal functionerende analytische apparatuur, 
mijn 'lab-mentor' dhr Michel Broekman voor de introductie van mijn per-
soon als hoofdvakstudent in september 1983 op het farmacologisch lab, voor 
de talloze in diepte gaande discussies over zeer uiteenlopende zaken, voor 
de beginselen van HPLC, 'farmfitten' en tekstverwerken die hij mij 
bijbracht, en voor zijn dynamische benadering van gebaks- en taartsyste-
men, 
tal van medewerkers van het Universitaire Rekencentrum die mij behulpzaam 
waren bij voorkomende problemen met rekenprogrammatuur, grafische program-
ma's of tekstverwerking, 
de medewerkers van de afdelingen Medische illustratie en Medische 
Fotografie voor de vele tekeningen, posters, dia's, clichedrukken en 
copyproof-foto's die zij vakkundig en punctueel vervaardigden in het kader 
van een congres, symposium, of voor dit proefschrift, 
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dhr Jan Lintsen (instrumentele dienst) voor zijn kundige stapeling van de 
door mij gebruikte 'reversed-phase' HPLC-kolommen, 
de medewerkers van het inmiddels verhuisde doping-laboratonum, voor hun 
inschikkelijkheid in het gemeenschappelijk gebruik van analyse-apparatuur, 
in het bijzonder Drs Douwe de Boer, die ik meermalen tot wanhoop dreef 
door ongewild de retentietijden van zijn 'anabolen' te veranderen bij het 
ombouwen van de injectiepoort van de GC-MSD van 'splitless' naar 'split' 
en vice versa, 
mijn medepromovendi op het instituut Drs Ger van Lingen voor zijn hulp 
in mijn eeuwige gevecht met soft- en hardware. Drs Douwe de Boer voor het 
ei van Columbus waarop hij mij zo nu en dan vergastte, en Dr Maikel 
Raghoebar en Dr Frans Hussel voor goede raadgevingen en tips, en voor de 
sfeervolle late uurtjes doorgebracht m menige congresstad her en der in 
den (buiten-)lande, 
Dhr С Leistikow van de afdeling anesthesiologie voor zijn medewerking 
bij het verkrijgen van gaszakjes voor de opvang van uitgeademde lucht, 
de medewerkers van de glasinstrumentmakenj voor de kraantjes, toegesneden 
op genoemde gaszakjes, 
gevoelens van diepe dankbaarheid koester ik voorts jegens de ongeveer 50 
proefpersonen die de moed opbrachten met mij een experiment aan te gaan 
Een eervolle vermelding verdienen vier onverbeterlijke vrijwilligers 
Charlotte, Eric, Björn en Gabri Zij participeerden in maar liefst zes 
proeven, de laatste zelfs in zeven Zij spekten mijn intra-individuele 
databank, maakten het Farmacologisch Instituut kapitalen aan proefpersoon-
vergoedingen lichter en kenden de experimentele protocollen op den duur 
even goed als ik, 
mijn meest diepgevoelde erkentelijkheid gaat tenslotte uit naar mijn vrouw 
Anna In haar voormalige positie als secretaresse overbrugde zij menigmaal 
telefonisch drie verdiepingen ter bevordering van de contacten tussen pro-
motor en promovendus Zij zette puntjes en cijfertjes op en onder V ., VR, 
l, etc , overal waar dit met de tekstverwerker niet mogelijk was De 
ι 
meeste dankbaarheid echter ben ik haar verschuldigd voor haar eindeloze 
geduld, liefde en begrip in met name het laatste jaar voorafgaand aan de 
promotiedatum, dat voor ons beiden niet makkelijk was Voor dit alles, 
Anna, dank ik je 
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STELLINGEN 
behorend bi j de d isser tat ie 
"CL IN ICAL PHARMACOKINETICS OF NICOTINE, CAFFEINE, AND QUININE" 
"A Systems Dynamics Approach" 
HARALD W A. TEEUWEN NIJMEGEN/BRUSSEL, 23 DECEMBER 1987 
I 
De in de farmacokinetische compartimentenleer gangbare wiskundige 
benader ing van het fenomeen absorptie als een (meestal na een dode t i j d ) 
momentaan aanzwellend, en daarna s t r i k t monoexponentieel aflopend gebeuren 
is fys io logisch laakbaar en dient te worden verworpen ten gunste van de 
b e r e k e n i n g van de absorpt iesnelheidscurve als f u n c t i e van de t i j d . 
Deze dissertatie 
II 
De vraag gesteld in de t i te l van het a r t i k e l van Ashton et al "Should 
intake of carbon monoxide be used as a guide of intake of other smoke con 
s t i t u e n t s ? " l i j k t voor rookbestanddelen die grotendeels of geheel m de 
aerosolfase van de rook voorkomen, zoals n icot ine, waarschi jn l i jk met "neen" 
te moeten worden beantwoord 
Ashton И, Stepney R, Thompson JU, Br Hed J 282 (1981) 10-13 
Deze dissertatie 
I I I 
De g e v o l g t r e k k i n g van Bonati et al als zou de kmetiek van caffeìne niet 
dos is-afhankel i jk zijn bij doses en plasmaspiegels van het alkaloid waaraan de 
doorsnee gebru ike r van caffemehoudende dranken zich blootstelt is gebaseerd 
op een zeer beperk t aantal waarnemingen, en wordt m twi j fe l getrokken door 
getabel leerde gegevens in het ar t ikel zelf 
Donati H, Latini R, Gaietti F, Young JF, Tognoni G, Garattini S, 
Clin Pharm Ther 32 (1982) 98 (Table Ι, ρ 100) 
IV 
De wijze waarop Ber l in et al het schi jnbare verdel ing^volume van k imne 
m het menselijk lichaam berekenen is discutabel 
CH Berlin, JH Stackman, ES Vesell, Clin Pharm Ther 18 (1975) 670 
V 
Een eenvoudig inhaleertoestel dat een stootsgewijze a f g i f t e en absorpt ie van 
nicot ine in de alveoli kan bewerkste l l igen, zou als hulpmiddel om te stoppen 
met roken wel l icht meer effect sorteren dan de weinig succesvolle n icotme-
kauwgom. 
Rüssel МАИ, and Feyerabend С, Cigarette smoking· a depen­
dence on high-nicotine boli. Drug Metab Rev 8 (1978) 29 
VI 
De zin van de wette l i jk v e r p l i c h t e n icot ine- en teergetal len op s igaret-
tepakjes zou moeten z i j n , een realist ische voorspel l ing te leveren van de 
inname van nicotine en teer door de doorsnee menselijke roker van sigaretten 
van het merk m kwestie Als genoegzaam duidel i jk is dat menselijke rookpa-
t r o n e n tussen sigarettenklassen wezenlijk v e r s c h i l l e n , zou dienovereenkomstig 
de standaard machinale roo к procedo r e , waarmee de nicotine en teergetal len 
worden bepaald, naar s igaretten-klasse moeten worden g e d i f f e r e n t i e e r d . 
V I I 
"Act ieve" rokers dienen op basis van goede omgangsvormen de i r r i t a t i e en 
het l ichamelijk ongemak, die/dat het ongewild inhaleren van met tabaksrook 
v e r o n t r e i n i g d e lucht voor velen m deze samenleving met zich meebrengt, 
zoveel mogelijk te voorkomen, onafhankel i jk van de mate waarin de gezondheid 
door "passief ' roken w o r d t bedre igd 
V I I I 
De door de consument zo gewaardeerde " n a t u u r l i j k e " (biogene) herkomst 
van levens- en genotmiddelen en cosmetica en van eventueel daarin v e r w e r k t e 
k leu r - , g e u r - , en smaakstoffen garandeert geenszins de onschadel i jkheid voor 
de gezondheid van derge l i j ke middelen en add i t ieven. 
IX 
Het poneren van stel l ingen bij een disser tat ie biedt de promovendus een 
goede mogeli jkheid tot het ad dissertâtlonem vent i le ren van eventuele beleids-
matige of poli t iek get inte consequenties van zijn we rk , die in het wetenschap-
pel i jke kader van de dissertat ie zelf minder op hun plaats z i jn . Mede daarom 
moet de afschaf f ing van de stel l ingen aan de Rijks Univers i te i t Ut recht per 1 
september 1987 jongst leden dan ook worden b e t r e u r d . 
X 
Na de invoer ing van het facu l ta i r "onged i f fe rent ieerde" doctoraat aan de 
K . U . Nijmegen per 1 januar i 196S l i j k t de t i te lpagina van Nijmeegse d isser-
taties een onhandig geformuleerd en inhoudel i jk gekunste ld compromis tussen 
vóór- en tegenstanders van het noemen van de facul ta i re inde l ing . De z in -
snede "Een wetenschappel i jke proeve op het gebied van . . . ( vo lg t : f acu l -
teitsnaam zonder het woord " f a c u l t e i t " ) " is weinig informat ief , doet a fb reuk 
aan de volwaardigheid van het m de disser tat ie beschreven w e r k , en kan 
beter in zi jn geheel worden weggelaten. 
X I 
Mocht het College van Bestuur van de K . U . Nijmegen alsnog beslui ten om 
de hoofdconclusie van het onderzoek naar het "imago" van de K . U . N . , u i t -
gevoerd door o a. het Adviesbureau Ve rdonk , O t ten , Dick, Б Wieger ink, met 
langer te negeren en de katholieke s i g n a t u u r van de Nijmeegse U n i v e r s i t e i t 
beleidsmatig te verdoezelen, dan v e r d i e n t de mogel i jkheid van naamsveran­
d e r i n g van de K . U . N , in "Keizer Karel U n i v e r s i t e i t " , zoals reeds m 1962 
voorgesteld door het Nijmeegse d ispuut " O l i v i e r " , serieuze o v e r w e g i n g . 
Nijmeegs Universiteits Blad 5 okt. 1962, K.U. Nieuws 31 okt. 1985 
X I I 
De a u t h o n t e i t die ui tgaat van de o p d r u k op s igaret tepakjes, l u i d e n d : 
"Roken Bedreigt de Gezondheid. De Minister van Volksgezondheid en Mi l ieu­
hygiëne" word t ondergraven door het niet bestaan van genoemde min is ter . 
X I I I 
De m de lekenpers veelvuld ig gehanteerde woordcombinatie "chemische 
s to f fen" is een schoolvoorbeeld van een pleonasme. 
X I V 
Het sociaal gedrag van medewerkers van een farmacoklnet isch laborator ium 
kan onderhev ig zi jn aan beïnvloeding door de v luch t ighe idskarak tens t ieken 
van de m het laborator ium onderzochte genees- of genotmiddelen. 
Deze dissertatie. 
XV 
Te oordelen naar het verb i j s te rend lage salaris dat wordt toegekend aan 
assistenten m ople id ing ( A . I . O 's) m met name het beginjaar van hun "tweede 
fase" zou de a fko r t i ng van hun func t ie evenals hun portemonnaie zonder 
gevaar voor ver l ies van inhoud omgedraaid kunnen worden to t " O . I .A . " : 
"Onderzoeker In Armoede 
XVI 
This unimpeachable thesis contains f i ve a 's, two b's, three c 's , two d 's , 
twenty -s ix e's, six f ' s , two g 's , eight h 's, twelve i s , four I's, two m's, 
four teen n's, eleven o 's , two p's, seven r 's , t h i r t y - o n e s 's , twenty t ' s , f i ve 
u s , seven v ' s , nine w ' s , three x ' s , and four y ' s . 



